US20070134656A1

US20070134656A1 - Product and method

Info

Publication number: US20070134656A1
Application number: US10/535,414
Authority: US
Inventors: Praveen Sharma; Narinder Sahni; Anders Lonneborg
Original assignee: Diagenic AS
Current assignee: Diagenic AS
Priority date: 2002-11-21
Filing date: 2003-11-21
Publication date: 2007-06-14
Also published as: ATE459726T1; US20130143761A1; CY1110543T1; ZA200503797B; AU2003286262C1; GB0227238D0; NZ540750A; DK1565574T3; NO20052544L; WO2004046382A2; PT1565574E; CN102191319A; DE60331577D1; AU2003286262B2; AU2003286262A1; CA2506887A1; HK1079554A1; WO2004046382A3; AP2333A; CN1742101A

Abstract

The present invention relates to oligonucleotide probes, for use in assessing gene transcript levels in a cell, which may be used in analytical techniques, particularly diagnosis techniques and kits containing the same.

Description

The present invention relates to oligonucleotide probes, for use in assessing gene transcript levels in a cell, which may be used in analytical techniques, particularly diagnostic techniques. Conveniently the probes are provided in kit form. Different sets of probes may be used in techniques to prepare gene expression patterns and identify, diagnose or monitor different states, such as diseases, conditions or stages thereof. Also provided are methods of identifying suitable probes and their use in methods of the invention.
The identification of quick and easy methods of sample analysis for, for example, diagnostic applications, remains the goal of many researchers. End users seek methods which are cost effective, produce statistically significant results and which may be implemented routinely without the need for highly skilled individuals.
The analysis of gene expression within cells has been used to provide information on the state of those cells and importantly the state of the individual from which the cells are derived. The relative expression of various genes in a cell has been identified as reflecting a particular state within a body. For example, cancer cells are known to exhibit altered expression of various proteins and the transcripts or the expressed proteins may therefore be used as markers of that disease state.
Thus biopsy tissue may be analysed for the presence of these markers and cells originating from the site of the disease may be identified in other tissues or fluids of the body by the presence of the markers. Furthermore, products of the altered expression may be released into the blood stream and these products may be analysed. In addition cells which have contacted disease cells may be affected by their direct contact with those cells resulting in altered gene expression and their expression or products of expression may be similarly analysed.
However, there are some limitations with these methods. For example, the use of specific tumour markers for identifying cancer suffers from a variety of defects, such as lack of specificity or sensitivity, association of the marker with disease states besides the specific type of cancer, and difficulty of detection in asymptomatic individuals.
In addition to the analysis of one or two marker transcripts or proteins, more recently, gene expression patterns have been analysed. Most of the work involving large-scale gene expression analysis with implications in disease diagnosis has involved clinical samples originating from diseased tissues or cells. For example, several recent publications, which demonstrate that gene expression data can be used to distinguish between similar cancer types, have used clinical samples from diseased tissues or cells (Alon et al. 1999, PNAS, 96, p6745-6750; Golub et al. 1999, Science, 286, p531-537; Alizadeh et al, 2000, Nature, 403, p503-511; Bittner et al., 2000, Nature, 406, p536-540).
However, these methods have relied on analysis of a sample containing diseased cells or products of those cells or cells which have been contacted by disease cells. Analysis of such samples relies on knowledge of the presence of a disease and its location, which may be difficult in asymptomatic patients. Furthermore, samples can not always be taken from the disease site, e.g. in diseases of the brain.
In a finding of great significance, the present inventors identified the previously untapped potential of all cells within a body to provide information relating to the state of the organism from which the cells were derived. WO98/49342 describes the analysis of the gene expression of cells distant from the site of disease, e.g. peripheral blood collected distant from a cancer site.
This finding is based on the premise that the different parts of an organism's body exist in dynamic interaction with each other. When a disease affects one part of the body, other parts of the body are also affected. The interaction results from a wide spectrum of biochemical signals that are released from the diseased area, affecting other areas in the body. Although, the nature of the biochemical and physiological changes induced by the released signals can vary in the different body parts, the changes can be measured at the level of gene expression and used for diagnostic purposes.
The physiological state of a cell in an organism is determined by the pattern with which genes are expressed in it. The pattern depends upon the internal and external biological stimuli to which said cell is exposed, and any change either in the extent or in the nature of these stimuli can lead to a change in the pattern with which the different genes are expressed in the cell. There is a growing understanding that by analysing the systemic changes in gene expression patterns in cells in biological samples, it is possible to provide information on the type and nature of the biological stimuli that are acting on them. Thus, for example, by monitoring the expression of a large number of genes in cells in a test sample, it is possible to determine whether their genes are expressed with a pattern characteristic for a particular disease, condition or stage thereof. Measuring changes in gene activities in cells, e.g. from tissue or body fluids is therefore emerging as a powerful tool for disease diagnosis.
Such methods have various advantages. Often, obtaining clinical samples from certain areas in the body that is diseased can be difficult and may involve undesirable invasions in the body, for example biopsy is often used to obtain samples for cancer. In some cases, such as in Alzheimer's disease the diseased brain specimen can only be obtained post-mortem. Furthermore, the tissue specimens which are obtained are often heterogeneous and may contain a mixture of both diseased and non-diseased cells, making the analysis of generated gene expression data both complex and difficult.
It has been suggested that a pool of tumour tissues that appear to be pathogenetically homogeneous with respect to morphological appearances of the tumour may well be highly heterogeneous at the molecular level (Alizadeh, 2000, supra), and in fact might contain tumours representing essentially different diseases (Alizadeh, 2000, supra; Golub, 1999, supra). For the purpose of identifying a disease, condition, or a stage thereof, any method that does not require clinical samples to originate directly from diseased tissues or cells is highly desirable since clinical samples representing a homogeneous mixture of cell types can be obtained from an easily accessible region in the body.
We have now identified a set of probes of surprising utility for identifying one or more diseases. Thus, we now describe probes and sets of probes derived from cells which are not disease cells and which have not contacted disease cells, which correspond to genes which exhibit altered expression in normal versus disease individuals, for use in methods of identifying, diagnosing or monitoring certain conditions, particularly diseases or stages thereof.
Thus the invention provides a set of oligonucleotide probes which correspond to genes in a cell whose expression is affected in a pattern characteristic of a particular disease, condition or stage thereof, wherein said genes are systemically affected by said disease, condition or stage thereof. Preferably said genes are metabolic or house-keeping genes and preferably are constitutively moderately or highly expressed. Preferably the genes are moderately or highly expressed in the cells of the sample but not in cells from disease cells or in cells having contacted such disease cells.
Such probes, particularly when isolated from cells distant to the site of disease, do not rely on the development of disease to clinically recognizable levels and allow detection of a disease or condition or stage thereof very early after the onset of said disease or condition, even years before other subjective or objective symptoms appear.
As used herein “systemically” affected genes refers to genes whose expression is affected in the body without direct contact with a disease cell or disease site and the cells under investigation are not disease cells.
“Contact” as referred to herein refers to cells coming into close proximity with one another such that the direct effect of one cell on the other may be observed, e.g. an immune response, wherein these responses are not mediated by secondary molecules released from the first cell over a large distance to affect the second cell. Preferably contact refers to physical contact, or contact that is as close as is. sterically possible, conveniently, cells which contact one another are found in the same unit volume, for example within 1 cm³.
A “disease cell” is a cell manifesting phenotypic changes and is present at the disease site at some time during its life-span, e.g. a tumour cell at the tumour site or which has disseminated from the tumour, or a brain cell in the case of brain disorders such as Alzheimer's disease.
“Metabolic” or “house-keeping” genes refer to those genes responsible for expressing products involved in cell division and maintenance, e.g. non-immune function related genes.
“Moderately or highly” expressed genes refers to those present in resting cells in a copy number of more than 30-100 copies/cell (assuming an average 3×10⁵mRNA molecules in a cell).
Specific probes having the above described properties are provided herein.
Thus in one aspect, the present invention provides a set of oligonucleotide probes, wherein said set comprises at least 10 oligonucleotides selected from:

- an oligonucleotide as described in Table 1 or derived from a sequence described in Table 1, or an oligonucleotide with a complementary sequence, or a functionally equivalent oligonucleotide.

“Table 1” as referred to herein refers to Table 1a and/or Table 1b. Table 1b contains reference to additional clones and sequences as disclosed herein. Similarly Tables 2 and 4 comprise 2 parts, a and b.
The invention also provides one or more oligonucleotide probes, wherein each oligonucleotide probe is selected from the oligonucleotides listed in Table 1, or derived from a sequence described in Table 1, or a complementary sequence thereof. The use of such probes in products and methods of the invention, form further aspects of the invention.
As referred to herein an “oligonucleotidell” is a nucleic acid molecule having at least 6 monomers in the polymeric structure, ie. nucleotides or modified forms thereof. The nucleic acid molecule may be DNA, RNA or PNA (peptide nucleic acid) or hybrids thereof or modified versions thereof, e.g. chemically modified forms, e.g. LNA (Locked Nucleic acid), by methylation or made up of modified or non-natural bases during synthesis, providing they retain their ability to bind to complementary sequences. Such oligonucleotides are used in accordance with the invention to probe target sequences and are thus referred to herein also as oligonucleotide probes or simply as probes.
An “oligonucleotide derived from a sequence described in Table 1” (or any other table) refers to a part of a sequence disclosed in that Table (e.g. Table 1-4), which satisfies the requirements of the oligonucleotide probes as described herein, e.g. in length and function. Preferably said parts have the size described hereinafter.
Preferably the oligonucleotide probes forming said set are at least 15 bases in length to allow binding of target molecules. Especially preferably said oligonucleotide probes are from 20 to 200 bases in length, e.g. from 30 to 150 bases, preferably 50-100 bases in length.
As referred to herein the term “complementary sequences” refers to sequences with consecutive complementary bases (ie. T:A, G:C) and which complementary sequences are therefore able to bind to one another through their complementarity.
Reference to “10 oligonucleotides” refers to 10 different oligonucleotides. Whilst a Table 1 oligonucleotide, a Table 1 derived oligonucleotide and their functional equivalent are considered different oligonucleotides, complementary oligonucleotides are not considered different. Preferably however, the at least 10 oligonucleotides are 10 different Table 1 oligonucleotides (or Table 1 derived oligonucleotides or their functional equivalents). Thus said 10 different oligonucleotides are preferably able to bind to 10 different transcripts.
Preferably said oligonucleotides are as described in Table 1 or are derived from a sequence described in Table 1. Especially preferably said oligonucleotides are as described in Table 2 or Table 4 or are derived from a sequence described in either of those tables. Especially preferably the oligonucleotide (or the oligonucleotide derived therefrom) has a high occurrence as defined in Table 3, especially preferably >40%, e.g. >80 or >90, e.g. 100%.
A “set” as described refers to a collection of unique oligonucleotide probes (ie. having a distinct sequence) and preferably consists of less than 1000 oligonucleotide probes, especially less than 500 probes, e.g. preferably from 10 to 500, e.g. 10 to 100, 200 or 300, especially preferably 20 to 100, e.g. 30 to 100 probes. In some cases less than 10 probes may be used, e.g. from 2 to 9 probes, e.g. 5 to 9 probes.
It will be appreciated that increasing the number of probes will prevent the possibility of poor analysis, e.g. misdiagnosis by comparison to other diseases which could similarly alter the expression of the particular genes in question. Other oligonucleotide probes not described herein may also be present, particularly if they aid the ultimate use of the set of oligonucleotide probes. However, preferably said set consists only of said Table 1 oligonucleotides, Table 1 derived oligonucleotides, complementary sequences or functionally equivalent oligonucleotides, or a sub-set thereof (e.g. of the size as described above), preferably a sub-set for which sequences are provided herein (see Table 1 and its footnote). Especially preferably said set consists only of said Table 1 oligonucleotides, Table 1 derived oligonucleotides, or complementary sequences thereof, or a sub-set thereof.
Multiple copies of each unique oligonucleotide probe, e.g. 10 or more copies, may be present in each set, but constitute only a single probe.
A set of oligonucleotide probes, which may preferably be immobilized on a solid support or have means for such immobilization, comprises the at least 10 oligonucleotide probes selected from those described hereinbefore. Especially preferably said probes are selected from those having high occurrence as described in Table 3 and as mentioned above. As mentioned above, these 10 probes must be unique and have different sequences. Having said this however, two separate probes may be used which recognize the same gene but reflect different splicing events. However oligonucleotide probes which are complementary to, and bind to distinct genes are preferred.
As described herein a “functionally equivalent” oligonucleotide to those described in Table 1 or derived therefrom refers to an oligonucleotide which is capable of identifying the same gene as an oligonucleotide of Table 1 or derived therefrom, ie. it can bind to the same mRNA molecule (or DNA) transcribed from a gene (target nucleic acid molecule) as the Table 1 oligonucleotide or the Table 1 derived oligonucleotide (or its complementary sequence). Preferably said functionally equivalent oligonucleotide is capable of recognizing, ie. binding to the same splicing product as a Table 1 oligonucleotide or a Table 1 derived oligonucleotide. Preferably said mRNA molecule is the full length mRNA molecule which corresponds to the Table 1 oligonucleotide or the Table 1 derived oligonucleotide.
As referred to herein “capable of binding” or “binding” refers to the ability to hybridize under conditions described hereinafter.
Alternatively expressed, functionally equivalent oligonucleotides (or complementary sequences) have sequence identity or will hybridize, as described hereinafter, to a region of the target molecule to which molecule a Table 1 oligonucleotide or a Table 1 derived oligonucleotide or a complementary oligonucleotide binds. Preferably, functionally equivalent oligonucleotides (or their complementary sequences) hybridize to one of the MRNA sequences which corresponds to a Table 1 oligonucleotide or a Table 1 derived oligonucleotide under the conditions described hereinafter or has sequence identity to a part of one of the mRNA sequences which corresponds to a Table 1 oligonucleotide or a Table 1 derived oligonucleotide. A “part” in this context refers to a stretch of at least 5, e.g. at least 10 or 20 bases, such as from 5 to 100, e.g. 10 to 50 or 15 to 30 bases.
In a particularly preferred aspect, the functionally equivalent oligonucleotide binds to all or a part of the region of a target nucleic acid molecule (mRNA or CDNA) to which the Table 1 oligonucleotide or Table 1 derived oligonucleotide binds. A “target” nucleic acid molecule is the gene transcript or related product e.g. MRNA, or cDNA, or amplified product thereof. Said “region” of said target molecule to which said Table 1 oligonucleotide or Table 1 derived oligonucleotide binds is the stretch over which complementarity exists. At its largest this region is the whole length of the Table 1 oligonucleotide or Table 1 derived oligonucleotide, but may be shorter if the entire Table 1 sequence or Table 1 derived oligonucleotide is not complementary to a region of the target sequence.
Preferably said part of said region of said target molecule is a stretch of at least 5, e.g. at least 10 or 20 bases, such as from 5 to 100, e.g. 10 to 50 or 15 to 30 bases. This may for example be achieved by said functionally equivalent oligonucleotide having several identical bases to the bases of the Table 1 oligonucleotide or the Table 1 derived oligonucleotide. These bases may be identical over consecutive stretches, e.g. in a part of the functionally equivalent oligonucleotide, or may be present non-consecutively, but provide sufficient complementarity to allow binding to the target sequence.
Thus in a preferred feature, said functionally equivalent oligonucleotide hybridizes under conditions of high stringency to a Table 1 oligonucleotide or a Table 1 derived oligonucleotide or the complementary sequence thereof. Alternatively expressed, said functionally equivalent oligonucleotide exhibits high sequence identity to all or part of a Table 1 oligonucleotide. Preferably said functionally equivalent oligonucleotide has at least 70% sequence identity, preferably at least 80%, e.g. at least 90, 95, 98 or 99%, to all of a Table 1 oligonucleotide or a part thereof. As used in this context, a “part” refers to a stretch of at least 5, e.g. at least 10 or 20 bases, such as from 5 to 100, e.g. 190 to 50 or 15 to 30 bases, in said Table 1 oligonucleotide. Especially preferably when sequence identity to only a part of said Table 1 oligonucleotide is present, the sequence identity is high, e.g. at least 80% as described above.
Functionally equivalent oligonucleotides which satisfy the above stated functional requirements include those which are derived from the Table 1 oligonucleotides and also those which have been modified by single or multiple nucleotide base (or equivalent) substitution, addition and/or deletion, but which nonetheless retain functional activity, e.g. bind to the same target molecule as the Table 1 oligonucleotide or the Table 1 derived oligonucleotide from which they are further derived or modified. Preferably said modification is of from 1 to 50, e.g. from 10 to 30, preferably from 1 to 5 bases. Especially preferably only minor modifications are present, e.g. variations in less than 10 bases, e.g. less than 5 base changes.
Within the meaning of “addition” equivalents are included oligonucleotides containing additional sequences which are complementary to the consecutive stretch of bases on the target molecule to which the Table 1 oligonucleotide or the Table 1 derived oligonucleotide binds. Alternatively the addition may comprise a different, unrelated sequence, which may for example confer a further property, e.g. to provide a means for immobilization such as a linker to bind the oligonucleotide probe to a solid support.
Particularly preferred are naturally occurring equivalents such as biological variants, e.g. allelic, geographical or allotypic variants, e.g. oligonucleotides which correspond to a genetic variant, for example as present in a different species.
Functional equivalents include oligonucleotides with modified bases, e.g. using non-naturally occurring bases. Such derivatives may be prepared during synthesis or by post production modification.
“Hybridizing” sequences which bind under conditions of low stringency are those which bind under non-stringent conditions (for example, 6×SSC/50% formamide at room temperature) and remain bound when washed under conditions of low stringency (2×SSC, room temperature, more preferably 2×SSC, 42° C.). Hybridizing under high stringency refers to the above conditions in which washing is performed at 2×SSC, 65° C. (where SSC=0.15M NaCl, 0.015M sodium citrate, pH 7.2).
“Sequence identity” as referred to herein refers to the value obtained when assessed using ClustalW (Thompson et al., 1994, Nucl. Acids Res., 22, p4673-4680) with the following parameters:

Pairwise alignment parameters—Method: accurate, Matrix: IUB, Gap open penalty: 15.00, Gap extension penalty: 6.66;
Multiple alignment parameters—Matrix: IUB, Gap open penalty: 15.00, % identity for delay: 30, Negative matrix: no, Gap extension penalty: 6.66, DNA transitions weighting: 0.5.

Sequence identity at a particular base is intended to include identical bases which have simply been derivatized.
The invention also extends to polypeptides encoded by the mRNA sequence to which a Table 1 oligonucleotide or a Table 1 derived oligonucleotide binds. The invention further extends to antibodies which bind to any of said polypeptides.
As described above, conveniently said set of oligonucleotide probes may be immobilized on one or more solid supports. Single or preferably multiple copies of each unique probe are attached to said solid supports, e.g. 10 or more, e.g. at least 100 copies of each unique probe are present.
One or more unique oligonucleotide probes may be associated with separate solid supports which together form a set of probes immobilized on multiple solid support, e.g. one or more unique probes may be immobilized on multiple beads, membranes, filters, biochips etc. which together form a set of probes, which together form modules of the kit described hereinafter. The solid support of the different modules are conveniently physically associated although the signals associated with each probe (generated as described hereinafter) must be separately determinable.
Alternatively, the probes may be immobilized on discrete portions of the same solid support, e.g. each unique oligonucleotide probe, e.g. in multiple copies, may be immobilized to a distinct and discrete portion or region of a single filter or membrane, e.g. to generate an array.
A combination of such techniques may also be used, e.g. several solid supports may be used which each immobilize several unique probes.
The expression “solid support” shall mean any solid material able to bind oligonucleotides by hydrophobic, ionic or covalent bridges.
“Immobilization” as used herein refers to reversible or irreversible association of the probes to said solid support by virtue of such binding. If reversible, the probes remain associated with the solid support for a time sufficient for methods of the invention to be carried out.
Numerous solid supports suitable as immobilizing moieties according to the invention, are well known in the art and widely described in the literature and generally speaking, the solid support may be any of the well-known supports or matrices which are currently widely used or proposed for immobilization, separation etc. in chemical or biochemical procedures. Such materials include, but are not limited to, any synthetic organic polymer such as polystyrene, polyvinylchloride, polyethylene; or nitrocellulose and cellulose acetate; or tosyl activated surfaces; or glass or nylon or any surface carrying a group suited for covalent coupling of nucleic acids. The immobilizing moieties may take the form of particles, sheets, gels, filters, membranes, microfibre strips, tubes or plates, fibres or capillaries, made for example of a polymeric material e.g. agarose, cellulose, alginate, teflon, latex or polystyrene or magnetic beads. Solid supports allowing the presentation of an array, preferably in a single dimension are preferred, e.g. sheets, filters, membranes, plates or biochips.
Attachment of the nucleic acid molecules to the solid support may be performed directly or indirectly. For example if a filter is used, attachment may be performed by UV-induced crosslinking. Alternatively, attachment may be performed indirectly by the use of an attachment moiety carried on the oligonucleotide probes and/or solid support. Thus for example, a pair of affinity binding partners may be used, such as avidin, streptavidin or biotin, DNA or DNA binding protein (e.g. either the lac I repressor protein or the lac operator sequence to which it binds), antibodies (which may be mono- or polyclonal), antibody fragments or the epitopes or haptens of antibodies. In these cases, one partner of the binding pair is attached to (or is inherently part of) the solid support and the other partner is attached to (or is inherently part of) the nucleic acid molecules.
As used herein an “affinity binding pair” refers to two components which recognize and bind to one another specifically (ie. in preference to binding to other molecules). Such binding pairs when bound together form a complex.
Attachment of appropriate functional groups to the solid support may be performed by methods well known in the art, which include for example, attachment through hydroxyl, carboxyl, aldehyde or amino groups which may be provided by treating the solid support to provide suitable surface coatings. Solid supports presenting appropriate moieties for attachment of the binding partner may be produced by routine methods known in the art.
Attachment of appropriate functional groups to the oligonucleotide probes of the invention may be performed by ligation or introduced during synthesis or amplification, for example using primers carrying an appropriate moiety, such as biotin or a particular sequence for capture.
Conveniently, the set of probes described hereinbefore is provided in kit form.
Thus viewed from a further aspect the present invention provides a kit comprising a set of oligonucleotide probes as described hereinbefore immobilized on one or more solid supports.
Preferably, said probes are immobilized on a single solid support and each unique probe is attached to a different region of said solid support. However, when attached to multiple solid supports, said multiple solid supports form the modules which make up the kit. Especially preferably said solid support is a sheet, filter, membrane, plate or biochip.
Optionally the kit may also contain information relating to the signals generated by normal or diseased samples (as discussed in more detail hereinafter in relation to the use of the kits), standardizing materials, e.g. mRNA or cDNA from normal and/or diseased samples for comparative purposes, labels for incorporation into CDNA, adapters for introducing nucleic acid sequences for amplification purposes, primers for amplification and/or appropriate enzymes, buffers and solutions. Optionally said kit may also contain a package insert describing how the method of the invention should be performed, optionally providing standard graphs, data or software for interpretation of results obtained when performing the invention.
The use of such kits to prepare a standard diagnostic gene transcript pattern as described hereinafter forms a further aspect of the invention.
The set of probes as described herein have various uses. Principally however they are used to assess the gene expression state of a test cell to provide information relating to the organism from which said cell is derived. Thus the probes are useful in diagnosing, identifying or monitoring a disease or condition or stage thereof in an organism.
Thus in a further aspect the invention provides the use of a set of oligonucleotide probes or a kit as described hereinbefore to determine the gene expression pattern of a cell which pattern reflects the level of gene expression of genes to which said oligonucleotide probes bind, comprising at least the steps of:
a) isolating mRNA from said cell, which may optionally be reverse transcribed to cDNA;
b) hybridizing the mRNA or cDNA of step (a) to a set of oligonucleotide probes or a kit as defined herein; and
c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce said pattern.
The mRNA and cDNA as referred to in this method, and the methods hereinafter, encompass derivatives or copies of said molecules, e.g. copies of such molecules such as those produced by amplification or the preparation of complementary strands, but which retain the identity of the mRNA sequence, ie. would hybridize to the direct transcript (or its complementary sequence) by virtue of precise complementarity, or sequence identity, over at least a region of said molecule. It will be appreciated that complementarity will not exist over the entire region where techniques have been used which may truncate the transcript or introduce new sequences, e.g. by primer amplification. For convenience, said mRNA or cDNA is preferably amplified prior to step b). As with the oligonucleotides described herein said molecules may be modified, e.g. by using non-natural bases during synthesis providing complementarity remains. Such molecules may also carry additional moieties such as signalling or immobilizing means.
The various steps involved in the method of preparing such a pattern are described in more detail hereinafter.
As used herein “gene expression” refers to transcription of a particular gene to produce a specific mRNA product (ie. a particular splicing product). The level of gene expression may be determined by assessing the level of transcribed mRNA molecules or cDNA molecules reverse transcribed from the mRNA molecules or products derived from those molecules, e.g. by amplification.
The “pattern” created by this technique refers to information which, for example, may be represented in tabular or graphical form and conveys information about the signal associated with two or more oligonucleotides. Preferably said pattern is expressed as an array of numbers relating to the expression level associated with each probe.
Preferably, said pattern is established using the following linear model:
y=Xb+f Equation 1
wherein, X is the matrix of gene expression data and y is the response variable, b is the regression coefficient vector and f the estimated residual vector. Although many different methods can be used to establish the relationship provided in equation 1, especially preferably the partial Least Squares Regression (PLSR) method is used for establishing the relationship in equation 1.
The probes are thus used to generate a pattern which reflects the gene expression of a cell at the time of its isolation. The pattern of expression is characteristic of the circumstances under which that cells finds itself and depends on the influences to which the cell has been exposed. Thus, a characteristic gene transcript pattern standard or fingerprint (standard probe pattern) for cells from an individual with a particular disease or condition may be prepared and used for comparison to transcript patterns of test cells. This has clear applications in diagnosing, monitoring or identifying whether an organism is suffering from a particular disease, condition or stage thereof.
The standard pattern is prepared by determining the extent of binding of total mRNA (or cDNA or related product), from cells from a sample of one or more organisms with the disease or condition or stage thereof, to the probes. This reflects the level of transcripts which are present which correspond to each unique probe. The amount of nucleic acid material which binds to the different probes is assessed and this information together forms the gene transcript pattern standard of that disease or condition or stage thereof. Each such standard pattern is characteristic of the disease, condition or stage thereof.
In a further aspect therefore, the present invention provides a method of preparing a standard gene transcript pattern characteristic of a disease or condition or stage thereof in an organism comprising at least the steps of:
a) isolating MRNA from the cells of a sample of one or more organisms having the disease or condition or stage thereof, which may optionally be reverse transcribed to cDNA;
b) hybridizing the mRNA or cDNA of step (a) to a set of oligonucleotides or a kit as described hereinbefore specific for said disease or condition or stage thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation; and
c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce a characteristic pattern reflecting the level of gene expression of genes to which said oligonucleotides bind, in the sample with the disease, condition or stage thereof.
For convenience, said oligonucleotides are preferably immobilized on one or more solid supports.
The standard pattern for a great number of diseases or conditions and different stages thereof using particular probes may be accumulated in databases and be made available to laboratories on request.
“Disease” samples and organisms as referred to herein refer to organisms (or samples from the same) with an underlying pathological disturbance relative to a normal organism (or sample), in a symptomatic or asymptomatic organism, which may result, for example, from infection or an acquired or congenital genetic imperfection. Such organisms are known to have, or which exhibit, the disease or condition or stage thereof under study.
A “condition” refers to a state of the mind or body of an organism which has not occurred through disease, e.g. the presence of an agent in the body such as a toxin, drug or pollutant, or pregnancy.
“Stages” thereof refer to different stages of the disease or condition which may or may not exhibit particular physiological or metabolic changes, but do exhibit changes at the genetic level which may be detected as altered gene expression. It will be appreciated that during the course of a disease or condition the expression of different transcripts may vary. Thus at different stages, altered expression may not be exhibited for particular transcripts compared to “normal” samples. However, combining information from several transcripts which exhibit altered expression at one or more stages through the course of the disease or condition can be used to provide a characteristic pattern which is indicative of a particular stage of the disease or condition. Thus for example different stages in cancer, e.g. pre-stage I, stage I, stage II, II or IV can be identified.
“Normal” as used herein refers to organisms or samples which are used for comparative purposes. Preferably, these are “normal” in the sense that they do not exhibit any indication of, or are not believed to have, any disease or condition that would affect gene expression, particularly in respect of the disease for which they are to be used as the normal standard. However, it will be appreciated that different stages of a disease or condition may be compared and in such cases, the “normal” sample may correspond to the earlier stage of the disease or condition.
As used herein a “sample” refers to any material obtained from the organism, e.g. human or non-human animal under investigation which contains cells and includes, tissues, body fluid or body waste or in the case of prokaryotic organisms, the organism itself. “Body fluids” include blood, saliva, spinal fluid, semen, lymph. “Body waste” includes urine, expectorated matter (pulmonary patients), faeces etc. “Tissue samples” include tissue obtained by biopsy, by surgical interventions or by other means e.g. placenta. Preferably however, the samples which are examined are from areas of the body not apparently affected by the disease or condition. The cells in such samples are not disease cells, e.g. cancer cells, have not been in contact with such disease cells and do not originate from the site of the disease or condition. The “site of disease” is considered to be that area of the body which manifests the disease in a way which may be objectively determined, e.g. a tumour or area of inflammation. Thus for example peripheral blood may be used for the diagnosis of non-haematopoietic cancers, and the blood does not require the presence of malignant or disseminated cells from the cancer in the blood. Similarly in diseases of the brain, in which no diseased cells are found in the blood due to the blood:brain barrier, peripheral blood may still be used in the methods of the invention.
It will however be appreciated that the method of preparing the standard transcription pattern and other methods of the invention are also applicable for use on living parts of eukaryotic organisms such as cell lines and organ cultures and explants.
As used herein, reference to “corresponding” sample etc. refers to cells preferably from the same tissue, body fluid or body waste, but also includes cells-from tissue, body fluid or body waste which are sufficiently similar for the purposes of preparing the standard or test pattern. When used in reference to genes “corresponding” to the probes, this refers to genes which are related by sequence (which may be complementary) to the probes although the probes may reflect different splicing products of expression.
“Assessing” as used herein refers to both quantitative and qualitative assessment which may be determined in absolute or relative terms.
The invention may be put into practice as follows. To prepare a standard transcript pattern for a particular disease, condition or stage thereof, sample mRNA is extracted from the cells of tissues, body fluid or body waste according to known techniques (see for example Sambrook et. al. (1989), Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) from a diseased individual or organism.
Owing to the difficulties in working with RNA, the RNA is preferably reverse transcribed at this stage to form first strand cDNA. Cloning of the cDNA or selection from, or using, a cDNA library is not however necessary in this or other methods of the invention. Preferably, the complementary strands of the first strand cDNAs are synthesized, ie. second strand cDNAs, but this will depend on which relative strands are present in the oligonucleotide probes. The RNA may however alternatively be used directly without reverse transcription and may be labelled if so required.
Preferably the cDNA strands are amplified by known amplification techniques such as the polymerase chain reaction (PCR) by the use of appropriate primers. Alternatively, the cDNA strands may be cloned with a vector, used to transform a bacteria such as E. coli which may then be grown to multiply the nucleic acid molecules. When the sequence of the cDNAs are not known, primers may be directed to regions of the nucleic acid molecules which have been introduced. Thus for example, adapters may be ligated to the cDNA molecules and primers directed to these portions for amplification of the cDNA molecules. Alternatively, in the case of eukaryotic samples, advantage may be taken of the polyA tail and cap of the RNA to prepare appropriate primers.
To produce the standard diagnostic gene transcript pattern or fingerprint for a particular disease or condition or stage thereof, the above described oligonucleotide probes are used to probe mRNA or cDNA of the diseased sample to produce a signal for hybridization to each particular oligonucleotide probe species, ie. each unique probe. A standard control gene transcript pattern may also be prepared if desired using mRNA or cDNA from a normal sample. Thus, mRNA or cDNA is brought into contact with the oligonucleotide probe under appropriate conditions to allow hybridization.
When multiple samples are probed, this may be performed consecutively using the same probes, e.g. on one or more solid supports, ie. on probe kit modules, or by simultaneously hybridizing to corresponding probes, e.g. the modules of a corresponding probe kit.
To identify when hybridization occurs and obtain an indication of the number of transcripts/cDNA molecules which become bound to the oligonucleotide probes, it is necessary to identify a signal produced when the transcripts (or related molecules) hybridize (e.g. by detection of double stranded nucleic acid molecules or detection of the number of molecules which become bound, after removing unbound molecules, e.g. by washing).
In order to achieve a signal, either or both components which hybridize (ie. the probe and the transcript) carry or form a signalling means or a part thereof. This “signalling means” is any moiety capable of direct or indirect detection by the generation or presence of a signal. The signal may be any detectable physical characteristic such as conferred by radiation emission, scattering or absorption properties, magnetic properties, or other physical properties such as charge, size or binding properties of existing molecules (e.g. labels) or molecules which may be generated (e.g. gas emission etc.). Techniques are preferred which allow signal amplification, e.g. which produce multiple signal events from a single active binding site, e.g. by the catalytic action of enzymes to produce multiple detectable products.
Conveniently the signalling means may be a label which itself provides a detectable signal. Conveniently this may be achieved by the use of a radioactive or other label which may be incorporated during cDNA production, the preparation of complementary cDNA strands, during amplification of the target mRNA/cDNA or added directly to target nucleic acid molecules.
Appropriate labels are those which directly or indirectly allow detection or measurement of the presence of the transcripts/cDNA. Such labels include for example radiolabels, chemical labels, for example chromophores or fluorophores (e.g. dyes such as fluorescein and rhodamine), or reagents of high electron density such as ferritin, haemocyanin or colloidal gold. Alternatively, the label may be an enzyme, for example peroxidase or alkaline phosphatase, wherein the presence of the enzyme is visualized by its interaction with a suitable entity, for example a substrate. The label may also form part of a signalling pair wherein the other member of the pair is found on, or in close proximity to, the oligonucleotide probe to which the transcript/cDNA binds, for example, a fluorescent compound and a quench fluorescent substrate may be used. A label may also be provided on a different entity, such as an antibody, which recognizes a peptide moiety attached to the transcripts/cDNA, for example attached to a base used during synthesis or amplification.
A signal may be achieved by the introduction of a label before, during or after the hybridization step. Alternatively, the presence of hybridizing transcripts may be identified by other physical properties, such as their absorbance, and in which case the signalling means is the complex itself.
The amount of signal associated with each oligonucleotide probe is then assessed. The assessment may be quantitative or qualitative and may be based on binding of a single transcript species (or related cDNA or other products) to each probe, or binding of multiple transcript species to multiple copies of each unique probe. It will be appreciated that quantitative results will provide further information for the transcript fingerprint of the disease which is compiled. This data may be expressed as absolute values (in the case of macroarrays) or may be determined relative to a particular standard or reference e.g. a normal control sample.
Furthermore it will be appreciated that the standard diagnostic gene pattern transcript may be prepared using one or more disease samples (and normal samples if used) to perform the hybridization step to obtain patterns not biased towards a particular individual's variations in gene expression.
The use of the probes to prepare standard patterns and the standard diagnostic gene transcript patterns thus produced for the purpose of identification or diagnosis or monitoring of a particular disease or condition or stage thereof in a particular organism forms a further aspect of the invention.
Once a standard diagnostic fingerprint or pattern has been determined for a particular disease or condition using the selected oligonucleotide probes, this information can be used to identify the presence, absence or extent or stage of that disease or condition in a different test organism or individual.
To examine the gene expression pattern of a test sample, a test sample of tissue, body fluid or body waste containing cells, corresponding to the sample used for the preparation of the standard pattern, is obtained from a patient or the organism to be studied. A test gene transcript pattern is then prepared as described hereinbefore as for the standard pattern.
In a further aspect therefore, the present invention provides a method of preparing a test gene transcript pattern comprising at least the steps of:
a) isolating mRNA from the cells of a sample of said test organism, which may optionally be reverse transcribed to CDNA;
b) hybridizing the mRNA or cDNA of step (a) to a set of oligonucleotides or a kit as described hereinbefore specific for a disease or condition or stage thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation; and
c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce said pattern reflecting the level of gene expression of genes to which said oligonucleotides bind, in said test sample.
This test pattern may then be compared to one or more standard patterns to assess whether the sample contains cells having the disease, condition or stage thereof.
Thus viewed from a further aspect the present invention provides a method of diagnosing or identifying or monitoring a disease or condition or stage thereof in an organism, comprising the steps of:

- a) isolating mRNA from the cells of a sample of said organism, which may optionally be reverse transcribed to cDNA;
- b) hybridizing the mRNA or cDNA of step (a) to a set of oligonucleotides or a kit as described hereinbefore specific for said disease or condition or stage thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation;
- c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce a characteristic pattern reflecting the level of gene expression of genes to which said oligonucleotides bind, in said sample; and
- d) comparing said pattern to a standard diagnostic pattern prepared according to the method of the invention using a sample from an organism corresponding to the organism and sample under investigation to determine the presence of said disease or condition or a stage thereof in the organism under investigation.

The method up to and including step c) is the preparation of a test pattern as described above.
As referred to herein, “diagnosis” refers to determination of the presence or existence of a disease or condition or stage thereof in an organism. “Monitoring” refers to establishing the extent of a disease or condition, particularly when an individual is known to be suffering from a disease or condition, for example to monitor the effects of treatment or the development of a disease or condition, e.g. to determine the suitability of a treatment or provide a prognosis.
The presence of the disease or condition or stage thereof may be determined by determining the degree of correlation between the standard and test samples' patterns. This necessarily takes into account the range of values which are obtained for normal and diseased samples. Although this can be established by obtaining standard deviations for several representative samples binding to the probes to develop the standard, it will be appreciated that single samples may be sufficient to generate the standard pattern to identify a disease if the test sample exhibits close enough correlation to that standard. Conveniently, the presence, absence, or extent of a disease or condition or stage thereof in a test sample can be predicted by inserting the data relating to the expression level of informative probes in test sample into the standard diagnostic probe pattern established according to equation 1.
Data generated using the above mentioned methods may be analysed using various techniques from the most basic visual representation (e.g. relating to intensity) to more complex data manipulation to identify underlying patterns which reflect the interrelationship of the level of expression of each gene to which the various probes bind, which may be quantified and expressed mathematically. Conveniently, the raw data thus generated may be manipulated by the data processing and statistical methods described hereinafter, particularly normalizing and standardizing the data and fitting the data to a classification model to determine whether said test data reflects the pattern of a particular disease, condition or stage thereof.
The methods described herein may be used to identify, monitor or diagnose a disease, condition or ailment or its stage or progression, for which the oligonucleotide probes are informative. “Informative” probes as described herein, are those which reflect genes which have altered expression in the diseases or conditions in question, or particular stages thereof. Probes of the invention may not be sufficiently informative for diagnostic purposes when used alone, but are informative when used as one of several probes to provide a characteristic pattern, e.g. in a set as described hereinbefore.
Preferably said probes correspond to genes which are systemically affected by said disease, condition or stage thereof. Especially preferably said genes, from which transcripts are derived which bind to probes of the invention, are metabolic or house-keeping genes and preferably are moderately or highly expressed. The advantage of using probes directed to moderately or highly expressed genes is that smaller clinical samples are required for generating the necessary gene expression data set, e.g. less than 1 ml blood samples.
Furthermore, it has been found that such genes which are already being actively transcribed tend to be more prone to being influenced, in a positive or negative way, by new stimuli. In addition, since transcripts are already being produced at levels which are generally detectable, small changes in those levels are readily detectable as for example, a certain detectable threshold does not need to be reached.
In preferred methods of the invention, the set of probes of the invention are informative for a variety of different diseases, conditions or stages thereof. A sub-set of the probes disclosed herein may be used for diagnosis, identification or monitoring a particular disease, condition or stage thereof.
Thus the probes may be used to diagnose or identify or monitor any condition, ailment, disease or reaction that leads to the relative increase or decrease in the activity of informative genes of any or all eukaryotic or prokaryotic organisms regardless of whether these changes have been caused by the influence of bacteria, virus, prions, parasites, fungi, radiation, natural or artificial toxins, drugs or allergens, including mental conditions due to stress, neurosis, psychosis or deteriorations due to the ageing of the organism, and conditions or diseases of unknown cause, providing a sub-set of the probes as described herein are informative for said disease or condition or stage thereof.
Such diseases include those which result in metabolic or physiological changes, such as fever-associated diseases such as influenza or malaria. Other diseases which may be detected include for example yellow fever, sexually transmitted diseases such as gonorrhea, fibromyalgia, candida-related complex, cancer (for example of the stomach, lung, breast, prostate gland, bowel, skin, colon, ovary etc), Alzheimer's disease, disease caused by retroviruses such as HIV, senile dementia, multiple sclerosis and Creutzfeldt-Jakob disease to mention a few.
The invention may also be used to identify patients with psychiatric or psychosomatic diseases such as schizophrenia and eating disorders. Of particular importance is the use of this method to detect diseases, conditions, or stages thereof, which are not readily detectable by known diagnostic methods, such as HIV which is generally not detectable using known techniques 1 to 4 months following infection. Conditions which may be identified include for example drug abuse, such as the use of narcotics, alcohol, steroids or performance enhancing drugs.
Preferably said disease to be identified or monitored is a cancer or a degenerative brain disorder (such as Alzheimer's or Parkinson's disease).
In particular, a set of oligonucleotide probes, wherein said set comprises at least 10 oligonucleotides selected from:

- an oligonucleotide as described in Table 4 or an oligonucleotide derived therefrom or an oligonucleotide with a complementary sequence, or a functionally equivalent oligonucleotide,
  may be used for diagnosis or identification or monitoring the progression of Alzheimer's disease. Similarly Table 2 probes and Table 2 derived probes and their functional equivalents may be used to diagnose, identify or monitor the progression of breast cancer. Especially preferably the probes used for breast cancer analysis are selected based on their occurrence as set forth in Table 3 and as described hereinbefore.

The diagnostic method may be used alone as an alternative to other diagnostic techniques or in addition to such techniques. For example, methods of the invention may be used as an alternative or additive diagnostic measure to diagnosis using imaging techniques such as Magnetic Resonance Imagine (MRI), ultrasound imaging, nuclear imaging or X-ray imaging, for example in the identification and/or diagnosis of tumours.
The methods of the invention may be performed on cells from prokaryotic or eukaryotic organisms which may be any eukaryotic organisms such as human beings, other mammals and animals, birds, insects, fish and plants, and any prokaryotic organism such as a bacteria.
Preferred non-human animals on which the methods of the invention may be conducted include, but are not limited to mammals, particularly primates, domestic animals, livestock and laboratory animals. Thus preferred animals for diagnosis include mice,. rats, guinea pigs, cats, dogs, pigs, cows, goats, sheep, horses. Particularly preferably the disease state or condition of humans is diagnosed, identified or monitored.
As described above, the sample under study may be any convenient sample which may be obtained from an organism. Preferably however, as mentioned above, the sample is obtained from a site distant to the site of disease and the cells in such samples are not disease cells, have not been in contact with such cells and do not originate from the site of the disease or condition. In such cases, although preferably absent, the sample may contain cells which do not fulfil these criteria. However, since the probes of the invention are concerned with transcripts whose expression is altered in cells which do satisfy these criteria, the probes are specifically directed to detecting changes in transcript levels in those cells even if in the presence of other, background cells.
It has been found that the cells from such samples show significant and informative variations in the gene expression of a large number of genes. Thus, the same probe (or several probes) may be found to be informative in determinations regarding two or more diseases, conditions or stages thereof by virtue of the particular level of transcripts binding to that probe or the interrelationship of the extent of binding to that probe relative to other probes. As a consequence, it is possible to use a relatively small number of probes for screening for multiple disorders or diseases. This has consequences with regard to the selection of probes, discussed in relation to random identification of probes hereinafter, but also for the use of a single set of probes for more than one diagnosis. Table 9 which represents preferred probes of the invention discloses probes which are informative for both Alzheimer's and breast cancer.
Thus, the present invention also provides sets of probes for diagnosing, identifying or monitoring two or more diseases, conditions or stages thereof, wherein at least one of said probes is suitable for said diagnosing, identifying or monitoring at least two of said diseases, conditions or stages thereof, and kits and methods of using the same. Preferably at least 5 probes, e.g. from 5 to 15 probes, are used in at least two diagnoses.
Thus, in a further preferred aspect, the present invention provides a method of diagnosis or identification or monitoring as described hereinbefore for the diagnosis, identification or monitoring of two or more diseases, conditions or stages thereof in an organism, wherein said test pattern produced in step c) of the diagnostic method is compared in step d) to at least two standard diagnostic patterns prepared as described previously, wherein each standard diagnostic pattern is a pattern generated for a different disease or condition or stage thereof.
Whilst in a preferred aspect the methods of assessment concern the development of a gene transcript pattern from a test sample and comparison of the same to a standard pattern, the elevation or depression of .expression of certain markers may also be examined by examining the products of expression and the level of those products. Thus a standard pattern in relation to the expressed product may be generated:
In such methods the levels of expression of a set of polypeptides encoded by the gene to which an oligonucleotide of Table 1 or a Table 1 derived oligonucleotide, binds, are analysed.
Various diagnostic methods may be used to assess the amount of polypeptides (or fragments thereof) which are present. The presence or concentration of polypeptides may be examined, for example by the use of a binding partner to said polypeptide (e.g. an antibody), which may be immobilized, to separate said polypeptide from the sample and the amount of polypeptide may then be determined.
“Fragments” of the polypeptides refers to a domain or region of said polypeptide, e.g. an antigenic fragment, which is recognizable as being derived from said polypeptide to allow binding of a specific binding partner. Preferably such a fragment comprises a significant portion of said polypeptide and corresponds to a product of normal post-synthesis processing.
Thus in a further aspect the present invention provides a method of preparing a standard gene transcript pattern characteristic of a disease or condition or stage thereof in an organism comprising at least the steps of:
a) releasing target polypeptides from a sample of one or more organisms having the disease or condition or stage thereof;
b) contacting said target polypeptides with one or more binding partners, wherein each binding partner is specific to a marker polypeptide (or a fragment thereof) encoded by the gene to which an oligonucleotide of Table 1 (or derived from a sequence described in Table 1) binds, to allow binding of said binding partners to said target polypeptides, wherein said marker polypeptides are specific for said disease or condition thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation; and
c) assessing the target polypeptide binding to said binding partners to produce a characteristic pattern reflecting the level of gene expression of genes which express said marker polypeptides, in the sample with the disease, condition or stage thereof.
As used herein “target polypeptides” refer to those polypeptides present in a sample which are to be detected and “marker polypeptides” are polypeptides which are encoded by the genes to which Table 1 oligonucleotides or Table 1 derived oligonucleotides bind. The target and marker polypeptides are identical or at least have areas of high similarity, e.g. epitopic regions to allow recognition and binding of the binding partner.
“Release” of the target polypeptides refers to appropriate treatment of a sample to provide the polypeptides in a form accessible for binding of the binding partners, e.g. by lysis of cells where these are present. The samples used in this case need not necessarily comprise cells as the target polypeptides may be released from cells into the surrounding tissue or fluid, and this tissue or fluid may be analysed, e.g. urine or blood. Preferably however the preferred samples as described herein are used. “Binding partners” comprise the separate entities which together make an affinity binding pair as described above, wherein one partner of the binding pair is the target or marker polypeptide and the other partner binds specifically to that polypeptide, e.g. an antibody.
Various arrangements may be envisaged for detecting the amount of binding pairs which form. In its simplest form, a sandwich type assay e.g. an immunoassay such as an ELISA, may be used in which an antibody specific to the polypeptide and carrying a label (as described elsewhere herein) may be bound to the binding pair (e.g. the first antibody:polypeptide pair) and the amount of label detected.
Other methods as described herein may be similarly modified for analysis of the protein product of expression rather than the gene transcript and related nucleic acid molecules.
Thus a further aspect of the invention provides a method of preparing a test gene transcript pattern comprising at least the steps of:
a) releasing target polypeptides from a sample of said test organism;
b) contacting said target polypeptides with one or more binding partners, wherein each binding partner is specific to a marker polypeptide (or a fragment thereof) encoded by the gene to which an oligonucleotide of Table 1 (or derived from a sequence described in Table 1) binds, to allow binding of said binding partners to said target polypeptides, wherein said marker polypeptides are specific for said disease or condition thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation; and
c) assessing the target polypeptide binding to said binding partners to produce a characteristic pattern reflecting the level of gene expression of genes which express said marker polypeptides, in said test sample.
A yet further aspect of the invention provides a method of diagnosing or identifying or monitoring a disease or condition or stage thereof in an organism comprising the steps of:
a) releasing target polypeptides from a sample of said organism;
b) contacting said target polypeptides with one or more binding partners, wherein each binding partner is specific to a marker polypeptide (or a fragment thereof) encoded by the gene to which an oligonucleotide of Table 1 (or derived from a sequence described in Table 1) binds, to allow binding of said binding partners to said target polypeptides, wherein said marker polypeptides are specific for said disease or condition thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation; and
c) assessing the target polypeptide binding to said binding partners to produce a characteristic pattern reflecting the level of gene expression of genes which express said marker polypeptides in said sample; and
d) comparing said pattern to a standard diagnostic pattern prepared as described hereinbefore using a sample from an organism corresponding to the organism and sample under investigation to determine the degree of correlation indicative of the presence of said disease or condition or a stage thereof in the organism under investigation.
The methods of generating standard and test patterns and diagnostic techniques rely on the use of informative oligonucleotide probes to generate the gene expression data. In some cases it will be necessary to select these informative probes for a particular method, e.g. to diagnose a particular disease, from a selection of available probes, e.g. the probes described hereinbefore (the Table 1 oligonucleotides, the Table 1 derived oligonucleotides, their complementary sequences and functionally equivalent oligonucleotides). The following methodology describes a convenient method for identifying such informative probes, or more particularly how to select a suitable sub-set of probes from the probes described herein.
Probes for the analysis of a particular disease or condition or stage thereof, may be identified in a number of ways known in the prior art, including by differential expression or by library subtraction (see for example WO98/49342). As described hereinafter, in view of the high information content of most transcripts, as a starting point one may also simply analyse a random sub-set of mRNA or CDNA species and pick the most informative probes from that sub-set. The following method describes the use of immobilized oligonucleotide probes (e.g. the probes of the invention) to which mRNA (or related molecules) from different samples is bound to identify which probes are the most informative to identify a particular type of sample, e.g. a disease sample.
The immobilized probes can be derived from various unrelated or related organisms; the only requirement is that the immobilized probes should bind specifically to their homologous counterparts in test organisms. Probes can also be derived from commercially available or public databases and immobilized on solid supports or, as mentioned above, they can be randomly picked and isolated from a cDNA library and immobilized on a solid support.
The length of the probes immobilised on the solid support should be long enough to allow for specific binding to the target sequences. The immobilised probes can be in the form of DNA, RNA or their modified products or PNAs (peptide nucleic acids). Preferably, the probes immobilised should bind specifically to their homologous counterparts representing highly and moderately expressed genes in test organisms. Conveniently the probes which are used are the probes described herein.
The gene expression pattern of cells in biological samples can be generated using prior art techniques such as microarray or macroarray as described below or using methods described herein. Several technologies have now been developed for monitoring the expression level of a large number of genes simultaneously in biological samples, such as, high-density oligoarrays (Lockhart et al., 1996, Nat. Biotech., 14, p1675-1680), cDNA microarrays (Schena et al, 1995, Science, 270, p467-470) and CDNA macroarrays (Maier E et al., 1994, Nucl. Acids Res., 22, p3423-3424; Bernard et al., 1996, Nucl. Acids Res., 24, p1435-1442).
In high-density oligoarrays and cDNA microarrays, hundreds and thousands of probe oligonucleotides or cDNAs, are spotted onto glass slides or nylon membranes, or synthesized on biochips. The MRNA isolated from the test and reference samples are labelled by reverse transcription with a red or green fluorescent dye, mixed, and hybridised to the microarray. After washing, the bound fluorescent dyes are detected by a laser, producing two images, one. for each dye. The resulting ratio of the red and green spots on the two images provides the information about the changes in expression levels of genes in the test and reference samples. Alternatively, single channel or multiple channel microarray studies can also be performed.
In cDNA macroarray, different cDNAs are spotted on a solid support such as nylon membranes in excess in relation to the amount of test mRNA that can hybridise to each spot. mRNA isolated from test samples is radio-labelled by reverse transcription and hybridised to the immobilised probe cDNA. After washing, the signals associated with labels hybridising specifically to immobilised probe cDNA are detected and quantified. The data obtained in macroarray contains information about the relative levels of transcripts present in the test samples. Whilst macroarrays are only suitable to monitor the expression of a limited number of genes, microarrays can be used to monitor the expression of several thousand genes simultaneously and is, therefore, a preferred choice for large-scale gene expression studies.
A macroarray technique for generating the gene expression data set has been used to illustrate the probe identification method described herein. For this purpose, mRNA is isolated from samples of interest and used to prepare labelled target molecules, e.g. mRNA or CDNA as described above. The labelled target molecules are then hybridised to probes immobilised on the solid support. Various solid supports can be used for the purpose, as described previously. Following hybridization, unbound target molecules are removed and signals from target molecules hybridizing to immobilised probes quantified. If radio labelling is performed, PhosphoImager can be used to generate an image file that can be used to generate a raw data set. Depending on the nature of label chosen for labelling the target molecules, other instruments can also be used, for example, when fluorescence is used for labelling, a FluoroImager can be used to generate an image file from the hybridised target molecules.
The raw data corresponding to mean intensity, median intensity, or volume of the signals in each spot can be acquired from the image file using commercially available software for image analysis. However, the acquired data needs to be corrected for background signals and normalized prior to analysis, since, several factors can affect the quality and quantity of the hybridising signals. For example, variations in the quality and quantity of mRNA isolated from sample to sample, subtle variations in the efficiency of labelling target molecules during each reaction, and variations in the amount of unspecific binding between different macroarrays can all contribute to noise in the acquired data set that must be corrected for prior to analysis.
Background correction can be performed in several ways. The lowest pixel intensity within a spot can be used for background subtraction or the mean or median of the line of pixels around the spots' outline can be used for the purpose. One can also define an area representing the background intensity based on the signals generated from negative controls and use the average intensity of this area for background subtraction.
The background corrected data can then be transformed for stabilizing the variance in the data structure and normalized for the differences in probe intensity. Several transformation techniques have been described in the literature and a brief overview can be found in Cui, Kerr and Churchill http://www.jax.org/research/churchill/research/expression/Cui-Transform.pdf). Normalization can be performed by dividing the intensity of each spot with the collective intensity, average intensity or median intensity of all the spots in a macroarray or a group of spots in a macroarray in order to obtain the relative intensity of signals hybridising to immobilised probes in a macroarray. Several methods have been described for normalizing gene expression data (Richmond and Somerville, 2000, Current Opin. Plant Biol., 3, p108-116; Finkelstein et al., 2001, In “Methods of Microarray Data Analysis. Papers from CAMDA, Eds. Lin & Johnsom, Kluwer Academic, p57-68; Yang et al., 2001, In “Optical Technologies and Informatics”, Eds. Bittner, Chen, Dorsel & Dougherty, Proceedings of SPIE, 4266, p141-152; Dudoit et al, 2000, J. Am. Stat. Ass., 97, p77-87; Alter et al 2000, supra; Newton et al., 2001, J. Comp. Biol., 8, p37-52). Generally, a scaling factor or function is first calculated to correct the intensity effect and then used for normalising the intensities. The use of external controls has also been suggested for improved normalization.
One other major challenge encountered in large-scale gene expression analysis is that of standardization of data collected from experiments performed at different times. We have observed that gene expression data for samples acquired in the same experiment can be efficiently compared following background correction and normalization. However, the data from samples acquired in experiments performed at different times requires further standardization prior to analysis. This is because subtle differences in experimental parameters between different experiments, for example, differences in the quality and quantity of mRNA extracted at different times, differences in time used for target molecule labelling, hybridization time or exposure time, can affect the measured values. Also, factors such as the nature of the sequence of transcripts under investigation (their GC content) and their amount in relation to the each other determines how they are affected by subtle variations in the experimental processes. They determine, for example, how efficiently first strand cDNAs, corresponding to a particular transcript, are transcribed and labelled during first strand synthesis, or how efficiently the corresponding labelled target molecules bind to their complementary sequences during hybridization. Batch to batch difference in the printing process is also a major factor for variation in the generated expression data.
Failure to properly address and rectify for these influences leads to situations where the differences between the experimental series may overshadow the main information of interest contained in the gene expression data set, i.e. the differences within the combined data from the different experimental series. FIG. 1 provides one such example showing a classification based on Principal Component Analysis (PCA) of combined data from two experimental series where the main goal is to distinguish between Alzheimer/non-Alzheimer patients.
PCA (also known as singular value decomposition) is a technique for studying interdependencies and underlying relationships of a set of variables. The data are modelled in terms of a few significant factors or principal components (PC's), plus residuals. The PC's contain the main phenomena and define the systematic variability present in the data, while the residuals represent the variability interpreted as noise. Details on PCA can be found in Jollife (1986, Principal Component Analysis, Springer-Verlag, N.Y.), and Jackson (1991, A User's Guide to Principal Components, Wiley, N.Y.). The results of FIG. 1 show that two clusters are formed representing the data from two experimental series rather than the Alzheimer/non-Alzheimer differentiation. There were eight samples in common between the two series of experiments, which ideally should have fallen on top of, or in near proximity to, each other if appropriately standardized.
We have now found that gene expression data between different experiments can be efficiently standardized by including a subset of samples from one experimental series in the next experimental series and using a direct standardization method (DS), originally described by Wang and Kowalski (Anal. Chem., 1991, 63, p2750 and J. Chemometrics, 1991, 5, p129-145). Although the method of DS is well known in the field of analytical chemistry, it remains undescribed and unused in the field of gene expression data analysis.
In DS, the secondary data representing for example experimental series 2 (secondary measurements, R₂) are corrected to match the data measured on the primary measurements representing data from series 1 (R₁), while the calibration model remains unchanged. In DS, response matrices for both experimental series are related to each other by a transformation matrix F, i.e.
R₁=R₂F (1)
Where F is a square matrix dimensioned gene by gene. From (1), the transformation matrix is calculated as:
F=R₂ ⁺R₁ (2)
The transformation matrix F in equation (2) is calculated using a relatively small subset of samples which are measured on both the master primary and the secondary series of data.
Finally, the response of the unknown sample measured on the secondary series r^T _2,un, is standardized to the response vector {circumflex over (r)}^T _1,unexpected from the primary series
{circumflex over (r)}^T _1,un=rT_21,un{circumflex over (F)} (3)
From the preceding equation it can be seen that the column i of the transformation matrix contains the multiplication factors for a set of genes measured in the secondary series to obtain the intensity at spot i of the corrected series.
The number of samples that are repeated in the experimental series, R₁and R₂, should be equal to their ranks, which in this case is equal to the number of principal components retained for explaining the variation in the R₁and R₂. For example, if three principal components are retained for explaining the variation in the data set, a minimum of three samples should be repeated between R₁and R₂. The samples that should be repeated between different series should ideally be those that exhibit high leverages in the gene expression pattern. At times, two samples may suffice, while at other times, more than two samples should be ideally be included for good representativity. In some cases, the samples selected can be the same in all the experimental series to be compared (reference samples), while in other cases, representative samples can be selected sequentially by analyzing the expression pattern after each experiment. The selected samples with high leverages are then included in the next experimental series. The results of using Direct Standardization are shown in FIG. 1.
Another approach for normalizing and standardizing the gene expression data set is to hybridize each DNA array with target molecules prepared from a test sample and an equal amount of labelled target molecules. prepared from representative reference samples. In order to measure the intensity of labelled target molecules hybridizing to the immobilized probes it is necessary that the labelled molecules are prepared from test and reference samples using different labels, for example, different fluorescent dyes can be used for preparing the labelled material. The labelled molecules prepared from reference samples can be added to the hybridization solution together with the labelled material prepared from test samples. A data file from each array representing the expression pattern of different genes in the test sample and reference samples can then be obtained, normalized and standardized by the direct standardization method as described above. An instant advantage of including the differentially labelled target molecules from reference samples during hybridization is that it enables an efficient comparison of new test samples to the data sets already stored in a database.
Monitoring the expression of a large number of genes in several samples leads to the generation of a large amount of data that is too complex to be easily interpreted. Several unsupervised and supervised multivariate data analysis techniques have already been shown to be useful in extracting meaningful biological information from these large data sets. Cluster analysis is by far the most commonly used technique for gene expression analysis, and has been performed to identify genes that are regulated in a similar manner, and or identifying new/unknown tumour classes using gene expression profiles (Eisen et al., 1998, PNAS, 95, p14863-14868, Alizadeh et al. 2000, supra, Perou et al. 2000, Nature, 406, p747-752; Ross et al, 2000, Nature Genetics, 24(3), p227-235; Herwig et al., 1999, Genome Res., 9, p1093-1105; Tamayo et al, 1999, Science, PNAS, 96, p2907-2912).
In the clustering method, genes are grouped into functional categories (clusters) based on their expression profile, satisfying two-criteria: homogeneity—the genes in the same cluster are highly similar in expression to each other; and separation—genes in different clusters have low similarity in expression to each other.
Examples of various clustering techniques that have been used for gene expression analysis include hierarchical clustering (Eisen et al., 1998, supra; Alizadeh et al. 2000, supra; Perou et al. 2000, supra; Ross et al, 2000, supra), K-means clustering (Herwig et al., 1999, supra; Tavazoie et al, 1999, Nature Genetics, 22(3), p. 281-285), gene shaving (Hastie et al., 2000, Genome Biology, 1(2), research 0003.1-0003.21), block clustering (Tibshirani et al., 1999, Tech repot Univ Stanford.) Plaid model (Lazzeroni, 2002, Stat. Sinica, 12, p61-86), and self-organizing maps (Tamayo et al. 1999, supra). Also, related methods of multivariate statistical analysis, such as those using the singular value decomposition (Alter et al., 2000, PNAS, 97(18), p10101-10106; Ross et al. 2000, supra) or multidimensional scaling can be effective at reducing the dimensions of the objects under study.
However, methods such as cluster analysis and singular value decomposition are purely exploratory and only provide a broad overview of the internal structure present in the data. They are unsupervised approaches in which the available information concerning the nature of the class under investigation is not used in the analysis. Often, the nature of the biological perturbation to which a particular sample has been subjected is known. For example, it is sometimes known whether the sample whose gene expression pattern is being analysed derives from a diseased or healthy individual. In such instances, discriminant analysis can be used for classifying samples into various groups based on their gene expression data.
In such an analysis one builds the classifier by training the data that is capable of discriminating between member and non-members of a given class. The trained classifier can then be used to predict the class of unknown samples. Examples of discrimination methods that have been described in the literature include Support Vector Machines (Brown et al, 2000, PNAS, 97, p262-267), Nearest Neighbour (Dudoit et al., 2000, supra), Classification trees (Dudoit et al., 2000, supra), Voted classification (Dudoit et al., 2000, supra), Weighted Gene voting (Golub et al. 1999, supra), and Bayesian classification (Keller et al. 2000, Tec report Univ of Washington). Also a technique in which PLS (Partial Least Square) regression analysis is first used to reduce the dimensions in the gene expression data set followed by classification using logistic discriminant analysis and quadratic discriminant analysis (LD and QDA) has recently been described (Nguyen & Rocke, 2002, Bioinformatics, 18, p39-50 and 1216-1226).
A challenge that gene expression data poses to classical discriminatory methods is that the number of genes whose expression are being analysed is very large compared to the number of samples being analysed. However in most cases only a small fraction of these genes are informative in discriminant analysis problems. Moreover, there is a danger that the noise from irrelevant genes can mask or distort the information from the informative genes. Several methods have been suggested in literature to identify and select genes that are informative in microarray studies, for example, t-statistics (Dudoit et al, 2002, J. Am. Stat. Ass., 97, p77-87), analysis of variance (Kerr et al., 2000, PNAS, 98, p8961-8965), Neighbourhood analysis (Golub et al, 1999, supra), Ratio of between groups to within groups sum of squares (Dudoit et al., 2002, supra), Non parametric scoring (Park et al., 2002, Pacific Symposium on Biocomputing, p52-63) and Likelihood selection (Keller-et al., 2000, supra).
In the methods described herein the gene expression data that has been normalized and standardized is analysed by using Partial Least Squares Regression (PLSR). Although PLSR is primarily a method used for regression analysis of continuous data (see Appendix A), it can also be utilized as a method for model building and discriminant analysis using a dummy response matrix based on a binary coding. The class assignment is based on a simple dichotomous distinction such as breast cancer (class 1)/healthy (class 2), or a multiple distinction based on multiple disease diagnosis such as breast cancer (class 1)/Alzheimer (class 2)/healthy (class 3). The list of diseases for classification can be increased depending upon the samples available corresponding to other diseases or conditions or stages thereof.
PLSR applied as a classification method is referred to as PLS-DA (DA standing for Discriminant analysis). PLS-DA is an extension of the PLSR algorithm in which the Y-matrix is a dummy matrix containing n rows *(corresponding to the number of samples) and K columns (corresponding to the number of classes). The Y-matrix is constructed by inserting 1 in the kth column and −1 in all the other columns if the corresponding ith object of X belongs to class k. By regressing Y onto X, classification of a new sample is achieved by selecting the group corresponding to the largest component of the fitted, ŷ(x)=(ŷ₁(x), ŷ₂(x), . . . , ŷ_k(x)). Thus, in a −1/1 response matrix, a prediction value below 0 means that the sample belongs to the class designated as −1, while a prediction value above 0 implies that the sample belongs to the class designated as 1.
An advantage of PLSR-DA is that the results obtained can be easily represented in the form of two different plots, the score and loading plots. Score plots represent a projection of the samples onto the principal components and shows the distribution of the samples in the classification model and their relationship to one another. Loading plots display correlations between the variables present in the data set.
It is usually recommended to use PLS-DA as a starting point for the classification problem due to its ability to handle collinear data, and the property of PLSR as a dimension reduction technique. Once this purpose has been satisfied, it is possible to use other methods such as Linear discriminant analysis, LDA, that has been shown to be effective in extracting further information, Indahl et al. (1999, Chem. and Intell. Lab. Syst., 49, p19-31). This approach is based on first decomposing the data using PLS-DA, and then using the scores vectors (instead of the original variables) as input to LDA. Further details on LDA can be found in Duda and Hart (Classification and Scene Analysis, 1973, Wiley, USA).
The next step following model building is of model validation. This step is considered to be amongst the most important aspects of multivariate analysis, and tests the “goodness” of the calibration model which has been built. In this work, a cross validation approach has been used for validation. In this approach, one or a few samples are kept out in each segment while the model is built using a full cross-validation on the basis of the remaining data. The samples left out are then used for prediction/classification. Repeating.the simple cross-validation process several times holding different samples out for each cross-validation leads to a so-called double cross-validation procedure. This approach has been shown to work well with a limited amount of data, as is the case in some of the Examples described here. Also, since the cross validation step is repeated several times the dangers of model bias and overfitting are reduced.
Once a calibration model has been built and validated, genes exhibiting an expression pattern that is most relevant for describing the desired information in the model can be selected by techniques described in the prior art for variable selection, as mentioned elsewhere. Variable selection will help in reducing the final model complexity, provide a parsimonious model, and thus lead to a reliable model that can be used for prediction. Moreover, use of fewer genes for the purpose of providing diagnosis will reduce the cost of the diagnostic product. In this way informative probes which would bind to the genes of relevance may be identified.
We have found that after a calibration model has been built, statistical techniques like Jackknife (Effron, 1982, The Jackknife, the Bootstrap and other resampling plans. Society for Industrial and Applied mathematics, Philadelphia, USA), based on resampling methodology, can be efficiently used to select or confirm significant variables (informative probes).
The approximate uncertainty variance of the PLS regression coefficients B can be estimated by: $S^{2} B = \sum_{m = 1}^{M} {((B - B_{m}) g)}^{2}$
where

S²B=estimated uncertainty variance of B;
B=the regression coefficient at the cross validated rank A using all the N objects;
B_m=the regression coefficient at the rank A using all objects except the object(s) left out in cross validation segment m; and
g=scaling coefficient (here: g=1).

In our approach, Jackknife has been implemented together with cross-validation. For each variable the difference between the B-coefficients B_iin a cross-validated sub-model and B_totfor the total model is first calculated. The sum of the squares of the differences is then calculated in all sub-models to obtain an expression of the variance of the B_iestimate for a variable. The significance of the estimate of B_iis calculated using the t-test. Thus, the resulting regression coefficients can be presented with uncertainty limits that correspond to 2 Standard Deviations, and from that significant variables are detected.
No further details as to the implementation or use of this step are provided here since this has been implemented in commercially available software, The Unscrambler, CAMO ASA, Norway. Also, details on variable selection using Jackknife can be found in Westad & Martens (2000, J. Near Inf. Spectr., 8, p117-124).
The following approach can be used to select informative probes from a gene expression data set:
a) keep out one unique sample (including its repetitions if present in the data set) per cross validation segment;
b) build a calibration model (cross validated segment) on the remaining samples using PLSR-DA;
c) select the significant genes for the model in step b) using the Jackknife criterion;
d) repeat the above 3 steps until all the unique samples in the, data set are kept out once (as described in step a). For example, if 75 unique samples are present in the data set, 75 different calibration models are built resulting in a collection of 75 different sets of significant probes;
e) select the most significant variables using the frequency of occurrence criterion in the generated sets of significant probes in step d). For example, a set of probes appearing in all sets (100%) are more informative than probes appearing in only 50% of the generated sets in step d).
Once the informative probes for a disease have been selected, a final model is made and validated. The two most commonly used ways of validating the model are cross-validation (CV) and test set validation. In cross-validation, the data is divided into k subsets. The model is then trained k times, each time leaving out one of the subsets from training, but using only the omitted subset to compute error criterion, RMSEP (Root Mean Square Error of Prediction). If k equals the sample size, this is called “leave-one-out” cross-validation. The idea of leaving one or a few samples out per validation segment is valid only in cases where the covariance between the various experiments is zero. Thus, one sample at-a-time approach can not be justified in situations containing replicates since keeping only one of the replicates out will introduce a systematic bias in our analysis. The correct approach in this case will be to leave out all replicates of the same samples at a time since that would satisfy assumptions of zero covariance between the CV-segments.
The second approach for model validation is to use a separate test-set for validating the calibration model. This requires running a separate set of experiments to be used as a test set. This is the preferred approach given that real test data are available.
The final model is then used to identify a disease, condition or stage thereof in test samples. For this purpose, expression data of selected informative genes is generated from test samples and then the final model is used to determine whether a sample belongs to a diseased or non-diseased class or has a condition or stage thereof.
Thus viewed from a yet further aspect the present invention provides a method of identifying probes useful for diagnosing or identifying or monitoring a disease or condition or stage thereof in an organism, comprising the steps of:

- a) immobilizing a set of oligonucleotide probes, preferably as described hereinbefore, on a solid support;
- b) isolating mRNA from a sample of a normal organism (normal sample), which may optionally be reverse transcribed to CDNA;
- c) isolating mRNA from a sample from an organism, corresponding to the sample and organism of step (b), which is known to have said disease or condition or a stage thereof (diseased sample), which may optionally be reverse transcribed to cDNA;
- d) hybridizing the mRNA or cDNA of steps (b) and (c) to said set of immobilized oligonucleotide probes of step (a); and
- e) assessing the amount of mRNA or cDNA hybridizing to each of said oligonucleotide probes to determine the level of gene expression of genes to which said oligonucleotide probes bind in said normal and diseased samples to generate a gene expression data set for each sample;
- f) normalizing and standardizing said data set of step (e);
- g) constructing a calibration model for classification, preferably using the statistical techniques Partial Least Squares Discriminant Analysis (PLS-DA) and Linear Discriminant Analysis (LDA);
- h) performing JackKnife analysis and identifying those oligonucleotide probes which are required for classification of said disease and normal samples into their respective groups.

Preferably a model for classification purposes is generated by using the data relating to the probes identified according to the above described method. Preferably the sample is as described previously. Preferably the oligonucleotides which are immobilized in step (a) are randomly selected as described below or are the probes as described hereinbefore. Such oligonucleotides may be of considerable length, e.g. if using CDNA (which is encompassed within the scope of the term “oligonucleotide”). The identification of such CDNA molecules as useful probes allows the development of shorter oligonucleotides which reflect the specificity of the cDNA molecules but are easier to manufacture and manipulate.
The above described model may then be used to generate and analyse data of test samples and thus may be used for the diagnostic methods of the invention. In such methods the data generated from the test sample provides the gene expression data set and this is normalized and standardized as described above. This is then fitted to the calibration model described above to provide classification.
The method described herein can also be used to simultaneously select informative probes for several related and unrelated diseases or conditions. Depending upon which diseases or conditions have been included in the calibration or training set, informative probes can be selected for the said diseases or conditions. The informative probes selected for one disease or condition may or may not be similar to the informative probes selected for another disease or condition of interest. It is the pattern with which the selected genes are expressed in relation to each other during a disease, condition, or stage thereof, that determines whether or not they are informative for the disease, condition or stage thereof.
In other words, informative genes are selected based on how their expression correlates with the expression of other selected informative genes under the influence of responses generated by the disease, condition or stage thereof under investigation. In examples 1 and 2 provided hereinafter, 139 informative probes were selected for breast cancer diagnosis and 182 probes were selected for Alzheimer's disease diagnosis by training the gene expression data set of genes representing 1435 or 758 randomly picked cDNA clones for breast cancer/non breast cancer samples, or Alzheimer/non-Alzheimer samples, respectively. Among the probes selected for breast cancer and Alzheimer, about 10 probes were informative both for breast cancer and Alzheimer disease diagnosis.
For the purpose of isolating informative probes or identifying several related and unrelated diseases, conditions and stages thereof simultaneously, the gene expression data set must contain the information on how genes are expressed when the subject has a particular disease, condition or stage thereof under investigation. The data set is generated from a set of healthy or diseased samples, where a particular sample may contain the information of only one disease, condition or stages thereof or may also contain information about multiple diseases, conditions or stages thereof. For example, if the isolation of informative probes for Alzheimer disease, breast cancer and diabetes is sought, whole blood samples can be obtained from an Alzheimer patient who has breast cancer and diabetes. Hence, the method also teaches an efficient experimental design to reduce the number of samples required for isolating informative probes by selecting samples representing more than one disease, condition or stage thereof.
As mentioned previously, in view of the high information content of most transcripts, the identification and selection of informative probes for use in diagnosing, monitoring or identifying a particular disease, condition or stage thereof may be dramatically simplified. Thus the pool of genes from which a selection may be made to identify informative probes may be radically reduced.
Unlike, in prior art technologies where informative probes are selected from a population of thousands of genes that are being expressed in a cell, like in microarray, in the method described herein, the informative probes are selected from a limited number of randomly obtained genes. For example, from a population of 1435 cDNA clones, randomly picked from a human whole blood cDNA library, we were able to select 139 informative probes for breast cancer diagnosis (see Example 1 and Table 2).
Thus in a preferred aspect of the above mentioned method of identifying probes useful for diagnosing or identifying or monitoring a disease or condition or stage thereof in an organism, said set of oligonucleotides which are immobilized in step (a) are randomly selected from a larger set of oligonucleotides, e.g. from a cDNA library or other oligonucleotide pool, which may be, but is preferably not selected from the set provided herein. Preferably said larger set comprises oligonucleotides which correspond to moderately or highly expressed genes. Thus preferably in methods of the invention, the set of oligonucleotides according to the invention are replaced with a set of oligonucleotides which are randomly selected, e.g. from commercially available oligonucleotide or cDNA libraries.
As referred to herein “random” refers to selection which is not biased based on the extent of information carried by the transcripts in relation to the disease, condition or organism under study, ie. without bias towards their likely utility as informative probes. Whilst a random selection may be made from a pool of transcripts (or related products) which have been biased, e.g. to highly or moderately expressed transcripts, preferably random selection is made from a pool of transcripts not biased or selected by a sequence-based criterion. The larger set may therefore contain oligonucleotides corresponding to highly and moderately expressed genes, or alternatively, may be enriched for those corresponding to the highly and moderately expressed genes.
Random selection from highly and moderately expressed genes can be achieved in a wide variety of ways. A strategy used in this work, but not limiting in itself involves randomly picking a significant number of CDNA clones from a cDNA library constructed from a biological specimen under investigation. Since, in a cDNA library, the cDNA clones corresponding to transcripts present in high or moderate amount are more frequently present than transcripts corresponding to CDNA present in low amount, the former will tend to be picked up more frequently than the latter. A pool of cDNA enriched for those corresponding to highly and moderately expressed genes can be isolated by this approach.
To identify genes that are expressed in high or moderate amount among the isolated population for use in methods of the invention, the information about the relative level of their transcripts in samples of interest can be generated using several prior art techniques. Both non-sequence based methods, such as differential display or RNA fingerprinting, and sequence-based methods such as microarrays or macroarrays can be used for the purpose. Alternatively, specific primer sequences for highly and moderately expressed genes can be designed and methods such as quantitative RT-PCR can be used to determine the levels of highly and moderately expressed genes. Hence, a skilled practitioner may use a variety of techniques which are known in the art for determining the relative level of MRNA in a biological sample.
Especially preferably the sample for the isolation of MRNA in the above described method is as described previously and is preferably not from the site of disease and the cells in said sample are not disease cells and have not contacted disease cells.
The following examples are given by way of illustration only in-which the Figures referred to are as follows:
FIG. 1 shows the effect of Direct Standardization (DS) on the Alzheimer data measured in two different series of experiments in which AD denotes Alzheimer's samples and A,B are non-Alzheimer's samples. The samples in both series have been labelled systematically as (xx _—7/xx_—8), whereas the corrected samples from series 8 (in b, c, d) have been labelled as (xx_c), thus, for example, AD2-7 denotes Alzheimer disease sample number 2 in experiment series 7. The circled spots represent the samples chosen as the transfer samples. The connecting lines in figures b,c,d show the proximity of the replicated samples after applying DS. The dashed lines in figures a,c,d represent the decision boundary separating the classes. These lines have not been drawn on the basis of any statistical criteria, but serve the purpose of visually separating the classes. All the four figures show scores plot (PC1-PC2) from PCA analysis based on (a) non-standardized data, (b) scores plot after direct standardization using 3 transfer samples, (c) scores plot after direct standardization using 4 transfer sample, (d) scores plot after direct standardization using 8 transfer samples;
FIG. 2 shows the projection of normal (including benign) and breast cancer samples onto a classification model generated by PLSR-DA using the data of 44 informative genes, in which PC is the principal components and N and C are normal and breast cancer samples, respectively;
FIG. 3 shows the projection of individuals with and without Alzheimer's disease onto a classification model generated by PLSR-DA using 182 informative genes;
FIGS. 4, 6 and 8 show projection plots as FIG. 2 in which the classification model is generated using 719, 111 and 345 cDNAs, respectively, wherein PC is the principal components, N denotes normal and B denotes breast cancer samples;
FIGS. 5, 7 and 9 show prediction plots based on 3 principal components using the data of 719, 111 and 345 cDNAs, respectively;
FIG. 10 shows a projection plot as FIG. 3 in which the classification model is generated using 520 cDNAs; and
FIG. 11 is the prediction plot corresponding to FIG. 10.

EXAMPLE 1

Diagnosis of Breast Cancer

Methods
Whole blood was obtained from the arms of breast cancer patients and patients with benign tumours (Ullevål and Haukland hospitals in Norway). All of the patients with breast cancer had a malignant tumour of the breast (disease samples). Healthy blood was collected from the above two hospitals, or collected at a Health station at Ås, Norway or at DiaGenic AS, Norway, from the arms of female donors with no reported signs of breast cancer. The blood from healthy individuals or with benign tumours comprise the normal samples. The blood was either collected in tubes containing EDTA and stored immediately at −80° C. or was collected in PAXgene tubes and stored for 12-24 hours at room temperature before finally storing them at −80° C. before use. Further details of the breast cancer and benign tumour patients from which blood was taken is provided in Table 5. mRNA was isolated from the blood of the 29 breast cancer patients and 46 normal donors and used to prepare labelled probes by reverse transcribing in the presence of α³³P-dATP. The first strand cDNA of the normal and diseased samples was bound, separately to 1435 cDNA clones immobilized on a solid support (nylon membrane). These cDNA clones were randomly picked, without any prior knowledge of their gene sequences, from a cDNA library constructed using whole blood of 550 healthy individuals (Clontech, Palo Alto, USA). These methods were conducted as follows.
For amplification of inserts, bacterial clones were grown in microtiter plates containing 150 μl LB with 50 μg/ml carbenicillin, and incubated overnight with agitation at 37° C. To lyse the cells, 5 μl of each culture were diluted with 50 μl H2O and incubated for 12 min. at 95° C. Of this mixture, 2 μl were subjected to a PCR reaction using 20 pmoles of M13 forward and reverse primer in presence of 1.5 mM MgCl₂. PCR reactions were performed with the following cycling protocol: 4 min. at 95° C., followed by 25 cycles of 1 min. at 94° C., 1 min. at 60° C. and 3 min. at 72° C. either in a RoboCyclere® Temperature Cycler (Stratagene, La Jolla, USA) or DNA Engine Dyad Peltier Thermal Cycler (MJ Research Inc., Waltham, USA). The amplified products were denatured by incubating with NaOH (0.2 M, final concentration) for 30 min. and spotted onto Hybond-N+ membranes (Amersham Pharmacia Biotech, Little Chalfont, UK), using MicroGrid II workstation according to the manufacturer's instructions (BioRobotics Ltd, Cambridge England). The immobilized cDNAs were fixed using a UV cross-linker (Hoefer Scientific Instruments, San Francisco, USA).
In addition to the 1435 cDNAs, the printed arrays also contained controls for assessing background level, consistency and sensitivity of the assay. These were spotted at multiple positions and included controls such as PCR mix (without any insert); positive and negative controls of SpotReport™ 10 array validation system (Stratagene, La Jolla, USA) and cDNAs corresponding to constitutively expressed genes such as b-actin, g-actin, GAPDH, HOD and cyclophilin. Also, oligonucleotides corresponding to SIX1, b-tubulin, TRP-2, MDM2, Myosin Light C, CD44, Maspin, Laminin, and SRP 19 were included to detect disseminated cancer cells.
The total RNA from blood collected in EDTA tubes was purified using Trizol LS Reagent protocol (Invitrogen/Life Technologies). From blood contained in PAXgene tubes, the total RNA was purified according to the supplier's instructions (PreAnalytix, Hombrechtikon, Switzerland). Contaminating DNA was removed from the isolated RNA by DNAase I treatment using DNA-free kit (Ambion, Inc. Austin, USA). RNA quality was determined visually by inspecting the integrity of 28S and 18S ribosomal bands following agarose gel electrophoresis. The concentration and purity of extracted RNA was determined by measuring the absorbance at 260 nm and 280 nm. mRNA was isolated from the total RNA using Dynabeads as per the supplier's instructions (Dynal AS, Oslo, Norway).
Labelling and hybridization experiments were performed in batches. The number of samples assayed in each batch varied from six to nine. In the case of samples that were assayed more than once (replicates), aliquots derived from the same mRNA pool were used for probe synthesis. For probe synthesis, aliquots of MRNA corresponding to 4-5 μg of total RNA were mixed together with oligodT_25NV(0.5 μg/ml) and mRNA spikes of SpotReport™10 array validation system (10 pg; Spike 2, 1 pg), heated to 70° C. to remove secondary structures, and then chilled on ice. Probes were prepared in 35 μl reaction mixes by reverse transcription in the presence of 50 μCi [(α³³p] DATP, 3.5 μM DATP, 0.6 mM each of dCTP, dTTP, dGTP, 200 units of SuperScript reverse transcriptase (Invitrogen, LifeTechnologies) and 0.1 M DTT, labelling for 1.5 hr at 42° C. Following synthesis, the enzyme was deactivated for 10 min. at 70° C. and mRNA removed by incubating the reaction mix for 20 min. at 37° C. in 4 units of Ribo H (Promega, Madison USA). Unincorporated nucleotides were removed using ProbeQuant G 50 Columns (Amersham Biosciences, Piscataway, USA).
Prior to hybridization, the membranes were equilibrated in 4×SSC for 2 hr at room temperature and prehybridized overnight at 65° C. in 10 ml prehybridisation solution (4×SSC, 0.1 M NaH₂PO₄, 1 mM EDTA, 8% dextran sulphate, 10× denhardt's solution, 1% SDS). Freshly prepared probes were added to 5 ml of the same prehybridisation solution, and hybridization continued overnight at 65° C. The membranes were washed at 65° C. at increasing stringency (2×30 min. each in 2×SSC, 0.1% SDS; 1×SSC, 0.1% SDS; 0.1×SSC, 0.1% SDS) to remove unspecific signals.
The amount of labelled first strand cDNA binding to each spot was assessed and quantified using a Phospholmager to generate a gene expression data set. The data was generated using Phoretix software version 3 (Non Linear Dynamics, England). Background subtraction was performed on the generated data by subtracting the median of the line of pixels around each spot outline from the total intensity obtained from the respective spots.
The background-subtracted data was then normalized and transformed by selecting out 50 lowest and 50 maximum signals from each membrane. This step was to exclude genes that were expressed with a high degree of variance. Since the genes varied from membrane to membrane, the expression data from 497 genes were removed from the data set. The values for the remaining 938 genes were then normalised by using different approaches such as external controls, dividing each spot by the median intensity of the observed signal in the respective membrane, range normalizing the data from each membrane, and then log transforming the data obtained.
The processed data obtained above was then used to isolate the informative probes by:
a) keeping one unique sample (including all repetitions of the selected sample) out per cross validation segment;
b) building a calibration model (cross validated) on the remaining samples using PLSR-DA;
c) selecting the set of significant genes for the model in step b using the Jackknife criterion;
d) repeating steps a), b) and a) until all the unique samples were kept out once (hence, in all 75 different calibration models were built (after repeating step b) 75 times), resulting in 75 different sets of significant probes (after repeating step c) 75 times));
e) selecting significant variables using the frequency of occurrence criterion amongst the 75 different sets of significant probes.
The selected informative probes based on occurrence criterion were used to construct a classification model. The result of the classification model based on probes appearing in at least 90% of the generated sets after the step of isolating informative probes as described above is shown in FIG. 2 in which it is seen that the expression pattern of these genes was able to classify most women with breast cancer and women with no breast cancer into distinct groups. In this figure PC1 and PC2 indicate the two principal components statistically derived from the data which best define the systemic variability present in the data. This allows each sample, and the data from each of the informative probes to which the sample's labelled first strand cDNA was bound, to be represented on the classification model as a single point which is a projection of the sample onto the principal components—the score plot.
The ability of the generated model, based on isolated informative probes, to predict future samples was determined by the double cross-validation approach. The performance of the diagnostic test for breast cancer based on the occurrence criterion is presented in Table 6.
Correct prediction of most breast cancer cells was achieved. These included all three samples obtained from women with ductal carcinoma in situ (DCIS), 11/15 samples obtained from women with stage I breast cancer, all five samples obtained from women with stage II breast cancer, and one of two samples obtained from women with stage III breast cancer. Interestingly, two correctly predicted stage I samples were obtained from women having a tumour size of <5 mm in diameter.
The model also correctly predicted the class of most non-cancer samples (41/46), including those that were obtained from women with non-cancerous breast abnormalities.
Confirmation that the gene transcripts are not from cells which are disseminated disease cells has been confirmed by several lines of evidences. Firstly, the informative genes were expressed constitutively at high or moderate levels in blood cells of women irrespective of whether they had cancer or not. Secondly, in the assay described in this Example, in order to identify transcripts, at least 720 disseminated cells in blood samples would be required. Since, the average number of disseminated cells present in blood during different stages of breast cancer is much lower (organ confined breast cancer, 0.8 cells per ml; invasive breast cancer spread to lymph nodes only, 2.4 cells per ml; and metastatic breast cancer, 6 cells per ml; SD>100%) (29), we believe that the signals being detected originated from peripheral blood cells and could not have originated from disseminated cells. Thirdly, we were not able to detect any signal from the eight cancer markers known to have elevated expression in malignant cancer cells, including cancer cells that are disseminated in the blood.

EXAMPLE 2

Diagnosis of Alzheimer's Disease

Similar experiments were conducted with samples from Alzheimer's patients. In this method 7 patients diagnosed with Alzheimer's Disease at the Memory Clinic at Ullevål University Hospital were used in the trial. The patients were confirmed as having Alzheimer's disease based on the following criteria:

A standardized interview with a care-giver using IQCODE, an ADL scale and a scale measuring behaviour of the patient (Green scale).
Neuropsychological evaluation using MMSE, Clock drawing test, Trailmaking test A and B (TMT A and B), Kendrick object learning test (visual memory test), part of the Wechsler battery and Benton test.
A psychiatric evaluation using scales for detection of depression, MADRS for interviewing the patient and Cornell scale for interviewing the care-giver.
A physical examination.
Laboratory tests of blood samples to rule out other diseases.
CT scan of the brain.
SPECT of the brain.

The mean age of the patients was 72.3 with an age range of 69-76. The mean MMSE score was 22.0 (the maximum score attainable being 30).
Six age-matched individuals without diagnosed Alzheimer's disease were used as a control. All had been tested with MMSE and had a minimum score of 28 (mean: 28.4). The mean age of the normal control group was 73.0 and the age range 66-81. A sample from a 16-year old individual, with a consequent minimal chance of having Alzheimer's disease, was also included as an additional control.
Using the methods described above (except that hybridization to 758 rather than 1435 cDNA clones was performed), informative probes were selected based on occurrence criterion and used to construct a classification model. The results of the classification model based on probes appearing at least once in the generated sets after the method to isolate informative probes as described above is shown in FIG. 3 in which it will be seen that the expression pattern of these genes was able to classify individuals with or without Alzheimer's disease into distinct groups. In this Figure PC1 and PC2 indicate the 2 principal components statistically derived from the data which define the systematic variability present in the data. This allows each sample, and the data from each of the informative probes to which the samples' cDNA was bound, to be represented on the classification model as a single point which is a projection of the sample onto the principal components—the score plot.
The ability of the generated model, based on isolated informative probes, to predict future samples was determined by the double cross-validation. The performance of the diagnostic test for Alzheimer's disease is presented in Table 7.
Appendix A
Partial Least Squares regression (PLSR)
Let a multivariate regression model be defined as:
Y=XB+F
where

X a N×P matrix with N predictor variables (genes);
Y (N×J) being the 3 predicted variables. In our case Y represents a matrix containing dummy variables;
B is a matrix of regression coefficients; and
F is a N×J matrix of residuals.

The structure of the PLSR model can be written as:
X=TP ^T +E _A, and
Y=TQ ^T +F _A, where
where

T (N×A) is a matrix of score vectors which are linear combinations of the x-variables;
P (P×A) is a matrix with the x-loading vectors p_aas columns;
Q (J×A) is a matrix with the y-loading vectors q_aas columns;
E_a(N×P) is the matrix for X after A factors; and
F_a(N×T) is the matrix for Y after A factors.

The criterion in PLSR is to maximize the explained covariance of [X, Y]. This is achieved by the loading weights vector w_a+1, which is the first eigenvector of E_a ^TF_aF_a ^TE_a(E_aand F_aare the deflated X and Y after a factors or PLS components).
The regression coefficients are given by:
B=W(P ^T W)⁻¹ Q ^T
A PLSR model with full rank, i.e. maximum number of components, is equivalent to the MLR solutions. Further details on PLSR can be found in Marteus & Naes, 1989, Multivariate Calibration, John Wiley & Sons, Inc., USA and Kowalski & Seasholtz, 1991, supra.

EXAMPLE 3

Validation of Example 1, Diagnosis of Breast Cancer

The results in Example 1 were validated by using the informative probes identified in Example 1 on new beast cancer and control samples.
Methods
The methods, essentially as described in Example 1, were used. Blood was taken from patients as described in Table 8. However, blood was collected in PAXgene tubes and the first strand labelled cDNAs were hybridized to 719 cDNAs spotted on nylon-membranes along with other controls as described in Example 1. After background subtraction using control spots, the data of each membrane was normalized using the inter quantile range. The data was analysed as described in Example 1 and the model validated by cross validation.
The 719 cDNAs which were spotted are a subset of the cDNAs spotted in Example 1 and include 111 cDNAs described in Table 2 and which were found to be informative in Example 1.
Results
The results are shown in FIGS. 4 to 9. FIGS. 4, 6 and 8 are projection plots similar to FIG. 2 and show the projection of normal and breast cancer patients' samples onto a classification model generated using all 719 cDNA. FIG. 6 is similar but uses a classification model generated with the 111 probes common to Example 1. FIG. 8 uses the 345 sequences of the 719 for which sequence information is provided herein. In each case classification of normal and breast cancer groups was possible. FIGS. 5, 7 and 9 show prediction plots which reflect the ability of the generated models to correctly diagnose breast cancer. In the 3 prediction plots shown, the disease samples appear on the x axis at +1 and the non-disease samples appear at −1. The y axis represents the predicted class membership. During prediction, if the prediction is correct, disease samples should fall above zero and non-disease samples should fall below zero. In each case almost all samples are correctly predicted.

EXAMPLE 4

Validation of Example 2, Diagnosis of Alzheimers

The results in Example 2 were validated by using the informative probes identified in Example 2 on new Alzheimer's patient samples.
Methods
The methods, essentially as described in Example 2, were used. Twelve female patients diagnosed with Alzheimer's disease at the Memory Clinic at Ullevål University Hospital who were confirmed as having Alzheimer's disease based on the criteria of Example 2 were used in the trial. The mean age of the patients was 72.3 with an age range of 66-83. The mean MMSE score was 22.0 (the maximum score attainable being 30).
Sixteen age-matched female individuals without diagnosed Alzheimer's disease were used as the normal control group. All had been tested with MMSE and had a minimum score of 29. The mean age of the normal control group was 74.0 and the age range 66-86.
After transfer of the blood to PAXgene tubes, total mRNA was isolated from the blood of the Alzheimer's disease and from the control group donors according to the manufacturers's instructions (PreAnalytiX, Hombrechtikon, Switzerland). The isolated mRNA was labelled during reverse transcription in the presence of α³³P-dATP, yielding a labelled first strand CDNA. Hybridization was performed as described previously onto 730 CDNA clones picked from a cDNA library from whole blood of 550 healthy individuals without knowledge of the gene sequence of the random CDNA clones.
Results

The results are shown in FIGS. 10 and 11. FIG. 10 is a projection plot generated using 520 probes which have been sequenced. FIG. 11 is a prediction plot and shows correct prediction of almost all samples.

TABLE 1a


List of probes informative for disease diagnosis

	Sequence	No. of
Clone ID	ID	nucleotides

1	I-01	—	—
2	I-02	—	—
3	I-13	—	—
4	I-21	—	—
5	I-24	308	373
6	I-28	310	564
7	I-30	1180	622
8	I-34	313	554
9	I-37	—	—
10	I-42	—	—
11	I-52	—	—
12	I-54	1181	155
13	I-58	326	654
14	I-71	—	—
15	I-72	—	—
16	I-86	—	—
17	I-95	—	—
18	II-03	361	622
19	II-05	363	628
20	II-06	364	528
21	II-10	368	329
22	II-24	381	534
23	II-25	382	444
24	II-26	383	566
26	II-33	390	523
26	II-34	391	566
27	II-41	397	534
28	II-42	398	612
29	II-47	—	—
30	II-57	411	505
31	II-61	415	596
32	II-69	423	387
33	II-70	424	420
34	II-75	429	535
35	II-83	—	—
36	II-84	438	577
37	II-87	441	552
38	II-88	442	606
39	II-90	—	—
40	II-94	448	329
41	III-02	453	747
42	III-05	—	—
43	III-06	458	682
44	III-08	460	536
45	III-10	—	—
46	III-13	464	615
47	III-15	—	—
48	III-17	—	—
49	III-20	1183	479
50	III-23	473	694
51	III-26	476	476
52	III-35	485	551
53	III-39	487	224
54	III-40	488	349
55	III-43	490	382
56	III-44	491	382
57	III-53	500	390
58	III-56	503	109
59	III-57	504	374
60	III-60	—	—
61	III-60	—	—
62	III-61	507	521
63	III-63	509	575
64	III-68	—	—
65	III-74	518	502
66	III-80	523	585
67	III-82	—	—
88	III-85	526	516
69	III-89	530	660
70	III-92	—	—
71	III-96	—	—
72	IV-14	684	545
73	IV-15	1185	628
74	IV-23	—	—
76	IV-26	1186	494
75	IV-26	—	—
77	IV-29	—	—
78	IV-31	687	268
79	IV-32	688	569
80	IV-34	—	—
81	IV-35	—	—
82	IV-41	—	—
88	IV-45	—	—
84	IV-53	61	362
85	IV-62	—	—
86	IV-69	192	286
87	IV-80	701	579
88	IV-82	—	—
89	IV-93	—	—
90	IX-10	736	641
91	IX-12	—	—
92	IX-38	757	583
93	IX-39	758	424
94	IX-42	—	—
95	IX-48	764	626
96	IX-77	785	556
97	V-01	—	—
98	V-02	—	—
99	V-03	706	496
100	V-04	707	397
101	V-06	—	—
102	V-07	708	293
103	V-11	1188	599
104	V-12	711	498
105	V-15	—	—
106	V-17	—	—
107	V-21	—	—
108	V-25	—	—
109	V-32	—	—
110	V-35	—	—
111	V-39	—	—
112	V-42	—	—
113	V-43	—	—
114	V-47	—	—
115	V-49	—	—
116	V-52	—	—
117	V-54	—	—
118	V-55	77	412
119	V-58	—	—
120	V-59	—	—
121	V-65	—	—
122	V-68	—	—
123	V-71	—	—
124	V-75	—	—
125	V-79	—	—
126	V-80	726	260
127	V-90	—	—
128	V-91	—	—
129	V-92	—	—
130	V-94	—	—
131	VI-02	—	—
132	VI-04	865	122
133	VI-07	93	405
134	VI-09	—	—
135	VI-10	—	—
136	VI-12	869	667
137	VI-14	871	642
138	VI-17	—	—
139	VI-20	876	115
140	VI-21	—	—
141	VI-23	878	634
142	VI-34	—	—
143	VI-41	—	—
144	VI-42	—	—
145	VI-43	—	—
146	VI-44	—	—
147	VI-48	891	626
148	VI-49	—	—
149	VI-50	893	585
150	VI-52	—	—
151	VI-53	895	560
152	VI-55	897	509
153	VI-65	—	—
154	VI-70	108	550
155	VI-71	—	—
156	VI-72	—	—
157	VI-74	905	655
158	VI-76	907	582
159	VI-78	—	—
160	VI-79	—	—
161	VI-84	—	—
162	VI-87	911	595
163	VI-88	912	651
164	VI-90	—	—
165	VI-93	—	—
166	VI-95	915	230
167	VI-96	—	—
168	VII-02	—	—
169	VII-03	1196	412
170	VII-06	—	—
171	VII-10	—	—
172	VII-11	—	—
173	VII-15	1199	439
174	VII-19	562	580
175	VII-21	564	671
176	VII-25	—	—
177	VII-32	571	457
178	VII-36	575	209
179	VII-39	576	541
180	VII-42	579	502
181	VII-43	580	316
182	VII-46	583	631
183	VII-47	1200	526
184	VII-48	1201	613
185	VII-59	593	565
186	VII-60	—	—
187	VII-63	595	98
188	VII-66	598	362
189	VII-67	—	—
190	VII-72	600	595
191	VII-73	601	522
192	VII-75	—	—
193	VII-76	603	624
194	VII-77	1203	692
195	VII-80	605	338
196	VII-81	606	556
197	VII-83	—	—
198	VII-86	—	—
199	VII-88	—	—
200	VII-90	612	576
201	VII-91	613	341
202	VII-93	615	379
203	VIII-01	—	—
204	VIII-02	—	—
205	VIII-03	—	—
206	VIII-06	—	—
207	VIII-09	618	598
208	VIII-10	—	—
209	VIII-15	—	—
210	VIII-20	628	419
211	VIII-22	—	—
212	VIII-26	—	—
213	VIII-28	634	511
214	VIII-29	635	592
215	VIII-30	636	572
216	VIII-31	637	482
217	VIII-32	638	545
218	VIII-33	639	624
219	VIII-39	—	—
220	VIII-41	645	649
221	VIII-42	646	600
222	VIII-44	—	—
223	VIII-46	649	425
224	VIII-48	651	251
225	VIII-58	—	—
226	VIII-64	663	627
227	VIII-65	—	—
228	VIII-66	665	345
229	VIII-67	666	252
230	VIII-74	—	—
231	VIII-76	675	591
232	VIII-78	—	—
233	VIII-82	—	—
234	VIII-83	—	—
235	VIII-85	—	—
236	VIII-87	—	—
237	VIII-91	—	—
238	VIII-92	—	—
239	VIII-93	—	—
240	VIII-95	—	—
241	X-04	—	—
242	X-07	808	641
243	X-15	814	132
244	X-29	821	370
245	X-34	—	—
246	X-35	—	—
247	X-54	837	603
248	X-56	839	71
249	X-68	1207	642
250	X-72	849	622
251	X-94	860	501
252	XI-07	—	—
253	XI-13	1209	620
254	XI-50	—	—
255	XI-58	—	—
256	XI-81	1212	374
257	XII-07	1213	567
258	XII-17	—	—
259	XII-26	—	—
260	XII-27	—	—
261	XII-31	—	—
262	XII-32	—	—
263	XII-35	1214	620
264	XII-36	—	—
265	XII-52	—	—
266	XII-59	1216	484
267	XIII-19	1219	559
268	XIII-29	—	—
269	XIII-52	939	513
270	XIII-62	—	—
271	XIII-84	—	—
272	XIII-92	1221	741
273	XV-18	—	—
274	XV-22	1099	561
275	XV-24	—	—
276	XV-25	1224	485
277	XV-28	—	—
278	XV-34	—	—
279	XV-42	—	—
280	XV-68	—	—
281	XV-74	—	—
282	XV-93	—	—
283	XV-94	—	—
284	XV-96	—	—
285	XVI-36	1056	435
286	XVI-53	1230	741
287	XVI-59	—	—
288	XVI-66	1074	689
289	XVI-76	1083	198
290	XVI-77	1084	198
291	XVII-07	—	—
292	XVII-08	—	—
293	XVII-17	—	—
294	XVII-28	—	—
295	XVII-29	—	—
296	XVII-31	1139	503
297	XVII-36	—	—
298	XVII-39	—	—
299	XVII-40	1231	203
300	XVII-48	1148	587
301	XVII-55	—	—
302	XVII-58	—	—
303	XVII-67	—	—
304	XVII-72	—	—
305	XVII-76	1160	650
306	XVII-82	—	—
307	XVII-87	1165	502
308	XVII-95	1172	648

TABLE 1b


List of sequences of probes informative for disease diagnosis
Please see the note at the bottom

	Clone ID	Sequence ID

	I-09	298
	I-10	299
	I-13	1331
	I-14	1178
	I-15	300
	I-16	301
	I-17	302
	I-19	304
	I-20	305
	I-22	306
	I-23	307
	I-24	308
	I-25	309
	I-28	310
	I-30	1180
	I-31	311
	I-32	312
	I-34	313
	I-37	1440
	I-38	314
	I-39	315
	I-40	316
	I-42	1332
	I-44	317
	I-45	318
	I-46	319
	I-47	320
	I-48	321
	I-49	322
	I-53	323
	I-54	1181
	I-56	324
	I-57	325
	I-58	326
	I-60	327
	I-64	328
	I-67	330
	I-69	331
	I-71	332
	I-72	333
	I-73	334
	I-77	335
	I-79	336
	I-80	337
	I-81	338
	I-82	339
	I-86	1336
	I-88	1182
	I-95	1337
	II-02	360
	II-03	361
	II-05	363
	II-06	364
	II-07	365
	II-08	366
	II-09	367
	II-10	368
	II-11	369
	II-12	370
	II-13	371
	II-14	372
	II-15	373
	II-16	374
	II-17	375
	II-18	376
	II-20	377
	II-21	378
	II-22	379
	II-23	380
	II-24	381
	II-25	382
	II-26	383
	II-27	384
	II-28	385
	II-29	386
	II-30	387
	II-31	388
	II-32	389
	II-33	390
	II-34	391
	II-35	392
	II-37	393
	II-38	394
	II-39	395
	II-40	396
	II-41	397
	II-42	398
	II-43	399
	II-44	400
	II-46	401
	II-47	402
	II-48	403
	II-49	404
	II-50	405
	II-52	406
	II-53	407
	II-54	408
	II-55	409
	II-56	410
	II-57	411
	II-58	412
	II-59	413
	II-60	414
	II-61	415
	II-62	416
	II-63	417
	II-64	418
	II-65	419
	II-66	420
	II-67	421
	II-68	422
	II-69	423
	II-70	424
	II-71	425
	II-72	426
	II-73	427
	II-74	428
	II-75	429
	II-76	430
	II-77	431
	II-78	432
	II-79	433
	II-80	434
	II-81	435
	II-82	436
	II-83	437
	II-84	438
	II-85	439
	II-86	440
	II-87	441
	II-88	442
	II-89	443
	II-90	444
	II-91	445
	II-92	446
	II-93	447
	II-94	448
	II-95	449
	II-96	450
	III-01	452
	III-02	453
	III-03	454
	III-04	455
	III-05	457
	III-06	458
	III-07	459
	III-08	460
	III-09	461
	III-11	462
	III-12	463
	III-13	464
	III-14	465
	III-15	466
	III-16	467
	III-17	468
	III-18	469
	III-19	470
	III-20	1183
	III-21	471
	III-22	472
	III-23	473
	III-24	474
	III-25	475
	III-26	476
	III-27	477
	III-28	478
	III-29	479
	III-31	481
	III-32	482
	III-33	483
	III-34	484
	III-35	485
	III-37	486
	III-39	487
	III-40	488
	III-42	489
	III-43	490
	III-44	491
	III-45	492
	III-46	493
	III-47	494
	III-48	495
	III-49	496
	III-50	497
	III-51	498
	III-52	499
	III-53	500
	III-54	501
	III-55	502
	III-56	503
	III-57	504
	III-58	505
	III-59	506
	III-61	507
	III-62	508
	III-63	509
	III-64	510
	III-65	511
	III-66	512
	III-67	513
	III-69	514
	III-70	515
	III-71	516
	III-73	517
	III-74	518
	III-76	519
	III-77	520
	III-78	521
	III-79	522
	III-80	523
	III-81	524
	III-82	1348
	III-83	525
	III-85	526
	III-86	527
	III-87	528
	III-88	529
	III-89	530
	III-91	531
	III-92	1351
	III-93	532
	III-94	533
	III-95	534
	III-96	535
	IV-02	681
	IV-04	682
	IV-13	683
	IV-14	684
	IV-15	1185
	IV-17	685
	IV-23	1353
	IV-26	1186
	IV-28	686
	IV-31	687
	IV-32	688
	IV-35	1355
	IV-37	g6
	IV-38	689
	IV-40	690
	IV-42	691
	IV-43	1239
	IV-44	692
	IV-47	693
	IV-53	61
	IV-55	694
	IV-56	695
	IV-61	696
	IV-64	697
	IV-65	698
	IV-69	192
	IV-72	699
	IV-73	700
	IV-80	701
	IV-82	196
	IV-85	702
	IV-93	703
	IV-95	704
	IV-96	705
	IX-10	736
	IX-12	738
	IX-13	739
	IX-24	747
	IX-38	757
	IX-39	758
	IX-48	764
	IX-50	766
	IX-56	768
	IX-62	773
	IX-65	776
	IX-72	782
	IX-77	785
	IX-91	796
	IX-96	801
	V-01	1361
	V-03	706
	V-04	707
	V-07	708
	V-08	709
	V-09	710
	V-11	1188
	V1-16	873
	V1-19	875
	V-12	711
	V-17	1364
	V-18	712
	V-20	713
	V-24	714
	V-25	1365
	V-28	1189
	V-35	1366
	V-37	716
	V-38	1190
	V-39	1109
	V-40	717
	V-41	718
	V-47	1368
	V-48	719
	V-49	1369
	V-55	77
	V-57	720
	V-58	1370
	V-61	721
	V-64	722
	V-65	723
	V-68	1448
	V-71	1495
	V-74	724
	V-75	1372
	V-80	726
	V-81	727
	V-87	728
	V-90	1374
	VI-02	340
	VI-03	341
	VI-04	342
	VI-06	343
	VI-07	344
	VI-08	345
	VI-09	346
	VI-11	347
	VI-12	869
	VI-13	870
	VI-14	871
	VI-16	873
	VI-18	348
	VI-19	349
	VI-20	350
	VI-21	351
	VI-22	352
	VI-23	878
	VI-24	879
	VI-25	353
	VI-26	354
	VI-27	355
	VI-31	356
	VI-32	885
	VI-33	357
	VI-35	358
	VI-39	887
	VI-43	1382
	VI-44	1193
	VI-45	889
	VI-48	359
	VI-49	892
	VI-50	893
	VI-53	895
	VI-55	897
	VI-58	899
	VI-66	903
	VI-67	904
	VI-70	108
	VI-71	1387
	VI-74	905
	VI-75	906
	VI-76	907
	VI-77	110
	VI-79	1389
	VI-80	908
	VI-85	910
	VI-87	911
	VI-88	912
	VI-90	1390
	VI-93	1391
	VI-95	915
	VI-96	1392
	VII-02	547
	VII-03	548
	VII-04	549
	VII-05	550
	VII-06	551
	VII-07	552
	VII-08	553
	VII-09	554
	VII-10	555
	VII-11	556
	VII-12	557
	VII-14	558
	VII-15	559
	VII-17	560
	VII-18	561
	VII-19	562
	VII-20	563
	VII-21	564
	VII-22	565
	VII-23	566
	VII-24	567
	VII-25	1397
	VII-26	250
	VII-27	568
	VII-28	569
	VII-29	570
	VII-32	571
	VII-33	572
	VII-34	573
	VII-35	574
	VII-36	575
	VII-39	576
	VII-40	577
	VII-41	578
	VII-42	579
	VII-43	580
	VII-44	581
	VII-45	582
	VII-46	583
	VII-47	1200
	VII-48	584
	VII-49	585
	VII-50	586
	VII-52	587
	VII-53	588
	VII-54	589
	VII-55	590
	VII-57	591
	VII-58	592
	VII-59	593
	VII-62	594
	VII-63	595
	VII-64	596
	VII-65	597
	VII-66	598
	VII-67	1399
	VII-71	599
	VII-72	600
	VII-73	601
	VII-74	602
	VII-76	603
	VII-77	604
	VII-80	605
	VII-81	606
	VII-82	607
	VII-83	608
	VII-84	609
	VII-86	1453
	VII-87	610
	VII-89	611
	VII-90	612
	VII-91	613
	VII-92	614
	VII-93	615
	VII-94	616
	VII-96	617
	VIII-09	618
	VIII-10	619
	VIII-11	620
	VIII-12	621
	VIII-13	622
	VIII-15	623
	VIII-16	624
	VIII-17	625
	VIII-18	626
	VIII-19	627
	VIII-20	628
	VIII-21	629
	VIII-22	1455
	VIII-23	630
	VIII-24	631
	VIII-25	632
	VIII-26	1456
	VIII-27	633
	VIII-28	634
	VIII-29	635
	VIII-30	636
	VIII-31	637
	VIII-32	638
	VIII-33	639
	VIII-34	640
	VIII-36	641
	VIII-37	642
	VIII-38	643
	VIII-40	644
	VIII-41	645
	VIII-42	646
	VIII-43	647
	VIII-45	648
	VIII-46	649
	VIII-47	650
	VIII-48	651
	VIII-50	652
	VIII-51	653
	VIII-53	654
	VIII-54	655
	VIII-55	656
	VIII-56	657
	VIII-57	658
	VIII-58	659
	VIII-59	660
	VIII-60	661
	VIII-61	662
	VIII-64	663
	VIII-65	664
	VIII-66	665
	VIII-67	666
	VIII-68	667
	VIII-69	668
	VIII-70	669
	VIII-71	670
	VIII-72	671
	VIII-73	672
	VIII-74	673
	VIII-75	674
	VIII-76	675
	VIII-77	676
	VIII-78	677
	VIII-79	678
	VIII-80	679
	X-07	808
	X-15	814
	X-20	817
	X-29	821
	X-34	825
	X-46	833
	X-54	837
	X-56	839
	X-68	1207
	X-72	849
	X-73	1208
	X-94	860
	XI-13	1209
	XI-37	1460
	XI-43	1210
	XI-67	1211
	XI-81	1212
	XII-07	1213
	XII-35	1214
	XII-36	1215
	XII-59	1216
	XII-65	1028
	XII-92	1217
	XIII-03	917
	XIII-04	1218
	XIII-19	1219
	XIII-24	926
	XIII-51	938
	XIII-52	939
	XIII-67	947
	XIII-69	949
	XIII-88	1220
	XIII-92	1221
	XV-22	1099
	XV-24	1101
	XV-25	1224
	XV-42	1108
	XV-62	1226
	XV-64	1118
	XV-84	1125
	XVI-19	1228
	XVI-36	1056
	XVI-53	1230
	XVI-60	1071
	XVI-66	1074
	XVI-74	1081
	XVI-76	1083
	XVI-77	1084
	XVII-31	1139
	XVII-40	1231
	XVII-48	1148
	XVII-76	1160
	XVII-87	1165
	XVII-95	1172

	Note
	Sequences not available for sequence IDs in Table 1, and corresponding sequence Ids in Table 2 and 4.
	298, 301, 305, 307, 312, 317, 318, 319, 320, 332, 333, 334, 336, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 367, 372, 375, 376, 377, 379, 385, 392, 393, 404, 437, 439, 440, 443, 444, 445, 449, 455, 457, 465, 466, 467, 468, 470, 486, 498, 501, 511, 514, 516, 517, 520, 522, 528, 531, 535, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 573, 584, 604, 608,
	# 616, 620, 623, 640, 659, 662, 664, 667, 668, 673, 677, 678, 679, 681, 695, 702, 712, 716, 825, 886, 894, 902, 909, 916, 1101, 1108, 1109, 1177, 1187, 1193, 1204, 1220, 1239, 1255, 1256, 1342, 1347, 1354, 1357, 1362, 1363, 1364, 1373, 1375, 1379, 1403, 1404, 1405, 1406, 1413

TABLE 2a


List of informative probes for diagnosis of breast cancer

	Clone ID	Sequence ID

	I-24	308
	I-28	310
	I-30	1180
	I-52	—
	I-54	1181
	II-41	397
	II-70	424
	II-87	441
	III-06	458
	III-20	1183
	III-40	488
	III-57	504
	III-60	—
	III-61	507
	III-89	530
	IV-14	684
	IV-15	1185
	IV-26	1186
	IV-32	688
	IV-41	—
	IV-53	61
	IV-62	—
	IV-69	192
	IV-80	701
	IV-82	196
	IX-10	736
	IX-12	—
	IX-38	757
	IX-39	758
	IX-42	—
	IX-48	764
	IX-77	785
	V-11	1188
	V-32	—
	V-39	—
	V-55	77
	V-80	726
	V-94	—
	VI-07	93
	VI-34	—
	VI-41	—
	VI-48	891
	VI-49	—
	VI-52	—
	VI-55	897
	VI-65	—
	VI-70	108
	VI-72	—
	VI-78	—
	VI-84	—
	VII-03	1196
	VII-15	1199
	VII-32	571
	VII-39	576
	VII-47	1200
	VII-48	1201
	VII-60	—
	VII-73	601
	VII-77	1203
	VII-90	612
	VIII-20	628
	VIII-29	635
	VIII-30	636
	VIII-31	637
	VIII-39	—
	VIII-44	—
	VIII-46	649
	VIII-48	651
	VIII-66	865
	VIII-74	—
	VIII-76	675
	X-04	—
	X-07	808
	X-15	814
	X-29	821
	X-34	—
	X-35	—
	X-54	837
	X-56	839
	X-68	1207
	X-72	849
	X-94	860
	XI-07	—
	XI-13	1209
	XI-50	—
	XI-58	—
	XI-81	1212
	XII-07	1213
	XII-17	—
	XII-26	—
	XII-27	—
	XII-31	—
	XII-32	—
	XII-35	1214
	XII-36	—
	XII-52	—
	XII-59	1216
	XIII-19	1219
	XIII-29	—
	XIII-52	939
	XIII-62	—
	XIII-84	—
	XIII-92	1221
	XV-18	—
	XV-22	1099
	XV-24	—
	XV-25	1224
	XV-28	—
	XV-34	—
	XV-42	—
	XV-68	—
	XV-74	—
	XV-93	—
	XV-94	—
	XV-96	—
	XVI-36	1056
	XVI-53	1230
	XVI-59	—
	XVI-66	1074
	XVI-76	1083
	XVI-77	1084
	XVII-07	—
	XVII-08	—
	XVII-17	—
	XVII-28	—
	XVII-29	—
	XVII-31	1139
	XVII-36	—
	XVII-39	—
	XVII-40	1231
	XVII-48	1148
	XVII-55	—
	XVII-58	—
	XVII-67	—
	XVII-72	—
	XVII-76	1160
	XYII-82	—
	XVII-87	1165
	XVII-95	1172

TABLE 2b


List of sequences of probes informative for breast cancer
Please see the note at the bottom of Table 1. Some sequences
are missing.

	Clone ID	Sequence ID

	I-13	1331
	I-14	1178
	I-24	308
	I-25	309
	I-28	310
	I-30	1180
	I-37	1440
	I-42	1332
	I-48	321
	I-54	1181
	I-60	327
	I-72	1335
	I-81	338
	I-82	339
	I-86	1336
	I-88	1182
	I-95	1337
	II-02	360
	II-03	361
	II-06	364
	II-07	365
	II-10	368
	II-21	378
	II-23	380
	II-24	381
	II-25	382
	II-27	384
	II-33	390
	II-34	391
	II-41	397
	II-42	398
	II-46	401
	II-47	1338
	II-48	403
	II-52	406
	II-57	411
	II-58	412
	II-59	413
	II-60	414
	II-61	415
	II-62	416
	II-64	418
	II-67	421
	II-69	423
	II-70	424
	II-74	428
	II-80	434
	II-82	436
	II-84	438
	II-87	441
	II-88	442
	II-96	450
	III-01	452
	III-02	453
	III-06	458
	III-08	460
	III-12	463
	III-13	464
	III-17	1344
	III-18	469
	III-20	1183
	III-21	471
	III-23	473
	III-24	474
	III-25	475
	III-26	476
	III-27	477
	III-28	478
	III-29	479
	III-32	482
	III-33	483
	III-35	485
	III-39	487
	III-40	488
	III-42	489
	III-45	492
	III-46	493
	III-47	494
	III-48	495
	III-56	503
	III-57	504
	III-58	505
	III-59	506
	III-61	507
	III-62	508
	III-63	509
	III-64	510
	III-66	512
	III-67	513
	III-70	515
	III-74	518
	III-75	519
	III-78	521
	III-80	523
	III-81	524
	III-82	1348
	III-85	526
	III-86	527
	III-88	529
	III-89	530
	III-92	1351
	III-93	532
	III-95	534
	III-96	1352
	IV-04	682
	IV-13	683
	IV-14	684
	IV-15	1185
	IV-17	685
	IV-23	1353
	IV-26	1186
	IV-31	687
	IV-32	688
	IV-35	1355
	IV-37	g6
	IV-38	689
	IV-42	691
	IV-43	1239
	IV-47	693
	IV-53	61
	IV-61	696
	IV-64	697
	IV-69	192
	IV-72	699
	IV-80	701
	IV-82	196
	IV-85	702
	IV-93	1360
	IV-96	705
	IX-10	736
	IX-12	738
	IX-13	739
	IX-24	747
	IX-38	757
	IX-39	758
	IX-48	764
	IX-50	766
	IX-56	768
	IX-62	773
	IX-65	776
	IX-72	782
	IX-77	785
	IX-91	796
	IX-96	801
	V-01	1361
	V-03	706
	V-04	707
	V-07	708
	V-08	709
	V-11	1188
	V-12	711
	V-17	1364
	V-24	714
	V-25	1365
	V-28	1189
	V-35	1366
	V-38	1190
	V-39	1109
	V-41	718
	V-47	1368
	V-49	1369
	V-55	77
	V-57	720
	V-58	1370
	V-61	721
	V-64	722
	V-65	1371
	V-68	1448
	V-71	1495
	V-74	724
	V-75	1372
	V-80	726
	V-90	1374
	VI-03	864
	VI-04	865
	VI-07	93
	VI-08	867
	VI-09	1378
	VI-12	869
	VI-13	870
	VI-14	871
	VI-16	873
	VI-19	875
	VI-20	876
	VI-21	1380
	VI-23	878
	VI-24	879
	VI-25	1192
	VI-26	881
	VI-32	885
	VI-39	887
	VI-43	1382
	VI-44	1193
	VI-45	889
	VI-48	891
	VI-49	892
	VI-50	893
	VI-53	895
	VI-55	897
	VI-58	899
	VI-66	903
	VI-67	904
	VI-70	108
	VI-71	1387
	VI-74	905
	VI-75	906
	VI-76	907
	VI-77	110
	VI-79	1389
	VI-80	908
	VI-85	910
	VI-87	911
	VI-88	912
	VI-90	1390
	VI-93	1391
	VI-95	915
	VI-96	1392
	VII-02	1195
	VII-03	1196
	VII-06	1394
	VII-08	1197
	VII-09	1198
	VII-10	1395
	VII-11	1396
	VII-15	1199
	VII-17	560
	VII-19	562
	VII-21	564
	VII-22	565
	VII-23	566
	VII-24	567
	VII-25	1397
	VII-26	250
	VII-27	568
	VII-29	570
	VII-32	571
	VII-33	572
	VII-36	575
	VII-39	576
	VII-41	578
	VII-42	579
	VII-43	580
	VII-46	583
	VII-47	1200
	VII-48	1201
	VII-49	585
	VII-54	589
	VII-57	591
	VII-58	592
	VII-59	593
	VII-62	594
	VII-63	1202
	VII-64	596
	VII-66	598
	VII-67	1399
	VII-72	600
	VII-73	601
	VII-77	1203
	VII-80	605
	VII-82	607
	VII-86	1453
	VII-87	610
	VII-90	612
	VII-91	613
	VII-92	614
	VII-93	615
	VII-96	617
	VIII-09	618
	VIII-10	619
	VIII-13	622
	VIII-16	624
	VIII-20	628
	VIII-21	629
	VIII-22	1455
	VIII-23	630
	VIII-24	631
	VIII-25	632
	VIII-26	1456
	VIII-27	633
	VIII-28	634
	VIII-29	635
	VIII-30	636
	VIII-31	637
	VIII-32	638
	VIII-33	639
	VIII-34	1204
	VIII-38	643
	VIII-40	644
	VIII-41	645
	VIII-46	649
	VIII-48	651
	VIII-55	656
	VIII-57	658
	VIII-59	660
	VIII-60	661
	VIII-61	1205
	VIII-64	663
	VIII-66	665
	VIII-73	672
	VIII-74	673
	VIII-76	675
	VIII-80	679
	X-07	808
	X-15	814
	X-20	817
	X-29	821
	X-34	825
	X-46	833
	X-54	837
	X-56	839
	X-68	1207
	X-72	849
	X-73	1208
	X-94	860
	XI-13	1209
	XI-37	1460
	XI-43	1210
	XI-67	1211
	XI-81	1212
	XII-07	1213
	XII-35	1214
	XII-36	1215
	XII-59	1216
	XII-65	1028
	XII-92	1217
	XIII-03	917
	XIII-04	1218
	XIII-19	1219
	XIII-24	926
	XIII-51	938
	XIII-52	939
	XIII-67	947
	XIII-69	949
	XIII-88	1220
	XIII-92	1221
	XV-22	1099
	XV-24	1101
	XV-25	1224
	XV-42	1108
	XV-62	1226
	XV-64	1118
	XV-84	1125
	XVI-19	1228
	XVI-36	1056
	XVI-53	1230
	XVI-60	1071
	XVI-66	1074
	XVI-74	1081
	XVI-76	1083
	XVI-77	1084
	XVII-31	1139
	XVII-40	1231
	XVII-48	1148
	XVII-76	1160
	XVII-87	1165
	XVII-95	1172

TABLE 3


List of informative probes (Clone ID) selected for breast cancer diagnosis based
on their occurrence criterion during variable selection.

Occurrence*	Clone ID

100%	XI-8, XVI-66, VIII-66, XVI-59, VII-03, XIII-19, XII-35, X-35, XI-
	50, XII-26, IV-53, XIII-29, XIII-62, I-30, III-06, XV-22, XV-94, VII-
	15, VII-39, IX-39, XVII-39, III-40, VII-32
90%	I-52, VI-65, VI-34, IV-62, XV-34, XVII-58, V-11, VI-78, XII-36, XIII-
	92, VIII-29, XVI-53, XVI-77, XI-13, XIII-84, IV-14, XII-31, V-80, VII-
	48, XVII-29, XVII-72
80%	III-60, VIII-74, IX-12, X-04, XIII-52, VIII-30, IX-38
70%	VI-49, X-29, VIII-48
60%	IV-82, IX-10, VI-52, X-68, VII-77
50%	IV-15
40%	XV-28, II-70, V-55
30%	XVII-17, XVII-67
20%	XI-58, XVI-36, VIII-39, VIII-44, III-61, IV-69, XV-68, X-72
10%	IX-42, IX-77, X-94, XV-96, XVII-55
5%	XII-59, XVI-76, I-54, XV-18, V-94, X-54, VI-07, VII-47, XVII-
	31, XVII-87, XVII-48
In at lcast	II-41, VI-41, III-57, III-89, VII-73, XV-25, IV-26, X-34, IV-41, VII-
one modal	90, XV-42, XVII-82, XII-27, VIII-20, I-28, VII-60, VIII-76, III-20, VI-
	84, XI-07, XVII-28, XII-17, XVII-36, XII-52, XVII-76, VIII-46, VI-
	70, XV-74, XV-93, VIII-31, II-87, V-39, VI-55, X-07, X-15, XII-
	07, XVII-07, XVII-08, XVII-95, I-24, IV-32, V-32, VI-48, VI-72, IV-
	80, IX-48, X-56, XV-24, XII-32, XVII-40

*100% = Genes appearing in all the 75 cross validated models; 90% = Additional genes appearing in at least 68 out of 75 cross validated models; 5% = Additional genes appearing in at least 4 out of 75 cross validated models and so on.

TABLE 4a


List of informative probes for diagnosis of Alzheimer disease

	Clone ID	Sequence ID

	I-01	—
	I-02	—
	I-13	—
	I-21	—
	I-34	313
	I-37	—
	I-42	—
	I-58	326
	I-71	—
	I-72	—
	I-86	—
	I-95	—
	II-03	361
	II-05	363
	II-06	364
	II-10	368
	II-24	381
	II-25	382
	II-26	383
	II-33	390
	II-34	391
	II-42	398
	II-47	—
	II-57	411
	II-61	415
	II-69	423
	II-75	429
	II-83	—
	II-84	438
	II-88	442
	II-90	—
	II-94	448
	III-02	453
	III-05	—
	III-06	458
	III-08	460
	III-10	—
	III-13	464
	III-15	—
	III-17	—
	III-23	473
	III-26	476
	III-35	485
	III-39	487
	III-43	490
	III-44	491
	III-53	500
	III-56	503
	III-60	—
	III-63	509
	III-68	—
	III-74	518
	III-80	523
	III-82	—
	III-85	526
	III-92	—
	III-96	—
	IV-23	—
	IV-26	—
	IV-29	—
	IV-31	687
	IV-34	—
	IV-35	—
	IV-45	—
	IV-80	701
	IV-82	—
	IV-93	—
	V-01	—
	V-02	—
	V-03	706
	V-04	707
	V-06	—
	V-07	708
	V-12	711
	V-15	—
	V-17	—
	V-21	—
	V-25	—
	V-35	—
	V-42	—
	V-43	—
	V-47	—
	V-49	—
	V-52	—
	V-54	—
	V-58	—
	V-59	—
	V-65	—
	V-68	—
	V-71	—
	V-75	—
	V-79	—
	V-80	726
	V-90	—
	V-91	—
	V-92	—
	VI-02	—
	VI-04	865
	VI-09	—
	VI-10	—
	VI-12	869
	VI-14	871
	VI-17	—
	VI-20	876
	VI-21	—
	VI-23	878
	VI-41	—
	VI-42	—
	VI-43	—
	VI-44	—
	VI-48	891
	VI-49	—
	VI-50	893
	VI-53	895
	VI-71	—
	VI-74	905
	VI-76	907
	VI-78	—
	VI-79	—
	VI-87	911
	VI-88	912
	VI-90	—
	VI-93	—
	VI-95	915
	VI-96	—
	VII-02	—
	VII-03	—
	VII-06	—
	VII-10	—
	VII-11	—
	VII-19	562
	VII-21	564
	VII-25	—
	VII-36	575
	VII-42	579
	VII-43	580
	VII-46	583
	VII-59	593
	VII-63	595
	VII-66	598
	VII-67	—
	VII-72	600
	VII-73	601
	VII-75	—
	VI-02	—
	VI-04	866
	VI-09	—
	VI-10	—
	VI-12	873
	VI-14	875
	VI-17	—
	VII-91	613
	VII-93	616
	VIII-01	—
	VIII-02	—
	VIII-03	—
	VIII-06	—
	VIII-09	618
	VIII-10	—
	VIII-15	—
	VIII-22	—
	VIII-26	—
	VIII-28	634
	VIII-30	636
	VIII-32	638
	VIII-33	639
	VIII-41	645
	VIII-42	646
	VIII-48	651
	VIII-58	—
	VIII-64	663
	VIII-65	—
	VIII-67	666
	VIII-78	—
	VIII-82	—
	VIII-83	—
	VIII-85	—
	VIII-87	—
	VIII-91	—
	VIII-92	—
	VIII-93	—
	VIII-95	—

TABLE 4b


List of sequences of probes informative for Alzheimer disease
Please see note to Table 1

	Clone ID	Sequence ID

	I-09	298
	I-10	299
	I-15	300
	I-16	301
	I-17	302
	I-19	304
	I-20	305
	I-22	306
	I-23	307
	I-24	308
	I-25	309
	I-28	310
	I-31	311
	I-32	312
	I-34	313
	I-38	314
	I-39	315
	I-40	316
	I-44	317
	I-45	318
	I-46	319
	I-47	320
	I-48	321
	I-49	322
	I-53	323
	I-56	324
	I-57	325
	I-58	326
	I-60	327
	I-64	328
	I-67	330
	I-69	331
	I-71	332
	I-72	333
	I-73	334
	I-77	335
	I-79	336
	I-80	337
	I-81	338
	I-82	339
	VI-02	340
	VI-03	341
	VI-04	342
	VI-06	343
	VI-07	344
	VI-08	345
	VI-09	346
	VI-11	347
	VI-18	348
	VI-19	349
	VI-20	350
	VI-21	351
	VI-22	352
	VI-25	353
	VI-26	354
	VI-27	355
	VI-31	356
	VI-33	357
	VI-35	358
	VI-48	359
	II-02	360
	II-03	361
	II-05	363
	II-06	364
	II-07	365
	II-08	366
	II-09	367
	II-10	368
	II-11	369
	II-12	370
	II-13	371
	II-14	372
	II-15	373
	II-16	374
	II-17	375
	II-18	376
	II-20	377
	II-21	378
	II-22	379
	II-23	380
	II-24	381
	II-25	382
	II-26	383
	II-27	384
	II-28	385
	II-29	386
	II-30	387
	II-31	388
	II-32	389
	II-33	390
	II-34	391
	II-35	392
	II-37	393
	II-38	394
	II-39	395
	II-40	396
	II-41	397
	II-42	398
	II-43	399
	II-44	400
	II-46	401
	II-47	402
	II-48	403
	II-49	404
	II-50	405
	II-52	406
	II-53	407
	II-54	408
	II-55	409
	II-56	410
	II-57	411
	II-58	412
	II-59	413
	II-60	414
	II-61	415
	II-62	416
	II-63	417
	II-64	418
	II-65	419
	II-66	420
	II-67	421
	II-68	422
	II-69	423
	II-70	424
	II-71	425
	II-72	426
	II-73	427
	II-74	428
	II-75	429
	II-76	430
	II-77	431
	II-78	432
	II-79	433
	II-80	434
	II-81	435
	II-82	436
	II-83	437
	II-84	438
	II-85	439
	II-86	440
	II-87	441
	II-88	442
	II-89	443
	II-90	444
	II-91	445
	II-92	446
	II-93	447
	II-94	448
	II-95	449
	II-96	450
	III-01	452
	III-02	453
	III-03	454
	III-04	455
	III-05	457
	III-06	458
	III-07	459
	III-08	460
	III-09	461
	III-11	462
	III-12	463
	III-13	464
	III-14	465
	III-15	466
	III-16	467
	III-17	468
	III-18	469
	III-19	470
	III-21	471
	III-22	472
	III-23	473
	III-24	474
	III-25	475
	III-26	476
	III-27	477
	III-28	478
	III-29	479
	III-31	481
	III-32	482
	III-33	483
	III-34	484
	III-35	485
	III-37	486
	III-39	487
	III-40	488
	III-42	489
	III-43	490
	III-44	491
	III-45	492
	III-46	493
	III-47	494
	III-48	495
	III-49	496
	III-50	497
	III-51	498
	III-52	499
	III-53	500
	III-54	501
	III-55	502
	III-56	503
	III-57	504
	III-58	505
	III-59	506
	III-61	507
	III-62	508
	III-63	509
	III-64	510
	III-65	511
	III-66	512
	III-67	513
	III-69	514
	III-70	515
	III-71	516
	III-73	517
	III-74	518
	III-75	519
	III-77	520
	III-78	521
	III-79	522
	III-80	523
	III-81	524
	III-83	525
	III-85	526
	III-86	527
	III-87	528
	III-88	529
	III-89	530
	III-91	531
	III-93	532
	III-94	533
	III-95	534
	III-96	535
	VII-02	547
	VII-03	548
	VII-04	549
	VII-05	550
	VII-06	551
	VII-07	552
	VII-08	553
	VII-09	554
	VII-10	555
	VII-11	556
	VII-12	557
	VII-14	558
	VII-15	559
	VII-17	560
	VII-18	561
	VII-19	562
	VII-20	563
	VII-21	564
	VII-22	565
	VII-23	566
	VII-24	567
	VII-27	568
	VII-28	569
	VII-29	570
	VII-32	571
	VII-33	572
	VII-34	573
	VII-35	574
	VII-36	575
	VII-39	576
	VII-40	577
	VII-41	578
	VII-42	579
	VII-43	580
	VII-44	581
	VII-45	582
	VII-46	583
	VII-48	584
	VII-49	585
	VII-50	586
	VII-52	587
	VII-53	588
	VII-54	589
	VII-55	590
	VII-57	591
	VII-58	592
	VII-59	593
	VII-62	594
	VII-63	595
	VII-64	596
	VII-65	597
	VII-66	598
	VII-71	599
	VII-72	600
	VII-73	601
	VII-74	602
	VII-76	603
	VII-77	604
	VII-80	605
	VII-81	606
	VII-82	607
	VII-83	608
	VII-84	609
	VII-87	610
	VII-89	611
	VII-90	612
	VII-91	613
	VII-92	614
	VII-93	615
	VII-94	616
	VII-96	617
	VIII-09	618
	VIII-10	619
	VIII-11	620
	VIII-12	621
	VIII-13	622
	VIII-15	623
	VIII-16	624
	VIII-17	625
	VIII-18	626
	VIII-19	627
	VIII-20	628
	VIII-21	629
	VIII-23	630
	VIII-24	631
	VIII-25	632
	VIII-28	634
	VIII-29	635
	VIII-30	636
	VIII-31	637
	VIII-32	638
	VIII-33	639
	VIII-34	640
	VIII-36	641
	VIII-37	642
	VIII-38	643
	VIII-40	644
	VIII-41	645
	VIII-42	646
	VIII-43	647
	VIII-45	648
	VIII-46	649
	VIII-47	650
	VIII-48	651
	VIII-50	652
	VIII-51	653
	VIII-53	654
	VIII-54	655
	VIII-55	656
	VIII-56	657
	VIII-57	658
	VIII-58	659
	VIII-59	660
	VIII-60	661
	VIII-61	662
	VIII-64	663
	VIII-65	664
	VIII-66	665
	VIII-67	666
	VIII-68	667
	VIII-69	668
	VIII-70	669
	VIII-71	670
	VIII-72	671
	VIII-73	672
	VIII-74	673
	VIII-75	674
	VIII-76	675
	VIII-77	676
	VIII-78	677
	VIII-79	678
	VIII-80	679
	IV-02	681
	IV-04	682
	IV-13	683
	IV-14	684
	IV-17	685
	IV-28	686
	IV-31	687
	IV-32	688
	IV-38	689
	IV-40	690
	IV-42	691
	IV-44	692
	IV-47	693
	IV-55	694
	IV-56	695
	IV-61	696
	IV-64	697
	IV-65	698
	IV-72	699
	IV-73	700
	IV-80	701
	IV-85	702
	IV-93	703
	IV-95	704
	IV-96	705
	V-03	706
	V-04	707
	V-07	708
	V-08	709
	V-09	710
	V-12	711
	V-18	712
	V-20	713
	V-24	714
	V-37	716
	V-40	717
	V-41	718
	V-48	719
	V-57	720
	V-61	721
	V-64	722
	V-65	723
	V-74	724
	V-80	726
	V-81	727
	V-87	728
	VI-13	870
	VI-14	871
	VI-16	873
	VI-23	878
	VI-24	879
	VI-28	883
	VI-32	885
	VI-38	886
	VI-39	887
	VI-45	889
	VI-46	890
	VI-49	892
	VI-50	893
	VI-52	894
	VI-53	895
	VI-54	896
	VI-55	897
	VI-57	898
	VI-58	899
	VI-63	900
	VI-65	902
	VI-66	903
	VI-67	904
	VI-74	905
	VI-75	906
	VI-76	907
	VI-80	908
	VI-81	909
	VI-85	910
	VI-87	911
	VI-88	912
	VI-91	913
	VI-94	914
	VI-95	915
	VI-96	916
	I-13	1177
	I-14	1178
	I-30	1180
	I-54	1181
	I-88	1182
	III-20	1183
	IV-15	1185
	IV-26	1186
	IV-62	1187
	V-11	1188
	V-28	1189
	V-38	1190
	V-45	1191
	VI-44	1193
	VII-47	1200
	I-42	1332
	I-52	1333
	I-86	1336
	I-95	1337
	III-10	1342
	III-60	1347
	III-82	1348
	III-92	1351
	IV-23	1353
	IV-34	1354
	IV-35	1355
	IV-41	1356
	IV-45	1357
	IV-82	1359
	V-01	1361
	V-02	1362
	V-06	1363
	V-17	1364
	V-25	1365
	V-35	1366
	V-42	1367
	V-47	1368
	V-49	1369
	V-58	1370
	V-75	1372
	V-79	1373
	V-90	1374
	V-91	1375
	V-94	1376
	VI-10	1379
	VI-41	1381
	VI-43	1382
	VI-71	1387
	VI-72	1388
	VI-79	1389
	VI-90	1390
	VI-93	1391
	VII-25	1397
	VII-60	1398
	VII-67	1399
	VIII-22	1403
	VIII-26	1404
	VIII-39	1405
	VIII-44	1406
	I-37	1440
	V-32	1445
	V-52	1447
	V-68	1448
	V-92	1449
	VI-42	1450
	VI-78	1452
	VII-86	1453
	VII-88	1454
	IV-29	1490
	V-15	1491
	V-39	1492
	V-54	1493
	V-59	1494
	V-71	1495

TABLE 5


Samples

	Diagnosis	No. of women

	Normal/Benign	42*
	DCIS	3
	Invasive cancer	26

*From one woman, whole blood was collected at

weeks

1, 2, 3, 4, 5

following menstruation. Hence, the number of unique normal/benign

samples tested in the experiment is 75

Information about women with breast cancer

				Size hist.
Sample	AGE	Stage	Cancer type	(mm)	Nodes

1	51	II	IDC	20	1/7
2	84	II	IDC	22	2/2
3	50	I	DCIS + 1	>50 DCIS;	0/7
			IDC	5 × 14
4	47	I	IDC		15	0
5	69	III	ILCg.2 + tubular	50 + 3	1 av 12 + 1 av 7
			adeno carcinoma
6	50	II	IDC	24	0
7	65	I	IDC		15	0
8	63	II	IDC	23	0
9	55	I	IDC + DCIS	4	0 av 1
10	52	0	DCIS + small	50 + 3	0
			colloid carcinoma
			foci
11	60	II	IDC	24	0
12	54	I	IDC	11	0
13		0	DCIS	20	0
14	49	0	DCIS	9	0
15	48	I	IDC	4	0
16	56	I	IDC	4	0
17	68	I	IDC	14	0
18	68	I	IDC	7	0
19	63	I	IDC	10	0
20	45	I	IDC	19	1
21	57	III	IDC	60	8/20
22	55	II	IDC/DCIS	35 + 55	0
23	71	I	IDC/extensive	8	0
			DCIS
24	56	I	IDC	9	?
25	66	II	IDC	26	0
26	66	I	IDC	15	?
27	61	I	IDC	9	?
28	?	?	?	?	?
29	65	I	IDC	11	0

Other diseases/conditions present in the women tested

Disease/condition

	Diabetes
	Asthma
	Ulcerous colitis
	Hemochromatose
	Crohn's disease
	Fibromyalgia
	Psoraiasis
	Atopic eczema
	Rheumatism
	Allergies

Prior history of cancer in the women tested

	Cancer type	No. of women

	Breast	3
	Colon	2
	Stomach	1
	Skin	1

TABLE 6


Number of samples tested by double cross validation and success of the diagnostic test
for breast cancer based on selected informative genes

Number of samples tested by double cross validation

	Number Of unique samples	75
	tested
	Number of unique non	48
	cancer samples tested
	Number of cancer samples	29
	tested

Success of the diagnostic test for breast cancer based on selected informative genes

	Number of				False	False
Occurrence in	informative				Positive	negative
percentage*	probes	Specificity	Sensitivity	Accuracy	rate	rate	Total error rate

100.00	23	84.78	75.86	81.33	15.22	24.14	18.67
90.00	44	91.30	79.31	86.67	8.70	20.69	13.33
80.00	51	86.96	79.31	84.00	13.04	20.69	16.00
70.00	54	89.13	75.86	84.00	10.87	24.14	16.00
60.00	58	89.13	75.86	84.00	10.87	24.14	16.00
50.00	59	89.13	75.86	84.00	10.87	24.14	16.00
40.00	63	89.13	75.86	84.00	10.87	24.14	16.00
30.00	66	86.96	75.86	82.67	13.04	24.14	17.33
20.00	74	89.13	75.86	84.00	10.87	24.14	16.00
10.00	79	89.13	75.86	84.00	10.87	24.14	16.00
5.00	90	86.96	79.31	84.00	13.04	20.69	16.00
1.33	139	84.78	72.41	80.00	15.22	27.59	20.00

*100% = Genes appearing in all the 75 cross validated models; 90% = Genes appearing in at least 68 out of 75 cross validated models; 5% = Genes appearing in at least 4 out of 75 cross validated models; and so on.

TABLE 7


Double cross-validation and details of the success of the
diagnostic test for Alzheimer disease based on the expression
182 informative genes

Validation Result

	Total number of samples tested	14
	Number of Alzheimer's disease	7
	samples tested
	Number of Alzheimer's disease	1
	samples incorrectly predicted
	Number of non_Alzheimer's	7
	disease samples tested
	Number of non-Alzheimer's	0
	disease samples incorrectly
	predicted

Success of diagnostic test

Performance	Description	%

Accuracy	Percentage of the total	92.9
	number of predictions that
	were correct
Sensitivity	Percentage of positive	85.7
	cases that were correctly
	Identified
Specificity	Percentage of negatives	100
	cases that were correctly
	predicted
False positive rate	Percentage of negatives	0.0
	cases that were incorrectly
	classified as positive
False negative rate	Percentage of positives	14.3
	cases that were incorrectly
	classified as negative
Total error rate	Percentage of the total	7.1
	cases incorrectly predicted

TABLE 8


Some relevant features of the blood donors.

	Cancer type/
	breast	Size Hist.	mRNA
AGE	abnormality	(mm)	Quality

1	B1	na	IDC	5	++
2	B2	49	DCIS	8	nd
3	B3	54	IDC	18	++
4	B4	59	IDC	12	+
5	B5	61	DCIS + micro	15 + 1.5	++
			invasive cancer
6	B6	55	IDC	12 + 17	nd
7	B6		IDC		12 + 17	nd
8	N1	45	Fibroadenoma	—	nd
9	N2	52	na	—	+
10	N3	55	cyst	—	++
11	N4	54	na	—	++
12	N5	51	Benign ductal	—	nd
			epitelhelium
13	N6	57	Benign	—	nd
14	N7	50	na	—	++
15	N8	52	na	—	+

B, Female donors with breast cancer;
N, Female donors with suspected mammogram but no breast cancer;
IDC, invasive ductal carcinoma;
DCIS, ductal carcinoma in situ;
na, not available
nd, not determined;
++, no degradation of mRNA and no ribosomal contamination in the sample,
+, no degradation of mRNA but ribosomal contamination in the sample.

TABLE 9


List of sequence of probes informative for both alzheimer and
breast cancer disease

	Clone ID	Sequence ID

	I-24	308
	I-25	309
	I-28	310
	I-48	321
	I-60	327
	I-72	333
	I-81	338
	I-82	339
	II-02	360
	II-03	361
	II-06	364
	II-07	365
	II-10	368
	II-21	378
	II-23	380
	II-24	381
	II-25	382
	II-27	384
	II-33	390
	II-34	391
	II-41	397
	II-42	398
	II-46	401
	II-47	402
	II-48	403
	II-52	406
	II-57	411
	II-58	412
	II-59	413
	II-60	414
	II-61	415
	II-62	416
	II-64	418
	II-67	421
	II-69	423
	II-70	424
	II-74	428
	II-80	434
	II-82	436
	II-84	438
	II-87	441
	II-88	442
	II-96	450
	III-01	452
	III-02	453
	III-06	458
	III-08	460
	III-12	463
	III-13	464
	III-17	468
	III-18	469
	III-21	471
	III-23	473
	III-24	474
	III-25	475
	III-26	476
	III-27	477
	III-28	478
	III-29	479
	III-32	482
	III-33	483
	III-35	485
	III-39	487
	III-40	488
	III-42	489
	III-45	492
	III-46	493
	III-47	494
	III-48	495
	III-56	503
	III-57	504
	III-58	505
	III-59	506
	III-61	507
	III-62	508
	III-63	509
	III-64	510
	III-66	512
	III-67	513
	III-70	515
	III-74	518
	III-75	519
	III-78	521
	III-80	523
	III-81	524
	III-85	526
	III-86	527
	III-88	529
	III-89	530
	III-93	532
	III-95	534
	III-96	535
	IV-04	682
	IV-13	683
	IV-14	684
	IV-17	685
	IV-31	687
	IV-32	688
	IV-38	689
	IV-42	691
	IV-47	693
	IV-61	696
	IV-64	697
	IV-72	699
	IV-80	701
	IV-85	702
	IV-93	703
	IV-96	705
	V-03	706
	V-04	707
	V-07	708
	V-08	709
	V-12	711
	V-24	714
	V-41	718
	V-57	720
	V-61	721
	V-64	722
	V-65	723
	V-74	724
	V-80	726
	VI-03	341
	VI-04	342
	VI-07	344
	VI-08	345
	VI-09	346
	VI-12	869
	VI-14	871
	VI-19	349
	VI-20	350
	VI-21	351
	VI-23	878
	VI-25	353
	VI-26	354
	VI-48	359
	VI-50	893
	VI-53	895
	VI-74	905
	VI-76	907
	VI-87	911
	VI-88	912
	VI-95	915
	VII-02	547
	VII-03	548
	VII-06	551
	VII-08	553
	VII-09	554
	VII-10	555
	VII-11	556
	VII-15	559
	VII-17	560
	VII-19	562
	VII-21	564
	VII-22	565
	VII-23	566
	VII-24	567
	VII-27	568
	VII-29	570
	VII-32	571
	VII-33	572
	VII-36	575
	VII-39	576
	VII-41	578
	VII-42	579
	VII-43	580
	VII-46	583
	VII-48	584
	VII-49	585
	VII-54	589
	VII-57	591
	VII-58	592
	VII-59	593
	VII-62	594
	VII-63	595
	VII-64	596
	VII-66	598
	VII-72	600
	VII-73	601
	VII-77	604
	VII-80	605
	VII-82	607
	VII-87	610
	VII-90	612
	VII-91	613
	VII-92	614
	VII-93	615
	VII-96	617
	VIII-09	618
	VIII-10	619
	VIII-13	622
	VIII-16	624
	VIII-20	628
	VIII-21	629
	VIII-23	630
	VIII-24	631
	VIII-25	632
	VIII-28	634
	VIII-29	635
	VIII-30	636
	VIII-31	637
	VIII-32	638
	VIII-33	639
	VIII-34	640
	VIII-38	643
	VIII-40	644
	VIII-41	645
	VIII-46	649
	VIII-48	651
	VIII-55	656
	VIII-57	658
	VIII-59	660
	VIII-60	661
	VIII-61	662
	VIII-64	663
	VIII-66	665
	VIII-73	672
	VIII-74	673
	VIII-76	675
	VIII-80	679



Nucleotide sequences

Sequence ID - 93 nt: 405
GGATCCTGTGGCCCACAGAGCTGCCCCAGCAGACGCTCCGCCCCACCCGG
TGATGGAGCCCCGGGGGGACAATCGTGCCTGGGGAGGAGCAGGGTACAGC
CCATTCCCCCAGCCCTGGCTGACCTGGCCTAGCAGTTTGGCCCTGCTGGC
CTTAGCAGGGAGACAGGGGAGCAAAGAACGCCAAGCCGGAGGCCCGAGGC
CAGCCGGCCTCTCGAGAGCCAGAGCAGCAGTTGAATGTAATGCTGGGGAC
AGGCATGCTGCCGCCAGTAGGGCGGGGACCCGGACAGCCAGGTGACTACC
AGTCCTGGGGACACACTCACCATAAACACATCCCCAGGCAGGACAGATCG
GGGAAGGGGTGTGTACCAGGCTATGATTTCTCTTGCATTAAAATGTATTA
TTATT

Sequence ID - 108 nt: 550
GGCTTTGACAGAGTGCAAGACGATGACTTGCAAAATGTCGCATCTGGAAC
GCAACATAGANACCATCATCAACACCTTCCACCAATACTCTGTGAAGCTG
GGGCACCCAGACACCCTGAACCAGGGGGAATTCAAAGAGCTGGTGCGAAA
AGATCTGCAAAATTTTCTCAAGAAGGAGAATAAGAATGAAAAGGTCATAG
AACACATCATGGAGGACCTGGACACAAATGCAGACAAGCAGCTGAGCTTC
GAGGAGTTCATCATGCTGATGGCGAGGCTAACCTGGGCCTCCCACGAGAA
GATGCACGAGGGTGACGAGGGCCCTGGCCACCACCATAAGCCAGGCCTCG
GGGAGGGCACCCCCTAAGACCACAGTGGCCAAGATCACAGTGGCCACGGC
CACGGCCACAGTCATGGTGGCCACGGCCACAGCCACTAATCAGGAGGCCA
GGCCACCCTGCCTNTACCCAACCAGGGCCCCGGGGCCTGTTATGTCAAAC
TGTCTTGGCTGTGGGGCTAGGGGCTGGGGCCAAATAAAGTCTCTTTCTCC

Sequence ID 110
ACGAAGACAGACATCTGTGGAATGATTCACATCCTCTCAAGTTAGGAGGA
TGGAGGCCTGCTTCATTAAGAAGCTGGGGGTAGGGTGGGGGTGGGGAGAA
CACTTAACAACATGGGGACCAGTCAGGGGAATCCCCTTATTTCTGTTTTG
CATATGAGGAACCCTAGAGCAGCCAGGTGAGGCTCTCTAGTTTAATAAAA
ATCATGGAAAGACTCTTAATGCAGACTCTTCTTAAGTGTTAATAGGGATT
TTTTCAGCTTATTTTGGTTGCAGTTTCCAATTTTTAAAAATGTTGAGGTA
ATCTTTCCCACCTTCCCAAACCTAATTCTTGTAGATGCATTAGTGTTGAA
CCAATGCTTTCTCATGTCTCAATTCTTTGTATATGCATTCTTTTCAGATG
TATTAAACAAACAAAAACCCTTC

Sequence ID - 192 nt: 286
CCGGTAATAGAATAGAAAAGGGAGAGTGTCTTCATGCAATGTGGCATCCT
GGATTGGGTCTCGNNACAAAAACAGGACATTAGTGGGAAAATTGGAAATC
TGAAAAAAGTCTGAATTTTAGTTAATATACCAATTTCAGTCTCTTGGTTT
TGACAGATGTACCATGGTGATGTAAGATGTTGACCTTGGGGTAGGCTGGG
TGAAGGGTATACAGGAACTCTTTGTACTATCTCTGCAACTTCTCTGTAAA
TCTAGTATCATTCCAAAATAAAAGTTTATTTAATTT

Sequence ID 250
GTGGAAGTGACATCGTCTTTAAACCCTGCGTGGCAATCCCTGACGCACCG
CCGTGATGCCCAGGGAAGACAGGGCGACCTGGAAGTCCAACTACTTCCTT
AAGATCATCCAACTATTGGATGATTATCCGAAATGTTTCATTGTGGGAGC
AGACAATGTGGGCTCCAAGCAGATGCAGCAGATCCGCATGTCCCTTCGCG
GGAAGGCTGTGGTGCTGATGGGCAAGAACACCATGATGCGCAAGGCCATC
CGAGGGCACCTGGAAAACAACCCAGCTCTGGAGAAACTGCTGCCTCATAT
CCGGGGGAATGTGGGCTTTGTGTTCACCAAGGAGGACCTCACTGAGATCA
GGGACATGTTGCTGGCCAATAAGGTGCCAGCTGCTGCCCGTGCTGGTGCC
ATTGCCCCATGTGAAGTCACTGTGCCAGCCCAGAACACTGGTCTCGGGCC
CGAGAAGACCTCCTTTTTCCAGGCTTTAGGTATCACCACTAAAATCTCCA
GGGGCACCATTGAAATCCTGAGTGATGTGCACTGATCAAGACTGG

Sequence ID 299
CAGCGCAGGGGCTTCTGCTGAGGGGGCAGGCGGAGCTTGAGGAAACCGCA
GATAAGTTTTTTTCTCTTTGAAAGATAGAGATTGNTACAACTACTTAAAA
AATATAGTCAATAGGTTACTAAGATATTGCTTAGCGTTAAGTTTTTAACG
TAATTTTAATAGCTTAAGATTTTAAGAGAAAATATGAAGACTTAGAAGAG
TAGCATGAGGAAGGAAAAGATAAAAGGTTTCTAAAACATGACGGAGGTTG
AGATGAAGCTTCTTCATGGAGTAAAAAATGTATTTAAAAGAAAATTGAGA
GAAAGGACTACAGAGCCCCGAATTAATACCAATAGAAGGGCAATGCTTTT
AGATTAAAATGAAGGTGACTTAAACAGCTTAAAGTTTAGTTTAAAAGTTG
TAGGTGATTAAAATAATTTGAAGGCGATCTTTTAAAAAGAGATTAAACCG
AAGGTGATTAAAAGACCTTGAAATCCATGACGCANGGAGAATTGCGCATT
TAAAGCCTAGTTACGCATTTACTAAACGCAGACGAAAATGGGAAGATTAA
TTGGGAGTGGTAGGATGAAACAATTTTGGAGAAGATAGAAG

Sequence ID 300
CTCAAAGGAGAAAAAAAACCTTGTAAAAAAAGCAAAAATGACAACAGAAA
AACAATCTTATTCCGAGCATTCCAGTAACTTTTTTGTGTATGTACTTAGC
TGTACTATAAGTAGTTGGTTTGTATGAGATGGTTAAAAAGGCCAAAGATA
AAAGGTTTCTTTTTTTTTCCTTTTTTGTCTATGAAGTTGCTGTTTATTTT
TTTTGGCCTGTTTGATGTATGTGTGAAACAATGTTGTCCAACAATAAACA
GGAATTTTATTTTGCTGAGTTGTTCTAAAAAAAAAAAAAAAAAAAAA

Sequence ID 302
AGTAGAGACGGGGTTTCACTGTGTTAGCCAGGATGGTCTCGATCTCCTGA
CCTCGTGATCCGGCCACCTCGGCCTCCCGAAAGTGCTGGGATTACAGGCG
TGAGCCACGGCGCCCAGCCCCAGCCTGTCACTTAAACTGATAAACGACAG
ATTAACAGTAGAAAAATTTTATTTTGCATACATAATGAGGCTTCACAAAA
GAGAAGTGAAAACCCAAGTAGGAGTTTAGGGCTGGGGGCTTATATACCAT
TTAACAAGGGGTGATAAATTGTAAGAGAATAG

Sequence ID 304
TCCTTGGTTTCGATTTGTGGCAACAATCCAGTCTTTTTGTTTTTTTCAGG
GATACCATATGTAACAGGTGCCATTGTTACTGTAACTTTTCACACATGCC
TTCAGTTTGATGTCAAAGTCATCATTTAGTGTAAACAGCAAGTTATCTGT
TAGGCTGCACATCATGAACTTTACTTTTAGAAAGTCTTATCTTTTATGCC
ACAGAAATAGCATTTGGCTATTAGTCATGGATGGCAAAGAAATTAATTTT
GAGTTGTTTGGATAAAAATGTTTCAGTTGACTGTAGTGTGTATTGAGAGA
CACTGCCAGTAAACAAACTCTCTTGGTAGGTGGAAATCCCCTAGAAGTTA
CAGAAAATTGGGAGGAGGTGAACTTAATTAAATAACTTGAATTGTTTAGA
CATATTCAGAGCTTCTTATGACCTTGAAGAAATCACCCAACTTCAAAAGA
CCTCGGTTTCTTCATTTGTAAAATTAGGGAGTTTGACTAGATGTGTAAAT
CTAGTTGTTAGTTAACTTCTAAGATGTAAAAACCCTCTTGTTTAACAAAA
ACCTACAAGATCAAGTTGCTTATCTGAAATCTTTATGAATCAACACTAGT
CACTAAGTCTAGCTCGACC

Sequence ID 306
CTTTTCCTCCCGCTGTCCCCCACGGAGGGGACTGCTCTCCCCCGCTGCAT
CCTTTCTGTGAGGTACCTTACCCACCTCAGCACCTGAGAGGGTGAAATAG
AATTCTAACCTCGACATTCGGGAAGTGTTTTTGAGAAGTCTCGGTCGGTA
AGGGAAGTCTTCCAAGTCCGTGCAGCACTAACGTATTGGCACCTGCCTCC
TCTTCGGCCACCCCCCAGATGAGGCAGCTGTGACTGTGTCAAGGGAAGCC
ACGACTCTGACCATAGTCTTCTCTCAGCTTCCACTGCCGTCTCCACAGGA
AACCCAGAAGTTCTGTGAACAAGTCCATGCTGCCATCAAGGCATTTATTG
CAGTGTACTATTTGCTTCCAAAGGATCAGGCCCTGAGAACAATGACCTTA
TTTCCTACAACAGTGTCTGGGTTGCGTGCCAGCAGATGCCTCAGATACCA
AGAGATAACAAAGCTGCAGCTCTTTTGATGCTGACCAAGAATGTGGATTT
TGTGAAGGATGCNCATGAANAAATGGACNAGCTGTG

Sequence ID - 308 nt: 373
AAGTGGGTCTTGCCATCCCTGAACTGNAATCATCCCTAACATATTCATAC
CTGTTTTCATTTTAAAAGTTGGGTCAGTTTTTTTATTAGTACATGTATTT
CTATCCTACTGATTTATTTGCTATATCATCTAATTTAGTTTGAATATTCC
ATAATTTACTTAATTAGTCCTGTATGGAGACCTAGCTCTTCTCAGTGTCT
ACTATTATAAACAATGCTACAGTGAATATTGGTGNATAAATCCATACNCA
CCACGTACATATCTTAAGTTCTGGAAGAGATATTGCTAAACCAGAAGATA
ACCTGCATTTAAAATTTGACTGCTAGGGNCAGGGNCACATTTAATTAAAT
TAGAACAANGAATGCATAATGNC

Sequence ID 309
CCGGAATCGCGGCCGCGTCGACGAAAATATGTGCCCTGGCCAACTCCACA
GGACTAGTTCTAGGCAATCTGAAGGAAACCAGAAAATGTGAATTTCTCTT
CCCTCAAAAAGCTATACTGAAGTAGTATTTAATATTCAAGTACTTGTAAA
TTTGCAGAACAGTACTTTTTAATTTGACCCATGAATTCTATTTAAATTTG
TCACTTAATATTTAGCCAAGAAGCAAACCATCTAAAAAGATTTCTGGTTT
ATTTCTCCAACTCCTAATAAATAGGGTCACATATTTTTTAACTTTTTTCT
AATTTGAAAAGTAATACAGGCATATGGTATTTTAAAAATGAAACAACACA
AAGGGATATGTTTTGAAAAGTGGTCTTGCCATCCCTGAACTGTAATCATC
CCTAACATATTCATACCTGTTTTCATTTTAAAAGTTGGGTCAGTTTTTTT
ATTAGTACATGTATTTCTATCCTACTGATTTATTTGCTATATCATCTAAT
TTAGTTTGAATATTCCATAATTTACTTAATTAGTCCTGTATGGAGACCTA
GCTCTTCTCAGTGTCTACTATTATAAACAATGCTACAGTGAATATTGGTG
NATAAATCCTACACACCACGTAACATATCTTAAGTTCCTGGAAGAGATAT
TGCTAAACCAGAAGATAACCTGCATTTAAAATTTGACTGCTAGGGTCAGG
GTCACATTTAAATTAAATTAGAACAAGGAATGCATAATGTCTTCGATAGC
AATCTATTCAAGGTGCACCGTGGTCACAAAGGAAAGCAAAACTGTC

Sequence ID - 310 nt: 564
CCTGGNCAGAGGCCTCTATCCTGTANTGATAATTGCCATCAAAATTGTCA
AAAANGATTTAATTTCTATGGGNAATAGTCCTTTTCTTAGCTTCTGCCNN
TCACTTGCTTATTTTTTGTGTGGGAATGGGGTTGGATAAACCAATGAACT
TTATTATAAACAAATCCCACCTATATCTANCAAATTTATATTTTCGGTGA
AATACAGATATTTGCCTTTCTGGAGTANTATAGAAGCTGTCAATATGTAT
CTACTGTACAGTACTAAATAGTATTCATTTATGAAATGAGTAGTGTTTGG
GTGGCTGGGGTTAAGGAAAAATGAGACTTGGAATTGTAGCTTTTATCCAA
GTTTTGAGTATAAATAGGGTTTTGTTTTGTTTTTTTTAACCTAAAAACTG
AAATGCCATATAGAAAAACAGCATTGTTTTTACAGTTTGTAGTAAGTAAC
TTTTTAAAGATTTTATCAAAAAGAATTTTGTCTATNGTGAGTAAAAGAAG
TTCTAATAATGGCCTAATCACTGCATTTTTAAAAAACAAAGTTCAACACA
AATGACATTTGTTT

Sequence ID 311
CCTCTCCTCCATCTAAAGGCAACATTCCTTACCCATTAGTCTCAGAAATT
GTCTTAAGCAACAGCCCCAAATGCTGGCTGCCCCCGGCCAAGCATTGGGG
CCGCCATCCTGCCTGGCACTGGCTGATGGGCACCTCTGTTGGTTCCATCA
GCCAGAGCTCTGCCAAAGGCCCCGCAGTCCCTCTCCCAGGAGGACCCTAG
AGGCAATTAAATGATGTCCTGTTCCATTGG

Sequence ID - 313 nt: 554
CCCGGAATCGCGGCCCGCGTCGACAACAAACCTGCATGTTCTGCACATGT
ATCCAGGAACTTAAAAAAAAAAAAAGATAGTTTGTGTGTCTTAATTGAAT
AATAGTAGATTTATAGATTAAAGATCTATGGGTTTTTAATATGGATTANA
AATCTGTGGGTTTTTGATATGGATTANAAATCTGTGGGTTTTTAATATGG
ATTGGAAATCTGTGGGTTTTTAATATGGATTAAAAAACATCTGTGGGTTT
TTAATATGGATTAAACATCTGTGGGTTTTTAATATGGATTAAACATCTGG
GTTTTTAATATGGATTAAACATCTGTGGGTTTTTAATATGGGTTAAAAAT
CAAAAGAAAATGAACTATTTGCTCCAGTGCAGGAAAATACAGGCAATACT
GGATACAATTAGATGGTCAGGAGCGATAACCCGGTTGCCATTGTTTGAAG
AAGAGAATAAGGNGCTAGCATTCCTATCCGTAGATAATTTGACAGCTAGG
AAATAGGGGGAGTCTTCTATGTAGTTAGTGAAGGCTAAATGAACTATTAT
ATGC

Sequence ID 314
CTTTTCCTCCCGCTGTCCCCCACGGAGGGGACTGCTCTCCCCCGCTGCAT
CCTTTCTGTGAGGTACCTTACCCACCTCAGCACCTGAGAGGGTGAAATAG
AATTCTAACCTCGACATTCGGGAAGTGTTTTTGAGAAGTCTCGGTCGGTA
AGGGAAGTCTTCCAAGTCCGTGCAGCACTAACGTATTGGCACCTGCCTCC
TCTTCGGCCACCCCCCAGATGAGGCAGCTGTGACTGTGTCAAGGGAAGCC
ACGACTCTGACCATAGTCTTCTCTCAGCTTCCACTGCCGTCTCCACAGGA
AACCCAGAAGTTCTGTGAACAAGTCCATGCTGCCATCAAGGCATTTATTG
CAGTGTACTATTTGCTTCCAAAGGATCAGGCCCTGAGAACAATGACCTTA
TTTCCTACAACAGTGTCTGGGTTGCGTGCCAGCAGATGCCTCAGATACCA
AGAGATAACAAAGCTGCAGCTCTTTTGATGCTGACCAAGAATGTGGATTT
TGTGAAGGATGCACATGAAGAAATGGAGCAGGCTGTGGAAGAATGTGACC
CTTACTCTGGCCTCTTGAATGATACTGAGGAGAACAACTCTGACAACCAC
AATCATGAGG

Sequence ID 315
TGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACC
AGCAGCCCCTCAGCATCCAGCAGCATGAGCGGAGGCATTTTCCTTTTCTT
CGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGAGGTGACACGT
CTCAGCCTTAGCCCTGTGCCCCCTGAAACAGCTGCCACCATCACTCGCAA
GAGAATCCCCTCCATCTTTGGGAGGGGTTGATGCCAGACATCACCAGGTT
GTAGAAGTTGACAGGCAGTGCCATGGGGGCAACAGCCAAAATAGGGGGGT
AATGATGTACGGGCCAAGCACTGCCCAGCTGGGGGTCAATAAAGTTACCC
TTGTACTTG

Sequence ID 316
CGCCACTTATCCAGTGAACCACTATCACGAAAAAAACTCTACCTCTCTAT
ACTAATCTCCCTACAAATCTCCTTAATTATAACATTCACAGCCACAGAAC
TAATCATATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAA

Sequence ID 321
CAGAACAGTACTTTTTAATTTGACCCATGAATTCTATTTAAATTTGTCAC
TTAATATTTAGCCAAGAAGCAAACCATCTAAAAAGATTTCTGGTTTATTT
CTCCAACTCCTAATAAATAGGGTCACATATTTTTTAACTTTTTTCTAATT
TGAAAAGTAATACAGGCATATGGTATTTTAAAAATGAAACAACACAAAGG
GATATGTTTTGAAAAGTGGTTCTTGCCATCCCTGAACTGTAATCATCCCT
AACATATTCATACCTGTTTTCATTTTAAAAGTTGGGTCAGTTTTTTTATT
AGTACATGTATTTCTATCCTACTGATTTATTTGCTATATCATCTAATTTA
GTTTGAATATTCCATAATTTACTTAATTAGTCCTGTATGGAGACCTAGCT
CTTCTCAGTGTCTACTATTATAAACAATGCTACAGTGAATATTGGTGTAT
AAATCCATACACACCACGTAACATATCTTAAGTTCCTGGAAGAGATATTG
CTAAACCAGAAGATAACCTGCATTTAAAATTTTGACTGCTAGGGTCAGGG
TCACATTTAAATTAAATTAGAACAAGGAATGCATAATGTCTTCGATAGCA
ATCTATTCCAGGTGCACCGTGGTCACAAAGGAAAGCAAAACTGTCAATAA
CTTTCTTCTCA

Sequence ID 322
TAGCATTTGGCCTTTTAAAACATTTGTTTATTTTTTTTCTGAGAATGGCT
AACACACTTTATTGAGGTTCGAAATTAATAAAGAAAATAAAAGAAATGTA
TCTTCATTCATTCTGTATGTTAGTGTTTTAATTACCCTTAGAATATATGG
ATAAAAAATACTATTCTTTGTCTTGGAGAAGGTAAGAGTCTAGTTAGATG
AATAAGGGTTATCTATGTAGAACAACTAGAGAATGAGAAGAGAGCTTATG
AGATTGAGTACTACGTTATGCAGTAGAGTAGCACGTCATCTGCTACTGAG
TATGGTGTGATAACATTGTGTAACAGGAAAGTATGATCAATATCTACTTA
AAATTAAGGACAATATTAGCACTACATTGCTTTATTTTAAAGTAAAAATT
AGAGAACTAAACACAAGCATTGTAAGTACAATAAAAGCTGATCTTTCTAG
TTAAGCAGAATAATACATGTTCAAGCATCTGCTAAATCATTAAATATAAG
AATATAGGGGTTTTCTATAATCTTATTTTCTTTGGAAGAGTACCTCATTT
TCAAGANGAGAAGTTTCTAATTGCCACTTCTTTAAAAATAAAACAGGGTT
TTAATGTTCCCAGCACAAAAATTAATATCTCTTCAAAAAGTCTCTTGTGA
TTAAGTTTGAATCCCTTGTCATACTGCTTCTAATATTGACACTGACCTCC
TTAGGTATTTTTCAGGGGTTATAATCTTTTCTTAAGGTATCTTTTTTCAA
GAATTGGATACCTTGGGCTT

Sequence ID 323
CGCGTCGACTTTTAAAGTCATCTCTATAGGAAGGTGCTGGGCAGGGATCC
CAGAGAAAGAAAGGGTCCAAGACTCCATTAACTGCCCTGGATGAAGGGCA
CTGCTACAGCAGCTAGTACCAGAGACTCTCCTATCTCACGGTTGAGGCAG
ACCCAGGATAGAATAGAGAATAAAAGGAATGCTTATAGGAAACAATTTTG
TATGGAATGCTAGATGGCCAAGCCTCAGCCTTTGGTCCAGTGCAACCCTT
GCCTCGCTTGTCAACAGTGAAAAATTAGTTTGGTTAGAAGAACCATCTGG
AAACACACCAGCTTCTGCTACCTTCATGCTCATTGTTAAAAAAAGATTAA
CCAGTGTGAACATTCTGATCTGTTAATTCCAGGGACTGTTTTCTTTCCAA
TGGACTGTTTGTTGGTAGAATAACCCCCAAAAGCTCAAAGCTAAAATGCA
TCATCAGTCCTAGTCGGCAGTTCCTTAAGAATGGACTGGCGGCGTGGTTG
AGCTGATATGGAAAAGCTGCACCTTCCTGCAGAAGATCAACTGACCTGCT
ATCCCACCCCAAATTCAACCTGAGGTATATTTCAGTGAAGCAGGTAGCTG
TGCTTCTCAAAGCAGAGAAGCAGTTTTAAGAACCAAAAAGGTAGAGGAAA
TCTA

Sequence ID 324
GTTTGTTACAGGCAGAATTGGATAGATACAGCCCTACAAATGTATATGCC
CTCCCCTGAAAAAAATTGGATGAAAATCTGCACAGCAAAGTGAAACACAC
AGATAATAGGAACAAAATGTAGTTCCCATGTGCCAAACAAAATAAATGAA
ATCTCTGCATGTTTGCAGCATATCTGCCTTTTGGGAATGTAATCAAGGNA
TAATCTTTGGCTAGTGTTATGTGCCTGTATTTTTTTAAAATGGTACACCA
GAAAAGGACTGGCAGTCTACTTCTACCATAGTTAAACTTCACCCTCTTTA
ATTTCACAACATATTCTTTGGAAGCAGGAAGAAATGCTCATAAAGAGGAT
CAGACCTTCTTTCCCGTGAAACCAGTATTTGGCGCCATATATAAGCCTGG
TTAAATTGGTCATCTAAAGCTGTCAAATAAGACATTCTGTGAAAGGTAAA
CATCGAAACTGGTTATAAGTAAAACCATCAAGCCAACAACAGGGTCTTGA
GATAACCTTTGAAGCTTATTGTCTGGCCTGCACCAGAAGATGTCTGCATT
ACTCATTGCTAAAAATGTGTACACAGAACTGCACTAGGATTAATTGGTTC
AAGAAGAAATTTAAACTTACGTTTGGGTTTCCATACAGCACTCTATTGAA
TACATGCATCTGAATTTAAGTTGCAA

Sequence ID 325
GACCAGTAATGGCTTTTAAGAGTCCATTTTGTCATTGTCTCCCTAGTTAA
TTACAGGTGGGGGATCTTTTGCCTCTATTCTCTTCATATTGAAATGAATC
ATACTCATGTTTTGTGGAACTCCTTAAAGTTGTAGCTGTCATGATCAGAT
TTTTTTTATATTTCCTCAGCTTAACTCTGCTACTTGATTTACAGTGACCC
ATAACCTACTCATCCTTGGTTTATAGTGACACATAATCTTATCTCTTTAT
AGAACCTTAAATTTTATCATTATTTTCGCTTAGAATACAGCATTTCTTTG
CTTCTGTTGCTGGTTTGACTTAAGAAATAAGGCAGTAACTCTGATCAATC
AATTATCCATAAGGAAGGGCTTTTCATGGGTTCTATTAATTTGTTAGTAC
CCTAAGTATATCTGAAAAATATGTCTATTGAGAGAAGATTTTGGCATTCC
AGATGGTATAGTCTATATATATTTAAAGTTTTGAATTTGCTTATATATAC
TCAGCTTTCTTTTTCTAGCATTTTTGCATTTACCTGTTAATTGAAGTATA
CCCCCCACATATAAAAGTTCCTCTTAAAGACACTGGACTCTTTCTGGGGG
GCTAAAATA

Sequence ID - 326 nt: 554
CCCGGAATCGCGGCCCGCGTCGACAACAAACCTGCATGTTCTGCACATGT
ATCCAGGAACTTAAAAAAAAAAAAAGATAGTTTGTGTGTCTTAATTGAAT
AATAGTAGATTTATAGATTAAAGATCTATGGGTTTTTAATATGGATTANA
AATCTGTGGGTTTTTGATATGGATTANAAATCTGTGGGTTTTTAATATGG
ATTGGAAATCTGTGGGTTTTTAATATGGATTAAAAAACATCTGTGGGTTT
TTAATATGGATTAAACATCTGTGGGTTTTTAATATGGATTAAACATCTGG
GTTTTTAATATGGATTAAACATCTGTGGGTTTTTAATATGGGTTAAAAAT
CAAAAGAAAATGAACTATTTGCTCCAGTGCAGGAAAATACAGGCAATACT
GGATACAATTAGATGGTCAGGAGCGATAACCCGGTTGCCATTGTTTGAAG
AAGAGAATAAGGNGCTAGCATTCCTATCCGTAGATAATTTGACAGCTAGG
AAATAGGGGGAGTCTTCTATGTAGTTAGTGAAGGCTAAATGAACTATTAT
ATGC

Sequence ID 327
CGGCTACCGACAGAAGGACTATTTCATCGCCACCCAGGGGCCACTGGCAC
ACACGGTTGAGGACTTCTGGAGGATGATCTGGGAGGGGAAGTCCCACACT
ATCGTGATGCTGACGGAGGTGCAGGAGAGAGAGCAGGATAAATGCTACCA
GTATTGGCCAACCGAGGGCTCAGTTACTCATGGAGAAATAACGATTGAGA
TAAAGAATGATACCCTTTCAGAAGCCATCAGTATACGAGACTTTCTGGTC
ACTCTCAATCAGCCCCAGGCCCGCCAGGAGGAGCAGGTCCGAGTAGTGCG
CCAGTTTCACTTCCACGGCTGGCCTGAGATCGGGATTCCCGCCGAGGGCA
AAGGCATGATTGACCTCATCGCAGCCGTGCAGAAGCANCAGCAGCAGACA
GGCAACCACCCCATCACCGTGCACTGCAGTGCCGGAGCTGGGCGAACAGG
TACATTCATAGCCCTCAGCAACATTTTGGAGCGAGTAAAAGCCGAGGGAC
TTTTANATGTATTTCAAGCTGTGAAGAGTTTACGACTTCAGAGACCACAT
ATGGTGCAACCCTGGAACAGTATGAAATGTGCTACAAAGTGGTACAAGAT
TTATTGATATATTTCTGATTATGCTAATTTCAATGAAGATCCTGCCTTAA
ATATTTTTTAATTTAATGGCANAT

Sequence ID 328
CAAGACTCCATCTCAAAAAAAAAAAAAAATCTACAGTGCTGAGTATATAA
AATTATTAACACATTTCACAACAATATGTGTTTGTGGAGTTAAATATTTT
TTGTCTTTAAAACAGGTAATTTTAGTGCATACTTAATTTGATGATTAAAT
ATGGTAGAATTAAGCATTTTAAATGTTAATGTTTGTTACATTGTTCAAGA
AATAAGTAGAAATATATTCCTTTGTTTTTTATTTAAATTTTTGTTCCTCT
GTAAACTAAAAGAACACGAAGTAATTGGTCACAATTACTGGTGTTTAACT
GCCAAATATGGGTAAATAAGGGAAAATTTTGTTTAATATTTAGTCCTTCT
GAGATGGCTTGAATATTTGAATTTTGTTGTACGTCTATACTGGGTAGTCA
CAAGTCTTATAAACACTTTAGAGGAAAGATGGATTTCAGTCTGTATTTTT
AAACATCATTTATTTTAAATCTGGTGCTGAAAAATAAGAAAAAAATTAAA
CTGCATTCTGCTGTTCTTCTTTANAAGCATTCCTGCGTAAATACTGCTGT
AATACTGTCATGCAAAGTGTATCCTTTCTTGTCGTATCCTTTTTGGGGCA
GTGGTTTTT

Sequence ID 330
GCGGGAATCGCGGCCCGCGTCGACCTCAAAGGAGAAAAAAAACCTTGTAA
AAAAAGCAAAAATGACAACAGAAAAACAATCTTATTCCGAGCATTCCAGT
AACTTTTTTGTGTATGTACTTAGCTGTACTATAAGTAGTTGGTTTGTATG
AGATGGTTAAAAAGGCCAAAGATAAAAGGTTTCTTTTTTTTTCCTTTTTT
GTCTATGAAGTTGCTGTTTATTTTTTTTGGCCTGTTTGATGTATGTGTGA
AACAATGTTGTCCAACAATAAACAGGAATTTTATTTTGCTGAGTTGTTCT
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
TTTTAAAATTTTTAAAATAAAACCCTTGGTTAT

Sequence ID 331
GCCGCGTCGACCTGCATGAGCCACAGTTTCTTGACTGGAGGCCATCAACC
CTCTTGGTTGAGGCCTTGTTCTGAGCCCTGACATGTGCTTGGGCACTGGT
GGGCCTGGGCTTCTGAGGTGGCCTCCTGCCCTGATCAGGGACCCTCCCCG
CTTTCCTGGGCCTCTCAGTTGAACAAAGCAGCAAAACAAAGGCAGTTTTA
TATGAAAGATTANAAGCCTGGAATAATCAGGCTTTTTAAATGATGTAATT
CCCACTGTAATAGCATAGGGATTTTGGAAGCAGCTGCTGGTGGCTTGGGA
CATCANTGGGGCCAAGGGTTCTCTGTCCCTGGTTCAACTGTGATTTGGCT
TTCCCGTGTCTTTCCTGGTGATGCCTTGTTTGGGGTTCTGTGGGTTTGGG
TGGGAAGAGGGCCATCTGCCTGAATGTAACCTGCTAGCTCTCCGAAGCCC
TGCGGGCCTGGCTTGTGTGAGCGTGTGGACAGTGGTGGCCGCGCTGTGCC
TGCTCGTGTTGCCTACATGTCCCTGGCTTGTTGAGGCGCTGCTTCAACCT
GCACCCCTCCTTGTCTCATAGATGCTCCTTTTGACCTTTTCAAAATTAAT
ATGGATGGGAAAGCTCCTATGCCTTTTGGCTTCCTGGTAGAAGGCGGGAT
GCCCAAGGGTCTGCCTGGGTGTGGATTGGATGCTTGGGGTGTGGGGGTTG
GAAACTGTCTTGTGGCCCACTTGGGCCCC

Sequence ID 335
CCCGCGTCGACTTTTAAAGTCATCTCTATAGGAAGGTGCTGGGCAGGGAT
CCCAGAGAAAGAAAGGGTCCAAGACTCCATTAACTGCCCTGGATGAAGGG
CACTGCTACAGCAGCTAGTACCAGAGACTCTCCTATCTCACGGTTGAGGC
AGACCCAGGATAGAATAGAGAATAAAAGGAATGCTTATAGGAAACAATTT
TGTATGGAATGCTAGATGGCCAAGCCTCAGCCTTTGGTCCAGTGCAACCC
TTGCCTCGCTTGTCAACAGTGAAAAATTAGTTTGGTTAGAAGAACCATCT
GGAAACACACCAGCTTCTGCTACCTTCATGCTCATTGTTAAAAAAAGATT
AACCAGTGTGAACATTCTGATCTGTTAATTCCAGGGACTGTTTTCTTTCC
AATGGACTGTTTGTTGGTAGAATAACCCCCAAAAGCTCAAAGCTAAAATG
CATCATCAGTCCTAGTCGGCAGTTCCTTAAGAATGGACTGGCGGCGTGGG
TGAGCTGATTTGGAAAACTGCCCTTCTGCAAAAAACACTGGCCTGCTTTC
CA

Sequence ID 337
CAAGACTCCATCTCAAAAAAAAAAAAAAATCTACAGTGCTGAGTATATAA
AATTATTAACACATTTCACAACAATATGTGTTTGTGGAGTTAAATATTTT
TTGTCTTTAAAACAGGTAATTTTAGTGCATACTTAATTTGATGATTAAAT
ATGGTAGAATTAAGCATTTTAAATGTTAATGTTTGTTACATTGTTCAAGA
AATAAGTAGAAATATATTCCTTTGTTTTTTATTTAAATTTTTGTTCCTCT
GTAAACTAAAAGAACACGAAGTAATTGGTCACAATTACTGGTGTTTAACT
GCCAAATATGGGTAAATAAGGGAAAATTTTGTTTAATATTTAGTCCTTCT
GAGATGGCTTGAATATTTGAATTTTGTTGTACGTCTATACTGGGTAGTCA
CAAGTCTTATAAACACTTTAGAGGAAAGATGGATTTCAGTCTGTATTTTT
AAACATCATTTATTTTAAATCTGGTGCTGAAAAATAAGAAAAAAATTAAA
CTGCATTCTGCTGTTCTTCTTTAGAAGCATTCCTGCGTAAATACTGCTGT
AATACTGTCATGCAAAGTGTATCCTTTCTTGTCGTATCCTTTTTGGGGCA
GTGGTT

Sequence ID 338
CTGGACTGCATGACCAGATCTGATGGGTGAGACTCAGGTGGCATGGAAGA
GCCGAAAGAGGATACCATATGTGGGTGCCGGGGGGGATAGGTGAGAAGTA
CTAGAAGGCGGAATGGAAGGACACTTCTGCTCAGCTCTGTGACACGGGCA
GGGACCCTGCAGGGCTCAGGTCCTTTAACACAGCAGCTTCATTCTAACAC
CAGCAGCGTTGGAACACACGTACAAGTATGCAGACTAAGCTCTTGCTTGG
CTGATACGGCTTTTTGGGTTTTTAGAGAACATGCATATATGTTCTCATTC
ATGGTACATGAACTCAGAAGCCTTACTGCCTATTTTTGTTAATACTTCTG
GGCAAACATTACCACTTACAACTCACACCAGTTAGAAATCATTTGTAAAA
TGTTATTTAATAAAGCCAAAGAACTAAATCATATTTATTTTCCAAGGNTT
TCTAAGATCTCTGAAACTAATGAGGTTTTTTAAATCCCCATTAAGTACTC
ATCACTGCTAGTAAAAGCAGTTGTCTTTACCTTTAATTCCAGTGAGTCCC
CTTAAATTTATTTTTTATTATCTTTGGCTACATTGCCTTAGACAAAATGT
GGTCACCCTAATTTAANGGATAAAATTCACATCCTCACAGATTTCTTATT
AAGAGGGTCTAANCCTTGAATAATCANCAGTGGAAATGGAAGTCTTCTTT
ACTGGNTTTNATCCTTTCCCTTTTTTATCCCATG

Sequence ID 339
TTTTTTTTTAAATAAAGCTGTCGGCACTCAAGGGTAATTTCATATCAGTG
TGNTCTACAAGCTGGGGGAAAATGAGTTCTAATTGTCANAGCTACCAAAT
CCTTCACCTTTAGCATAAAGGTTTAAAGATATCACAAAGATGCCAAGTGA
TTAATAATGTTTTAAACCACCCCTTTTTCTGTCTGAAAAAACAACTAAAA
CAATATTACAACAGTATAGTTACAGAAGGGTTCTATTTTCATATGTTTTA
TGCACACTGTGCCTCAAAGGTACTATTTAAATATATATACTTTTGAGGGG
GTGGCTAATGCAGAAACACCCAAGACCTAAGGAAGATACAACCCCATTTC
TAGGTGTGAGGTCTAAATGCTTCACACACCCACTTGTGACCTTTTTTCAT
GAAGAATCATAACACTGTGCAGTGAGAAACAGTGGCAAAGCAATACTGAA
AGCATTTTAAATTATTTACTAGGTTAAAAGGGTGAACTGATACTTTAAAT
ACATCAAATTTCATCAT

Sequence ID 360
GCAAGTGAGAGCCGGACGGGCACTGGGCGACTCTGTGCCTCGCTGAGGAA
AAATAACTAAACATGGGCAAAGGAGATCCTAAGAAGCCGAGAGGCAAAAT
GTCATCATATGCATTTTTTGTGCAAACTTGTCGGGAGGAGCATAAGAAGA
AGCACCCAGATGCTTCAGTCAACTTCTCAGAGTTTTCTAAGAAGTGCTCA
GAGAGGTGGAAGACCATGTCTGCTAAAGAGAAAGGAAAATTTGAAGATAT
GGCAAAAGCGGACAAGGCCCGTTATGAAAGAGAAATGAAAACCTATATCC
CTCCCAAAGGGGAGACAAAAAAGAAGTTCAAGGATCCCAATGCACCCAAG
AGGCCTCCTTCGGCCTTCTTCCTCTTCTGCTCTGAGTATCGCCCAAAAAT
CAAAGGAGAACATCCTGGCCTGTCCATTGGTGATGTTGCGAAGAAACTGG
GAGAGATGTGGAATAACACTGCTGCAGATGACAAGCAGCCTTATGAAAAG
AAGGCTGCGAAGCTGAAGGAAAAATACGAAAAGGTA

Sequence ID - 361 nt: 622
CTGTNATNGAATCTGCTTGTNACTNAAATGCTAAACTCAATTCTGTAATT
CAATAGGTGCACCTNTCTGAGAAACATANNAGACAATGAGGAAAAGGATT
CANCATTCCGTGGAATTTGTACCATGATCAGTGTGAATCCCANTGGCGTA
ATCCAAGTAAGATGTTCACAAAGATTTGTTTTTAATGTCTAATTAATAAA
ATTTTAAAGGAAGAAACATTCTAATACTTTAATTATAAAAAGTTAACTAT
TTTCAAAGGTATCAAAATACAGTTAAACCTTTAAAATGTATATTTCTTAA
TATCTTGAAATTGTAATGCCTTTTTTTTTTCCTAAATTTTTTTTGTCATG
AAATGAGATAGTAACAGCAGATTGGGACAACAAGGTTATATTCTTGTCTT
GAATCAGGCCATGGCTTCTTTCATCCAAATTTCAGACCTCATTTATTTAC
TTTGTCCCTGCCTCCCATCCCTGGATATCANGTTTGTGGATATCTACAGT
TAATAGAGTGACCAAATAGTAGGAATACTGTCTCTCTATTCTGAATAAAA
TACTTTGAATCAGATTTAGAAATAATGAATAAAATACAAATCACCATTGA
AATTGCTCTAATTTTGAGAGCT

Sequence ID - 363 nt: 628
ATCACNTGAGGCAAGAGTTTGAGCCAGCCTAGCTAACATGGTGAAACCCC
ATCTCTACAAAAATATAAAAATTAGCCTGGGTGGTGATGGGCACCTGTAA
CCCCAGCTACTCGGGAGGCTGAGGTAGGAGAATCACTTGAACCCGGGAGA
TGGAGGTTGCAGTGAGCCAAGATCGTGCCACTGCACTCCAGCCTGTGTGA
CAGAACAAGACTCTGTCTCAAAAAAAAATAATAATAATAATAATAATAAA
AAGGAATAACATAGCTAGGAATAAATTTAATCAAAGAGGTGAAAGACTTA
TACACTTAAAACTACAAAAAAAAAATCACTGAAGGAATTATAGACCCAAA
TAAAAATAAATAAAAAGACATTCTGTGTTTTAGGGAAAGAAGACTTAATA
TTGTTAAGATGTCAATACTACCCAAAGTGATCTACAGATTCAACATAATC
CCTATCAAAATTCCAACAGCCTACTTTGTAGAAATGGAAAAGCCAATTTT
CAAATTCAGATGGAATTGCGAGGGGTTCTGAATAACAAAAACAATCTTGG
GGAAAAAAAACAAAAAACAAAGTCAAAGAACTCACACTTCTCTATTTATA
AATTTACTACAAAGTTATAGTAATCAAA

Sequence ID - 364 nt: 528
TGAACATCCAGCCATGTCATTTCTTCCATTCCTGCCCTGGAGTAAAGTAG
ATTTACTGAGCTGATGACTTGTGTGCATTTGTACATTGCAACCTTAGCTT
ACCTCTTGAAGCATGTAGAGCATTCATCACCCACCATTCATTCACTGCCT
ACTCCCACCACAGCTGTTTCGTGGTCTGTCTGCTCCCTGTGCCACCCCCA
CCCCATCAGGTGGGCCTTTTGCAAGTGATGAAGTCACCTGTGGGGGAAGA
GCTTTCCTTTCCTCTCCTCAACTCAGAAGGCCTCTTCCTCTTGCTCAAGA
GGGTGCTGCTGCTTTCTGCCTCCTTCCCCGGCCGGCCTCCATCCCAGTTC
ACCTTTTCAGAAATGGCCCCTCAGTCAACTCTTCCCTTTTCTCCTGGCTT
TTTATTTCTCCCAGTCTCTTAAGAGTATCCTTAGCTTTAAAAACAATAAC
ACAGAGGATGGGTGCAGTGGCTCATGCCTGTAATCCCAGCACTTTGGAGC
CTGGGGCGGGCGGATCACTTGAGGNCA

Sequence ID 365
GTCCCGGAATCGCGGCCGCGTCGACCTTTTCTATGCCTGCTATATAAACA
GTACCTTGCAAGATGTCCTGTCTGATATCCACAAAGGGGTATTGTCAACC
CCAAGTTCAGACAGCTTTGTATTCTTCTGTCCCTGGATACATGAATTACT
GCCATCTTTACACAGCGCCCTAAAATACCAACGCGAAGTTACCTGCTCAG
CTTGAAGCTGCGCTGTACCCTGGAACCAGCACTTCTGCTGAATGACTCAG
GATGAAGCCTCGACTTCTCCTTCCCATCCCATGCCCAGACCCCAGTGGCT
CCTTTCCCAATCTGATCCAGTGACTTTAAGTCCAGCTGTTGCAACCTGGG
CATGAGGAGGAGTGCAAGATGGCTTTGTCCTACCTGGAAAGAGGCTTTCT
GGA

Sequence ID 366
CACCATTTACACACAGTGGGTCCTTGAATAGCATCGTTTTATTCAATGTC
ATTTTGTTATAACATTGAGAAAAAAATTGATTCCCGGCTGGGGCCACTGT
CTGTGCACCGT

Sequence ID - 368 nt: 329
GAAAGATCTAAAATCGACACCCTAACATCACAATTAAAAGAACTAGAGAA
GCAAGAGCAAATTCAAAAGCTAGCAGAAGGCAAGAAATAACTAAGATCAG
AGCAGAGCTGAAAGAGATAGAGACACAAAAAACCATTCAAAAAAAAACAA
TGAATCCAGGAGTTTTTTTTTTAAAAAGATCAACAGAATTGACAGACTGC
TAGCAAGACTAATAAAGAAGAGAGAAGCATCAAATAGACTCAATAAAAAA
TGATAAAGGGGATATCACCACCAATCCCACAGAAATACAAACTACCATCA
GAGAACACTATAAACACCTCTATGCAAAT

Sequence ID 369
GAAAGATCTAAAATCGACACCCTAACATCACAATTAAAAGAACTAGAGAA
GCAAGAGCAAATTCAAAAGCTAGCAGAAGGCAAGAAATAACTAAGATCAG
AGCAGAGCTGAAAGAGATAGAGACACAAAAAACCATTCAAAAAAAAACAA
TGAATCCAGGAGTTTTTTTTTTAAAAAGATCAACAGAATTGACAGACTGC
TAGCAAGACTAATAAAGAAGAGAGAAGCATCAAATAGACTCAATAAAAAA
TGATAAAGGGGATATCACCACCAATCCCACAGAAATACAAACTACCATCA
GAGAACACTATAAACACCTCTATGCAAATAAACTAGAAAAT

Sequence ID 370
GAAAGATCTAAAATCGACACCCTAACATCACAATTAAAAGAACTAGAGAA
GCAAGAGCAAATTCAAAAGCTAGCAGAAGGCAAGAAATAACTAAGATCAG
AGCAGAGCTGAAAGAGATAGAGACACAAAAAACCATTCAAAAAAAAACAA
TGAATCCAGGAGTTTTTTTTTTAAAAAGATCAACA

Sequence ID 371
GCCCGGAATCGCGGCCGCGTCGACGTAAGCTCGGCTGAATCCACGGTTCA
AGAACAGGAAAGAAGGCCAAGGCATAGGGAGTGGGGCAGTTGGGTGAATA
TTAGTACCTTTCCCTCAGNTNCATTAATTACCCCTGCCTACTCTGCACAA
AAGGATNTAACAACAGTTTCCTTTTTAATGGCCAGGTACAGCTGCTTATA
TGGANGGGCATTTNTNAATGATATCCTTNATCACTGTCTTAATCATCACA
TNCTTAAAACAATCACTTTATTGTGTTAAGGAAGATAAAAATGGCTGGGT
TCAATTTCCGTTCTGGAAGAAATCGANTNAAAAGGTAACCATTTAATAAT
GCANAGGGCANTTTCACTGCAGACCCTAATACTGGAAATTTTTAAAAACA
AATGAAAAACTTCTACTTTTTCTTCTAAGCTTACTTAACCACCCAAATTT
TCCAGCCACATATCTTCCTAGTCTACAACTGCCTTTAACTTTAAGAGATG
CTCAAAAAAATGTAAATTCTCAAATACATTCTTATTACAATTACTGCTAA
CCT

Sequence ID 373
CCAGTGTGCTGGGATTACAGGCATGAGCCCTGCACCCAGCCTCTTAAACT
GATCATATGATATTGGTTCTCAACCAAGGGTGACTTTGCCCCCAGAGGAT
ACTTGGCAATGTCTGGAGATACTCAGTTGTCATGACTTGGACAGGTGCTA
CTGTCACCCAGTGGGTAGAGGTCAGGGATGGTGCTAAACATAGGACAGCT
GTCAAGAGAAAAGAATGTACCCAGCCCCAAATGTCAGTAGGGCTGAGGTT
GAGAAACCCAGCTGTAGCTGACGTGTGAAGGACAGACTGGCCTGGAAGTG
TGTTTTCTGCCCCTTTCCACCCCTGCATATTAGTTAAGGCCAAAGGAAAA
AAGGAATGCAGGAAATGCCCGTTAAAAATCTTCAAAACAATATAAAATGA
TCAATTCCACTAAAACCCTTTACACATTTAAGTATAAAGGTATTGGTAGG
AAAATTTGTTATTCACTGCTTTTCTCAGTGTCATGAAATAATTATTTCTG
CTGTCAGTTT

Sequence ID 374
AAAAAAAAAATCACTGAAGGAATTATAGACCCAAATAAAAATAAATAAAA
AGACATTCTGTGTTTTAGGGAAAGAAGACTTAATATTGTTAAGATGTCAA
TACTACCCAAAGTGATCTACAGATTCAACATAATCCCTATCAAAATTCCA
ACAGCCTACTTTGTAGAAATGGAAAAGCCAATTTTCAAATTCAGATGGAA
TTGCGAGGGGTTCTGAATAACAAAAACAATCTTGGGGAAAAAAAACAAAA
AACAAAGTCAAAGAACTCACACTTCTCTATTTATAATTTACTACAAAGTT
ATAGTAATCAAAGTCGACGCGGCCGCGATTCCGGG

Sequence ID 378
CGACTGCGGCTCTTCCTCGGGCAGCGGAAGCGGCGCGGCGGTCGGAGAAG
TGGCCTAAAACTTCGGCGTTGGGTGAAAGAAAATGGCCCGAACCAAGCAG
ACTGCTCGTAAGTCCACCGGTGGGAAAGCCCCCCGCAAACAGCTGGCCAC
GAAAGCCGCCAGGAAAAGCGCTCCCTCTACCGGCGGGGTGAAGAAGCCTC
ATCGCTACAGGCCCGGGACCGTGGCGCTTCGAGAGATTCGTCGTTATCAG
AAGTCGACCGAGCTGCTCATCCGGAAGCTGCCCTTCCAGAGGTTGGTGAG
GGANATCGCCCAGG

Sequence ID 380
GCAATTTAATTTTTAATAACAAAGATACTGTATTTTAACATGGTGAAATA
TACTTGGCTAAGTCCAGATTAAAAAAAAAAAGTATCTAGCCCAACAGTAC
AATTATACAGCTTTGTACAGAACATTCCATAGATCAACAGAAAATACATT
TGAGCGCAAAAATAAAAAATATTTAAGGAGAATCTCTAAGCAGCATTTTA
TTTCTGCAAAAGACATATCTTGTCTGATTAAATATCTACAAGTGCTTTTC
CTTTCAAAAATACATATATTCTTAATAGACTAAGTCATTAACAATGACCT
GGTAATTCTTTCACTTCAATTTGAATGATTTATAAGCTAAATCTTCAACC
ACAAAAAGGTTTTTATTTGTATTAAGATGTTACCACTTTTGACAAAAAGC
TTAAAATATTTTATATTTCAAAGGAAAATTAGCAACATAACTTTACAATA
TATTCTATGATATTTTGATTGTGAGGGCTACTCTATTTAAAACTGATGAT
CTCTGTTGTGTTGCTCAGATGCAGGAAAGCAGCAAAA

Sequence ID - 381 nt: 534
GACTTANATCTAAATGGACCACATTCTCTACTTAAAAAAATGCTATTAAC
CATGTGATCTTCTCAGTCATGAGGTAATCTGGTGACTACCCTTCCTCAAA
GCCAGTTGGGATATTCTTTGAATAGAGTAAAACAGTGTTTCTAGGCTGGG
AGACACCAGACATAGTTGAGGACAGAGGTGCTAGAAAATAGGAAGTTTAA
AAGCATGTGCGGTGATGCTCAGAGGAGGTAAACCCCACCCTCATGCTCAT
AGCTTCCAATCATTTTCTCTAGTTCTTAACTCTTAAATGTGAGAAATGCT
TGAAGATTCTAGTCATCTGAAGAAAGTCTCTTTATTAAAGATTTTCATAA
AAGAGACCAAAGCAGACAAACAGAAAAAGACATCTTGGGGAAAAAAACAA
GGATAATGGGAAGAGAAGGAAAGTTTTAAAAATTATCAATATCCTCAGGG
GGACAAAATATTATATCCTATAAAGACAGATTTTTATTTTTTAAAAAAAT
AGAAAGCAAAACAAGCTCCTAAAAATAAAGTTTG

Sequence ID - 382 nt: 444
GTTAAGGAAGTCAGCACTTACATTAAGAAAATTGGCTACAACCCCGACAC
AGTAGCATTTGTGCCAATTTCTGGTTGGAATGGTGACAACATGCTGGAGC
CAAGTGCTAACATGCCTTGGTTCAAGGGATGGAAAGTCACCCGTAAGGAT
GGCAATGCCAGTGGAACCACGCTGCTTGAGGCTCTGGACTGCATCCTACC
ACCAACTCGTCCAACTGACAAGCCCTTGCGCCTGCCTCTCCAGGATGTCT
ACAAAATTGGTGGTATTGGTACTGTTCCTGTTGGCCGAGTGGAGACTGGT
GTTCTCAAACCCGGTATGGTGGTCACCTTTGCTCCAGTCAACGTTACAAC
GGAAGTAAAATCTGTCGAAATGCACCATGAAGCTTTGAGTGAAGCTTTTC
CTGGGGACAATGTGGGCTTCAATGTCAAGAATGTGTCTGTCAAG

Sequence ID - 383 nt: 566
CTTTGAAGAACTTTGCCAAATACTTTCTTACCAATCTCATGAGGAGAGGG
AACATGCTGAGAAACTGATGAAGCTGCAGAACCAACGAGGTGGCCGAATC
TTCCTTCAGGATATCAAGAAACCAGACTGTGATGACTGGGAGAGCGGGCT
GAATGCAATGGAGTGTGCATTACATTTGGAAAAAAATGTGAATCAGTCAC
TACTGGAACTGCACAAACTGGCCACTGACAAAAATGACCCCCATTTGTGT
GACTTCATTGAGACACATTACCTGAATGAGCAGGTGAAAGCCATCAAAGA
ATTGGGTGACCACGTGACCAACTTGCGCAAGATGGGAGCGCCCGAATCTG
GCTTGGCGGAATATCTCTTTGACAAGCACACCCTGGGAGACAGTGATAAT
GAAAGCTAAGCCTCGGGCTAATTTCCCCATAGCCGTGGGGTGACTTCCCT
GGTCACCAAGGCAGTGCATGCATGTTGGGGTTTCCTTTACCTTTTCTATA
AGTTGTACCAAAACATCCACTTAAGTTCTTTGATTTGTCCATTCCTTCAA
ATAAAGAAATTTGGTA

Sequence ID 384
TTTTGGGGTTTATATATAAGCCTGGTTCTTGCTGAAACTGCTTATGTTGA
TAACCAGTTAGTGAGTTCCTCTCTATTGACTTGCTGGGAAGTTTATAGAG
ACATTTTTTATGCATTCAGAGATTTCAGTACAAATCTTGAAAAAGGGACA
TTTAGGCCGGGCGCGGTGGCTCACATCTGTAACCCTAGCACTCTGGGAGG
CTGAGGTGGGTGGATCATGAAGTCAAGAGATAGAGACCATCCTGGCAAAA
ATTAGCTGGGCGTGGTGGGGTGCGCCCGTAGTCCCAGCTACTCGGGAGGC
TGAGGCAGGAGAATTGCTTGAGCCCGGGAGGCGGAGGTTTCATTGAGCCG
AGATAGTGCCACTGCACTCCAGCCTGGACAACAGAGCGAGACTGTGTCTT

Sequence ID 386
CTAAGGGTTTAAAGATGGAAAGAGGCATTGATGAACAGCTGGGGAAGGAG
TAGTTTGAGGTAGATGTGCAGATGGAATGAAGAGAAGGTCTCAAGAAGAG
GGTGGAGCCAAAGAGGGCTGCAGATTTAGAAGGCTAAAGTCTTTAGATGG
CTTTGGATAGCCTGTTGTATCTTGGACCATGCAGGTTACAGTGGAGCATG
GAGTGGGGACAGAAGTGGAGGAAGGAACCAGGGAACATGGAGTGAGAAGC
TAAAGGAAAGTGATGCAGTAGATACATGGCTCTAAAGTACTCAGGACTTT
CAGAGGCTTAAACATAGGGTGACCAACTATCCCACTATGCCTGATACTAA
GGGCATTCCCTGGATGTGGACCTTTCATTCCCCAAATTAGGAAAGTCTTG
GGCATACCAAGACAAGTTGGCCACCCTACTCAAAAGTATGTAAGCTAACA
TATCTGTTCTCTAAGAGGTTAAAGCTGGATGGGGATACCAGATGTATGTA
CGTGATGCAGTTAAACAGCAATACAAGGGGGCAAGTCTACCTGATCGGCC
AATTCAATGGGA

Sequence ID 387
GAAGCCAAACCAAAGGAGCTTCTACTTCATGATGCCATTTATGTAAAGTT
CAGGCAGAGAAAATCAGTGGTTTAAGAAGTTAGAATAATGATTATCTTTG
GAGGGATTGCAACTGGAAGAAGTCATGATTGGGATTTCTGGGTCCTAATA
GTGCTCTGTGTCTTGATCTGAGTGCCGACTACATGAGTGGTTAGGTTTGC
AAAATTCATTGAGTTATGCACTTAATGGTGTTGTCTTATTAGAGCTGATG
GAGGAGAGAGGGCTTCAATTTGCACAACTGAGTAATCAGCTAGGCCCAGT
CACTAGGTGAACAACTTACTGCTCCAATCAGCCTTAGAGCAGGAATCAAA
CTCATGTCTCAGAAAAGTTATTAATTCAGCTTGTCTTGGGACTTCCTTCA
GAGTCACTCTTGAATAGCTGAAATAGTAAATGTTAAATCTGTGGATGCAA
GTGTGTAAATTATTTTAGTCATCAGCTCTAATAAGATGGCCTTTGGGGAA
ATGAGTATAAGGTCACGAAAATGAAATGGCAAGAAGGAGGTCTACTATTT
CTTCTGTAATACTGATTTTTACCCCATCAGGGTCAGTCCCCAGAGGTTGT
AAATGTGAAGCTTG-TCTTTTTCTTTAATAA

Sequence ID 388
CTTTGGACACTAGGAAAAAACCTTGTAGAGAGAGTAAAAAATTTAACACC
CATAGTAGGCCTAAAAGCAGCCACCAATTAAGAAAGCGTTCAAGCTCAAC
ACCCACTACCTAAAAAATCCCAAACATATAACTGAACTCCTCACACCCAA
TTGGACCAATCTATCACCCTATAGAAGAACTAATGTTAGTATAAGTAACA
TGAAAACATTCTCCTCCGCATAAGCCTGCGTCAGATTAAAACACTGAACT
GACAATTAACAGCCCAATATCTACAATCAACCAACAAGTCATTATTACCC
TCACTGTCAACCCAACACAGGCATGCTCATAAGGAAAGGTTAAAAAAAGT
AAAAGGAACTCGGCAAATCTTACCCCGCCTGTTTACCAAAAACATCACCT
CTAGCATCACCAGTATTAGAGGCACCGCCTGCCCAGTGACACATGTTTAA
CGGCCGCGGTACCCTAACCGTGCAAAGGTAGCATAATCACTTGTTCCTTA
ATTAGGGACCTGTATGAATGGCTCCACGAGGGTTCAGCTGTCTCTTACTT
TTAACCAGTGAAATTGACCTGCCCGTGAAGAGGCGGGCATAACACAGCAA
GACGAGAAGACCCTATGGAGCTTTAATTTATTAATGCAAACAGTCCTAAC
AAACCCCAGGTCCTAAACTCCAAACCTGCATTAAA

Sequence ID 389
CGACCCGGAATTCGCGGCCGCGTCGACTGAGTTCTTGACAAGAGTGTTTT
TCCCTTCCCGTCACAGAGTGGGCCCAACGACCTACGGCACTTTGACCCCG
AGTTTACCGAAGAGCCTGTCCCCAACTCCATTGGCAAGTCCCCTGACAGC
GTCCTCGTCACAGCCAGCGTCAAGGAAGCTGCCGAGGCTTTCCTAGGCTT
TTCCTATGCGCCTCCCACGGACTCTTTCCTCTGAACCCTGTTAGGGCTTG
GTTTTAAAGGATTTTATGTGTGTTTCCGAATGTTTTAGTTAGCCTTTTGG
TGGAGCCGCCAGCTGACAGGACATCTTACAAGAGAATTTGCACATCTCTG
GAAGCTTAGCAATCTTATTGCACACTGTTCGCTGGAAGCTTTTTGAAGAG
CACATTCTCCTCAGTGAGCTCATGAGGTTTTCATTTTTATTCTTCCTTCC
AACGTGGTGCTATCTCTGAAACGAGCGTTAGAGTGCCGCCTTAGACGGAG
GCAGGAGTTTCGTTAGAAAGCGGACGCTGTTCT

Sequence ID - 390 nt: 523
GAATCCCTAGAAAAAGAGAATTCCCAACTTGATGAGGAAAACTTAGAACT
GCGAAGGAATGTAGAATCTTTGAAGTGTGCAAGCATGAAAATGGCTCAGC
TACAGCTAGAAAACAAAGAACTGGAAAGTGAAAAAGAGCAACTTAAGAAG
GGTTTGGAGCTCCTGAAAGCATCTTTCAAGAAAACAGAACGCTTAGAAGT
TAGCTACCAGGGTTTAGATATAGAAAATCAAAGACTGCAAAAAACTTTAG
AGAACAGCAATAAAAAAATCCAGCAATTAGAGAGTGAACTACAAGACTTA
GAGATGGAAAATCAAACATTGCAGAAAAACCTAGAAGAACTAAAAATATC
TAGCAAAAGACTAGAACAGCTGGAAAAAGAAAATAAATCATTAGAGCAAG
AGACTTCTCAACTGGAAAAGGATAAGAAACAATTGGAGAAGGAAAATAAG
AGACTCCGACANCAAGCAGAAATTAAAGATCCACATTTGAAGAAAATAAT
GTGAAGATTGGAAATTTGGAAAA

Sequence ID - 391 nt: 566
CTTTGAAGAACTTTGCCAAATACTTTCTTACCAATCTCATGAGGAGAGGG
AACATGCTGAGAAACTGATGAAGCTGCAGAACCAACGAGGTGGCCGAATC
TTCCTTCAGGATATCAAGAAACCAGACTGTGATGACTGGGAGAGCGGGCT
GAATGCAATGGAGTGTGCATTACATTTGGAAAAAAATGTGAATCAGTCAC
TACTGGAACTGCACAAACTGGCCACTGACAAAAATGACCCCCATTTGTGT
GACTTCATTGAGACACATTACCTGAATGAGCAGGTGAAAGCCATCAAAGA
ATTGGGTGACCACGTGACCAACTTGCGCAAGATGGGAGCGCCCGAATCTG
GCTTGGCGGAATATCTCTTTGACAAGCACACCCTGGGAGACAGTGATAAT
GAAAGCTAAGCCTCGGGCTAATTTCCCCATAGCCGTGGGGTGACTTCCCT
GGTCACCAAGGCAGTGCATGCATGTTGGGGTTTCCTTTACCTTTTCTATA
AGTTGTACCAAAACATCCACTTAAGTTCTTTGATTTGTCCATTCCTTCAA
ATAAAGAAATTTGGTA

Sequence ID 394
GACCCGGAATCGCGGCCGCGTCGACCATTTTAGCCAAGGTGCCTCTATAG
GGGTCAAGACATCATGTGCCCAGACCTAAGGTCAGGAATGTCATATTTTT
CTGTTAAAATCATTTTATTTCTGTGTATCTTACCTTTAAATCATTGTGGT
TTACTCTGAGATTCTGTAGTCCTAATATTGTATCATTGTGCTGTCTGCAA
AACAACTTGAATCTATTTTGTTTGCATCTTTTGTTACATGTAACGCAGCT
GTACTTTATGTTCTTTGCAACTGTTTCCATTATGAGAACGCTGTGCTATT
TACAAGGTTACATTTTTCTTGGCCAGGCGAGGTGGTCATGCCTGTGATCC
CAGCACTTTGGGAGGCCAAGGTGGGCGGATCACTTGAGGTAAAGAGTTGA
GACCAGCCTGGCTAGCATGGCGAAGCCCAGTCTCTACTAAAAATACAAAA
ATTGGCCGGGTGAAATTAGCCGGGCGTGGTGGTGTGTGCTTGTAATCCCA
GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAATCCGGGAGGCAGAG
GTTGCAGTGAGCCAAGATCANGCCACTGCACTCCACCTCGGGGTCAAGAG
CGAAACTCTGTCTCAA

Sequence ID 395
CCGTTTTAGTCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCTGCC
TCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGCG
TAAATCAGGTTTTTTAAATGTTTGCCAAACCTTATCACTGACTTTTATAA
CAAAATTATTTACTATAATCATTAGGGAATATTTAAGTTCTGCTAATACT
TAAAATTGCAGAGTGCTAAAACCAGCAGTGAGTTTAGAATCAAGCTAAGC
TTTATTGTTGCTACTATTTGAGGCATATTAGTTGACTGGTGTTCATATGC
AAGGCAGTCTACTGGGTGCAACAAGGGTTAGAAGGATATTTTTAAAAAAC
TGACCCTATTCTCAGGATGAAAATAATACACTAGTAATAGTCTGCTCTGT
TGGTTAACTCCTCGTAAGGAGGTCAATTAAAATGCTGTAGTGTTGCAAGG
GAAGGAGAGGAAGAATCATATTCCTTCACTAGCAGGATCAAGAAAGCTTT
TATAGAAATATACAAAATCTTCACTTCTTGAAGGATTGGTAAAATTTAAT
AGCCAACATTGGGCACTTATTCATTCTCTGAGTAAATATTTATTGCAT

Sequence ID 396
CTTAAATCTAAATGGACCACATTCTCTACTTAAAAAAATGCTATTAACCA
TGTGATCTTCTCAGTCATGAGGTAATCTGGTGACTACCCTTCCTCAAAGC
CAGTTGGGATATTCTTTGAATAGAGTAAAACAGTGTTTCTAGGCTGGGAG
ACACCAGACATAGTTGAGGACAGAGGTGCTAGAAAATAGGAAGTTTAAAA
GCATGTGCGGTGATGCTCAGAGGAGGTAAACCCCACCCTCATGCTCATAG
CTTCCAATCATTTTCTCTAGTTCTTAACTCTTAAATGTGAGAAATGCTTG
AAGATTACTAGTCATCTGAAGAAAGTCTCTTTATTAAAGATTTTCATAAA
AGAGACCAAAGCAGACAAACAGAAAAAGACATCTTGGGGAAAAAAACAAG
GATAATGGGAAGAGAAGGAAAGTTTTAAAAATTATCAATATCCTCAGGGG
GACAAAATATTATATCCTATAAAGACAGATTTTTATTTTTTAAAAAAATA
GAAAGCAAAACAAGCTCCTAAAAA

Sequence ID - 397 nt: 534
GACCCGGAATCGCGGCCGCGTCGACGGAAGCTCCTGCCCCTCCTAAAGCT
GAAGCCAAAGCGAAGGCTTTAAAGGCCAAGAAGGCAGTGTTGAAAGGTGT
CCACAGCCACAAAAAGAAGGAGATCCGCACGTCACCCACCTTCCGGCGGC
CGAAGACACTGCGACTCCGGAGACAGCCCAAATATCCTCGGAAGAGCGCT
CCCAGGAGAAACAAGCTTGACCACTATGCTATCATCAAGTTTCCGCTGAC
CACTGAGTCTGCCATGAAGAAGATAGAAGACAACAACACACTTGTGTTCA
TTGTGGATGTTAAAGCCAACAAGCACCAGATTAAACAGGCTGTGAAGAAG
CTGTATGACATTGATGTGGCCAAGGTCAACACCCTGATTCGGCCTGATGG
AGAGAAGAAGGCATATGTTCGACTGGCTCCTGATTACGATGCTTTGGATG
TTGCCAACAAAATTGGGATCATTTAAACTGAGTCCAGCTGCCTAATTCTG
AATATATATATATATATATATCTTTTCACCATAA

Sequence ID - 398 nt: 512
GGGGAGCCCCCTCTTCCCTCAGTTGTTCCTACTCAGACTGTTGCACTCTA
AACCTAGGGAGGTTGAAGAATGAGACCCTTAGGTTTTAACACGAATCCTG
ACACCACCATCTATAGGGTCCCAACTTGGTTATTGTAGGCAACCTTCCCT
CTCTCCTTGGTGAAGAACATCCCAAGCCAGAAAGAAGTTAACTACAGTGT
TTTCCTTTGCACCGATCCCCACCCCAATTCAATCCCGGAAGGGACTTACT
TAGGAAACCCTTCTTTACTAGATATCCTGGCCCCCTGGGCTTGTGAACAC
CTCCTAGCCACATCACTACAGTACAGTGAGTGACCCCAGCCTCCTGCCTA
CCCCAAGATGCCCCTCCCCACCCTGACCGTGCTAACTGTGTGTACATATA
TATTCTACATATATGTATATTAAAACTGCACTGCCATGTCTGCCCTTTTT
TGTGGTGTCTAGCATTAACTTATTGTCTAGGCCAAAGCGGGGGTGGGAGG
GGAATGCCACAG

Sequence ID 399
TTTTGGCATTACTTAATCCAATTATAAAAACTGAATTTTTAAAAAACAGC
ACTTGTTTTTTCTTCCAAGATTAATTTGAATTTTTTTATGGACATTAGAA
AACATTGCAGTTTAGTCATAATCAAAAATAAATCTTGAGGCTGGTAGAGC
AGCTTTGTTGCTGTTTATATTTTTATTGCTTACTGGATTTCAGTGTTACC
TAGTGCCATCAGTTTGGTATTTTGCCACCTTGCACATTCAGTGATGTTTG
ATTTTTCTTTTTCCTTTTTTTCATATTACTTTTAAATCCTGAATAGTTTG
TGGCAGCTGGAGATCACCTAGTCCACCACTGTCCAACATGGCAATGGTAA
GTAATATTGAGTAAAGAATAGAAAATTAGTAAAATGCATGGCTTCAGAAT
TATAGCAATTTGCAAAATAGGTTAATGGATGAAAATTAGAATGACCAGTT
TAACTTTCCCCCCAGCAGATTCTTCTGTTAAACAATGCCCCTTCAAAATA
AAGGAAGAACAAGTGGGTGTTATACCTATGTTATTTGGCTATGTTAGCAC
AATATGATGGACTAATTTGAGAAAAAGCATTTACTTCCTTTACTATTACT
TCTTTTCTTTATAGGGCTAAGTCTGCCTTCTGGGTCTTTGAA

Sequence ID 400
GAAGAAGCGCGAAGAGCCGTTAGTCATGCCGGTGTGGTGGCGGCGGCGGA
GACTGCGGGCCCGTAGCTGGGCTCTGCGAGGTGCAAGAAAGCCTTTGAGG
TGAAGGTGTATGAAAGTCATCATAACAGATGTTTTCCAAAAACTTGTAGA
AGGTTGTGAAAAAACTACTAGGATCACGCGGCATGTATTGAGCATATAGG
TTGCTGTAGATGAATGTTCTTAGCTGTCATGTTTAAAAATACTTCTGCTT
CGTTACCTCAAGTGTGGCATGCAGCATTTTGGAAGGAAAATTGAAGACGT
GTTCAAGAAAACATGAACAGAAGCAAATGATGAAAATGAGCATTTTACTT
GATGTTGATAACATCACAATAAATTATGGAGAAAAATACATATTTGGCTA
ACTTTTAATTGCTGAACAATAAAGTGTTTTCTTTTAAATCNAAAAA

Sequence ID 401
GAAGCCAAACCAAAGGGAGCTTCTACTTCATGATGCCATTTATGTAAAGT
TCAGGCAGAGAAAATCAGTGGTTTAAGAAGTTAGAATAATGATTATCTTT
GGAGGGATTGCAACTGGAAGAAGTCATGATTGGGATTTCTGGGTCCTAAT
AGTGCTCTGTGTCTTGATCTGAGTGCCGACTACATGAGTGGTTAGGTTTG
CAAAATTCATTGAGTTATGCACTTAATGGTGTTGTCTTATTAGAGCTGAT
GGAGGAGAGAGGGCTTCAATTTGCACAACTGAGTAATCAGCTAGGCCCAG
TCACTAGGTGAACAACTTACTGCTACCAATCAGCCTTAGAGCAGGAATCA
AACTCATGTCTCAGAAAAGTTATTAATTCAGCTTGTCTTGGGACTTCCTT
CAGAGTCACTCTTGAATAGCTGAAATAGTAAATGTTAAATCTGTGGATGC
AAGTGTGTAAATTATTTTAGTCATCAGCTCTAATAAGATGGCCTTTGGGG
AAATGAGTATAAGGTCACGAAAATGAAATGGCAAGAAGGAGGTCTACTAT
TTCTTCTGTAATACTGATTTTTACCCCATCAGGGTCAGTCCCCAAAGGTT
GTAAATGTGAAGCTTGGTCTTTTTCTTTA

Sequence ID 402
GACCCTATTCTCAGGATGAAAATAATACACTAGTAATAGTCTGCTCTGTT
GGTTAACTCCTCGTAAGGAGGTACAATTAAAATGCTGTAGTGTTGCAAGG
GAAGGAGAGGAAGAATCATATTCCTTCACTAGCAGGATCAAGAAAGCTTT
TATAGAAATATACAAAATCTTCACTTCTTGAAGGATTGGTAAAATTTAAT
AGCCAACATTGGGCACTTATTCATTCTCTGAGTAAATATTTATTGCATGC
TTATCTTGTATCAACATTGNGATGAAAGCNCAAGAATGAAAGAGGAGGGA
GAATGTTTANAGAATAAGGCTGAAACACAGATTTTGTAGGGAGCGTAGGG
GAGACTGANAAAACAG

Sequence ID 403
AAGACACCTGATAGATTGTCTTGTATTATTTTTCCTTTGCCTTCTTACAA
TCTCAGTGATTAGAATTGGGCTGAAAACAATACATCAAATTCTCAGCAAA
ATCCTTATGGGTTGCTGGATACCGAGGGTTTTTAAGATCTTTAGACTTCA
CTATATAGAACAAATGTTGAATGGGAATTTTCTTTATTTCTATANCGTTT
NG

Sequence ID 405
CCCGGAATCGCGGCCGCGTCGACGATGAGCATTTTTTCATGTGTCTTTTG
GCTGCATAAATGTCTTCTTTTGAGAAGTGTCGGTTCATATCCTTTGCCCA
CTTTTTGATGGGGTTGTTTTTTTCTTGTAAATTTGTTTGAGTTCATTGTA
GATTCTGGATATTAGCCCTTTGTCAGATGAGTAGGTTGCGAAAATTTTCT
CCCATTTTGTAGGTTGCCTGTTCACTCTGATGGTAGTTTCATTTGCTGTG
CAGAAGCTCTTTAGTTTAATTAGATCCCATTTGTCAATTTTGGCTTTTGT
TGCCATTGCTTTTGGTGTTTTAGACTTGAAGTCCTTGCCCATGCCTATGT
CCTGAATGGTAATGCCTAGGTTTTCTTCTAGGGTTTTGATGGTTTTAGGT
CTAACGTTTCAGTCTTTAATCCATCTTTTAAAAGTCTCTTCACAGTACAT
GAGTAGTAGTGACACCAATAATGTCAGAGCAGGGAACTCCCAGGTTCTGC
CCATCCACAAAAACAACAAATAAGCTGGCAAAAACTTTAAGAATCAACTT
TTGCAGATCTCTGAAATCTAGTCAAAACTTAAACAGAGGAAAGATTAATA
AAGACNGGCTGCCTGAGATAACACTAACACACAC

Sequence ID 406
CATCAAATAAATAAATAAATAAATTTTAAAAGTCACAGCATTGAATTTTT
AAATGTTTGGGATGATAAAGCACCTGCTTATCATGAAGCTANAGAAATTC
AATGACACGTTTGCCAGGGTCTTTGCTAGTGATGTTGGAACAAGTCTGTA
ATGCTGATGAAACATCACTGTTCGGGCATTATTGCCCCAGAAAGACACTG
ACTGCAGCTGATGAAACAGCCCTTCCAAGAATTAAGGATGCCAAAGACCA
AATAACTGTGCTGAGATATACTTACGCAGCAGGCATGCATAAGTGTAAAC
TTGCTGTTATAAGCAAAAGCTTGCGTTCTCACTGTTTTCAAGGAGTGAAT
TTCATACCAATCCATTATTATGCTAATAAAAAGGCATGGATCACCAGGGA
CATCTTTTCAGATTGGTTTCACAAACATTTTGTACCAGCAGCTTGTGCTT
ACTGCAGGGAAGCTGACTGGATGATGACTGCAAGATTTTGTTATATCTTA
ACAACTGTTGTGCTCATCCTCCAGCTGAAATTCTCATCAAAAATAATGTT
TATGGCTCACACCTGTAATCTCAACACTTTGGGAGGATTGCCTGACCCAG
GAGTTCAAGCCCACCCTGGGCAACACAGCAAGACCCAACCTNTC

Sequence ID 407
TTTTAAAAATCATAAAACGTTTCTTACAAAAGAGCATTACATTNTGCACA
CTGCTCTGAACAGATGCCAGGGACATGTGGACTATTGTTACTTTTCCTCC
CTGTCCCACCCCCCAAATGTTACAGTGACCACAAAGCAAGGTGTTCACAA
TAATTACATGGGGGGAATTTTTTAAACCACCAACAATAACGAAAAATAAA
ATCCACTCACTCTGCTGCTGTTTCAAAATTTCAATGTTAGTTTTTGCACG
CCCTTCCCCCCCCCAACCCTGTTTGTAAGGAACTAAAACATTACATCTGG
TGAACAGCAAAGATTTCACTACACCTCAAATGCAGAACACCTATGAAGCA
GAGGAATGTTGGCTTTTTAAACAGAAGCAGATAAAAAAAAAAGATGCAGG
ACTCCTTCAGTTCTTCACTAGTCTTAGAAAAACTTTCCAGAATACTGCTT
CACACTATAAAAAAGAAAAAATATCTTGCATTAGAATCCTTCAACATCTG
CATACTGCTTCACACTGTTCGTTTCTAGGAGCACTTTGTCACAGGACACT
TCTGCTTATATTTCTTTAATCAGAACTTAGTTGGATGGGCCGGGCATGGT
GGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGG-GGGTGGATCA
CC

Sequence ID 408
CCATCTCCAAATTTAGTATTCATTCTGTTTAGCATATTATCAGTTGCCAT
CTATTTGTTTTAACTGATTACTTGAATCTGATTAAACATCACAGAAATGG
GCTTTGATAAGAACAATATTGAATAAGAAATTTTAAATAACAAAACAGCT
TATAGAAAAATTCAGCATAACTTTTCCATCACCTTCACCACCCTTGCCTT
TTATTATCCTGTCCTGTATCACTGCTTTCTGTTAGCAGTGTTGTGTGAGT
TAGGATTTGGGCAGGAAAGCAAAAGCAACCACCCGTCATTTTCCCAGAAT
GAAGGGTTTGACGTAGGATGTAGACTTTGTATAGTAGTTGGGAGAGCTGT
GGGAGTGAAGGTCAGGGATGTCACCTACAGAAGTCAGGGAATCTGCCACC
AGAGATCCTGCATCAGAAACAGCCAACAGCGTGCTTCTGAAGAACTAGTG
GGGAAGTGGCTATAATTCTTAGGAATCCCAGCAAGTCCGCACCACTGTCT
CAGTCTACAGCAGTGGAGAAAGGGGTTTCCAGGAGCTCTCTGGAAAGTTC
CTGCCCACACTTTGCAACAATCTTCAGAGGATAATGGGCTTCTCTTCCAG
CTTCCACACCCAACAAGAGTGCCTTTCATCGGCCAACTCTAACCTGGAAC
CCTATGGCAGAGGGGATTTAGGAGACAGTTTGTNATGTCTGTGGAATGCA
AATGAANANGTANCAATGCTTANTTGACAGCGGNCATACACAAATNTNGA
AA

Sequence ID 409
GATCCGTNGACT

Sequence ID 410
CTCTTCCCAGCCCCTGAGCCCAGCCCCTTCCCAAGTGGTGCCAGACAAAA
AACTACATGGCCCTTTCGTGTCTTGGGGGTGGAAAGGGAGGGATGAATTG
GGGTGATAGAACCCTGGTGAATTCAGAGTAATCTTTCTTTAGAAAACTGG
TGTTTTCTAAAGAAACAGGATAGGAGTTTAGAGAAGGCACCAAAGCTTTC
ACTTTGGTTTGGCACCAGTTTCTAACCATCTGTTTTTTCTACCCTAGCTA
TCTTTTATTGGTAAAATATAAATGTATAATTATGTTTGTAGAGCTTTACC
AAGGAGTTTCCCTCCTTTTTTGTTTGTTGATTAGCAAATTTTTGATTCTC
CATTTTCCAAAAGTAAGAGACTCCAGCATGGCCTTCTGTTTGCCCCGCAG
TAAAGTAACTTCCATATAAAATGGTATTTGAAAGTGAGAGTTCATGACAA
CAGACCGTTTTCCATTTCATCTGTATTTTATCTCCGTGACTCCACTTGTG
GGTTT

Sequence ID - 411 nt: 505
TGGAGCTGAAAAATTCCTATTACCTAGGGGCATCACAACGCATTGCATTT
CGCCCGTGTTTGGGATGATGCTGGTGTAAACCTACTATGCTGCCAGTCAT
GTAAAAGTATAGCACACACAATTAGTAGGTAATGCTTGCAAATAATAATG
AAAGACTCTGCTACTGGTTTATGTATTTACTATGCTATACTTTTTGTCAT
TACTTTAGAGTGTACTCCTACTTTTTTTTTTTTTTTTTTTGAGATGGAGT
TTCACTCTTGTCCTGTAGGCTGGAGCGAANTGGCGCGATCTCGGCTTACT
GCAACCTCCACCTCCTGGGTTCAAGCGATTCTCCTGCCTCANCTTCCCAG
AGTAGCTGAGATTACAGGCATGCACCGCCACGCACGGGTAATTTTGTATT
TTTGGTAGAGACAGGGTTTCACCATGTTGGCCAGGCTGGTCACCAACTCC
TGACCTCAGGTGACCCGCCTCCTCACCTCCAGAGTGTTGGGATTACAGGN
GTGAG

Sequence ID 412
ATAAAAATTAGCTGGGGGTGATGGGCCCTGTACCCCAGCTACTCGGGAGG
TGAGGTAGGAGAATCACTTGAACCCGGGAGATGGAGGTTGCAGTGAGCCA
AGATCGTGCCACTGCACTCCAGCCTGTGTGACAGAACAAGACTCTGTCTC
AAAAAAAAATAATAATAATAATAATAATAAAAAGGAATAACATAGCTAGG
AATAAATTTAATCAAAGAGGTGAAAGACTTATACACTTAAAACTACAAAA
AAAAAATCACTGAAGGAATTATAGACCCAAATAAAAATAAATAAAAAGAC
ATTCTGTGTTTTAGGGAAAGAAGACTTAATATTGTTAAGATGTCAATACT
ACCCAAAGTGATCTACAGATTCAACATAATCCCTATCAAAATTCCAACAG
CCTACTTTGTAGAAATGGAAAAGCCAATTTTCAAATTCAGATGGAATTGC
GAGGGGTTCTGAATAACAAAACACAATCTTGGGGAAAAAAAACAAAAAAC
AAAGTCAAAGAACTCACACTTCTCTATTTATAATTTACTACAAAGTTATA
GNATCAAAGTCGACGCGCCGCGATCCGGGC

Sequence ID 413
CACAGTACTCCATTTTGGGGTCCAAACTGTAATGCTCAAAATAATAAATG
CTTACACGAAAATTATTTATTGAGAATATTCATATAAAAATTACCTAAAG
CAAAGTAAAAAAAGTAAAATCAAGGTGGTATATTTGAAGTGAATGGTGAT
TGGAAATTTTTAGCTGTAACAAAAAGAAAGAAAACAACTTTTTTTAAAGC
CTCATTCTCTTTTCTTTCAAAATGTACCTTATTCCCACACACTCTTGGGC
TGACCTTTATTTTATCAATAAGCTCAATATTACTTTGTTTAAAATAAGAT
GCTTCAGCAAAAGTCATTCTCTCTTTAACCATATAATTTAAAAACTCCTC
TTCACGATTGATAGCAAAATCAGAAACGTTAGGGCACCAGTGAGTTGAAA
AAACTGGTCTTAAGTTGGAAAAACTATTATTAATAATATTATCCTATCCA
TCCATATCTATTGAAATTGTCAGGTCCATAATTTCATTTTAATTAATTAT
AGGAAAGAAGAAAAGATAATACCCATTTGTTCTAT

Sequence ID 414
CTCAGACTCTTTCTGCCCTAATGGCCATTACTATCCAGTCTGTATTGCTA
CAAGGGACCCACTGGTACCCCTTTTAGATTCTATCAAAAGGAACAGGGTT
TTCCTAGAGGCAGGCAGCCTGGTGGTATGGCACAGCAGAAGCTTACTGCT
AATGAAATGGGAACCTCCCCCTCCCTTGTGGTTTCAGCACAGAACCTGAA
TGCCAGGAAAAATTCCTGGGCCAAGAAGCTAAAGCTAAAGAAACCTTCCT
TTTTTCAACGTTTTTTTTTCTTTCAAACTGTAGGGTCACTTTTGATTGAG
GCAAAGGGGTCCTACTGTAAGTGGAAAAGACTCACTCCCCTAACATAAGT
TTTCACTGTGGTGGGATGGTGCCGCCCGATATGCTTGATATGCTTTTCCT
TCCACATGTTAAGCTAGGAAACCTAACAGGATGTCAGCAGGGCAGTTAAC
TCTGGACTCANAGCCCTCAAGGGCATGTGGCANAACCTCATGGCATNCAA
GACCA

Sequence ID - 415 nt: 596
GTATAATTGATTCTTTTGAACCTAAAGTATAAGACTTCACGATTAGAAAA
AAATTATCCAAAGACTAATGTAATTAAGTGAGGAAAAGGTGCTGGAGGAA
CTGGATAACCACATGGAAATGTATGAACCATGACCTCTATGTCACATACT
ATATATAAAACTTAATTTGAGGTGTATCACAGAGCTAACTGTGGGGGCTA
AAACGTTGAAGCCTTTGGATGGCCGCACAAGAGATGTCTGCATTCATAAC
CTTGGGGAGGGTATGAACATTTCTTGGTAACATGCAAAAAGCACTAACTG
TAAAAGAGAACAGTTGGTCAGTTGAATTTCATGAAACATTGTAAACTTCT
GCTAAACAACTGACACCATTAAGAATGTGGAAAAAGGCTGGGCACAGTGG
CTCATGCCTATAATCCCAGCATTTTGGGAGGCCGGGGCGGGAGAATCACT
TGAGGCCAGGAGTTTGAAACCAGCCTGGGCAACATGGCAAGACCCCGACT
CTACAAAAATATTTTTAAAAATTAGTTGGGTGTGGTGATGCACTCCTGTA
GTCCTAGCTGCCAGGANGCTAAGGNGGAAGGATCACTTAACCCTGG

Sequence ID 416
CTGGTGGCGGCGGTCGTGCGGACGCAAACATGCAGATCTTTGTGAAGACC
CTCACTGGCAAAACCATCACCCTTGAGGTCGAGCCCAGTGACACCATTGA
GAATGTCAAAGCCAAAATTCAAGACAAGGAGGGTATCCCACCTGACCAGC
AGCGTCTGATATTTGCCGGCAAACAGCTGGAGGATGGCCGCACTCTCTCA
GACTACAACATCCAGAAAGAGTCCACCCTGCACCTGGTGTTGCGCCTGCG
AGGTGGCATTATTGAGCCTTCTCTCCGCCAGCTTGCCCAGAAATACAACT
GCGACAAGATGATCTGCCGCAAGTGCTATGCTCGCCTTCACCCTCGTGCT
GTCAACTGCCGCAAGAAGAAGTGTGGTCACACCAACAACCTGCGTCCCAA
GAAGAAGGTCAAATAAGGTTGTTCTTTCCTTGAAGGGCAGCCTCCTGCCC
AGGCCCCGTGGCCCTGGAGCCTCAATAAAGTGTCCCTTTCATTGACTGGA
GCAG

Sequence ID 417
GCAGGGGCTTCTGCTGAGGGGGCAGGCGGAGCTTGAGGAAACCCGCAGAT
AAGTTTTTTTCTCTTTGAAAGATAGAGATTAATACAACTACTTAAAAAAT
ATAGTCAATAGGTTACTAAGATATTGCTTAGCGTTAAGTTTTTAACGTAA
TTTTAATAGCTTAAGATTTTAAGAGAAAATATGAAGACTTAGAAGAGTAG
CATGAGGAAGGAAAAGATAAAAGGTTTCTAAAACATGACGGAGGTTGAGA
TGAAGCTTCTTCATGGAGTAAAAAATGTATTTAAAAGAAAATTGAGAGAA
AGGACTACAGAGCCCCGAATTAATACCAATAGAAGGGCAATGCTTTTAGA
TTAAAATGAAGGTGACTTAAACAGCTTAAAGTTTAGTTTAAAAGTTGTAG
GTGATTAAAATAATTTGAAGGCGATCTTTTAAAAAGAGATTAAACCGAAG
GTGATTAAAAGACCTTGAAATCCATGACGCAGGGAGAATTGCGTCATTTA
AAGCCTAGTTAACGCATTTACTAAACGCAGACCAAAATGGAAAGATTAAT
TGGGAGTGGTAGGA

Sequence ID 418
CCCGGAATCGCGGCCGCGTCGACGGGAGGTGATAGCATTGCTTTCGTGTA
AATTATGTAATGCAAAATTTTTTTAATCTTCGCCTTAATACTTTTTTATT
TTGTTTTATTTTGAATGATGAGCCTTCGTGCCCCCCCTTCCCCCTTTTTT
GTCCCCCAACTTGAGATGTATGAAGGCTTTTGGTCTCCCTGGGAGTGGGT
GGAGGCAGCCAGGGCTTACCTGTACACTGACTTGAGACCAGTTGAATAAA
AGTGCACACCTTATAAAAAA

Sequence ID 419
CCCGGAATCGCGGCCGCGTCGACGGGAGGTGATAGCATTGCTTTCGTGTA
AATTAT GTAATGCAAAATTTTTTTAATCTTCGCCTTAATACTTTTTTAT
TTTGTTTTATTTTGAATGATGAGCCTTCGTGCCCCCCCTTCCCCCTTTTT
TGTCCCCCAACTTGAGATGTATGAAGGCTTTTGGTCTCCCTGGGAGTGGG
TGGAGGCAGCCAGGGCTTACCTGTACACTGACTTGAGACCAGTTGAATAA
AAGTGCACACCTTATAAAA

Sequence ID 420
CTTCATTTGAAATGGTTGAATCTGCTGTGTAATAAAGTGGTTCAACCATG
ATTAGGAACTGAAATTTAGTAGAAGAGGGAAAAGGAGTTAATGTAACAAA
TTATTTTAGCTACAAACCCCGGTAATAGAGCACTTGGGGGATGGGATGGG
GTGGGTTGGTGAGACAATCAGAATGGTAAATTGATTAAATGCTCCTAACC
CTGTAATTTTGTGCATAGAGCACCCTATGCTGTGGAAATAACTGTTCTTA
GATTTCATTGTAACTGGACTGTTCAGGTTGCCCAGAGGGAAAGAACATTC
CTAATTCTAATAAAATAAACTTTTATTTTGTTTA

Sequence ID 421
TGTCATTGAATCTGCTTGTTACTTAAATGCTAAACTCAATTCTGTAATTC
AATAGGTGCACCTCTCTGAGAAACATAAGAGACAATGAGGAAAAGGATTC
AGCATTCCGTGGAATTTGTACCATGATCAGTGTGAATCCCAGTGGCGTAA
TCCAAGTAAGATGTTCACAAAGATTTGTTTTTAATGTCTAATTAATAAAA
TTTTAAAGGAAGAAACATTCTAATACTTTAATTATAAAAAGTTAACTATT
TTCAAAGGTATCAAAATACAGTTAAACCTTTAAAATGTATATTTCTTAAT
ATCTTGAAATTGTAATGCCTTTTTTTTTTCCTAAATTTTTTTTGTCATGA
AATGAGATAGTAACAGCAGATTGGGACAACAAGGTTATATTCTTGTCTTG
AATCAGGCCATGGCTTCTTTCATCCAAATTTCAGACCTCATTTATTTACT
TTGTCCCTGCCTCCCATCCCTGGATATCAGTTTGTGGATATCTACAGTTA
ATAGAGTGACCAAATAGTAGGAATACTGTCTCTCTATTCTGAATAAAATC
TTTGAATCAGATTTAGAAATAATGAATAAAATACAAATCAGCCATTGAAA
TTGCTCTAATTTTGAGAGCTTATGATTTATTCATCTTTGGTTTCCAAGTT
CAAGTTATATGTAGACATTTTAATT

Sequence ID 422
GCTTCCTAGGTGAGGTCACGAGGAAACCTGCTGGCCAAGTGACCTGGCAG
GGTGTGGCCAGTGTGGCCAGGGCCGCCGAGCCTGCTTTCCTTCCCTGCAG
CAGGAACCCTTCTGGGGCTGTGATCCTGCGATGGTGCCTGGGTGGGAGTG
GGGGTGGGGGGCGGGATGGTCTCCCTACCTGCCAGCTTCTTGGTTTGAGG
TGAGGACAGCCCCGGAAGCTCANACTTGGCTCCTGTCCATGTACTTGGGG
CCATGAGCTCTGCAGGGACCTTGGAAAGANAGAGACGGGTGGTGTANGGC
ANGGGAAGGCATTGTCTTCAAACAGGAAAAAGCTGANAATGGAAACAGGC
GAAACTTACCAAGTGTAACATCACCTGGAACTGAAGGAGGGTGGGAAGGT
TTTAATTATTTTAAAAATAGAGATGGGGTCTCACTATGTTGCCCAGGCTG
GTCTCAAACTACTGGGCTCAAGTGAACCTCCTTCT

Sequence ID - 423 nt: 387
TGTTTCTCNAGGGCGAGAGGCTGTCTTANAGCACCATTCTCTGGCCCTNG
TCCCATGAGAAGGAACCGCACTCAGGAGCCACACTCTCCCACTNCCCTTG
CCCANAAGACTCACAGAGGGCACGGAGCTGGCTGTGGTGAGAGGAGGTCC
ANCAAATTCCTGTCTGCANAAGGGTTCTGAACACCACCGCCTGGCAGCGT
GCTGGAGGAGGGATTCCTCTTTTCCTCACAGCAATTCTGACCAGAAACCT
GTCAAATCAGGAATGGCTAAAATAAGACCAGGGTATGAATGACCATCAGC
CACAGTAAAACCAAGGCACAGCTCTCCTGAGCCCACCCAAGCTGCTGTGG
CCCAGACTGGTGACATCACCTCAGGGCAAAAAAAAAA

Sequence ID - 424 nt: 420
CGCAGAATGGCTCCCGCAAAGAAGGGTGGCGAGAAGAAAAAGGGCCGTTC
TGCCATCAACGAAGTGGTAACCCGAGAATACACCATCAACATTCACAAGC
GCATCCATGGAGTGGGCTTCAAGAAGCGTGCACCTCGGGCACTCAAAGAG
ATTCGGAAATTTGCCATGAAGGAGATGGGAACTCCAGATGTGCGCATTGA
CACCAGGCTCAACAAAGCTGTCTGGGCCAAAGGAATAAGGAATGTGCCAT
ACCGAATCCGTGTGCGGCTGTCCAGAAAACGTAATGAGGATGAAGATTCA
CCAAATAAGCTATATACTTTGGTTACCTATGTACCTGTTACCACTTTCAA
AAATCTACAGACAGTCAATGTGGATGAGAACTAATCGCTGATCGTCAGAT
CAAATAAAGTTATAAAATTG

Sequence ID 425
GGAAACTGATGCCAGTCAGAAACTCAGATCAAATGAAGGGGTGAAGAGAA
CCAGAATTGATCTCTCTGTAGGAGAATATAAATGACTTTTTTAAAGTACA
TATTTTCTGTGAAAGACAGTTTTTTGTTTAATGCAAAAATGTTAACAATG
TTTATATCATGTAGAAGTAAAAGATCGTGAAACAGCACAGAGAACAGTAG
TAAGACAGATTGAATTGCACTGTTGTAAGATGATGAACTTACAATATTAA
GTGAAGGTAGACTGTGATAGATTAAGGATATATATTGTAATCCCTAGAGC
AATTGTCAAAGTGGTACAGGTAAAAAGCCAATAGAGGTGATAAAATGGAA
TACTAAAAAATATCAGATGAATAATAAAGAAGACAGGAAATGAGGAACAG
TGGAACAGAATGAATAAAAAACAAGACCATTAACTTAATCATTAATAATT
ACTTTAAATGGGTTAAACATTATGGTTATAAGGCAGAGATTTTCAGACTA
GATAAAAGAGCAAGCTCCACTATATACTGTCTACAAGAGATATACTTTAA
AGTGTATATTATATTTAAATATAAAGATTTGGAATAAATAAACCTAAGAA
TAAGCTTACTAGGGAAGTGAAAGATCTGTACAACAAGAATTACAAAACAC
TGCTGAACGAAATCATAGGTGACCA

Sequence ID 426
GTCCCGGAATCGCGGCCGCGTCGACGTTTCCTCAAAATTTATCTTCCTGT
TAATGTCAGGCATGTATCTCCTTAGCTTGCCACAAATAACTATATATACC
ACAGACCTTCCTTTGTAGGGCTAACAGTGTTGCATTGTAAGTGGAGGCCT
CATAGATACCTGGCCTTTTCCTACCTTATTCCAAAGATGGTTGCATCTTA
TAAATAATGTCATTCTTCAGCAAATGGTATGGAAATGAGATTGTAATGTC
ATTATTTCCTCTTTAAATAATCAGGACAACTCATGATACAAAGAGCTCTT
CTCTATAAAAGGTGGGACTTTTTTTTTTAGTAATAGCAAAAATAAAATTG
TACCTCCTTAATCTTCTACAGAAAGATGGATTTCATTTTCAACATTAAGA
GGTAGTTTTAAGAAGCAGTAGAAGTCAGCCTGGGCAGCATGGTGAAACCC
CGTCTCTACAAAAAAGTTAGCTGGGCTTAGTAGTTGCAATCCCAGCTACT
CTGGAGGCTGAGGTTGGAGATCATCTGANCCTGGGGAGGTCNAGGCTGCA
ATGATACANTGAGCCCTGATTGTGCCACTCCACCTGGTTGCAGA

Sequence ID 427
TTCCAATCTTCGTGTTCACTTTAAGAACACTCGTGAAACTGCTCAGGCCA
TCAAGGGTATGCATATACGAAAAGCCACGAAGTATCTGAAAGATGTCACT
TTACAGAAACAGTGTGTACCATTCCGACGTTACAATGGTGGAGTTGGCAG
GTGTGCGCAGGCCAAGCAATGGGGCTGGACACAAGGTCGGTGGCCCAAAA
AGAGTGCTGAATTTTTGCTGCACATGCTTAAAAACGCAGAGAGTAATGCT
GAACTTAAGGGTTTAGATGTAGATTCTCTGGTCATTGAGCATATCCAAGT
GAACAAAGCACCTAAGATGCGCCGCCGGACCTACAGAGCTCATGGTCGGA
TTAACCCATACATGAGCTCTCCCTGCCACATTGAGATGATCCTTACGGAA
AAGGAACAGATTGTTCCTAAACCAGAAGAGGAGGTTGCCCAGAAGAAAAA
GATATCCCAGAAGAAACTGAAGAAACAAAAACTTATGGCACGGGAGTAAA
TTCAGCATTAAAATAAATGTAATTAAAAGG

Sequence ID 428
TGCAGGATCCGTCGACTCTAGATAACATGGCTAGAAAAGAGAATGAAAAA
GTTGGAATTTTTAATTGCCATGGTATGGGGGGTAATCAGGTTTTCTCTTA
TACTGCCAACAAAGAAATTAGAACAGATGACCTTTGCTTGGATGTTTCCA
AACTTAATGGCCCAGTTACAATGCTCAAATGCCACCACCTAAAAGGCAAC
CAACTCTGGGAGTATGACCCAGTGAAATTAACCCTGCAGCATGTGAACAG
TAATCAGTGCCTGGATAAAGCCACAGAAGAGGATAGCCAGGTGCCCAGCA
TTAGAGACTGCAATGGAAGTCGGTCCCAGCAGTGGCTTCTTCGAAACGTC
ACCCTGCCAGAAATATTCTGAGACCAAATTT

Sequence ID - 429 nt: 535
CACAGTACTCCATTTTGGGGTCCAAACTGTAATGCTCAAAATAATAAATG
CTTACACGAAAATTATTTATTGAGAATATTCATATAAAAATTACCTAAAG
CAAAGTAAAAAAAGTAAAATCAAGGTGGTATATTTGAAGTGAATGGTGAT
TGGAAATTTTTAGCTGTAACAAAAAGAAAGAAAACAACTTTTTTTAAAGC
CTCATTCTCTTTTCTTTCAAAATGTACCTTATTCCCACACACTCTTGGGC
TGACCTTTATTTTATCAATAAGCTCAATATTACTTTGTTTAAAATAAGAT
GCTTCAGCAAAAGTCATTCTCTCTTTAACCATATAATTTAAAAACTCCTC
TTCACGATTGATAGCAAAATCAGAAACGTTAGGGCACCAGTGAGTTGAAA
AAACTGGTCTTAAGTTGGAAAAACTATTATTAATAATATTATCCTATCCA
TCCATATCTATTGAAATTGTCAGGTCCATAATTTCATTTTAATTAATTAT
AGGAAAGAAGAAAAGATAATACCCATTTGTTCTAT

Sequence ID 430
CAGGGGCTTCTGCTGAGGGGGCAGGCGGAGCTTGAGGAAACCGCAGATAA
GTTTTTTTCTCTTTGAAAGATAGAGATTAATACAACTACTTAAAAAATAT
AGTCAATAGGTTACTAAGATATTGCTTAGCGTTAAGTTTTTAACGTAATT
TTAATAGCTTAAGATTTTAAGAGAAAATATGAAGACTTAGAAGAGTAGCA
TGAGGAAGGAAAAGATAAAAGGTTTCTAAAACATGACGGAGGTTGAGATG
AAGCTTCTTCATGGAGTAAAAAATGTATTTAAAAGAAAATTGAGAGAAAG
GACTACAGAGCCCCGAATTAATACCAATAGAAGGGCAATGCTTTTAGATT
AAAATGAAGGTGACTTAAACAGCTTAAAGTTTAGTTTAAAAGTTGTAGGT
GATTAAAATAATTTGAAGGCGATCTTTTAAAAAGAGATTAAACCGAAGGT
GATTAAAAGACCTTGAAATCCATGACGCAGGGAGAATTGCGTCATTTAAA
GCCTAGTTAACGCATTTACTAAACGCAGACGAAAATGGAAAGATTAATTG
GGAGTGGTAGGATGAAACAATTTGGAGAAGATAGAAGTTTGAAGTGGAAA
ACTGGAAGACAGAAGTACC

Sequence ID 431
CGCTGGGTGCCTGCAGCGCCTCCCTTGTCTCATATGGTGTGTCCAGCACT
CTATTGTTGTAAACTGTTGNTTTGNCTGACCTAAATTNTCTTTACTAAAC
ANATTTAATAGTTNAAAAAAAAAAAANANCA

Sequence ID 432
TTTTAAAGTCATCTCTATAGGAAGGTGCTGGGCAGGGATCCCAGAGAAAG
AAAGGGTCCAAGACTCCATTAACTGCCCTGGATGAAGGGCACTGCTACAG
CAGCTAGTACCAGAGACTCTCCTATCTCACGGTTGAGGCAGACCCAGGAT
AGAATAGAGAATAAAAGGAATGCTTATAGGAAACAATTTTGTATGGAATG
CTAGATGGCCAAGCCTCAGCCTTTGGTCCAGTGCAACCCTTGCCTCGCTT
GTCAACAGTGAAAAATTAGTTTGGTTAGAAGAACCATCTGGAAACACACC
AGCTTCTGCTACCTTCATGCTCATTGTTAAAAAAAGATTAACCAGTGTGA
ACATTCTGATCTGTTAATTCCAGGGACTGTTTTCTTTCCAATGGACTGTT
TGTTGGTAGAATAACCCCCAAAAGCTCAAAGCTAAAATGCATCATCAGTC
CTAGTCGGCAGTTCCTTAAGAATGGACTGGCGGCGTGGTTGAGCTGATAT
GGAAAAGCTGCACCTTCCTGCAGAAGATCAACTGACCTGCTATCCCACCC
CAAATTTCAACCTGAGGTATATTTCAATGAAGGCAGGTAGCTGTGCTTCT
CAGAGCA

Sequence ID 433
TCCCGGAATCGCGGCCGCGTCGACCCGCCGCCGAGGATTCAGCAGCCTCC
CCCTTGAGCCCCCTCGCTTCCCGACGTTCCGTTCCCCCCTGCCCGCCTTC
TCCCGCCACCGCCGCCGCCGCCTTCCGCAGGCCGTTTCCACCGAGGAAAA
GGAATCGTATCGTATGTCCGCTATCCAGAACCTCCACTCTTTCGACCCCT
TTGCTGATGCAAGTAAGGGTGATGACCTGCTTCCTGCTGGCACTGAGGAT
TATATCCATATAAGAATTCAACAGAGAAACGGCAGGAAGACCCTTACTAC
TGTCCAAGGGATCGCTGATGATTACGATAAAAAGAAACTAGTGAAGGCGT
TTAAGAAAAAGTTTGCCTGCAATGGTACTGTAATTGAGCATCCGGAATAT
GGAGAAGTAATTCAGCTACAGGGTGACCAACGCAAGAACATATGCCAGTT
CCTCGTAGAGATTGGACTGGCTAAGGACGATCAGCTGAAGGTTCATGGGT
TTTAAGTGCTTGTGGCTCACTGAAGCTTAAGTGAGGATTTCCTTGCAATG
AGTAGAATTTCCCTTCCTCCCTTGTCACAGGTTTAAAAACCTCACAGCTT
GTATAATGTAACCATTTGGGGTCCGCTTTTAACTTGGACTAGTGTAACTN
CTTCATGCAATAAACTGAAAAGACCATGCTGCTANTC

Sequence ID 434
TTCGGACGCAAGAAGACAGCGACAGCTGTGGCGCACTGCAAACGCGGCAA
TGGTCTCATCAAGGTGAACGGGCGGCCCCTGGAGATGATTGAGCCGCGCA
CGCTACAGTACAAGCTGCTGGAGCCAGTTCTGCTTCTCGGCAAGGAGCGA
TTTGCTGGTGTAGACATCCGTGTCCGTGTAAAGGGTGGTGGTCACGTGGC
CCANATTTATGCTATCCGTCAGTCCATCTCCAAAGCCCTGGTGGCCTATT
ACCANAAATATGTGGATGAGGCTTCCAAGAAGGAGATCAAAGACATCCTC
ATCCAGTATGACCGGACCCTGCTGGTAGCTGACCCTCGTCGCTGCGAGTC
CAAAAAGTTTGGAGGCCCTGGTGCCCGCGCTCGCTACCAGAAATCCTACC
GATAAGCCCATCGTGACTCAAAACTCACTTGTATAATAAACAGTTTTTGA
GGGATTTTAAAA

Sequence ID 435
CTGCAATGTGCAATAGTTGCACCACTGCACTCCAGCCTGGGTGACAGAGT
GAGAACCTATCTCTTAAAAAAAAAAAAAAAAAAAGGAAGAAGAGACATGA
GAGGGCCCAAGTCACTTGCTCACTCACTTTCCGTGTACATGTACCAAGAA
AAGGCCATGTGGGAAAGAGCAAGAAGGCAGCCGCCTTCAAGACAGGAAGA
GAGCCCTCACCAGAAACTGAGCCAGAACCTTGGAATTCCAGCCTCCANAA
CTGTGAGAAAAGAATTTTCTGTTGTTTCAGTCCCCCACACTATGGCATTT
TGTTACGGCAGCCTGAGCTAATACTCCTACTTTGTCCTGCATTTACTTGG
TCTTCCAGTTAGTTTTTTAGACTTTGGGAATCAGAGCAGTCAGTTGTCAG
ATTTTAGCTTACAGTTGTCCTACCTGTGCAACTGAAATTTCTTCCATTTT
AAACCAGAGCAGAGTTTTAGAGTCAAAAGAAACCAGATCTTTTAGTGCAG
AAGCTTTCCACTGTATTANAAGTGAGGAAGTTGGT

Sequence ID 436
AAAAAAACTCCAGAGAAGTTTATAGAAAGAGATGACATGTAAACCCTGCT
GAAAAATAGTTTCATTTGTTAGAATATAATTGTCTTCCACTAAAAAAAGA
AAAAAAAAAGCATTTAAGGCTCTAAGATCTCTTGAAGTACCACTTTTCCT
GAATCCCAGAGTTTTTATGTGCATTATTTTTATGCGTTTGTAGTTTGATA
TGTTGTATTTATAAGTAGTTTTAGCTTTCCATTATGAATTCTTCTTTGAC
CCATGAGTTATTTAGGTAAGTGTTTAAAAATTTACAATAGTTTATATATG
CAAATATTATGTTGTTAGAGTTGGTTTTCATGTCATTTTTACATATACAG
GGGCAGTTTCCCCAACTAAATTGTATATTCCTTAAAGCAGCACTCTTAAA
TTTTATTTCTGTGTCAATTTCTTGNCTGTGTTTCCTGGCATGGAATACAT
GGCATAAAATTTGTTATGTAATTAAATGAAATATTATTATACTTTCTATT
TTTTAGAAAAAA

Sequence ID - 438 nt: 577
GTCGACAGGGATGACATAACTATTAGTGGCAGGTTAGTTGTTGGTCACTT
TCAACTCTGGGTTCAAGCGATTCTCCTACCTCAGCCTCCCGAGTAGCTGG
GATTACAGGCATGCACCGCCACACCTAATTTTCTATTCTTAGTAGAGACG
GGGTTTCTCCCTGTTGGTCAGGCTGGTCTCGAACTCCCGACCTCAGGTGA
TCTGCCTGCCTCAGTCTCCCAAAGTCCTGGAACCACAGACATGAGCCACC
ACGCCTGGCCCCTTTTAAAATATTTCTGCTCATTGATGATGCACCCAGTC
ACCCAAGTGCTCTGATGGAGATGTATAAGGAGATGAATGCTGTTTTCATG
GCTGCTAATACAACATTCATTCTGCAACCCCCAAATCAAGAAGTAATTTT
GACTTTCAAGTCTTATTATTTAAGAAATATATTTTGCAAGACTATAGCTG
CCATAGACCGTGATTCCTCTGATGGATCAGACAAACTAAAATGAAAACCT
CCTGCAACGTATTCATCATTCTAGATCCCTGAGGAATCGCCACACTGACT
TNCACAATGGGTGAACTGGGTTACAGT

Sequence ID - 441 nt: 552
AAACAAAATTATTCTCTGAGAGGGAAAGGACATTTGAGGGAAACATCAAA
TTTCCCCATAAATAAATGAATGGAGTTTGCAGGAAGGTGAGGGTGAGCAG
AGATGTGTGTGGACATCTCTGACCATCCATCGCTGTATTCAAATGGATTG
TTTTATTCCATTCTGGTCTCAGGCATGACCACGTCCAGTGAAGACATTTG
AGGCAGCACATCTCAGGACCCAGGCAATAGACTGGCCCCAACTCAGGCTG
GACTAAGGTGTGATTAATTCTTTGTTTTTTGTGTGGAACAGCTCACCTTG
TCAGACAGCCTCAGGGCATCTCTGAGACACAGGGGCAGAAAATGACATTC
ATCTTTTGAGTCCTCATCCATGGAGTGCTGTGTTTGGGGGGCTGCATCTG
CTGAAGCGAGAACCCCATTCTGCCACCCCACCAGGATGCCCATTCTCCAG
GACTTCTCCAACTTACTATTAGACTAAACCAGAACAAGCAACAAACTGTA
TTTATGCAAGCAAAATTGATGAGAAAATTATATTCAAATAAAGCAAAAAT
TA

Sequence ID - 442 nt: 606
TCGTGCCACTGCACTCCAGCCTGGACGACAGAGTGAGACTCCATCTCAAA
ATAAATAAATAAATAAATAAATAAATAAATAAATAAAAAAATAAAAAATA
CTTCTGCTATGAAAAACCTAGTTGGTATTTTTGCTTATTTAATACTATAG
AAATATGGTGATCTCATCTTTAATAGAGTGCTTTTAAGGTCCCCAGTGAT
AATCTCCTAAAATCATGAACTTTAAGAATTTATAATGTTAATATGAGGAA
ATGAAATCTGGATTATCTCACCACATATTATATAATTCATTAGTGACAGA
GCAAGAACTCCAGGTCACCTGTCTATTCCATGTTTTTCCTATCTGCCTTT
AAATGTTGAGATACTACCCTTATCTCATGTGAATGGAGAAACTGCCTAAA
ATGCTAAAACTGACTCAGAGGCACCCAGACATAAGTGAAGTGTGATTAGA
AAATCCTGGTCAGTTGAGTCTTAGCCAAATGTGTACCTACTGTGTCTGCC
TCTATCAAGTCAATGAAAACATGATCTGAGAACTGTAAGTCCATTTATGG
AAAGGGTTGATTTANAGATATTTTGAACTTNCAGTGATGAGCCCCTTCTC
AAATAG

Sequence ID 446
CGGACTCCTGTGCTAATTGTCAGCTTACATATCATTGTATAGAGACTGTT
TATTCTGTACCAAACTGATTTCAAAAGTACTACATNGAAAATAAACCGGT
GACTGTTTTTCTTCATAAAGTTCTGCGTTTGGCATCTTCACTCTTTCCAA
AATGTATCTGTACATCANAAATGTCACTATTCCAAGTGTCTTTTTAGTGT
GGCTTTAGTATGGCTTCCTTTTAATATTGNACATACATTGNATCTTTGTT
TTATGGNAATAAGTAATAAAAATGTAGACTTCATATTTTGTACAAAATGT
CCTATGTACAGAATAAAAAAGTTCATAGAAACAGCCNANAA

Sequence ID 447
AGGCCGAGGCAGGCAGATCNCNTGAGGTCAAGAGTTTGAGACCAGCNTAG
CTAACATGGTGAAACCCCATCTCTACAAAAATATA-AAAATTAGCCTGG-
GTGGTGATGGGCACCTGTAACCCCAGCTACTCGGGAGGCTGAGGTAGGAG
AATCACTTGAACCCGGGAGATGGAGGTTGCAGTGAGCCAAGATCGTGCCA
CTGCACTCCAGCCTGTGTGACAGAACAAGACTCTGTCTCAAAAAAAAATA
ATAATAATAATAATAATAAAAAGGAATAACATAGCTAGGAATAAATTTAA
TCAAAGAGGTGAAAGACTTATACACTTAAAACTACAAAAAAAAAATCACT
GAAGGAATTATAGACCCAAATAAAAATAAATAAAAAGACATTCTGTGTTT
TAGGGAAAGAAGACTTAATATTGTTAAGATGTCAATACTACCCAAAGTGA
TCTACAGATTCAACATAATCCCTATCAAAATTCCAACAGCCTACTTTGTA
GAAATGGAAAAGCCAATTTTCAAATTCAGATGGAATTGCGAGGGGTTNTG
AATAACAAAACACNATCTTGGGGAAAAAAAACAAAAAACAAAGTCAAAGA
ACTCACACTTCTNTATTTATAAATTTACTACAAAGTTATAGTAATCNAA

Sequence ID - 448 nt: 329
TACGCACACGAGAACATGCCTCTCGCAAAGGATCTCCTTCATCCCTCTCC
AGAAGAGGAGAAGAGGAAACACAAGAAGAAACGCCTGGTGCAGAGCCCCA
ATTCCTACTTCATGGATGTGAAATGCCCAGGATGCTATAAAATCACCACG
GTCTTTAGCCATGCACAAACGGTAGTTTTGTGTGTTGGCTGCTCCACTGT
CCTCTGCCAGCCTACAGGAGGAAAAGCAAGGCTTACAGAAGGATGTTCCT
TCAGGAGGAAGCAGCACTAAAAGCACTCTGAGTCAAGATGAGTGGGAAAC
CATCTCAATAAACACATTTTGGGTTAAAA

Sequence ID 450
GAGCAGTGGCATGATCACACCTTACTGCGGCCTCCAACCCCTGAGCTTAA
GTGATTCTCCCGCATTATCCTCCTGAGTAGCTGAGACTACAGGTGCATGC
CACCATACACTACTAAATTTGGGTCGGGTGGTGGTGGTGATTTTTTAATA
TTTTTGTAGAGACAGGGTCTCACTGTGATGCCCAGGCTGGTCTTGAACTC
CTGGGCTCAAGCAGTCACCCACCTCAGCCTCCCAAAGCACTGGGATTACA
GGTGTGAGCCACCACACTGGCCAGCTTTGTTTTGTTTTGATGACTAAGCT
GCTCTTGCTAAAAGGGCTTCTCTCTGAACTTCCCTACCTTTCTTCTGTTT
CCCTGGGCTAGGGCTCCATGTTGGCAGTCCTACTCCCAATTAACCTGGGG
CTGTCTGGTTAACCTTTATAAGATCTGCAGTCATTGGGAGACCCGGGGAC
CAGGAATATTGTTGTTGAGGGAGCTACCCTGGAAAGTGGATGGGTGGCCA
AAGG

Sequence ID 452
TTTGGCTTTGCCTCTAGGCATTAGATGTTATCTTTGGAGGCATCCTTCTA
TGAGCATTCATTTTTGGACCAAGCCTGGATTTACAATTCTATTACTGGCC
CAGACTTCATTTCTATCCAATTTCATTCCACTGTGCTATAGTTTACAACA
TATAATTTGACTTATAAATAATTCCTGACTATGGGTTTAAAGACTGAAAA
TGGATCAATAGAAACTTTGAAAATGTTAACATCTTGATTGCTTTTCTCAG
TGTAGAAATGGACAATGTTTAGCTTAAAAACTGCATGTTTTTAATGAGAT
ACGGGGTTGAAAGACTTATTCCTGGAATTTATTGTTCTGGAGAAAGCCTG
TTGCTATCTGCCATACCTTGGTTTACTTTGTGCAAAATGAGCTTCTTTTT
AAGTAATGAGCTCTTTCCATGTTCAGCTTAAATTGCTGTCTTAGACACTT
CATCAGGGTTCCCTGCTCTGCCTCATTCCCCCTTTTGCTCACTTGCAGCC
TTTGACATAATCCTGGGAGGCAATTGGCATCATACATATTTTGCTTTGTA
ATCTCCTGCTTTGATTCTGACTGGGACCCAGC

Sequence ID - 453 nt: 747
GGATCTAAGACCAGCCTGGCAGCCACCAGATGGTGATTCTAGTCCTGGCT
CAGTCAGTAATAGGTCACTGACCCCAGAGAAATCAATTCAGCCTCCCCAG
GTCCTTGGATTTCTTTCTGTGAAAATGAAAGCATAGGTAGGAATTTCCCA
TGGAACAGCTAGCAGAGGAGAAATATTAAAAGTCAGGAGACTCATGCTAT
AGTTTTCATACTTCATTACAACAATGTTGTTTAGGACAAGTGAGTTAACC
TGTTAGCTTCCTCTATATAAAATGGAAAGTCATTAAAAACCTACATAGCA
GGGTTCTTGTGAAGATCAAGTGATAATGTAGGAAGCATGTACAAATGTCA
CATTCTGCCGTCACGTAATGGTCCTCACAGCTTGAGGTAGCATTTAGCAT
GTGTCATGATTTAGTACAAGGGTTGGCAAACTGTTGCTCTTGGATTAAGT
CTGGCTCATTGCCTGTTTTTCAAAGAAAAAAATTGTATATGTGTGTATAT
ATGTTATATATAGGTACACACACATATGTGCTATATATAGCATATATACA
CACATAATATATAAACATGTACATATATAGCATTATATATATACCGTGTA
TAATATCTCCAGTCCTCATGACCAGCCATGCTTGTTCATTTACATTTGCA
TACTCTATGATTGCTTTCATGCAACAATGGCAGAGTTGAGTGATTGTTTT
GCACAGANACTGTATGGCCCACTAAACCTAAAATATTAATCTCTGCC

Sequence ID 454
CTCCTGCCGGGCTCGTGGCGGCTTCTGTCCGCTCCGCGGAGGGAAGCGCC
TTCCCCACAGGACATCAATGCAAGCTTGAATAAGAAAAACAAATTCTTCC
TCCTAAGCCATGGCATATCAGTTATACAGAAATACTACTTTGGGAAACAG
TCTTCAGGAGAGCCTAGATGAGCTCATACAGTCTCAACAGATCACCCCCC
AACTTGCCCTTCAAGTTCTACTTCAGTTTGATAAGGCTATAAATGCAGCA
CTGGCTCAGAGGGTCAGGAACAGAGTCAATTTCAGGGGCTCTCTAAATAC
GTACAGATTCTGCGATAATGTGTGGACTTTTGTACTGAATGATGTTGAAT
TCAGAGAGGTGACAGAACTTATTAAAGTGGATAAAGTGAAAATTGTAGCC
TGTGATGGTAAAAATACTGGCTCCAATACTACAGAATGAATAGAAAAAAT
ATGACTTTTTTACACCATCTTCTGTTATTCATTGCTTTTGAAGAGAAGCA
TAGAAGAGACTTTTTATTTATT

Sequence ID - 458 nt: 682
TGCCACTGAAGATCCTGGTGTCGCCATGGGCCGCCGCCCCGCCCGTTGTT
ACCGGTATTGTAAGAACAAGCCGTACCCAAAGTCTCGCTTCTGCCGAGGT
GTCCCTGATGCCAAGATTCGCATTTTTGACCTGGGGCGGAAAAAGGCAAA
AGTGGATGAGTTTCCGCTTTGTGGCCACATGGTGTCAGATGAATATGAGC
AGCTGTCCTCTGAAGCCCTGGAGGCTGCCCGAATTTGTGCCAATAAGTAC
ATGGTAAAAAGTTGTGGCAAAGATGGCTTCCATATCCGGGTGCGGCTCCA
CCCCTTCCACGTCATCCGCATCAACAAGATGTTGTCCTGTGCTGGGGCTG
ACAGGCTCCAAACAGGCATGCGAGGTGCCTTTGGAAAGCCCCAGGGCACT
GTGGCCAGGGTTCACATTGGCCAAGTTATCATGTCCATCCGCACCAAGCT
GCAGAACAAGGAGCATGTGATTGAGGCCCTGCGCAGGGCCAAGTTCAAGT
TTCTGGCCGCAGAAGATCCACATCTCAAAGAAGTGGGGCTTCACCAAGTT
CAATGCTGATGAATTTGAAGACATGGTGGCTGAAAAGCGGCTCATCCCAN
ATGGCTGTGGGGTCAAGTACATCCCCAATCGTGGCCCTCTGGACAAGTGG
CGGCCCTGCACTCATGAAGGCTTTCAATGTGC

Sequence ID 459
TCCCGGAATCGCGGCCGCGTCGACCTTGTCCTTGAGCGTCAACCTTCTTT
CCCTGAAGTGGCTGGGGTTCCTGTTTCCTTCTTTGATTGACAACTTGTGT
TAACCCTCGCACATCTCTGGGCCAATTTTTGCTTGTAAGTCTTTCCGGAG
ACCCCTGGAATTTAAATCATTAGCACCGCGCCCTTCCCCGAAGAGTCTTC
GAAGGGTTGCCGCTTTTCGGTGGCGCAGTTCTCGCGAGAAGGTGACTTTC
TTTCTCGGTATTTCCTGGTTTCCAGAATCCTTAGCGCGAGGCGGAAAAAA
TATTTCTCCCAGCTTGTGTTGATGCCGCGATTTTGACTGAGACTTCTTCC
CACGATTTCTGTTTTTGCTTCTCCAAGGAAAATGGCAGCTCCCGAGCAGC
CGCTTGCGATATCAAGGGGATGCACGAGCTCCTCCTCGCTTTCCCCGCCT
CGGGGCGACCGAACCCTTCTGGTCAGGCACCTGCCGGCTGAGCTTACTGC
TGAGGAGAAAGAGGACTTGCTGAAGTACTTCGGGGCTCAGTCTGTGCGGG
TCCTGTCAGATAAGGGGCGACTGAAACATACAGCTTTTGCCACATTCCCT
AATGAAAAAGCAGCTNTAAAGGCATTGACAAACTNCATCAACTGAAACTT
TTAGTCATACTTTAATCG

Sequence ID - 460 nt: 536
CAGAGATCAAAATAGGCCTTACACAGTGCGACGCGAATTTAAAAGATTAC
CCCATTCAGGTGTATGGATTTTGCAGTATTAAAGATGCTGCCTGGAATAG
GTCATTATCTTCTCCAAGTACTCTGTTAAGTCAATGAGTCACATAGAGTA
TAAGGTTTATTATCTGCTTTTCTTTCATTAAATAAATCTTTATTGAATTT
CTACTACATTAAAAAACCAAACCAAAACAAAACAAACAAAAAAAACACTT
CCCTGAGCCATAAAGGAGAAGGTAGTTTTGACTGGAACCTTGAAGGATGG
GTAAACTTTCAGCAGATAAAGATTGAGAGAAGACCTTCCAGGTAGAGAAA
GCAGTGTGGGCACAGGCAAAGATGGAAGAACACACGTGGCTGTGGGAACA
CAGCTAGAAGCCAGTGCGGATAGAGAGTAGGCTATGATGTGGCAAAGGTT
ANACACTGGGAGAGACAGGTCCATGAGAGTAGCTTGGACTAACACAGGGA
GGGTTTGGAATCCCAACTGGGGAACCTANAAATCAA

Sequence ID 461
TAGGAGGCTTATTCACTGATTTCCCCTATTCTCAGGCTACACCCTAGACC
AAACCTACGCCAAAATCCATTTCACTATCATATTCATCGGCGTAAATCTA
ACTTTCTTCCCACAACACTTTCTCGGCCTATCCGGAATGCCCCGACGTTA
CTCGGACTACCCCGATGCATACACCACATGAAACATCCTATCATCTGTAG
GCTCATTCATTTCTCTAACAGCAGTAATATTAATAATTTTCATGATTTGA
GAAGCCTTCGCTTCGAAGCGAAAAGTCCTAATAGTAGAAGAACCCTCCAT
AAACCTGGAGTGACTATATGGATGCCCCCCACCCTACCACACATTCGAAG
AACCCGTATACATAAAAT

Sequence ID 462
TCTTTATCAAGTTGAGAAAGTTCCTCCCCTCTATTCCTAGTTTGCTAAGA
GTCCTTCTATCCTATTTCTTAATGGTTTAGTAGATGACTCTGTGGTACTT
TGAAGGTTGTTTGCAGAATTTCCATGCCATAGGCAATTTACCTTTCCTTG
ACATTTGAAGGATTGATGTTGGTGCCAAGTATAGAATCTTCACAGAGTCC
TCCTGTAGCTTCTAAAGGTTTAGCTTGAAAATGTTAATTGCTTAACGCTA
GTAAGTGAGTGAAAAAGCTGGGGATAAATTTTGTATCTTGCTTATATTTC
AGTTCCCACCTCTGTCCNGACNAAACCCCCATATATAA

Sequence ID 463
TAGTTTACATATCCCAACCTTTAAAAATATTCCTCTTATTAGCTTTATAT
TCACTTTATAGAAGTTGAGTTTTAATTAAAATTCTTGGCATCCTGAAGTA
TGTCACATAGCATGTGCTCCTTATAAATATGTTGATATCTCAGAAGACAG
CATCCCGGTTTTCATTTTATAAAGTACCATACTTAAGAATGCTGTAATAC
TTATCTTTTATAACATGTTTCCTTCGCTTTGCTTGNCTTTTATGNCATCA
GTTTTAACTGTTTACTTCATTTAACAGNTTACATCATNCAACAGTTTACT
TCATTAAACAGTAGGTGGAAAAATAGATGCCAGTCTATGAAAATCTTCCC
ATCTATATCAAAATACTTTCAAGGATATACTTT

Sequence ID - 464 nt: 615
CGACTTTCAACCATCAAGTGAGGAATACCTTCACATAACTGAGCCTCCCT
CTTTATCTCCTGACACAAAATTAGAACCTTCAGAAGATGATGGTAAACCT
GAGTTATTAGAAGAAATGGAAGCTTCTCCCACAGAACTTATTGCTGTGGA
AGGAACTGAGATTCTCCAAGATTTCCAAAACAAAACCTATGGTCAAGTTT
CTGGAGAAGCAATCAAGATGTTTCCCACCATTAAAACACCTGAGGCTGGA
ACTGTTATTACAACTGCCGATGAAATTGAATTAGAAGGTGCTACACAGTG
GCCACACTCTACTTCTGCTTCTGCCACCTATGGGGTCGAGGCAGGTGTGG
TGCCTTGGCTAAGTCCACAGACTTCTGAGAGGCCCACGCTTTCTTCTTCT
CCAGAAATAAACCCTGAAACTCAAGCAGCTTTAATCAGAGGGCAGGATTC
CACGATAGCAGCATCAGAACAGCAAGTGGCAGCGAGAATTCTTGATTCCA
ATGATCAGGCAACAGTAAACCCTGTGGAATTTAATACTGAGGGTGCAACA
CCCCATTTTCCCTTCTGGAGACTTCTAATGAAACANATTTCCTGATTGGC
ATTAATGAANAGTCA

Sequence ID 469
GATTTTTAAAAATACATATAGCAAAAATATTACAGGGTCAGGGGAGACAA
TTAGAATGATATAATTCAAAGTGGATTAAAAAAAAAACTGTCACCCAGAA
TACAATACCCAGCAAAGTTGTCCTTCATAAATGAAAGAAAAATNAAATCT
TTNCCNAACNA

Sequence ID 471
TCCCGGGAATCTGCAGGATCCGTCGACT

Sequence ID 472
GACAGTGCCCAGGGCTCTGATATGTCTNTCACANCTTGNAAAGTGTGAGA
CAGCTGCCTTGTGTGGGACTGAAAGGCAAGATTTGTTCCTGCCCTTCCCT
TTGTGACTTGAAGAACCCTGACTTTGTTTCTGCAAAGGCACCTGCATGTG
TCTGTGTTCTTGTAGGCATAATGTGAGGAGGTGGGGANACCACCCCACCC
CCATGTCCACCATGACCCTCTTNCCACNCTNACCTGTGCTCCCTCCCCAA
TCATNTTT

Sequence ID - 473 nt: 694
TGGGCTTTGGGCTGGCTGCAGTCTGTCTGAGGGCGGCCGAAGTGGCTGGC
TCATTTAAGATGAGGCTTCTGCTGCTTCTCCTAGNGGCGGCGTCTGCGAT
GGTCCGGAGCGAGGCCTCGGCCAATCTGGGCGGCGTGCCCAGCAAGAGAT
TAAAGATGCAGTACGCCACGGGGCCGCTGCTCAAGTTCCAGATTTGTGTT
TCCTGAGGTTATAGGCGGGTGTTTGAGGAGTACATGCGGGTTATTAGCCA
GCGGTACCCAGACATCCGCATTGAAGGAGAGAATTACCTCCCTCAACCAA
TATATAGACACATAGCATCTTTCCTGTCAGTCTTCAAACTAGTATTAATA
GGCTTAATAATTGTTGGCAAGGATCCTTTTGCTTTCTTTGGCATGCAAGC
TCCTAGCATCTGGCAGTGGGGCCAAGAAAATAAGGTTTATGCATGTATGA
TGGTTTTCTTCTTGAGCAACATGATTGAGAACCAGTGTATGTCAACAGGT
GCATTTGAGATAACTTTAAATGATGTACCTGTGTGGTCTAAGCTGGAATC
TGGTCACCTTCCATCCATGCAACAACTTGTTCAAATTCTTGACAATGAAA
TGAAACTCAATGTGCATATGGGATTCAATCCCCACCATCGATCATAGCAC
CCCCTATCAGCACTGNAAACTCTTTTGCATTAAGGGATCATTGC

Sequence ID 474
GGCAGCGCGGGGAGCCCGTCGGCGCCGGCGGGCGGGCCGGTTTCGAAGTT
GATGCAATCGGTTTAAACATGGCTGAACGCGTGTGTACACGGGACTGACG
CAACCCACGTGTAACTGTCAGCCGGGCCCTGAGTAATCGCTTAAAGATGT
TCCTACGGGCTTGTTGCTGTTGATGTTTTGTTTTGTTTTGTTTTTTGGTC
TTTTTTTGTATTATAAAAAATAATCTATTTCTATGAGAAAAGAGGCGTCT
GTATATTTTGGGAATCTTTTCCGTTTCAAGCATTAAGAACACTTTTAATA
AACTTTTTTTTGATAATGGTTAAAAAAAAAAAAAAAA

Sequence ID 475
CATAATAAAAAACAATCAACAAACAGGGAATGGAAAGAAACTTCCTCAGC
ATGGTGAAGGCCACATATGAAAATCCCACAGCTAACATCATACTCAATGA
TGAAAGACTGAAAGCTTTTCTCCTGAGATCAGGAACAAGACAAAGATGTC
ACCTTTTGTCACTTCTATTCAACTCATTATTGGAAGTTTTTGCCAGAGCA
ATTAGGTAAG

Sequence ID - 476 nt: 476
CAGAATCTTTTCATAGGCTGAATGTTGCTCCACAATGTGTCCTTTGACTA
TCTCTGGCTAATTATTATTTTAATCTCTTCTCAGCTTTTCCAAGAACATA
ACGTTAACCAAAGATCTTAGGCCATTCACAACTCTTTTGTAAAAATTAAT
GTGGATGTGAAACGAGGCAACAAATCCTGAAGTAGAAAGTTATTCCTGGC
CAGGCACGGTGGCTCACGCCTGTAATCCTGGCACTTTGGGAGGCCGAGGT
GGGTGGATCATGAGGACAGGAGATCGAGACCATCCTGGCCAACATGATGA
AACCCCATCTCTACTAAAATACAAAAAATTAGCTGGGCATGGTGACGCGT
GCCTGTAGTCCCAGTTACTCGGGAGGCTGAGGCAGGGGAATTGCTTGAAC
CTCGGAGGTGGGAGGTTGCAGTGTGCCGAGATCACGCTACTGCACTCCAG
CCTGGCAACAGAGCAAGACTCCATCT

Sequence ID 477
AAACAGAAAGTTTCTTCTAAAGGCATGATTCAGTTAAGTCATTCTTAAGT
GTTAAAAAATTGTGAAAAATGTGCCTGTAATCCCAACACTTTGGGAGGCC
GAGGCAGGCAGATCACGAGGTCAGGAGATCAAGACCATCCTGGCTAACAA
GGTGAAACCCCGTCTCTACGAAAAATACCAAAAACATTAGCCGGGCGTGG
TTGTGGGCGCCTGTAGTCCCAGCTACTTGAGAGGCTGAGGCAGGAGAATG

Sequence ID 478
TTCTTGGGATATTGATGACTACTGTCTGAGAGGTGCTGTGGGGAGATTTT
CAGGATTGTGTGGTCTTTGAGGGGGGTGTTTTTTTAAGACAACATTGACC
ACTGTCCACTGTCCACATGATCATTGTAAAATTGCAATGCCGCATGCTAG
TTGGTTACATAAGACATAATTCCAGTGATTGAAGGTGGTTACACTGTATG
GTGGTGTGTTCAAGATGGCACTGGCATCTTTGAGCAGAGCCTGGCTATGC
AGCATCATTTGAGTTTTTTAAACACCCTANAGGTCTGGTTGTTGTTGCTG
TTGTCCTTTCCTGTGAAAGTCACAANANAAGTTACAGTCCAGGTGAACCT
GGAGTTTATAGGTTGGTTTTGTTTCTGNTATATATATATATATATATATT
TTTTTTTTTTTTTAACATTTACCTGTAGTGCTGTAGCTGTTGATACTATC
ACCTGCATGCTATTTCTAGTGAGTGCTAAATACAGTATGGTCCAATGACA
ATAACAGCCCATGGTACTGCCAG

Sequence ID 479
CATCAGTCTGTTATCCATGCTGACTTTCCGAAGACTTGCAGCTACTGCAT
TGATATCTTTCCTGCCAATAAGCAAAGTGTTGAACACTTCACAAAATATT
TTACTGAGGCAGGCTTGAAAGAGCTTTCAGAATATGTTCGGAATCAGCAA
ACCATCGGAGCTCGTAAGGAGCTCCAGAAAGAACTTCAAGAACAGATGTC
CCGTGGTGATCCATTTAAGGATATAATTTTATATGTCAAGGAGGAGATGA
AAAAAAACAACATCCCAGAGCCAGTTGTCATCGGAATAGTCTGGTCAAGT
GTAATGAGCACTGTGGAATGGAACAAAAAAGAGGAGCTTGTAGCAGAGCA
AGCCATCAAGCACTTGAAGCAATACAGCCCTCTACTTGCTGCCTTTACTA
CTCAAGGTCAGTCTGAGCTGACTCTGTTACTGAAGATTAGGGAGTATTGC
TATGACAACATTCATTTCATGAAAGCCTTCCANAAAA

Sequence ID 481
CACACTTTCATGATAAAAACAGAACCTAGGAATGAAAAGAAATTATAGCA
ACATAATAAAGACCATATATGAGAAGCCCACAGCTAACATACTGTATGGT
GAAAAACTGAAAGCTCTTCCTCTAAGATCAGGAACAAGGCAAGGATGCCC
ATTCTTGCCACTTCTATCGAACGTAGTACTGGAAGCCCTAGCCAGAACAA
CTAGGCAATAGAAAGAAATTAAAGGCATCCATNTCAGAAAGGAAGAANCA
AAATGCTGTCTGTTTAANATGACA

Sequence ID 482
TTTCTATANAAAAAAATTTTTTAAAATAATTGTAAAGTTAGATTTAAAAT
TGTAAAATATAAAATCACAAAGGAATGTACCCAATAAAATGTAAATGCNC
CATAAAAAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID 483
CGNTAACGTGCAATCCGCCGCACGCCAGCAAACTGGACAAACTCCGGGAT
CTCATCGAAGCGATTGAGCACCAGTACCAGAGTAATACCGGACTGATGTA
ACGAGGCGAGTCGCTCATCCAGCTTGCTGACGTGAGGCAACATCCAGGCC
ATCGAACGGNTCATCAAGAATCAACAAGTCAGGCTCCGACATCAGCGCCT
GACACAGCAGGGTTTTTCGCGTCTCGCCAGTGGAAAGGTATTTAAAGCGT
CNGTCGAGGAGGGCGGTAATACCGAACTGCTGCGCCAGTTGCATGCAACG
CGGTGCATCCTTTACTTCATCCTGAATGATCTCAGCCGTAGTGCGTCCGG
TGCCATCTTCGCCAGGGCCGAGCATATCGGTGTTATTCCGCTGCCATTCG
TCGCTGACGAGTTTTTGCAATTGCTCGAAGGAGAGACGAGTGATGTGGGA
AAACTGGCTTTGCCGTTCACCTTTCAAAAGCGGGAAGTTCCCCCGCCAGC
GCGCGGGCCAGGGCCCGAT

Sequence ID 484
TTTTTTTTTTTTATTCTATTAAAAAATGTTNNTGAAAAAAGATACTTAAA
TTTTAAAGATAACTNAATTCCTAANGATTTAAAATAATCCAAGCAGAGAT
GAAAGANCAAATGCAAATGCNTAAAAAGACCCCANAGCATTGTTAGCAAA
AAGCAAATATAGTTAGCCAAGCATATATATNTCATAAAAGCAATAANAAG
GCNTAAAGCAAGTTTGGGGAGAGCTTATTTAAAACTTGTAAAAATCATTT
GAATTTTTAAAAGTTTTCAAAC

Sequence ID - 485 nt: 551
TTTGGAACACAAAGTTCCCTTTTTAGAAGAATAGGTATTGAGCCCTTGAG
CGTGGGTAGAAAGATAGAGACAGAGTGATTTGCAAAATAATGGAGGATCA
TATTTATATATGAATTTTCACTTATTTGAACTTTCAGATATCANCTTNAA
AANCTTTGGTTTAAGTAAAGTNTNTTAATGAGACTCCTTGGATGAAAGTA
ACCAAAACCAGTAAAAATAAGGTAATAAGGATGTAATAGTTTCTTATGGA
CACTCAACAGCTAGAATGCAGTTAGTCTCAGAAAAGAATTAGAACAAATA
ACTGGAAGGCCATCAGGAGTCCAAAACCATCACTCTTTTATATTTTATAT
TTTATTTTTCTCTCTTCANATGAGCATTCTCTTTCTATGTCCATATGGTA
NAAGGCGGCAGCTCCATAGATTATGGCTTCAGATGTTACAGTTCCGCTNA
ATGCAGGGACAGACTTGCTATCTTTCAGTCCCCTTACATATCCTGGGGAG
AGAGCAAATGATTGACTGGCTTGAGTCAGGTGCCCGTTCCCTTTCCAATC
T

Sequence ID - 487 nt: 224
GTTTGNTTGTGACCATCTGTACTTGTAATTTCTTTACNTTCATTGGTATG
AAAAATATGTTCTTAGAAGCANGAAAAAGAATTCAGNTTTGCTTTGTATA
CTAAATTAAATGCTGTAATTTTGATAAAATGAAAAATCTGCTTTATTTGC
AACAATTGGTTTCTTCCTTGACGTCAGCCTCACTCTTGGACTTTGGTATT
CAGCCNGNCACCCCTGGGAATTCC

Sequence ID - 488 nt: 349
GTGCCTCCCTGTGTGAGTAGCCTAAGGTGCATTGAAAAAGACTGGGATGT
GTTTTATTTTTTTGTATTAGATAGCATTAACCTTACTGTTGAAGTATTTT
TGGTGGAGTATTAGTGACAAGCCATTGAGTCTTAAGCCTTACGGCTTCCT
ATAAAATCACTAATTTCGTGTGTGTTTGTGTGTAGGTTACGTTATATATA
GGATTCGTGTTCGCCGTGGTGGCCGAAAACGCCCAGTTCCTAAGGGTGCA
ACTTACGGCAAGCCTGTCCATCATGGTGTTAACCAGCTAAAGTTTGCTCG
AAGCCTTCAGTCCGTTGCAGAGGANCGAGCTGGACNCCCTGGGGGGCTC

Sequence ID 489
TTAACAGCTGCATAGAGTTTTAAAAGTACATTATATTTTGTCAGACAAGT
AAAATATCTGTTTTTCACGCAAAAAAAGCCATGAAATACGTAATTTTTTA
AAGACAAAAAATCATCTTTTGAGTTTGCTCTTTGGTTTTTCTTCATTCCT
TTTGAGGATTGGGAAAACAGAAAGATTCTTTGATTTGGGTAATGAAGAGG
TAATTTGGGACAGTGTGGTGGTACCAGGAAGAAAGAGGATTGGAAAGGCC
AGTACTGTTTTAGTTGCTCGGCACTGTTGGTTTTGTTTTAATGTGGTTGC
CCTGTCCACTACATGGTTCTATCAGTAGTGTAATCCATTTTCAATGTAAA
GCTCTTTTAGTTTTTGTCATAGACATAAATTAATATTTTGAGAGGCATCC
CTCACCTGTTCATTTCTTCTGTGTTGAAATGAAGTACTTAAAATTACCGT
TATACATGAACTTTGTGGACTGTAAGATTTGTTATATATGTTCAAATGCC
TTTTAGCTGGCTTTTTAATTAATATGCCTGTTTTGAGTGCTTAATACAAT
GTAATGNGGATTGTAAATCATACCTATTTTAAATCATTCCTTCCTGTATA
TTTGNACTCAGAGAGCCTTATTTTATTCTTCCAGC

Sequence ID - 491 nt: 382
TTTTCTTAGAACTTTATTTTTTCTGGCCAGGCGCAGTGGCTCACACCTGT
AATCCCAGCACTTTGGGAGGCCAAGGCAGGTCGATCACCTGAGGTCAGGA
GCTCAAGACCAGCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAAT
ACAAAAATTAGCTGGGCGTGGTGGCGCATGCCTGTAATCCCANCTACTCA
GGAGGCTGAGGCAGGAGAATTGTTTGAACCCGGGAGGCGGAGGTTGCANT
GAGCCGAGATTGCGCCACTGCACTCCAGCCTGGGCAACAGAGCGAAACTC
CATCTCAAAAAAAAAAAAAAAAAACAACCTTTATTTTTTCTGATTTTAAA
AGTAATAACTAGTTTGTAGAAACATTAAAAGT

Sequence ID 492
ACCCTAAACATAACTTAAAATTTGTTNGGAATTTGAAAGTACAGAATTTT
CCTGTAATTGAGACTNTTTAAACTTTTGTGGTTGGAGAAGGTATTCTATT
TTTTGAAAATATCTGTAAGTTTTATCTAAATAGTAAACTCTAAGTATTCT
TCCCCTTTACTTACAGCCACCCTGGGAATCTGAGACTAGAGAAAATAAAG
TTTGTCTCTTGTTCTAAGGAGGGTCTGGTTTAGAAATCTGATTTAGACAT
AGAAAAATTGCAAGAAGCTTGAGGTGATTGGAAGATACGATTTTGTTATC
AAAGNATGTTTCTGTTTTATAGATTTTATTCATCTACAACTCCTTATTAA
TATATTTAAGAAGTCATTAACCCACCATTGATTACTTGATATAAAAGGAG
AANCGGTGGTAAAAGGTGAAATANAATTTTTAATTTTTTTTTTTTTAAGT
TTAGGATTTTTTTTTAAATTCTAAGAGTTTCTGTCATTTGGGGACAATCA
GAA

Sequence ID 493
TGGGAATCATAATTNGTTAACTGAAGCTNATAAGATGAGAGCATTCANAG
AGAAAAGAACGGAAAGATTGAATATCAGTTTCCCTTCTTTAAAAAAATTG
TGGATATGTGATCTAGCTTCTTGAGCATCACAGTGACTGATTGGCTCGTG
GTAATTGATCGCTATGCTGACAATCTTATCTCCACCTATGTCATTCAATT
TTCTAAGAGGCAAAATCCTTAATCAGGAGGAGAGTTTAGCTCTAGCTAAA
TTTCCCTTGTCCAGCATGCTCCTGCTCCCCCAACTTGTGGAAACAGCTAA
AGGATTGGACTAGGAGCANAAGTTTGGAATGGTTAAAATGTAGCAACATG
TGTTTCCTGAAACAAAATTCCACTATAATAAAAAAAGCATTTGAATGCTC
CCTTGTAATTCTGTTGGAGCTTGTTGCCTTTTTTATGACACAACCATAAT
CAGTGATAGACAGTAGCATAAAGAAGCAAGAGCAAAGCAATTAAGTAATA
ATAGCACTACAAAAATGTGTGCTGTACTTACCAAACACGACATTTATGAA
TTATTANATAGGAATAAGGGGATGGT

Sequence ID 494
GACCCAGCCATCTAAATAAGTTRTACATGTTGCGTATTTTTTTGTTAGGG
ACTTATCTTCCGAAGAGGAAAGGTTTATGAAACCTAAAGTAACAATGATA
GCTTGGAATCAAAATGATAGCATTGTTGGCACAGCTGTGAATGATCATGT
CCTCAAAGTGTGGAATTCTTACACTGGACAACTGCTTCATAACTTAATGG
GACATGCTGATGAAGTATTTGTTCTGGAGACACATCCCTTTGATTCCAGA
ATTATGTTATCTGCAGGACATGATGGCAGCATATTTATATGGGATATTAC
AAAAGGTACCAAGATGAAACATTATTTTAATATGGTAAGTGAAGTGAGAT
GTACCTTGATACATGCTTGATAATTTGTTTAGAGTATTTGGGTTATGCGG
CTTACCCAGAAATTGATCTGCTTGTTTTGGCAGTTTGTTTTTACAAATCA
ACATATTCAAAGCCTGCTAAATATTAGACAGCTACATGTATATACGTACA
TACATGAA

Sequence ID 495
TTTC

Sequence ID 496
CTCGCTGGCGGGAGGCCACGGGCTTTCCACAGCGCGGGGGAACGGGAGGC
TGCAGGATGGTCAAGCTGACGGCGGAGCTGATCGAGCAGGCGGCGCAGTA
CACCAACGCGGTGCGCGACCGGGAGCTGGACCTCCGGGGGTGATCTGGAC
CCTCTGGCATCTCTCAAATCGCTGACTTACCTAAGTATCCTAAGAAATCC
GGTAACCAATAAGAAGCATTACAGATTGTATGTGATTTATAAAGTTCCGC
AAGTCATAGTACTGGATTTCCAGAAAGTGAAACTAAAATTTTAATCCAGG
TGCTGGTTTGCCAACTGACAAAAAGAAAGGTGGGCCATCTCCAGGGGATG
TAAAAGCAATCAAGAATGCCATAGCAAATGCTTNAACTCTGGCTGAAGTG
GANAGGCTGAANGGGTTGCTGCAGTCTGGTC

Sequence ID 497
GAAGACCTCACATCTGAGAGCTCATCTGCGTTGGCATTCTGGAGAACGCC
CTTTTGTTTGTAACTGGATGTACTGTGGTAAAAGATTTACTCGAAGTGAT
GAATTACAGAGGCACAGAAGAACACATACAGGTGAGAAGAAATTTGTTTG
TCCAGAATGTTCAAAACGCTTTATGANAAGTGACCACCTTGCCAAACATA
TTAAAACACACCAGAATAAAAAAGGTATTGACTCTANCAGTACAGTGCTG
GCATCTGTGGAAGCTGCGCGAGATGATACTTTGATTACTGCAGGAGGAAC
AACGCTTATCCTTGCAAATATTCAACAAGGTTCTGTTTCAGGGATAGGAA
CTGTTAATACTTCCGCCACCAGCAATCAAGATATCCTTACCAACACTGAA
ATACCTTTACAGCTTGTCACAGTTTCTGGAAATGAGACAATGGGAGTAAA
TATTACACAAATACTTATTCATTGNGGTTATTTTTATACAGTAGTGAGAA
GAATATTGTTCCTAAGTTCTTAGATATCTTTTTTTGGATGTGCAAAAATT
TTTGGATTGACAGTAACTTGGGTATACATGACACTGAAATGCCTTACTTT
GGATGA

Sequence ID 499
TGCCTGCGGGCCAGGACCTCGCCCAGCCCATGTTCATCCAGTCAGCCAAC
CAGCCCTCCGANGGGCAGGCCCCCCAGGTGACCGGCGACTGAGGGCCTGA
GCTGGCAAGGCCAAGGACACCCAACACAATTTTTGCCATACAGCCCCAGG
CAATGGGCACAGCCTTCCTCCCCANAGGACCCGGCCGACCTCAGCGCCTC
CTGCAGGCTAGGACACTGGTGCACTACACCCCATGCCTGGGGGCCGAGAT
TCTCCAGCAGAAAGATGCAATATTTTTTGTTTCCTTTTTTTCCATTTTTT
TCTCTAAGGAATCAATATTTCAATATGTTGAGTGTGTGTCCAATGCTATG
AAATTAAAATATTAAATAACATATTTATGGCATTTTCTTGAAGAGTGTGG
TTGAAGAAATATTTCTCCTTTTGTTTTTCTTTTTTTTTTGNTTGNTACTG
CCACTTCTTTTTAGGAGCAAATCTCCCCAGGGGTGTACGGNATTTCTTGA
CTCTGGGAACAGCTGCTACCCCCAAGACTTGCCACGTTGTTCTGCCCTCA
AATGGAATTAAGTG

Sequence ID - 500 nt: 390
GGAATATGGTCAGGATCTTCTCCATACTGTCTTCAAGAATGGCAAGGTGA
CAAAAAGCTATTCATTTGATGAAATAAGAAAAAATGCACAGCTGAATATT
GAACTGGAAGCAGCACATCATTAGGCTTTATGACTGGGTGTGTGTTGTGT
GTATGTAATACATAATGTTTATTGTACANATGTGTGGGGTTTGTGTTTTA
TGATACATTACAGCCAAATTATTTGTTGGTTNATGGACATACTGCCCTTT
CATTTTTTTCTTTTCCAGTGTTTAGGTGATCTCAAATTAAGAAATGCATT
TAACCATGTAAAANATGANTGCTAAAGTCAGCTTTTTAGGGCCCTTTGCC
AATAGGTANTCATTCAATCTGGTATTGATCTTTTCACAAA

Sequence ID 502
ACCCGCCATCTTCCAGTAATTCGCCAAAATGACGAACACAAAGGGAAAGA
GGAGAGGCACCCGATATATGTTCTCTAGGCCTTTTANAAAACATGGAGTT
GTTCCTTTGGCCACATATATGCGAATCTATAAGAAAGGTGATATTGTAGA
CATCAAGGGAATGGGTACTGTTCAAAAAGGAATGCCCCACAAGTGTTACC
ATGGCAAAACTGGAAGAGTCTACAATGTTACCCAGCATGCTGTTGGCATT
GTTGTAAACAAACAAGTTAAGGGCAAGATTCTTGCCAAGAGAATTAATGT
GCGTATTGAGCACATTAAGCACTCTAAGAGCCGAGATAGCTTCCTGAAAC
GTGTGAAGGAAAATGATCAGAAAAAGAAAGAAGCCAAAGAGAAAGGTACC
TGGGTTCAACTAAAGCGCCAGCCTGCTCCACCCAGAGAAGCACACTTTGT
GAGAACCAATGGGAAGGAGCCTGAGCTGCTGGAACCTATTCCCTATGAAT
TCATGGCATAATAGGTGTTAAAAAAAAAAAATAAAGGACCTCTGGG

Sequence ID - 503 nt: 109
ACATTTTCCGGNCCTTTTGCCATACACAGTTACAGAGATCAGTCAAATCC
ATACCACCACTGAGATCTCATTTATTGCCACAGATGCACAAAATAAATAA
CCCAAAATC

Sequence ID - 504 nt: 374
CCAGCAACGACCCATACCTCAGACCCGACGGCCCGGAGCGGAGCGCGCCC
TGCCCTGGCGCAGCCAGAGCCGCCGGGTGCCCGCTGCAGTTTCTTGGGAC
ATAGGAGCGCAAAGAAGCTACAGCCTGGACTTACCACCACTAAACTGCGA
GAGAAGCTAAACGTGTTTATTTTCCCTTAAATTATTTTTGTAATGGTAGC
TTTTTCTACATCTTACTCCTGTTGATGCAGCTAAGGTACATTTGTAAAAA
GAAAAAAAACCAGACTTTTCANACAAACCCTTTGTATTGTANATAAGAGG
AAAAGACTGAGCATGCTCACTTTTTTATATTAATTTTTACAGTATTTGTA
AGAATAAAGCANCATTTGAAATCG

Sequence ID 505
GTACAGGAGGTAAATTGGATACCCCATCTAAGGGGATCTGTGAGACCAGG
TAGTTATTTGGAATGAAAGAGTAAGATATTAAACCAGCCAGCATGTCAAC
AGGTGGGTGATAGTCTTGTTCTCACAGACAACAGATGGCCATCATCTTAA
AACAACATTTATGTTAACCAGCAGATAAGGGACTCCTGCATTGTCAGTGG
ACTTTGAGCCTGAGTTTTTCTACTTGCATAGGTGAAAGTGGACTGCAATG
CTAGTATAAATGCCGTATGATGACTAGTACCCCTTAGGGAGCTCCAGTTT
GCCTTCCTGGGGAACCACAGACCCCAAGTGTAATTTCCTGAGGACAGCCC
GACTTCT

Sequence ID 506
GTTACTGTGAGCCTGTCAGTAGTGGGTACCAATCTTTTGTGACATATTGT
CATGCTGAGGTGNGACACCTGCTGCACTCATCTGATGTAAAACCATCCCA
NAGCTGGCGAGAGGATGGAGCTGGGTGGAAACTGCTTTGCACTATCGTTT
GCTTGGTGTTTGTTTTTAACGCACAACTTGCTTGTACAGTAAACTGTCTT
CTGTACTATTTAACTGTAAAATGGAATTTTGACTGATTTGTTACAATAAT
ATAACTCTGAGATGTGTGAAAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID - 507 nt: 521
CTGCGGTGGAGCCGCCACCAAAATGCAGATTTTCGTGAAAACCCTTACGG
GGAAGACCATCACCCTCGAGGTTGAACCCTCGGATACGATAGAAAATGTA
AAGGCCAAGATCCAGGATAAGGAAGGAATTCCTCCTGATCAGCAGAGACT
GATCTTTGCTGGCAAGCAGCTGGAAGATGGACGTACTTTGTCTGACTACA
ATATTCAAAAGGAGTCTACTCTTCATCTTGTGTTGAGACTTCGTGGTGGT
GCTAAGAAAAGGAAGAAGAAGTCTTACACCACTCCCAAGAAGAATAAGCA
CAAGAGAAAGAAGGTTAAGCTGGCTGTCCTGAAATATTATAAGGTGGATG
AGAATGGCAAAATTAGTCGCCTTCGTCGAGAGTGCCCTTCTGATGAATGT
GGTGCTGGGGTGTTTATGGCAAGTCACTTTGACAGACATTATTGTGGCAA
ATGTTGTCTGACTTACTGTTTCAACAAACCAGAAGACAAGTAACTGTATG
AGTTAATAAAAGACATGAACT

Sequence ID 508
AAGCTCATGATTTTAAATGTATTTTTCTAATAAACTATACTCCCATTTAA
AAATCACCAATACCTTAATGTTTCAATTATATAAGCTAATTAAAAATAAA
GGCTGGGCGTGGTGGCTCACTTTGGAAGACCGAGGCAGGCAGATCACCTG
AGGTCAGGAGTTCGAGACCAGCCTGCCCAACATGGAGAAACCCCATCTCT
ACTAAAAATACAAAATTAGCCAGGCATGGTGGCACATGCCCGTAATCCCA
GCTACTGGGGAAGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCAGGG
GCTGCAGTGAGCCGAGATCATGCCATTGCACTCCAGTCTGGGCAACAATA
GTGGAACTCCATCTCAAAAATAATAAAAAAAATAAAATAAAAATAAAATT
CAAACCTAAAATAGATGCTCTACTTCAGGAGTGGGCAAATTAATCACCTG
CATCCTTTTTTTGGGCTTTC

Sequence ID - 509 nt: 575
TTTTTTTCTAAATGGNGATTACTAATATATGTGGAGACTATTAATCTCTT
TTCTGTTGCCATTAGTTCATTTTTCCCCAAAAGCCAATACATGTTCATTA
CAAAAATGAATTATAAAATATAAGTTAAAAGAAAAACATAAAACCCTACA
ATCTTACCCACCCAGACAACTACTATTAATACCTTAGTATTAACATATAC
ACATCATGTATATGTATAAATTTATCTTAAACAAAAATAAAATTATTCTT
TACATATTGTTTTAAAACCTATTTATCTGGCCAGGTGCCGTGGCTCACGC
TTGTAATCCCAGCACTTTGGGAGGCTGAGGCACGTGGATCACCTGAGGTC
AGGAATTCGAGACCAGCCCAGCCAACATGGTGAAACCCTGTCTCTAATGG
TTTAAATACCAAAAAATTAGCTGGGCATGGTGGCACATGCCTGTAATATC
AGCTAACATGGGAGGCTGAGGCAGGAGAATCACTTGAACCANGGAGGGGG
AGGTTGCAGTGAGCCGAAATCACACCACTTCACTGCAGCCTGGGCAACAA
AGCAAGACTGTCTCAAAAAGAAAAA

Sequence ID 510
CACTGTCATTCCCAGGAGGCTTTGGAGTCAGAACTGGATTCAAATTCTGA
CTNTATGTTGTGTGACTTGGGCCAATAGCTTCTTTNTGTGCCTCAGTTTC
TTTAGCTGTAAATANACGGGTAGGTCACCCCTTACCCCATAGGTTATGGG
GAAAGTTACAGAAAATGGTCAGCTGGGCNCAGTGGCTCAAGCCTGTGGTC
CCAGCNCCTTGGGAGGCCAAGGTGAGCAGATTGCTTGAGCCCAGGAGTTT
GACACCAGTNTGGCAACGTGACGAAACCCTATCNCTGTGAAAAATACAAA
AAATTAGCCAGGCATGGTGGTGTGTGTCTGTGGTTCCAGCTGCTTGAGAG
TTTGAAGTGGGAGGATCACCTGAGCCCAGAAGGTCGAGGCTGCAGTGAGC
TGTGATCGCGTCACTGCACTCCAGCCTGGC-GACAGAGTGAGA-CCCCT-
TTTGAAAAAAAAAAAAAAAAAAT

Sequence ID 512
GTGAGCGGTGGTGGTTTATTCTTCCGTGGAGTTAAGGGCTCCGTGGACAT
CTCAGGTCTTCAGGGTCTTCCATCTGGAACTATATAAAGTTCAGAAAACA
TGTCTCGAAGATATGACTCCAGGACCACTATATTTTCTCCAGAAGGTCGC
TTATACCAAGTTGAATATGCCATGGAAGCTATTGGACATGCAGGCACCTG
TTTGGGAATTTTAGCAAATGATGGTGTTTTGCTTGCAGCAGAGAGACNCA
ACATCCACAAGCTTCTTGATGAAGTCTTTTTTTCTGAAAAAATTTATAAA
CTCAATGAGGACATGGCTTGCAGTGTGGCAGGCATAACTTCTGATGCTAA
TGTTCTGACTAATGAACTAAGGCTCATTGCTCAAAGGTATTTATTACAGT
ATCAGGAGCCAATACCTTGTGAGCAGTTGGTTACAGCGCTGTGTGATATC
AAACAAGCTTATACACAATTTGGAGGAAAACGTCCCTTTGGTGTTTCATT
GCTGTACATTGGCTGGGATAAGCACTATGGCTTTCAGCTCTATCAGAGTG
ACCCTAGTGGAAATTCGGGGGATGGGAAGGCCACATGCATTGGAAATAAT
ANCGCTGCAGCTGTGTCAATGTTGAAACAAG

Sequence ID 513
TTTTTTTTTTATAAACTCCAATCATTTCCAGAGCTACTTAGCTCAGCATC
TTTTTTTTCCACGCTCTTAAGTTGTGTTTATACATTTTTGATACAGTTAG
ATTGTTTTTGTCACATTCTTCATTCTATCCTGGGATCCCCCAACCACCTA
AGTGGATTTTTTGATAATTTGCATGCTTTAAGGATAACTCTTCATTCTGN
AAAGGGCTATGGGTTTTGGCAAATGCAGAGTCATGTATCCAAGATTACAA
TATCGCACAGAAGAGTTTCATCACTATATAAAACTCACCAGTCTTCCTCC
TATTCAACCATCTCCATGCCTTCTTCCCAGCCCTAACTCCTTAAAACCAC
TCATATCTTTACTATTGCTATAGTATTGCCTCTTCCACCATGTCATATAA
ATGGAAACATACAGTATTAGTCTTCTCAAACTAGTTTCTTTTACCTAACA
ACATGCATTTAAGATTCATAGTGTCTTTTAATGACTTGATAGATTATTTC
TTTGTAGCTGAATAATATTGCATCTTATAGATGTAACCGTTTGTATATCC
ATATTTTCTCACAGCCTATGACTTGNCTTTTGATTCTCTGAACAGGCCAT
TCACAAAGGAGAAGTTTTAATTTTTATAAAGCTAATGNATCAACTT

Sequence ID 515
CCTGGATGACAGCATATCTGTTTATAGCTCAGTTTACTGAATACTTTAAG
CCCACTGTTGAAACCTGCT

Sequence ID - 518 nt: 502
GATGCATGTCCAGCATAGGCAGGATTGCTCGGTGGTGAGAAGGTTAGGTC
CGGCTCAGACTGAATAAGAAGAGATAAAATTTGCCTTAAAACTTACCTGG
CAGTGGCTTTGCTGCACGGTCTGAAACCACCTGTTCCCACCCTCTTGACC
GAAATTTCCTTGTGACACAGAGAAGGGCAAAGGTCTGAGCCCAGAGTTGA
CGGAGGGAGTATTTCAGGGTTCACTTCAGGGGCTCCCAAAGCGACAAGAT
CGTTAGGGAGAGAGGCCCAGGGTGGGGACTGGGAATTTAAGGAGAGCTGG
GAACGGATCCCTTAGGTTCAGGAAGCTTCTGTGCAAGCTGCGAGGATGGC
TTGGGCCGAAGGGTTGCTCTGCCCGCCGCGCTAGCTGTGAGCTGAGCAAA
GCCCTGGGCTCACAGCACCCCAAAAGCCTGTGGCTTCAGTCCTGCGTCTG
CACCACACATTCAAAAGGATCGTTTTGTTTTGTTTTTAAAGAAAGGTGAN
AT

Sequence ID 519
CTGCGATNGAGTTTTGAGAGGAAGGANTAAAGTNCTCATCTCNGACGGTG
AGAAAGATCATNACTAAGGAAACGCAGGGTTGGAAGCAGTGCTGANTGTC
CAGTTGAGTTTCATGANCAAACATTTGCTGTGGGACCAGTTTTCATGGNG
GTTTGTCATTTTGTCCAGCTGCCTGGAGCTGCTTGGTTGAAGGCACAGAA
TAATCAGGATTAATTGTTNAACTTGTATGAATTTCTTTATTTTAAAATAG
GAATAATATCTGCCTTGGGAGCAAGTTGTAAGAGTTAACTGAAAGCTTNA
GGAAAAACTTTCCCTTGCTATTTAAGTAGGGCTTTACAAGTTACAATTCT
ATCACAGTTTTAAGATTATAAAC

Sequence ID 521
GCGGCGCANCTGCGGATCCANAAGGNCATAAACGANCNGAACCTGCCCAA
NNCGTGTGATATCACCTTCTNAGATCCAGACNACCTCCTCAACTTCAAGC
TGGTCATCTGTCCTGATGAGGGCTTCNACAAGAGTGGGAAGTTTGTCTCA
AAAAA

Sequence ID - 523 nt: 585
GATTTACTGTGGGAATTTGCTCATGCAATTATGGAAACCTAGAAGTCCCA
TAATATGCCATCTTCAAGCTGGAATCCCAGGAAAGCAGGTGGTGTAATTC
TGAGATTGAAGTCTTGAGAACCGGGGGAGTCAATGGTGTAACTCCCAATC
TAGGGCTTAAGGCCCAAGGACCAGGGCTGCTGGTGTGCAGATGCAAATCC
TGGAGTTCAAAGGATTGAGAACCAGGAGCTCTGGTGTCTGAGGGCAGTAG
AAGATGGATGTTCCAGCTCAAGAAGGGAAAGTAAGAATCCGTCCTTCCTC
CACTTTTTTGTTCTATTCAGATGAGCCCTCAATGGACTGAACGATGCTCA
CCCACACTGTGAGGGCTGGTCTTCTTTATTCAATCCACTGACTTAAGTGC
TGATCTCTTCTGGAAACACCTTCACAGACACACCCAGAAATAATGTTCTA
CCAGCCATGGGCCTGTTACTTAGCCCAGTCAAGTTGACACAGAAAATTAG
CTATCACAACATCTGTGTGTGTATATACATATGTATTTGCATGTGTGTGT
ATATATGGNGTATATATATTCATGTGTGTGTATAT

Sequence ID 524
CTTTTGCCAGTAGGCCCCCTGAGTAGGTTCCTCTATCTTTTGGCATGACC
CCAGAAGTCTTTGATAACTTCCTTGCTTTCTGATGTGACAAGACATCCAG
GGCCAGATTGTCCATATCCTGCCCCGGATGCACGATGCACTGTTTCTCCA
AGAATCCCTGTGTCCTTTGCTGATGATGCCATGATTTTAAGTTCTCTAAT
ATAGTTTTATCTCTTTGTTTCAGATAATGCTTTTGTGTTCTCACATGTCC
TGCTCTCTCTCTCTCTCTCATTTTGGTGTTGATCAGTCTTTCCATAAGAT
TGTTTATTTCACTAGTCCTTCATTCTTCTTTTTTCTAAATTTACTCTTCT
TGACTAGTATCCTGTCACTTCTGAGGACTCATATTTTTGCAACTTGAAAA
TTATTCTTATTTATTTAAGTATATGTTNCTGAAACTCTCATTAGACACAT
TTTG

Sequence ID 525
GTTAAAAAAAGTAAAAGGAACTCGGCAAATCTTACCCCGCCTGTTTACCA
AAAACATCACCTGGTAGCATCACCAGTATTAGAGGCACCGCCTGCCCAGT
GACACATGTTTAACGGCCGCGGTACCCTAACCGTGCAAAGGTAGCATAAT
CACTTGTTCCTTAAATAGGGACCTGTATGAATGGCTCCACNAGGGTTCAN
CTGTCTCTTACTTTTAACCAGTGAAATTGACCTGCCCGTGAAGAGGCGGG
CATAACACAGCTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTTT

Sequence ID - 526 nt: 516
CTTTTCATGGTCTCTTGTTCATTAATCATCTAAAATCCAAGCNCAGAGAA
TTCAATTTTAGATGGTCTCCAGAGCAGAATTTGATGTATAATCTTAATTA
CAAATCATAGATAATTAATATTGNTTACAAAATCANAATACGATTAGAGG
TAGGGATCCTGCACACACCCTATTTTCCTCCCCAGTGTTCTGACCGAGAG
ACTAATTAATAATTCAAGGAACTTACAGTGAATGANAACCCATGGTTTTG
CTTAATTATCAGAACAGCTAGATCTGAGAACAGCTGTCTCCCACATGGAT
AGACACTTATTCCACCCATTTGCAGGTAGAATAGCTGGCAATAATAAGTC
CTTCCCATTGGATATGTTGAAAGGTGCCTGCCATGGCATAGTTGCCACAA
GAGAGGAAGAAATGGACACAAATGTAGGCTGTTTTCAGGGCANAGGGAAG
GTGGGAGGAAACCAANTTGCTGGTTTTCACACACCCTCTGGGGAACACCC
ATGCACCTATGANATG

Sequence ID 527
GACAAAAGCTGAGAGAATTTTTTTCTTGAATATTTGCACTAAAAGATAGG
TTAAAATTCTTCAGGCTGAAGAGAGCATACCAGGTGGAGATTTGGATCTA
CAAAAAGGAAGGAAGATTTGGAAATGGATTTGGCACCATTGACTCAATTT
CCAGAACAAGAAAGCAGGGACAGTTTTGGGAAGCTCAAGACACACTGCCC
ATGAGCAGCAATTTGGACCTCCTGCTGCATCCACTGTGCATCAAACACAC
ACTGTACAGACAAAGACTCCCAGGAAAAGAAGTATAAACATGGACTAACA
CAGAGATGGGCAAACTACAGCCTGTGACCCAGCCACCTGTTTATGTAGAA
TCCAAAGTAAGAATCTTTAACTTACACATAAACTT

Sequence 529; 660nt
GACAGCAGAGCACACAAGCTTNTAGGACAAGAGCCAGGAAGAAACCACCG
GAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGC
TCTCTTGGCAGCCTTCCTGATTTCTGCAGCTCTGTGTGAAGGTGCAGTTT
TGCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGACATACTCC
AAACCTTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGG
ACCACACTGCGCCAACACAGAAATTATTGTAAAGCTTTCTGATGGAAGAN
AGCTCTGTCTGGACCCCAAGGAAAACTGGGTGCANAGGGTTGTGGANAAG
TTTTTGAAGAGGGCTGAGAATTCATAAAAAAATTCATTCTCTGTGGTATC
CAAGAATCAGTGAAGATGCCAGTGAAACTTCAAGCAAATCTACTTCAACA
CTTCATGTATTGTGTGGGTCTGTTGTAGGGTTGCCAGATGCAATACAAGA
TTCCTGGTTAAATTTGAATTTCAGTAAACAATGAATAGTTTTTCATTGTA
CCATGAAATATCCAGAACATACTTATATGTAAAGTATTATTTATTTGAAT
CTACAAAAAACAACAAATAATTTTTAGATATAAGGATTTTCCTGGATATT
GCACGGGAGA

Sequence ID 529
GACAGCAGAGCACACAAGCTTNTAGGACAAGAGCCAGGAAGAAACCACCG
GAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGC
TCTCTTGGCAGCCTTCCTGATTTCTGCAGCTCTGTGTGAAGGTGCAGTTT
TGCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGACATACTCC
AAACCTTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGG
ACCACACTGCGCCAACACAGAAATTATTGTAAAGCTTTCTGATGGAAGAN
AGCTCTGTCTGGACCCCAAGGAAAACTGGGTGCANAGGGTTGTGGANAAG
TTTTTGAAGAGGGCTGAGAATTCATAAAAAAATTCATTCTCTGTGGTATC
CAAGAATCAGTGAAGATGCCAGTGAAACTTCAAGCAAATCTACTTCAACA
CTTCATGTATTGTGTGGGTCTGTTGTAGGGTTGCCAGATGCAATACAAGA
TTCCTGGTTAAATTTGAATTTCAGTAAACAATGAATAGTTTTTCATTGT

Sequence ID - 530 nt: 660
GACAGCAGAGCACACAAGCTTNTAGGACAAGAGCCAGGAAGAAACCACCG
GAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGC
TCTCTTGGCAGCCTTCCTGATTTCTGCAGCTCTGTGTGAAGGTGCAGTTT
TGCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGACATACTCC
AAACCTTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGG
ACCACACTGCGCCAACACAGAAATTATTGTAAAGCTTTCTGATGGAAGAN
AGCTCTGTCTGGACCCCAAGGAAAACTGGGTGCANAGGGTTGTGGANAAG
TTTTTGAAGAGGGCTGAGAATTCATAAAAAAATTCATTCTCTGTGGTATC
CAAGAATCAGTGAAGATGCCAGTGAAACTTCAAGCAAATCTACTTCAACA
CTTCATGTATTGTGTGGGTCTGTTGTAGGGTTGCCAGATGCAATACAAGA
TTCCTGGTTAAATTTGAATTTCAGTAAACAATGAATAGTTTTTCATTGTA
CCATGAAATATCCAGAACATACTTATATGTAAAGTATTATTTATTTGAAT
CTACAAAAAACAACAAATAATTTTTAGATATAAGGATTTTCCTGGATATT
GCACGGGAGA

Sequence ID 532
GAATTGTGATAGTTCAGCTTGAATGTCTCTTAGAGGGTGGGCTTTTGTTG
ATGAGGGAGGGGAAACTTTTTTTTTTTCTATAGACTTTTTTCANATAACA
TCTTCTGAGTCATAACCAGCCTGGCAGTATGATGGCCTANATGCAGAGAA
AACAGCTCCTTGGTGAATTGATAAGTAAAGGCAGAAAAGATTATATGTCA
TACCTCCATTGGGGAATAAGCATAACCCTGAGATTCTTACTACTGATGAG
AACATTATCTGCATATGCCAAAAAATTTTAAGCAAATGAAAGCTACCAAT
TTAAAGTTACGGAATCTACCATTTTAAAGTTAATTGCTTGTCAAGCTATA
ACCACAAAAATAATGAATTGATGAGAAATACAATGAAGAGGCAATGTCCA
TCTCAAAATACTGCTTTTACAAAAGCAGAATAAAAGCGAAAAGAAATGAA
AATGTTACACTACATTAATCCTGGAATAAAAGAAGCCGAAATAAATGAGA
GATGAGTTGGGATCAAGTGGGATTGANGANGCTGTGCTGTGT

Sequence ID 533
CTTGAACCTCGGAGGCAGAGGTTGCAGTGAGCCGAGATCACGCCACTGCA
CTCCAGCCTCGGGGACAGAGCAAGACTCCATCTCAAAACACACACACACA
CACACACACACACACACACACACACAAAACAGATATACACTGAACACAGC
ACAAGTGGGACATAAGAGATTTAAAAGGGTTAGAGATGTAAAATGGATCT
AGGAATGGAAACCATAAGGNGGGATTTATCAACTGGATTCTGCANAATGC
TGTTAAGGCCAGATGTTAGCAGGTGTTACATAAAAAAGGGATACCATGAG
CAAAAGTATTTGAACATGGGCAATGGTTGAAACAAGTTTAAACAGATTAT
NTTTATTACCAAATCTCTCAAACCTTTAATATGCTATAAACATTGTGAAA
CAATAAAAAAACTTTCCAAAA

Sequence ID 534
GGGAAGGGAGCTATGAGTGTGTGTGTTGTGTATGGACTCACTCCCAGGTT
CACCTGGCCACAGGTGCACCCTTCCCACACCCTTTACATTCCCCAGAGCC
AAGGGAGTTTAAGTTTGCAGTTACAGGCCAGTTCTCCAGCTCTCCATCTT
ANAGAGACAGGTCACCTTGCAGGCCTGCTTGCAGGAAATGAATCCAGCAG
CCAACTCGAATCCCCCTAGGGCTCAGGCACTGAGGGCCTGGGGACAGTGG
AGCATATGGGTGGGAGACAGATGGAGGGTACCCTATTTACAACTGAGTCA
GCCAAGCCACTGATGGGAATATACAGATTTAGGTGCTAAACCGTTTATTT
TCCACGGATGAGTCACAATCTGAAGAATCAAACTTCCATCCTGAAAATCT
ATATGTTTCAAAACCACTTGCCATCCTGTTAGATTGCCAGTTCCTGGGAC
CAGGCCTCANACTGTGAAAGTA

Sequence ID 560
GGCGGAGGTTGCAGTGAGCTGAGATGGCGCCATTGCTCTCCCAGCCTGGG
TGACAAGAGCAAAACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAGCAAT
TTACTTAAAAACATACAAACACAGAGACAAGTATTTTTGAGAAACAAATA
CCTTTTTCATTTTTTATACCAATGTAACAATAATCCATTAAACACACCTT
TACTAACTGTTTTCTAGGAGTCTGATATGATGAGGAAATAGGTAAACCTT
TAATAGCCAGTACTAAATTAGAGTGGCACAACTTTCACTGGGAAAAAAGA
TGGGTATTTTACTTTTCTGTTTTAGAAAAGTGGCTTGACAACAGTATGCT
TATGTCTTAGAGTTTGAAATTCAAGTTCTTGAACATTATTAATGGCTACA
ATCATTCATACCCACATTGGGCTGTATTCTTGATGAATCCAAAGTGATTT
TCACCTCAACTCTGAATTTCATTCTCCTCTTTTGAATATAATACAACCAT
CTCACTAGAGGAAGCATTTCAGTCTTTTCTGATTGGAGATTCATTATTGT
TTTAGATAATGTTTTCATTTGCTTATGGGTATATAAAAAATTTTATCTTA
AAAATATTTCCTCTCATTTAGCTAGCAACATTGTTTTC

Sequence ID 561
CTCAGGGTGATCTCTGAACCCAAACTTGCCCCAAAGAAGGTTGCTCTGTC
CTCTCCACATCCCCATCTCCTCCCTAGGGCCTTGTTGGGGAGAGGCTCCT
CCATCTTTCCCAAGTCACACCATCGTTTCCTACGTGGTCTGGACAAGAGC
AAGAGCACACCTTGTCCCCACCTTCTCCAGAGCAGCCAGAACCCACCTCA
GGTGCCTTCCCCATCCGGTGCAGTTAAGGCACTTCTGCCAGCACCATGGT
ATGAGCACTAGACTTGGAGTTAAGATTTGAGAGCCCCCTCTGTGACTGTG
GAAGCTTGAGCATGTTGCTTGATCTCTCTGAACCTTGTGTTTCTCATCTG
TGAAAGGTGATAATGTGGGGCTGCTGTGAGATTTAAAGGACATAATGCAC
CTACGGTCCAAGCACTGCCTGGAATACAGCANAAGCTCAACAGATACTGG
ACAACCCATCCCCTTAGTAGAGGCACTAACCATGTGACCCAAGGCAAAAG
TGCTTAAAAAAA

Sequence ID - 562 nt: 580
ATTGCATGCAAGTTTGCTGAGCTGAAGGAAAAGATTGATCGCCGTTCTGG
TAAAAAGCTGGAAGATGGCCCTAAATTCTTGAAGTCTGGTGATGCTGCCA
TTGTTGATATGGTTCCTGGCAAGCCCATGTGTGTTGAGAGCTTCTCAGAC
TATCCACCTTTGGGTCGCTTTGCTGTTCGTGATATGAGACAGACAGTTGC
GGTGGGTGTCATCAAAGCACTGGACAAGAAGGCTGCTGGAGCTGGCAAGG
TCACCAAGTCTGCCCAGAAAGCTCAGAAGGCTAAATGAATATTATCCCTA
ATACCTGCCACCCCACTCTTAATCAGTGGTGGAAGAACGGTCTCAGAACT
GTTTGTTTCAATTGGCCATTTAAGTTTAGTAGTAAAAGACTGGTTAATGA
TAACAATGCATCGTAAAACCTTCAGAAGGAAAGGAGAATGTTTTGTGGAC
CACTTTGGTTTTCTTTTTTGCGTGTGGCAGTTTTAAGTTATTAGTTTTTA
AAATCAGTACTTTTTAATGGAAACAACTTGACCAAAAATTTGTCACAGAA
TTTTGAGACCCATTAAAAAAGTTAAATGAG

Sequence ID 563
GCAACCTGCACAACCCCGCCCTGTTCGAGGGCCGGAGCCCTGCCGTGTGG
GAGCTGGCCGAGGAGTATCTGGACATCGTGCGGGAGCACCCCTGCCCCCT
GTCCTACGTCCGGGCCCACCTCTTCAAGCTGTGGCACCACACGCTGCAGG
TGCACCAGGAGCTGCGAGAGGAGCTGGCCAAGGTGAANACCCTGGAGGGC
ATCGCTGCTGTGAGCCAGGAGCTGAAGCTGCGGTGTCAGGAGGAGATATC
CAGGCAGGAGGGAGCGAAGCCCACCGGCGACTTGCCCTTCCACTGGATCT
GCCAGCCCTACATCCGGCCGGGGCCCAGGGAGGGGAGCAAGGAGAAGGCA
GGTGCGCGCAGCAAGCGGGCCCTGGAGGAAGAGGAGGGTGGCACGGAGGT
CCTGTCCAAGAACAAGCAAAAGAAGCAGCTGAGGAACCCCCACAAGACCT
TCGACCCCTCTCTGAACCAAAATATGCAAAGTGTGACCAGTGTGGAAACC
CAAAGGGCAACAGATGTGTGTTCAGCCTGTGCCGCGGNTTG

Sequence ID - 564 nt: 671
GGAATAGAATTTTAAATAGTAATAACTGCTTGTTTTTTTTGTGCAAGTAC
TTTTATACATAAGATAAACAAAAACCTTACCACCAAACATACCAAAATGC
ACCTCTTTCATAAGTGAGTTACTAAGATTTCTATACCTGGAATATCATGT
ATGTTTCATTTACTGGATGTTTACATTTTAGGAAGGAAAATAGTTTTGTT
TATTTAAACAACTGAATACTTATAAACTGTTGTTCCTGGAAGTTATTTAT
TCCATAAAAAATTTGTTCTTTTGTCATGAATTTATAATTCCTAAATGAAG
ACCAGAAAGTACAAATTGCTGGGAGGAAGAATAGGCTTTATTAATCAACT
GATGTCTTGATTTTTCTAAATGGGAAGATTGCTTTATTTTTAACACTAAT
TATGGGAGCAGATTCTTAGCAAACTTCTTTGGAAAAGTTAATGTTATGAT
GTGCATTAGGCTGCCCCATCGTGTATATAAATGAAGCAGATTTGATTTTT
GTATTCTTACGTTTCTCTGCTTTGTAGTTGTGGCTGTACTTAAAGAAATA
CAGAATTTCATATATTTAAAAATGTTTAAAATGTGACCCACAGACATTGT
AAATGGATTNAAAACTAACATGAAAAATATTCAACCTAAAAGAATTCTTA
ACTTCACAAGTGTTTTACTTC

Sequence ID 565
CTTGGTTCCGCGTTCCCTGCACAAAATGCCCGGCGAAGCCACAGAAACCG
TCCCTGCTACAGAGCAGGAGTTGCCGCAGCCCCAGGCTGAGACAGGGTCT
GGAACAGAATCTGACAGTGATGAATCAGTACCAGAGCTTGAAGAACAGGA
TTCCACCCAGGCAACCACACAACAAGCCCAGCTGGCGGCAGCAGCTGAAA
TCGATGAAGAACCAGTCAGTAAAGCAAAACAGAGTCGGAGTGAAAAGAAG
GCACGGAAGGCTATGTCCAAACTGGGTCTTCGGCAGGTTACAGGAGTTAC
TAGAGTCACTATCCGGAAATCTAAGAATATCCTCTTTGTCATCACAAAAC
CAGATGTCTACAAGAGCCCTGCTTCAGATACTTACATAGTTTTTGGGGAA
GCCAAGATCGAAGATTTATCCCAGCAAGCACAACTAGCAGCTGCTGAGAA
ATTCAAAGTTCAAGGTGAAGCTGTCTCAAACATTCAAGAAAACACACAGA
CTCCAACTGTACAAGAGGAGAGTGAAGAGGAAGAGGTCGATGAAACAGGT
GTAGAAGTTAAGGACATAGAATTTGGTCATTGTCACAAAGCAAATGTGTC
GAGAGCA

Sequence ID 566
GTCACCAAGAGCTTGTTGTCAGGTTTTCACTTGCTATTCGCAGAGATTTT
TTTTAAAGGCACTATTTGTAGTGTTAAAAGGGTGAATTTATCANAAGGCA
TAATAATCATAAATGTGTATATGCCTAATAATAGAACTTTAAAAGGCATG
AAGCAACACTCAAAAGGATTAAAGGGAGATCATCTCACCCCCTTCTTACC
AATTGATAGAATGATCTGATGAAAACAGTAAAATAACAACAGATCTGAAC
ACTGTCAACCATCTTGACAAATACTTATGCCTAGTGTTCCATTATTGGAA
CACTAAACATGTGGAATGATTTATATCCTACTGCTCAAGGTCATCACCAA
GGTCTAATTGTAAAATTTCAAAAAATTGCAACCTCAGGCATAAATGGGTT
AATCGACATTTATAGCACACACATGCAACATGTACCAGAGATTCCTTCTT
TTCTATGAACATGGTACTTCCACCAAGATAGACCACATTGTGAACTATAA
AACAAATCTAAAAACATTTGAAATGAAGGAAATTATATAAAATATGTTCT
CTTGATCTCAATGAAATTAAATTAATACTATAT

Sequence ID 567
CTCATGGCGGCCAATGTAGGCCCAAAACTTCCTCAAGTCAAACTCTCCAG
GCCCACCTTCTGCTTCCCGGTGGCATCAACAGGCCCAGCTTTGACTTGAG
AACAGCCTCTGCAGGCCCTGCTCTTGCCTCCCAGGGGCTTTTTCCAGGCC
CAGCTCTTGCCTCATGGCAGCTGCCCCAGGCCAAATTTCTGCCTGCCTGC
CAGCAGCCTCAACAGGCACAGCTCCTCCCTCACAGTGGCCCATTTAGGCC
CAACTCATGACTGTGAGGCCATTTCCAGGCCTAGTGCCTGCCTCGTGGCT
GACTCTTGAAGCCCAAAACTTCCTCAAATCAGCCTTTTGCCCAACTTCTG
TCTACTGTCGGACTCTACAGGTCAGCCTCTGCCTCACAGTGGACCCTCCA
GACCCAGATGGTGTCTNCTGTGGCATCCTCAGGCGAAGCTCCTGCCTTTC
GGCAGCCTCTCCAGGCCCAGCTCCTCCTGCTCCAGCCTTCTCTCCAGGCT
CTGAACTTTCTCAGGTCTCCCTCTGTTGTCCAAGGCTGGAGTGTAGTAG

Sequence ID 568
TATATATGTAATGCCCTTAACCTAGTGTTTGGCATGATCGTTGCTGAAAG
GGAAGCTTGTGGGTACAGTGTCCCCTCAGAAGCCAAAGCCCAGGGAAGGT
CGCCTGCCCAGGTCAGGCTCCCAGCGAGTTTGTCTGGGGAGGGGCCATTC
ATACCTCCAGGTCAGGACAGAGGCTCGGGCTGAGGGAACCCTACACAGGT
CCTGGAAGCAGATCCTTCCTGCCTAAGCCAGCAGGACAGCTCAACAGGAA
GCATCTTCCAGCCACGGGAGGAGAGGCAGCACCTTTTTTGGAACCATACA
GAGCTAAGAATGGTGGTACAAGTAATAGATTCTGTACTGGCAACCCCACT
TGGTGGAGCAAGTTCTAGGAAAAGGGGGCTGTCCTTGAGTCAGCCATGGG
GTCAGCCACACAGTCACCGCAGCTGCTCTTTGGCACCGGGCGCTGGAAAG
ACCTAGGATGACACAGCCTGGAAAGAGCTTGGGAAAAGCTCATCTTCCAC
AGAACTACCTGCTATACCAGCCAGGGCAGGTGCTTATTCCCACAACAGCC
CTCTGTTGTAGGCGGCAGTGCCATCCTGAANGTGCCGTGGTACCTTCTGA
ANACCCAGCTGAGGGCCTGTAATGGCACTTGCATGCCACATGGNACACCC
TTTCCCGGTTAA

Sequence ID 570
ACCGCGGCCGCGTNAANAAAAAAAAAAAAAGAATTCCACTTGATCAACTT
AATTCCTTNTCTTTATCTTCCCTCCCTCACTTCCCTTTTCTCCCACCCTC
TTTTCCAAGCTGTTTCGCTTTGCAATATATTACTGGTAATGAGTTGCAGG
ATAATGCAGTCATAACTTGTTTTCTCCTAAGTATTTGAGTTCAAAACTCC
TGTATCTAAAGAAATACGGTTGGGGTCATTAATAAAGAAAATCTTTCTAT
CTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID - 571 nt: 457
TTAGAGAGGTGAGGATCTGGTATTTCCTGGACTAAATTCCCCTTGGGGAA
GACGAAGGGATGCTGCAGTTCCAAAAGAGAAGGACTCTTCCAGAGTCATC
TACCTGAGTCCCAAAGCTCCCTGTCCTGAAAGCCACAGACAATATGGTCC
CAAATGACTGACTGCACCTTCTGTGCCTCAGCCGTTCTTGACATCAAGAA
TCTTCTGTTCCACATCCACACAGCCAATACAATTAGTCAAACCACTGTTA
TTAACAGATGTAGCAACATGAGAAACGCTTATGTTACAGGTTACATGAGA
GCAATCATGTAAGTCTATATGACTTCAGAAATGTTAAAATAGACTAACCT
CTAACAACAAATTAAAAGTGATTGTTTCAAGGTGATGCAATTATTGATGA
CCTATTTTATTTTTCTATAATGATCATATATTACCTTTGTAATAAAACAT
TTTTCCC

Sequence ID 572
CGTCTATTTGNGTTTCTTCTCACAATTGGTAAGTTCTCTGTATTGATTGA
TGGCTAAGTTTGATTAGTGTTTTTCTCTAGTTGGTAATTATATTCTAGTA
TTTTATCATCTTATTGTTTACTCAACTNAAAGTGNCACAGAAGAGTTGCC
AGGTTTCTCTTTGATATGAGATCTCTNNTTGATTTGGAATGCAAATCANA
AGTGTCATGTTTTGAATAAAGGGACCAGATGACTTATAGGTATTCTTTCT
CTAAATATAACTAAGGTAAGATTTTTGTTTTGAGGTACTTAATCTATATA
AGTGGTAAAGAATTTACTTGAATTTCTCCAAATTCTCATGTCTAAAGTCT
GATTGATTAAATTCATTCTTGGTATTTCATTTTGAAAAGAATGTAGCTTT
AGCAAACCTCTTTGTATAAATGCAGTGGGATTAAGGTCATTTAAAAAATT
GTTATATCATTGTATTTTTAAAATTTACCAGTTTTATTTTTCTTTTTACC
CTTTAGCCCGGCCTCAGAAAGTGTGTTTGTGTCCATTTCTCCCAGCGCAC
CCTCTGCATATCTCTACCCACTTGTCATAATTCAGCATCCAGCAGAGGAA
AACAAAGTGTTGCGTACAGTTCCTCTACTAGCAGCATGCCTCCCCCAGGA
CAAGTGTA

Sequence ID 574
TTATTGCTGACATAAAAATGGTGCACATCGGCCAGGGCCCAGGATGAATC
AGCCAATCTGCACCATTTATACATGGAACTGGAGAACATTGTGCCAATAA
TCATTTAATATATGCCAAATCTTACACGTCTACTCTAAACTGCTCTAATG
AAGTTTCAGTGACCTTGAGGGCTAAAGATTGTTCTTCTGGGTAAGAGCTC
TTGGGCTGGTTTTTCANAGCAGAGTTCTTGTTGTGGGTAGACTGTGACTA
GGTTCACAGCCTTTGTGGAACATTCCGTATAACGGCATTGTGGAAGCAAT
AACTAGTTCCTATGAAAGAACCAGAGCTGGGAAGATGGCTGGGAAGCCAG
GCCAAAGTGGGGGCAACAGCTTGCTTCTCTTTCTCTTCTCACCCTCAGTT
TGTATGGGAAAATGGAGATGTCCTCTCCACTTTATCCCACGATATCTAAA
TG

Sequence ID - 575 nt: 209
CAGGATATCGAGACCATCCCAGACAGCATGGTGAAACTCCGTCTCTACTG
GAATACAAAAAGTTAGCCGTGTGTGGTGGCACGCGCCTCTAATCCCAGCT
ATTCGGGAGGCTTAGGCAGGAGAATTACTTGAACCCGGGAGGCGAAGGTT
GCAGTGAGCTGAGATCGCACCATTGCACTCCACCCTGG-CGACAGAGCAA
GACTCCGTCT

Sequence ID - 576 nt: 541
CAGCCAACCCAGAAGGAGCCAGTCTACAACTATGCCTGATCCTCCTCATG
GCAGGCCACGAAGCATTGCTGCCATGTGTTGAATTATAAAACCCACATTG
CTTTTTGAACCCTGTTGCGGGTAAAAATAACCAAATTATCAGTCCTTGGA
AACCCAGGCAATCAAGTGAGTACAAGGTAAAGATAAGTATGGTTTAGAGG
AGAAATTATGTTCCTGAACTGGTGTCCTTTGATGGCAGCGTCAGCCTTGC
TAAGTCAGAGTAGAGGGAGCAGTGACCTTAATAAGCTTTGGTGAGCATCA
TGTGCACGCGTGGGTGGGAGTCCCTTTCACTGATGCTTTTAAAAGTGCTT
TTGCAGACCCTGGAAGGGATCCTCCACACATATGAGGTGTGGGACAGGTA
GGCCAGAGAGGATTAGCCCTGCTTTCGAGACTAGAAATCTACAGTCCTGA
AGGAGCAGTAATTAATTGGTACACCTGTCAGGGCCAGCCCCCAGGTCTCC
TGGCTTTTTCCAGGTTTTCTGTCTCACATGATTTTGCTTTT

Sequence ID 577
CTTTAATTTTTCAAGTGTTTAAAAAACAATTTTATACTTAAGCCAGCCTT
GAAGATAAGCACAAAATTTACCAGTTTACATTTAAAAAACAAACAAAAAA
CGACAACAACTCAAGCACCCGCTCTGTGCATAGCACTATTCTAGGTGCAA
TAAAAGGGAATCTTAACCTTAGAAATATGAGTTCACTTTCTGGAATTGTA
TTATCTCCTTTTCCAGAGAGTAAAAATAAATAAAATCACCATTGTTTACT
ACAGATCTGCCCCAAACCACATCTGGTTCACAGAAAGGCTAATTTCTGCC
AAATTAAAGATGTAATGAACTCAGTTCCTGCTTTCCCAAAAACACGAAAG
CAGAATTCCTTTTCACTGAAAAAAATAAACAGTTTTCCATGCAAGGGCAG
TTTGCTTCTAATAAGTATTTTTTAAAAAATTTTTTTTTCCTCTAGCTTTT
CTTTAAATTTTCTTCCTCTAATATTGCCTTTTCTTGTACAAGGCAGACCA
GGTATCTTTTTATGCTGTTTTTCCTTTACTAAGAAAAGTATTGCATCTTG
AAGACAAACCATTTCCCAGAGTAGTGATAAAAAATAACACTAAAAAAACT
TTAAAGGTGAGTCACTTCATCACCTTGATGAAGTAAAAAA

Sequence ID 578
GGAAAAAATATTTCCACTTAGATATTTTACATGGTTTTGTTTAAAATTAC
CATTACTTGTTTTTTAAAAACACATGACCACATATGTATATGTATATCTA
CCTAAACATTGTATCATGGTTTCAGTATGTTATTCATGTATTACTGGGAG
ATGCTACCAAGAAACCAACCCAAAGAAAATTCTGGAAAATACATTTCTAT
TTATAGAATAAATGTTTCATTTATATAAAAGCAAAAGAACTTAGAGTTCT
AATAAATGGGATGTCTAATAAATTATGAAGTTACTGATTTGAATATATTA
TATTTTTATAACTTCCTTGCCAAAGTCCTGATTTAGTACATTAGAGAACC
TGTGTTTCCTCTCTCCTCTACCATTCATCTCTCTTCCATACAGTCATTTG
GGCTTTTTACTCAAAGAGAATCAAGAAATAATAAGGTATAACAAGCTTGG
CAAAGTGTTGGCTTTTTAAAAAAAAATTTTTTTAATCTCTAGCAGTTTGG
TAATTTAGCAGCATCATTTATTTGGGATTCTTTTATCTGATTTCAACAGT
GAAAAACATCCCTATGATAAAGCCTAATGACCCATTTCCAAAAGATGGAA
TTGCCCTTCCTAGAAAATATGACGGAGAAAAGT

Sequence ID - 579 nt: 502
CGAATAGCCAAGTGGTCTGACAAGATCGAGAGTAATGAGGCCCATACTTT
AGTACAGTCTTGAATGGCCAGATGGTGCTGGGCATACCCCAACCAGAGAT
ATGTAAGTCTTTATGTTGTCAAAATTTCCCAGAAACATGAATTTCCCACT
AAGATTCATTAAGGAAAACTAGAATGAAAACAAAAACGTTCCTTGTATAA
TATTCATTANAAAGAAATGAAGAAGGCCGGGCATGGTGGCTCACGCCTGT
AATCCCAGCACTTTGAGAGGCCAAGGTAGGCAGATCATGAGGTCAGGAGT
TTGAGACCAGCCTGGCCAACATAGTGAAATCCCGTCTCTACCAAAAATAC
AAAAAAATTAGCCGGGCATGGTGGCACACACCTGTCATCCCAGCTACTCA
GGAGGCTGAGGCAGGAGAATTGCTTGAACCTGGGAGGTGGAGGTTGCAGT
GAGCTGAGATTGCACCACTGTACTACAGCCTAGGTGACAGTGCAAGACTC
TG

Sequence ID - 580 nt: 316
CCTATGCCAAACTAAAGAAAGCTTGCCTGGCCTACAGGCCTAAAGGTTCA
AATGNGGATTAAAAAAACACAGTAGTCACATAAAATGTCTGCTGGCTGGC
TGGAATTCCATCACCTACAATTTACCTGCTTTCAAAAACTGTGTTCAACA
TTGAGAAAACAGAAAACCACTTATCTTGAGCTTAATATGGGCTTCTTTTT
CCTTAACTGTAGAACACTTACTGAAATATCAAATCAATGGTTAGGATATG
TATCCTAGGCAGGCCTAAACCATTAACACTTGGTTTAAGCAACTTTGTAT
AATTNACCTCCTAAAT

Sequence ID 581
CTTCATGAGTGCCCGGTTGCCCAAGTCAAAAACCTGGGAGTGATATAAAC
TCCCCACACATCCAGTCAGTCACTCATCAACTCTATTGATTCTG-CTGCT
AAATATATCTCAATTGTATTAACTTAAACATATGCATAATACATCTTCTT
CTTCACTGCATTTTTGTGGGCTGCACTTACCTTTCAGGTAACAACAACAC
TGGCCCCTCTTGCCCTTCTAGTCAGAAGTGCCAAAATGATGAGAGCTAGC
CATGACAAACCCACAGCCAACATTACACTGAATGTGCAAAACTGGAAGGG
CATCCAAACAGAGGAGG

Sequence ID 582
TAGAATTCTCGCCTGCCTTGGCTTCTCCCTCTAGTTGTTCCTTCTCTGTC
TTCTGTGGGCTTCTTATTGTCTGCTCACTCCTTCTTCAGTGTCCTCTCAT
GGGCTTCCTTCCCTTCTCAGCTGATGCCATCACCTGGGGAATCACAGTTA
CTCAGCAGCACTGGGGCCTCTCTATCTCTATGCTGGTCATGCCTATGTGT
GAGCTGCAGACCCAGTGGAATTTCCATTTGTGCATCCCATGCCCAGCCCA
CCCTCCACCAGCCTCGAATGCAGCTGTTCAGCCCTACCCCAGTCCTCAGA
AAAGTTCCTCTCCCTGGATCCTCTTTTTCCTTCATGAGTGCCCGGTTGCC
CAAGTCAAAAACCTGGGAGTGATATAAACTCCCCACACATCCAGTCAGTC
ACTCATCAACTCTATTGATTCTGTCTGCTAAATATATCTCAATTGTATTA
ACTTAAACATATGCATAATACATCTTCTTCTTCACTGCATTTTTGTGGGC
TGCACTTACCTTTCAGGTAACAACAACACTGGCCCCTCTTGCCCTTCTAG
TCAGAAGTGCCAAAATGATGAGAGCTAGCCATGACAAACCCACAGCCAAC
ATTACACTGAATGTGCAAAACTGGAAGGGCATCCAAACAGAGGA

Sequence ID - 583 nt: 631
CTGAGGTGGGAGGATTCCACTCTCACCCATTTCTTCTTTCATTTTCAGTT
TCTCCAGTTAGTAACTGAAGATGTTCTTTGAGTAATTAAGTGAGTGAGAA
AATTTTTAAGTGAGAAATCTATAAAAAGAACCATGTTAACATAAATATTT
CAGTCCTTACAAGTTGGTATTGACTTTTCTCATTGGTAATCTGACTGATT
TAATACTGCTCATTCCAATATCTGGTGATGTAATTCTGGTTATGAATCCT
TGTATTAATAACACCTCCTGGGAGGTTTTTTTTCCCCAACATTACATTCA
GAATATTAGAGCTGAAAATACCTTTTTTAAGGTTATCAGGAGGAGGGAGC
TTATGTTTAATGTGGTGGATAAAACTTAACTGCTGGTTAATACAATTGTT
ATTCAGGTGAAATTCCCTAAACTTTTCACGTGCAAAGTTTTGTATGTATA
CAGACATTTGGGGAAAAGTTTTATCATCCCTAAAACCGGTTACTGTCCAG
AAAATGATAAGAATCCCTGGGTTCCAAATCCTTCATAAGGTATTTATTCA
TTTATTTATTCAACACATTTACTCAATGCCTCCGCTCTGCTGCAACTACA
CTGACATTCTGCTTCTAATCTAACCGAAAAT

Sequence ID 585
TTTCAAATTGTACAATAACACAAACAACTTTGTTAAGGCCATGTTTTATT
TGCTGATTAATGGACAAAAGGCAATGTAATTTATTTTCAAGTATTTTCTT
GAAAGTCTGTGCTCATAAAAATCATGAAAAGTTGGAAAGACTGTTAAATC
ACTGAAACTTCAAATATATCTTACACAATCTTGTTTGTACAAAAATACAA
GTTAAATATAAACATAAAGCAATCATGGTAATTTTATGCAAATCTGTTTT
ATGTGATCATCAGTTATATATAAAAGTTTCTCAGTTCTGTTATTTGTGAA
AAGATCAATACCAGATTGAATGACTACCTATTGGCAAAGGGCCCTAAAAA
GCTTACTTTAGCACTCATCTTTTACATGGTTAAATGCATTTCCTAATTTG
AGATCACCTAAACACTGGAAAAGAAAAAAAATGAAAGGGCAGTATGTCCA
TAAACCAACAAATAATTTGGCTGTAATGTATCATAAAACACAAACCCCAC
ACATCTGTACAATAAACATTATGTATTACATACACACAACACACACCCAG
TCATAAAGCCTAATGATGTGCTGCTTCCAGTTCAATATTCAGCTGTGCAT
TTTTTCTTATTTCATCAAATGAATAGCTTTTTGTCACC

Sequence ID 586
GTAAACTGTTCTCTCCGAGGGAAAAAATGGAAGTTATCCTCACAGTTCAC
TGCCGTGGTATTTCTTCTGTCCCATGCTTTGCATGACTGCCATGGTACAG
CCTTGTTTCAAACTGTTCACTGTGATCTGTGGGTCTTTGAGTTTCAGTGA
GTTTGCTGAAATGTCGAAGAAGTAGTTCCAAACTTCAATGTTCAATGAAA
TTTTTGTTCAAGTTTGAAATGGAGAGAGCAGCTTTAAAAGGTACTAAGCC
TTTTACAAATTGGTGAGTACTGGCACATGAGAT

Sequence ID 587
TTTTTTTTTTTCCTTAAAAGGTAACCCCTAAACACAGCTAAAACTATGCC
ATCAGCTGACTCCAAGGNACACACAGTCCTGTATCTGGAACTACTGAGTG
GCAGGCATCTTTCTCTGCCTCTGACAGTGGAGTCCCCATCACTGCAGAGC
ATAGCCAAAGGAGTCAAAGGTCTCAGCGGGTCACTGCCTTATCAACCCTC
ACCAGTCCCTTATGTTTTTTAATATTTTATAATCTTGACATGACACCAAG
ATGCTTTAATAAAAAAGCACCTCTAACTCGGTCTTGTATTCACTTACCTT
GAGCCTGGGACTTCTCTAGGCTCCTGAGGCAAAAACAGGTAGAGGGGAGA
TGGTGGAACATAAAACACAATTTTGCTTGGCACCCACCTTGGCGTCTGTC
CCCATGACCAGGTCTTTCAATTCGATGATTTTGTCATTGATGGAGGAGCG
ATATCGTTTCTCAATGATATTATGGGTTGTCCGCCTTTCTCCTTCTTTGG
GGGGCTCAAGCTGCTTGACTCCCCCAGGTACCTGCTTAATGGGGCACTTT
CTCTTGCCCCATCATTACAGGCATTGTGGTCAGAATGGTCCCACTGCTGC
CCACCAGGGTCTA

Sequence ID 588
CTAGTCTTTTCATAGTCTGCATAGAGTCTGGCCATTACCATCAGTTTTTA
AGATGTCCATATTGTGGCCGGGCGCGGTGGCTCACGCGTGGTAGTCCCAG
CACTTTGGGAGGCTGAGGCAGGTGGATCATGAGGTCAGGAGATCGAGACC
ATCCTGGCTAACACGGTGAAACCCGTCTCTACTAAAAAAAATATTAAAAA
ATTGGCCAGGCCTGGTGGTGGGCGCCTGTGGTCCCGGCTGCTTGGGAGGC
TGAGGCAGGANAATGGTGTGAACCCGGAAGTCGGAGGTTGCAGTGAGCCA
AGATTGCACCTGGGCAACACAGCGAGACTCCGTCTCAAAAAAAAAAAAAA

Sequence ID 589
CAATTATTTATTACCTTTCCATTTGTTCGCCTGATGATGTGACAATGCAT
GGTCTTTGTGCATGCTGCTAGACACTTTTCTTTCCCAGCCGAAAAGTCTA
TTATGTAATTTTTACATTCATAATTTTAATGTGGATGATCAGGATTAAAT
CAAGATATATATCTGGAACCTCTTATAAATGGAGCACTTAGAAATTTGTT
GTTCTGCACTTAACCTAGAGAGAGAAAAAATGCTTTTCTTTGTGAAAAAT
CTGAATTCCTGTCCTGACCTTCTGTGATGTGGAAACCCTAGGCTCTGAGA
CACACTCTCTGGTGTCTGAGACAGAACCAAAGCAATAACGTTGTGATGCC
CACAGGCCTGGAGCCAGCTAGCGACCTTGTGCCGCCCAGCTGTCCATGGC
CCGTGCAGAGCAGAGGACAGTGAGTGTCTGCACTGAGAACCTTAAACCAC
AGTTGAACATACCCACACCTGTTTGTCTTAAGCTATAGTGTAAAAACAAA
GTTTGGGCTCTGAAAATTTAACTGAAAAAGATTTCCTTGTT

Sequence ID 590
GTGGCAGCAGGCGCAGCCCAGCCTCGAAATGCAGAACGACGCCGGCGAGT
TCGTGGACCTGTACGTGCCGCGGAAATGCTCCGCTAGCAATCGCATCATC
GGTGCCAAGGACCACGCATCCATCCAGATGAACGTGGCCGAGGTTGACAA
GGTCACAGGCAGGTTTAATGGCCAGTTTAAAACTTATGCTATCTGCGGGG
CCATTCGTAGGATGGGTGAGTCAGATGATTCCATTCTCCGATTGGCCAAG
GCCGATGGCATCGTCTCAAAGAACTTTTGACTGGAGAGAATCACAGATGT
GGAATATTTGTCATAAATAAATAATGAAAACCTAAA

Sequence ID 591
CAGCAGCAGAAATGTTTGCAAGATAGGCCAAAATGAGTACAAAAGGTCTG
TCTTCCATCAGACCCAGTGATGCTGCGACTCACACGCTTCAATTCAAGAC
CTGACCGCTAGTAGGGAGGTTTATTCANATCGCTGGCAGCCTCGGCTGAG
CAGATGCACAGAGGGGATCACTGTGCAGTGGGACCACCCTCACTGGCCTT
CTGCAGCAGGGTTCTGGGATGTTTTCAGTGGTCAAAATACTCTGTTTAGA
GCAAGGGCTCAGAAAACAGAAATACTGTCATGGAGGTGCTGAACACAGGG
AAGGTCTGGTACATATTGGAAATTATGAGCAGAACAAATACTCAACTAAA
TGCACAAAGTATAAAGTGTAGCCATGT

Sequence ID 592
TACTCAATGAAAAACCATGATAATTCTTTGTATATAAAATAAACATTTGA
AAAAAAAAAAAAA

Sequence ID - 593 nt: 565
CAGGATCAAGGTGAAAAGGAGAACCCCATGCGGGAACTTCGCATCCGCAA
ACTCTGTCTCAACATCTGTGTTGGGGAGAGTGGAGACAGACTGACGCGAG
CAGCCAAGGTGTTGGAGCAGCTCACAGGGCAGACCCCTGTGTTTTCCAAA
GCTAGATACACTGTCAGATCCTTTGGCATCCGGAGAAATGAAAAGATTGC
TGTCCACTGCACAGTTCGAGGGGCCAAGGCAGAAGAAATCTTGGAGAAGG
GTCTAAAGGTGCGGGAGTATGAGTTAAGAAAAAACAACTTCTCAGATACT
GGAAACTTTGGTTTTGGGATCCAGGAACACATCGATCTGGGTATCAAATA
TGACCCAAGCATTGGTATCTACGGCCTGGACTTCTATGTGGTGCTGGGTA
GGCCAGGTTTCAGCATCGCAGACAAGAAGCGCAGGACAGGCTGCATTGGG
GCCAAACACAGAATCAGCAAAGAGGAGGCCATGCGCTGGTTCCAGCAGAA
GTATGATGGGATCATCCTTCCTGGCAAATAAATTCCCGTTTCTATCCAAA
AGAGCAATAAAAAGT

Sequence ID 594
CAGAAGAGTAAGCAAATCTCAAAGCAGCGAAAGGGAAGAAACTAAAAAAG
GTAGAGCAGAAATAAGAGAAAATAGAGAAGAGAACAATTGAGAAAAATAA
TTGAAACCAAAAGGTGGTTCTTTGAAAAGCCTAACAAAATGGACACATCT
TTAGTTAGAGTGACCAAGAAAAAAGGGCAGTGACTCAGATTACTTCATTC
AAGAGTGAAAGAGGGCACATCACTACCAATTTACAGAAATAAAAAGGATT
ATGAGGAAATACTACAGATAATTGATGACATTAACTTAGAAGAATATATT
TCAAGAAAGACACAAACTACTGAAACCGACTCAAGAAGAAACAGAAAATC
TGAACAGACCTATAAAAAATAGAGATTTAATTGATATTCAGAAAGTTTCC
CAAAAAGAAAAGCACTGGCCAAGATGACTTCACTGGTGAATTCTATCAAG
TGTCAAAGATGAATTACTGACATTCATTCACACTCCTTTAAGAAATAGAA
GAGGGGACATCACTTTTCAAAGCATCGACATTCTAATCATTAGTCCCTTG
GTTTCCTGCTCCCAAAGCCAGGTGATGTATCACAAAAAAACCCCTACAGA
CCCACTGGGCACAATGGCTTTATGCCTAT

Sequence ID - 595 nt: 98
CTTTGCTCGAATNGTCAGATAAGGATTCTGTGAANGGAGATGAGATTTCC
ATCCATGCTGACTTTGANAATACATGTTCCCGAATTGGGGNCCCCAAA

Sequence ID 596
CTCAAGTGTTCCCTCAGCTTAGGCTTTGTTTAAATGATCCCACCCAGGGG
CGATGGTAGGGAACAACAGGGTCACTAAACTATTTGGCTGGCTACAACTC
TGGGAAATGGTAAGACAGGGAAAGGCCATGTTGTTCATTCCCTTGTGCAG
ATCTAGGGAGAACCGCAGAGAGAACAGTTAGCATTTCTTGTTCAATGAAT
TATCCTATTAAGAACACTGGATGT

Sequence ID 597
CGGNCGCGGTCGACGCTACTCCTACCTATCTCCCCTTTTATACTAATAAT
CTTATAAAAAAAAAAAAAANAAAAAAAAAAA

Sequence ID - 598 nt: 362
GGCATGTGCCTGTAGTCCTAGTTGCTGAGGTAAGAGGATTGCTTGAGCCC
AAGAGTTCAAGGCTGCAACAAGCTTTGATTGCGCCACTGCACTCCANCCT
TGGCGACAGACTAAAACGCTGTCTCAAAAAAAAAACAAAAACGACNAAAA
AAAAACAAAACAGAAAAAATTAACTTAGGCAATGACAGTCCCTGGCAAAT
GCTGGGAGGGAGGCAACANTGGTCAAGGAAGGTAACCCTGAANCAGGACT
TGTAAAGCAAATAANATTGGGAGGCCAAGGTGGGTGGATCACNAGGTCAG
GAGTTCGAGACCAACCTGGCCAACATAGTGAAACCCCGTCTTTCTAAAAA
TACAAAAAAATT

Sequence ID 599
GACAAAAGAACCATTTGGATACATAGGTATGGTCTGAGCTATGATATCAA
TTGGCTTCCTAGGGTTTATCGTGTGAGCACACCATATATTTACAGTAGGA
ATAGACGTAGACACACGAGCATATTTCACCTCCGCTACCATAATCATCGC
TATCCCCACCGGCGTCAAAGTATTTAGCTGACTCGCCACACTCCACGGAA
GCAATATGAAATGATCTGCTGCAGTGCTCTGAGCCCTAGGATTCATCTTT
CTTTTCACCGTAGGTGGCCTGACTGGCATTGTATTAGCAAACTCATCACT
AGACATCGTACTACACGACACGTACTACGTTGTAGCTCACTTCCACTATG
TCCTATCAATAGGAGCTGTATTTGCCATCATAGGAGGCTTCATTCACTGA
TTTCCCCTATTCTCAGGCTACACCCTAGACCAAACCTACGCCAAAATCCA
TTTCACTATCATATTCATCGGCGTAAATCTAACTTTCTTCCCACAACACT
TTCTCGGCCTGTCCGGAATGCCCCGACGTTACTCGGACTACCCCGATGCA
TACACCACATGAAACATCCTATCATCTGGAG

Sequence ID - 600 nt: 595
TTCAAATTCTTGNTAANAGTCTTTGTTCTGAATTTTACTTTGTCTGTTAT
TCCTATAGCCTTTCCAATTTTCTTTCGCTTGGATTTTACGTGATAAGTTT
TTTCCCCCATTTTACTTTTANCAACTCTATATTTTTTAGTTGAGGTTGGG
TTTCTTGTAAACAGCATATAATTTGGGTTTTTTAATCCAATCTGAAAATT
AATGTCCTTAATTTTGTGTTTATACCATTTACACATAATGTACTCATATA
TAAGGTTTAACTGAAACCTACTATCTTGCTAGTTGTGCTCTACTTGAATT
TTTTTTTAGTATTCTGTTTTAATTGACCAACATTTGACTGTATCTCTTTG
TGTAATTCTTTTACAGGTTGCTGTAGGCATGACAATATATACACTTAACT
TTTCTCAGTACACTGAGAGTTGAAATTGTAGTACTTCGAGGAAAACATAG
AAAACTTGCAATGATATCGGTTACATTTTACCACCTCCATATGTTGCAAT
TATTAAATGTATTAGATCTGCCTACCTCGAAAACCCATCAGTCTTTTAAC
TTTGCTCTCAATGGTGATTCATATTTTTAAAAAAACTTGAGGCAA

Sequence ID - 601 nt: 522
TCGACCGGGTTTGGAGCAGTGCCTTGTTTGCTGTGCAGCGGATACTCTAC
AGGTACATTTCCTTTTTGGAACCAAAAGGGAGGGATTTGACAATATTGAT
GGTAGATCTTTTTTCTTTAGCAAGAATTAAGGATTTTGGTGGGTGGGGGG
AGGCTTCTGTGGGGACCAAGACAATGTACTGTCAGTCAGGATTTAAGTCG
AACTACCTCATCCCTTGCCCCAGAGAACAGTTGATCGTGTTTTAAACCAA
AAGGTGCGGAATGGAGAGAGGGAGGCGGTGCATTGCAGCTTCCGATAGAG
CTTTTTATTTTTGGATATCAGGAACCAATTTTGAAGATTTCTTAAGAAAG
TCATTTACATCAGGGACATGAAGAGCAAAGTAGGTATTTTTGGTCAGTAC
TTGAATTTGATAGGCTTTATGCAAACAACTCTCCCTCTGCTGGAGTCTGG
CAAGTTTGCTTTTCACTGGACGCTAATTCAAGTGCCATACAAAACTAAAA
TAANAGTTTTACTTATAACACA

Sequence ID 602
CAGAAATCGCAATTGAAGACCAGATTTGTCAAGGTTTGAAACTGACATTT
GATACTACCTTCTCACCAAACACAGGAAAGAAAAGTGGTAAAATCAAGTC
TTCTTACAAGAGGGAGTGTATAAACCTTGGTTGTGATGTTGACTTTGATT
TTGCTGGACCTGCAATCCATGGTTCAGCTGTCTTTGGTTATGAGGGCTGG
CTTGCTGGCTACCAGATGACCTTTGACAGTGCCAAATCAAAGCTGACAAG
GAATAACTTTGCAGTGGGCTACAGGACTGGGGACTTCCAGCTACACACTA
ATGTCAATGATGGGACAGAATTTGGAGGATCAATTTATCAGAAAGTTTGT
GAAGATCTTGACACTTCAGTAAACCTTGCTTGGACATCAGGTACCAACTG
CACTCGTTTTGGCATTGCAGCTAAATATCAGTTGGATCCCACTGCTTCCA
TTTCTGCAAAAGTCAACAACTCTAGCTTAATTGGAGTAGGCTATACTCAG
ACTCTGAGGCCTGGTGTGAAGCTTACACTCTCTGCTCTGGTAGATGGGAA
GAGCATTAATGCTGGAGGCCACAAGGTTGGGCTCG

Sequence ID - 603 nt: 624
GACACACGAGCATATTTCACCTCCGCTACCATAATCATCGCTATCCCCAC
CGGCGTCAAAGTATTTAGCTGACTCGCCACACTCCACGGAAGCAATATGA
AATGATCTGCTGCAGTGCTCTGAGCCCTAGGATTCATCTTTCTTTTCACC
GTAGGTGGCCTGACTGGCATTGTATTAGCAAACTCATCACTAGACATCGT
ACTACACGACACGTACTACGTTGTAGCCCACTTCCACTATGTCCTATCAA
TAGGAGCTGTATTTGCCATCATAGGAGGCTTCATTCACTGATTTCCCCTA
TTCTCAGGCTACACCCTAGACCAAACCTACGCCAAAATCCATTTCACTAT
CATATTCATCGGCGTAAATCTAACTTTCTTCCCACAACACTTTCTCGGCC
TATCCGGAATGCCCCGACGTTACTCGGACTACCCCGATGCATACACCACA
TGAAACATCCTATCATCTGTAGGCTCATTCATTTCTCTAACAGCAGTAAT
ATTAATAATTTTCATGATTTGAGAAGCCTTCGCTTCGAAGCGAAAAGTCC
TAATAGTAGAAGAACCCTCCATAAACCTGGAGTGACTATATGGATGCCCC
CCACCCTACCACACATTCGAAGAA

Sequence ID - 605 nt: 338
ACCTGAGGCCTCGGTGGGGCCAGTGCGACGCTGGCTTAAGGAGCTGGAGG
GGTTCCTAATACACATTTAATTCAGTTTCTCTTCCCTAAGAGGCTGCCGG
AGTTGGGGCCTCCTCCAGCAGAGACCCTCGGACCCCTGCAGGGCCTGGAC
TTGGGGTGAACAGGGCTTCAGTCAGCGCAAGTATTCCATTTGCATTTGGT
AATTTTTCATGCCACCTATTTATGAATATATAAATCTTTATACCAAATCT
ATTTTTTAAAACATGGAAAAGTTGCCTTTATGGAAACTTGGCAGAGCCAG
AGTGTACACATTCCTAAACCATTAAACAGATTTCTATA

Sequence ID - 606 nt: 556
GGATAATGATACCTCTGACCTTTCTTCCTTTTGGGAAGTACTTGAGTGTG
CAGCTGCATGAGGCCTCAGCAGGAGAGAGATTTTAGGTCCAAGAAGCTAT
ACCAGTAGGACAAGGCAGGAAAATACTACACTTTCAGGATCAAGCCCCTC
TGACTCTCATTTGGAAACTGGATGTTTGCTAAGCACCTGCTTCTTAAGGA
TGCCGAGGGATTTAATGATACTCCCAGAAACCTGGAGAGATTAATGGGGC
CTATGGAGAAGTGCTCTGAACTCAGTGTTGGGACTTGAATAAAATTAACC
ATTGTCATGTTTTCAGAACAACTAAGCTGTTTTATATTTCATGTGCATGA
AAGCCCTAGAACTAAGTTGTGTTATTTCCAGAAATGAAATAGATCCCACA
GTTAGATGATGTGGCCATTAGGAAGTACCAAATTTATAAAAATCACTGGA
GGTCTGTCTGAGCAGTACCTAATAAAATATAGTATACTGAAAGTGAACAG
ATCTTTGTCTCTTTCTTTGGCTGCTTGATACTTTATCTGTGTCTGCCGGA
CAGTGC

Sequence ID 607
CAATAAAAGCAGGTTAACCTCAATGATAGCAGTTAAAATGTTCTATCTTA
TGTATTTCTTTTAAGTATTACCATTATGGTGCTACTGAGCGTTTTCTTTT
GGTAAAAAGAAAAATGCCATGGGCTGCAGTCTTCTTCCATCACTTTTCCC
TACCAGGTCCATTAATATGCTTATAACACTAGTGCCAGTTATTTTATTTG
ATAATGCTTATGGTATTTGTATATTTGTTTGCATTCCAATTTTGTTTAAT
AATGAGTGTGTAAACTGCATACGTTAAATAAATGTAAATACTAATGTACT
GCTGC

Sequence ID 609
TTTTATTACCCAAGTTTTAACCTCTGTCTGGTGATTTGTTGTTGTTGTTG
TTGTNGTTGTTGTTGAAGTTCAGGCTGCATGTGGGATAGGTTTGCTCAGG
CATACTTCTTAGGAAGTAGTCACTTGCATGACTGTTTTTGGGATAACTCT
TTGAGTATTTGGAGAGGTCTATTGTAACTTCTGAAAGGCATTGTTTTTAC
GTATGAATGTTCTAAAATTCATTCTAAATGGTCATGAAAAGAAAAGGATT
CACATTTTAGAATGGCAATAGTCCCTGAGGACTATTATGTCTTTTAGATT
TCCTGTGGGTTTCTAGGAATGTTAGTGTAACTTANATTTCCACCTACCTG
ATTTCTGGATGTGCCTATTGGAACTTGCTGAGATCTTTTTTTTTCCTTAA
CATGTTGTCCCCTTGACCCGTACTTCGAAACTAAACATATTATTTTATTT
GCTTACACTTCAGGAGGCAATTGGCAGACACCAGGCCAACAGTCT

Sequence ID 610
GCTCTGACCCCAGTTGGAAATGTATCTGTACTTTGTCCGGCTTCCACTCA
AGGACCATTTATGACATTGCTTGGTGTCAGCTGACAGGGGCTCTGGCCAC
AGCTTGTGGGGATGACGCGATCCGCGTGTTTCAGGAGGATCCCAACTCGG
ATCCACAGCAGCCCACCTTCTCCCTGACAGCCCACTTGCATCAGGCCCAT
TCCCAGGATGTCAACTGTGTGGCCTGGAACCCCAAGGAGCCAGGGCTACT
GGCCTCCTGCAGTGATGATGGGGAGGTGGCCTTCTGGAAGTATCAGCGGC
CTGAAGGCCTCTGAGCTACCTCGACTTTGGACAGAGTAATGACTCCCCAG
AAAACGTCATATAAGACTTTACCAGCCCCTGAGAGGACCAGGAGGAGCAT
CCTTGACCTTCATTTAACTTGGCTCACTTCTCTTCANACTTGGGTAGAAG
TGCAGAGCCACAAAATTGCTTTCCTTCCCCGCCTTTGACATGAGGCCTTC
AGTAAAG

Sequence ID 611
TGCAGGATCCGTCGACT

Sequence ID - 612 nt: 576
GAGAAATATAAGATTATGTATAGATCAAATCTACCTCTATTTGGTGTCCT
GAAAGAGATGAGGAGAATGGGACAAACTTGGAAAGCTTATTTCAAGATAA
CATTCCTGAGAACTTCCCCAATCTTGCTAGAGAGGCCAACATTAAAATTC
AGTAAATGCTGAAAACTCCAGTAAGATATTTCTTAAGAAAATTATTCCCA
AGATATATACTCATCAAATTATCTAAGGTCAAATGAAGGAAAAAATTTTA
TAGGCAGCTAGAGAGAAATGTCAGGTCACCTACAAAGAGAATGGCATAAG
ACAAAAAGTAGAACTCCCAGCAGAAACTCTAAAAGCCAGAAGAGATTAGG
GGCCAATATTTAACATTCTGAAAGAAATTCCAACAAGGAATTTCATATCC
AGCCAAACTAAGCTTCATAATTGAAGGAGAAATAAGATATTTTCCAGACA
AGCAAATGCTGATGAAATCCATCACCACCAGACCTGCCTTATAAGAGCTC
CTGAGGGAAGCACTAAATATTGAAAGGGAAGAACTTTATGAACCATTTCA
AAAACACATTTAAGTNCACAAAGCAG

Sequence ID - 613 nt: 341
CCTTATTTTACAGGTGAAAAACCACGAATCAGATAGATTTTTATTTGCCC
AAGTCACATAATATTAAGAACAGGCCAAGTGTGGTGGCTCATGTCTGTAA
TCTGAGCACTTTGGGAGGCTAAGGCGGGTGGATTTCCTGAGCCTAGGAGT
TTGAGATCAGCCTGGGCAACATGGCGAAACCTCATCTCTACAAAACATAC
AAAAATTAGTCAGTGTGGTGGTGAGAGCCTGTAGTCCTGGCTACTCGTGA
GGCTGAGGTGGGAGCATCACCTGAGCCTGGGAAGTCGAGGCTGCAGTGGC
AACAGAATGGGTAACCTGGACATCAGAGTGAGACCCTGTCT

Sequence ID 614
CTCACACCTGTAATTCCATTACTTTGGAAGGCTGAGAGAGGAGGATCAGT
GGAGCCCAGGAGTTTGAGACCAGCCTGGGCAATATAGGGAGACCCTGTCT
CTACAAAAATGAAATAGCCAGGCGAGGTGGCATGTGCCTGTGGTCCCAGC
TACTTGGGAGACTGAGGTGGAAGGCTGCCTTGAGCCCAGGAGTTCCAGGC
TGCAGTGAGCCATCATTATGCCACTGCACTCCAACCTGGGAGACAGAGTG
AGAGAGACCCTGTCTCAAACAAACAAACCCAAAATAGGCCAGGCACAGTG
ACTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAAATAGGCGGATCAT
TTGAGGTCAGGAGTTCAAATTCAAGACCAGCCCGGCCAACATGGCAAAAC
CACATCTCTACTACAAATAAAAAATTAGTTGGGTGTGGNGGAGCATTCCT
GTAATCACAGCTATTCAGGAGGCTGAGGCATGANAACCGCTTCA

Sequence ID - 615 nt: 379
TAAATTTAAAACATTTTAATTAGCTGGCATGATGGCATGCACCTGTAGTC
CTACCTACTTGGGAGGCCAAGGCAGGAAGATTGCTTGAGCCCAGGAGTTT
GAGCTTACTGTGAGCTGTGATCACACCACTGCACTCCAGCCTGGGTGACA
AAGGAAGACCGTATTTCTAAAAAATAAAAAATACAAATACAACTACAAAC
TAGCACTAGACCAACAGTGACTATGTACCATGAACTGAGGAATATTATTA
ATTCCACCATTTGCATCTGAGGTTAACAATATGTCAATGACTTAAATAAC
ATCATATCTCTGAGAGTAATTTCTCCTATATTTCCATGACAAATGTTAGA
TAATTTTCCATTTTTTCCATTCAACAAAA

Sequence ID 617
TTTTCAGGCATGTCAGAGAAGGGAGGACTCACTAGAATTAGCAAACAAAA
CCACCCTGACATCCTCCTTCAGGAACACGGGGAGCAGAGGCCAAAGCACT
AAGGGGAGGGCGCATACCCGAGACGATTGTATGAAGAAAATATGGAGGAA
CTGTTACATGTTCGGTACTAAGTCATTTTCAGGGGATTGAAAGACTATTG
CTGGATTTCATGATGCTGACTGGCGTTAGCTGATTAACCCATGTAAATAG
GCACTTAAATAGAAGCAGGAAAGGGAGACAAAGACTGGCTTCTGGACTTC
CTCCCTGATCCCCACTCTTACTCATCACCTGCAGTGGCCAGAATTAGGGA
CTCAGAATCAAACCAGTGTAAGGCAGTGCTGGCTGCCATTGCCTGGTCAC
ATTGAAATTGGTGGCTTCATT

Sequence ID - 618 nt: 598
GATTAACTTTCATTTTAAGCTCTTCTCTACTAATTCTGTTCGTATGTTTA
TTCATTTTGCGTTGATCATATTTTGTACACCAGGCACTCTTCTCAGTTTT
ATATGTGTGTTAATTTACTCCTTTCAAGAGCCCTATGATACATGAATTTA
TCTCCATTTTATAGATGAGGAAATTAAGACCTAGAGTTACTGAACTTGCC
CAAGGTTATACAGCTGATGGGTAGGGCCAGAACTTTGCCTCAGAGAATCT
GAATTTCCAAAAAATAACCTAAAAGAGAAATTTAAGTACTAATTAGTAAG
CAAAGAAATGCACATTTAAGGAAGACAGTGCACATTTAAGGAAGACAGTA
ACCTTTTATCTATTAGAGAAAAACACACATTCTGTCTTTAACACACACAT
AAATCTTATATTGGCAGGGATTTTCTTTATTCAGCAATTATTTATTGGTT
GTCTGCTTTGTGGTACACATAAATGCTGGGGATAAACACTTAATAAAATA
TACTTCCTTCTCTTGAATATCTTGCACTTTAAGTGGGAAGGTAAGTCAAC
AGAGTAGAGGTGATATATCCAAGTGATAGACTGTTTCATTGCCAGTAG

Sequence ID 619
GTTGCCTGAGAGTGACCTTTGCATCTGCCTGTCCAGCCAGCATGGAACCA
AAGCGGATCAGAGAGGGCTACCTTGTGAAGAAGGGGAGCGTGTTCAATAC
GTGGAAACCCATGTGGGTTGTATTGTTAGAAGATGGAATTGAATTCTATA
AGAAGAAAAGTGACAACAGCCCCAAAGGAATGATCCCGCTGAAAGGGAGC
ACTCTGACTAGCCCTTGTCAAGACTTTGGCAAAAGGATGTTTGTGTTTAA
GATCACTATGACCAAACAGCAGGACCACTTCTTCCAGGCAGCCTTCCTGG
AGGAGAGAGATGCCTGGGTTCGGGATATCAATAAGGCCATTAAATGCATT
GAAGGAGGCCAGAAATTTGCCAGGAAATCTACCAGGAGGTCCATTCGACT
GCCAGAAACCATTGACTTAGGTGCCTTATATTTGTCCATGAAAGACACTG
AAAAAGGAATAAAAGAACTGAAT

Sequence ID 621
TGGTACTGAACCTACGAGTACACCGACTACGGCGGACTAATCTTCAACTC
CTACATACTTCCCCCATTATTCCTAGAACCAGGCGACCTGCGACTCCTTG
ACGTTGACAATCGAGTAGTACTCCCGATTGAAGCCCCCATTCGTATAATA
ATTACATCACAAGACGTCTTGCACTCATGAGCTGTCCCCACATTAGGCTT
AAAAACAGATGCAATTCCCGGACGTCTAAACCAAACCACTTTCACCGCTA
CACGACCGGGGGTATACTACGGTCAATGCTCTGAAATCTGTGGAGCAAAC
CACAGTTTCATGCCCATCGTCCTAGAATTAATTCCCCTAAAAATCTTTGA
AATAGGGCCCGTATTTACCCTATAGCACCCCCTCTACCCCCT

Sequence ID 622
TTTTTCTTGTTTTTGTGTGTCTACCTTGGCATATACTAAAGGAAGGTGTG
TATTCATTTATTACATGATATCTCTGGGTTATAATTATTTACATATATGA
ATTTGAAAGAAAGATTGAGAGGGATATGTGTGACCTTTGTTTCATTATGA
TCATTTACATGACTAAAGATAAAGATCATATGTCTGATTTTCAGTTTAAT
GGCAAGTTACTTAAAATAAATGAAATATGTTTTTATTGTTTTCGTGGGTT
TGATGCTTTGTGTTTTATTTCAAGTAACTTGAGAATGCATTGTGTTTGGT
ACTGTTTTTTATGAATATGATTAAAAATTTATTTAAGGAGAGAGTAATTT
TGCAATAATATTTTTGATTTATTTGAAAATAAAATTCAAGATAAATGAAA
TAATTGAAATTTTCTAAAGAAGGAATTGAATATATTTTTACATTTGAATG
AACTAAGGATTAACTGAACCATTTATATATAGTACTTTCAGAACTGAATG
TCTTAAATGATAAAGCTCTAATTGGTTAAAGTGACTTTCTTTCAAGTCAA
AGAACCCAGAAACTGAATAGATGATCTAACTACTGCCACTGAGGTTTTGG
ATTAGTGAGTATAAATTT

Sequence ID 624
TGCAGGATCCGTCGACT

Sequence ID 625
GACAATCAGAGCAGATCTTGGGCTTCTGTGGCTCATCTCAGCCCTTTATA
ACTGGCCTGAGAAGAGGGTTTATCTACTTGTGCAAGTGGCCCAGAAATCT
CACTCGTACATGAGGCTTTGGAACATCCTTGCAAAGGTACGCTGAAAGCA
AATTGCTGTTTTCCTGGTGGTTCTGCACGTTTCCTAACTTTTATCATAGT
TTGATTTTCATTATTTAAGAAAAAATAAAAAATCCAAAGACCATAAGATG
GCATTAGATTTTTTACCATTAAATTATTAATGCCTATTTGGTGCTCATAA
AGATTAATCATGTCACGCATGTTTCCAATCTTTCTTTTGCAGTATATTAT
TTTCTAAAAATTGTTACATGCAAATTTAAACCAAGATTTATCAGTA

Sequence ID 626
TTGGAAGAAATAAACCAAGGCAGAAAAATTTTAAATGGCCAAAATAAATT
GTATTGCTAACTTAGATGGCCACAGATGGGGGCAGGGGTGGAGAGAGGAG
AAATTGAAAACNCCACAAAGACCCCGCAATGGCTAGAACTTGAAATCTCT
GGATATTGCAACAATAGCAGCCTCCTTAAGTCAGCAAAAAGATAAAGATT
GATCCAATGTTCTATATTACAGAACAGAGCAGATTGTCAATATAGCAAAT
AAAGTTACCGTTGAGTGGACTGCGCTGTNTAAGCTGCTTGGTTGGCCTTA
AGTGCCGACAATTAAGAGATGAAGGCAATGAGAACTGAAACAAACATTTA
AGTTCAAGACCCAGTTTACTGACACTGGGACTATTACTATATCTCTTTGG
GCCTCAGTTTACTTATCTGTAACATTAAGAGGTTGGATTACATGATGTCT
CACGATTCTTTTTTTTTATTTAGAGATGGGGTTTTGCTCTGTTGCCCAGG
CTGGAGTGCAGTGGCATGATCATAGCTCACAGCAG

Sequence ID 627
CCAGCCTGTCACTGGCCTGGCCAAGGAGGAGAGACAGGCCAGGGATTCTG
GTCCTAACTCTACTGGCCACACTGTGTGGCCTGAGACCCCCCTTTCCCTC
CCAAGCCCCTGCCTCCGCATCTGCGTGGTGAAGGCCATTGGCCCTCATCG
GTGGATCTGCGTTTCCTCGGGCCTACACTGTCTAGGATTGTGCGGGGCTG
GTGAGAGAACAAGATCTCTTCCGTGTTCAAGGCAGACTTCCTGCCCCCTG
CACCCTGCTCTCTCCCAGGCCTTGAGGTCAGTGTGAGCCCCAAGGGCAAG
AACACTTCTGGAAGGGAGAGTGGATTTGGCTGGGCCATCTGGATGGAAGG
TAAAAAAAAGAAAATCCCTTGAAAGGAGATTGAGGGAAGTTT

Sequence ID - 628 nt: 419
AAGAGAAAGGACTCAGTGTGTGATCCGGTTTCTTTTTGCTCGCCCCTGTT
TTTTGTAGAATCTCTTCATGCTTGACATACCTACCAGTATTATTCCCGAC
GACACATATACATATGAGAATATACCTTATTTATTTTTGTGTAGGTGTCT
GCCTTCACAAATGTCATTGTCTACTCCTAGAAGAACCAAATACCTCAATT
TTTGTTTTTGAGTACTGTACTATCCTGTAAATATATCTTAAGCAGGTTTG
TTTTCAGCACTGATGGAAAATACCAGTGTTGGGTTTTTTTTTAGTTGCCA
ACAGTTGTATGTTTGCTGATTATTTATGACCTGAAATAATATATTTCTTC
TTCTAAGAAGACATTTTGTTACATAAGGATGACTTTTTTATACAATGGGA
ATAAATTATGGCATTTTTT

Sequence ID 629
CTGAGAGTCACTGTGTTTTTAGCCAAATCTAAGGGAGAAAATGAATATTG
ATAGCAGCATGCTGTAGCCAGCTCCTTAAAGGAAGGATGGTGCCTGGTAC
AGAGTTAGAGTTAGTGCTTCAGTAAATAATGAATGTGTGCTAGGTAGGTT
CTGCTGGGTAGGCTGCATGCATTGACCAATTTATTCCTCCTTGTTTCAAA
ACAGGATTTAAGGGCACTTATATATATATATTTTTTAGTTTTTTTAATGT
AAATGAGAGAATAAAGATATATATATATGTCTATATATGTATATATGTAT
ATATATGTCTATATGTCTATATGTATATATGTCTATATGTATATATGTGT
GTGTGTATATATATATATATATATATAAGTTTTCTGTTGCTAGCATAACA
AACTACCAGAAACTTAGCAACTGAAACAACATGAATTTATCTTACGGTTC
TATAGTTCAGAAGTCTAACGTGTCACTGGGATGAAATCCAGGTTTCAACA
GGACTGGGTTCCCTTCTAGCTCATTCAGCTACCTGGCTCATTCAGGTTGT
NGGCAGAATATACTTCCATGAAACTGTAGGGCTGAGACCCCGTTCCTTCC
TGGCTATCATCTGAAAACTTTC

Sequence ID 630
AGGCGCAGCCCAGCCTCGAAATGCAGAACGACGCCGGCGAGTTCGTGGAC
CTGTACGTGCCGCGGAAATGCTCCGCTAGCAATCGCATCATCGGTGCCAA
GGACCACGCATCCATCCAGATGAACGTGGCCGAGGTTGACAAGGTCACAG
GCAGGTTTAATGGCCAGTTTAAAACTTATGCTATCTGCGGGGCCATTCGT
AGGATGGGTGAGTCAGATGATTCCATTCTCCGATTGGCCAAGGCCGATGG
CATCGTCTCAAAGAACTTTTGACTGGAGAGAATCACAGATGTGGAATATT
TGTCATAAATAAATAATGAAAACCTAAAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID 631
TNCACTCACACACTCCCAAACCTTAACAAACACATACATGTGCAGCCAAC
CCAATGGGCCAGCCTCTTTTATGCTCCTCACATGTTTCCTTTAACTGGAA
TACCCATGACAGCTCCCTACATAGTTACTTGTAAACTCCTCCTCTCTGTA
TAAGTTTTCCTGAATTTTTTTGATAAAATTAAGTTGTGCCACCCCTTTAT
GCTCTCTTANAACTTTGTTCTGTTCTCATGGCTGTTCTGCAACGAATCTC
ATTGTGTTCTCCTACTCAATTACATTCCTGCGTCTCCCACTAGATGGCAG
ACTCTTTGAGAGTAGGAGATTCCCTTGTTATCTCTGGATCCCTGGCACTT
GCAGAAAGCCTGTTACGTAATAATTGCTCAACAATTAGTTTTTAAATAAA
TGAATTATTTTTAAAACGCCAAAATTACAATGATTGTGCATTAAGTGAAA
GATGACCATCTAAAAACATAAAGCCATGCTTCATGACATTGGC

Sequence ID 632
GACCATTCAGGGAAATTTTATAAAAAATGCAGATACTGTCTTGAGCAGAT
CGAAATGCCGATGAGGTGGATGCAATTTCCTTTTGTGCAAGCAGTGCACG
GTGCCCCCCCCTCGGGTGTCCGTGCTGTGCCTTAGCTTCCCCAGGTGCCG
GGACTCACACCTGCTAGGGGCTGGGCAAGGCCCCGGCTCTGCTTTCTCTG
AAGGGCTTGTCCAAGTTCATTGCCCTGTTACAGGTGGTCAAGACGTCCGG
CCGCCTTGACCCAGGCTACCCTTAGCCAATATCCTCTGCCCCTGGGTGGT
TGGTGGCTGGGCCTCAGGGTGGGCAACGTTAGGGGTTTGGCGAAAGCCCG
CCCCATGGGATTGAGGGACGGGGCTGCACTCCAACCGTCTGCACCTGCTC
TTCCCCCACCCCTGTGGGACCTCATCTTCACGTGCCATGTGTGCTGAAGG
CCGAGGGCCCAGCAGGGGGCAGTGGCACCTGTTGACGGAAAAGCCGAGGT
GCTTACCAATGGACCTTCTGGCCCGCCCTCCCCTGTACTTGTCGGGCATT
CAGGGCCCCGACCTGTGCCTACCCGCA

Sequence ID 633
CAACTGTGTTCACTAGCAACCTCAAACAGACACCATGGTGCACCTGACTC
CTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGAT
GAAGTTGGTGGTGAGGCCCTGGGCAGGCTGCTGGTGGTCTACCCTTGGAC
CCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTA
TGGGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTT
AGTGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTGCCACACT
GAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGGC
TCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGAA
TTCACCCCACCAGTGCAGGCTGCCTATCANAAAGTGGTGGCTGGTGTGGG
CTAATGCCTGGCCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTCCAA
TTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGG
ATATTATGAAGGGCCTTG

Sequence ID - 634 nt: 511
TTTTTTAATTTCACCAAAATTTGTTGACGTCCCTTGATTTGCTGATAGGG
ACAATAATTAAATATTTTCCACTTGTTTTTATAAAAACTGTAATGGTGAT
TTGTTTAACAGATGTTGACTTAGCACCTTCTCTCTTTTTTTTTTTTTTTT
TTTGAGTTGGAGTCTTGCTCTGTCACCCAGCTGGAGTGCAGTGGCACGAT
TTCGGCTCACTGCAACCTCCGCCTCCCAGGTTCGGGCGCTTCTCCTGCCT
CAGCCTCCCANATAGTTGGGATTACAGGTGCATGCCGCCACNCCTAGCTA
ATGTTTTTTGTATCTTGGTANANATGGNGTTTCACCTTGTTGCCCATGCC
GCTCTTGAACTCCTTGGCCTCCCAAAGTGTTAGGATTACAGGCGTGAGCC
ACTGTGCCTGGCCCCAATTTANCACCTTACTGGGTGCTGAGGCTGTGAGC
CATAGTAGAATGCATGTGATCCAGGGCCTTGCTGAATTCATGGGCTAATA
GGGAGCCTGAC

Sequence ID - 635 nt: 592
TGAGCGTTGGGCTGTAGGTCGCTGTGCTGTGTGATCCCCCAGAGCCATGC
CCGAGATAGTGGATACCTGTTCGTTGGCCTCTCCGGCTTCCGTCTGCCGG
ACCAAGCACCTGCACCTGCGCTGCAGCGTCGACTTTACTCGCCGGACGCT
GACCGGGACTGCTGCTCTCACGGTCCAGTCTCAGGAGGACAATCTGCGCA
GCCTGGTTTTGGATACAAAGGACCTTACAATAGAAAAAGTAGTGATCAAT
GGACAAGAAGTCAAATATGCTCTTGGAGAAAGACAAAGTTACAAGGGATC
GCCAATGGAAATCTCTCTTCCTATCGCTTTGAGCAAAAATCAAGAAATTG
TTATAGAAATTTCTTTTGAGACCTCTCCAAAATCTTCTGCTCTCCAGTGG
CTCACTCCTGAACAGACTTCTGGGAAGGAACACCCATATCTCTTTAGTCA
GTGCCAGGCCATCCACTGCAGAGCAATCCTTCCTTGTCAGGACACTCCTT
CTGNGAAATTAACCTATACTGCAGAGGTGTCTGTCCCTAAAGAACTGGTG
GCACTTATGAGTGCTATTCGTGATGGAGAAACACCTGACCCA

Sequence ID - 636 nt: 572
CTTANAAGAGTTGCTCATTCACACCCACGCCCTTGCCCAAGGCTGGCCCA
CTCAGAGCGAAACTTAACTTTTGTCTGGATGGGAAGAGAAGTAAGTCTAC
CCCGAGGTTGCCATGTTGAAGAGTGAGAGGTCCAAGTGATTCTGTGCATT
GAAACCAAGACACCCCACCCAGAACACTTCTTCCCTCCCTCAGCCCAAAC
CAAAGGCTGGGGTTCTCATCTCCAAGTGGCTGTTCTCCAACTTTCCCAAG
CCGCTTGCATTCCCCAGACTGGACTACTGTGGCGGTTAGGTTAGATTTGA
AGACGGGGCCCAGGCTGGGTATGAACGGGTGCAGCCCTCTTCTCCTCTTC
CCCCCCACATCTCTCATGAGAGAGGTAGTGGCATTTCCTTCTCAGGGAGC
TTCAATGGGAAAGGTCTCGAAAGCTTCAGGAGGAGCAGAATACCAACGCA
GGGGGATGGCTGTAACGATCTCACCGTCTCCTAACCTCAGTCCCTTTTTT
GAGAGTGAATGGTGGAGGGTGGGAAAGGGACCCAAATTTGTAGATCTCTT
TGTCTGGGGGAGGGGAANGATG

Sequence ID - 637 nt: 482
TTAAAACAGGCGCAGGGGTAAAAATGAGAATGAATCTGAAAAAAGAGAGT
TGGTGTTTAAAGAGGATGGACAAGAGTATGCTCAGGTAATCAAAATGTTG
GGAAATGGACGATTGGAAGCATTGTGTTTTGATGGTGTAAAGAGGTTATG
CCATATCAGAGGGAAATTGAGAAAAAAGGTTTGGATAAATACATCAGACA
TTATATTGGTTGGTCTACGGGACTATCAGGATAACAAAGCTGATGTAATT
TTAAAGTACAATGCAGATGAAGCTAGAAGCCTGAAGGCATATGGCGAGCT
TCCAGAACATGCTAAAATCAATGAAACAGACACATTTGGTCCTGGAGATG
ATGATGAAATCCAGTTTGACGATATTGGAGATGATGATGAAGACATTGAT
GATATCTAAATTGAACCAAGTGTTTTTACATGACAAGTTCTCTGAGGATG
GTTCTACAGTTGGGATTTTGGCCATCATCAAC

Sequence ID - 638 nt: 545
TTTGAAGGCAAAGAGGGATTAATCTGTGCTGGCATCATGTAAGGAGACTT
GATAGATAAGAAAAAGCTTTACCTAAGTTTTGAAGAATAGGTTTTTCATA
ATGGAAAATTTAAGGGAAAAATCTCCAAAAAAGTGCTACTCAAGTTTTAT
CCATTTGTATTTCCAACACAGCCTAGGACAGTACCTGCACATAGTAGGTG
ATTAATAAAAATTTAGAAAGCATTAATACTAAAGAGGAAAAATAGCAATG
GCAAGAAAACACATGTAGGGAACACATGTAGCCAAAAAATAATATATAAT
CAGAGAAATAATAGGACTTCTGGAAAAAAAAGATGAGATCAGATTGGTTA
GGATCTTTACTAACATGACAAGAGCATGAATTTTTTTTCTGTAGATAATA
AGTATGAAAGAATTTTAGCTTAAAAATTAGCATAATTTGGATCCACATAT
GCAAATCAATGAATGTAATTCATAATATAAACAGAACTAAACACAAAAAC
CACGTGATTATCTCAATAGACACAGAAAAGGCCTTCAAAAAAATT

Sequence ID - 639 nt: 624
GACACACGAGCATATTTCACCTCCGCTACCATAATCATCGCTATCCCCAC
CGGCGTCAAAGTATTTAGCTGACTCGCCACACTCCACGGAAGCAATATGA
AATGATCTGCTGCAGTGCTCTGAGCCCTAGGATTCATCTTTCTTTTCACC
GTAGGTGGCCTGACTGGCATTGTATTAGCAAACTCATCACTAGACATCGT
ACTACACGACACGTACTACGTTGTAGCCCACTTCCACTATGTCCTATCAA
TAGGAGCTGTATTTGCCATCATAGGAGGCTTCATTCACTGATTTCCCCTA
TTCTCAGGCTACACCCTAGACCAAACCTACGCCAAAATCCATTTCACTAT
CATATTCATCGGCGTAAATCTAACTTTCTTCCCACAACACTTTCTCGGCC
TATCCGGAATGCCCCGACGTTACTCGGACTACCCCGATGCATACACCACA
TGAAACATCCTATCATCTGTAGGCTCATTCATTTCTCTAACAGCAGTAAT
ATTAATAATTTTCATGATTTGAGAAGCCTTCGCTTCGAAGCGAAAAGTCC
TAATAGTAGAAGAACCCTCCATAAACCTGGAGTGACTATATGGATGCCCC
CCACCCTACCACACATTCGAAGAA

Sequence ID 641
CAAGATGACAAAGAAAAGAAGGAACAATGGTCGTGCCAAAAAGGGCCGCG
GCCACGTGCAGCCTATTCGCTGCACTAACTGTGCCCGATGCGTGCCCAAG
GACAAGGCCATTAAGAAATTCGTCATTCGAAACATAGTGGAGGCCGCAGC
AGTCAGGGACATTTCTGAAGCGAGCGTCTTCGATGCCTATGTGCTTCCCA
AGCTGTATGTGAAGCTACATTACTGTGTGAGTTGTGCAATTCACAGCAAA
GTAGTCAGGAATCGATCTCGTGAAGCCCGCAAGGACCGAACACCCCCACC
CCGATTTAGACCTGCGGGTGCTGCCCCACGTCCCCCACCAAAGCCCATGT
AAGGAGCTGAGTTCTTAAAGACTGAAGACAGGCTATTCTCTGGAGAAAAA
TAAAATGGAAATTGTACTTAA

Sequence ID 642
TGCTTGGCCCTCTACCTCCTGCCCTCTTCCTGTTCATCTCCCAACCACTG
CACTCTTGATTTTTATACCACACAGAAGGTAAGAAAATTCTAGGAACCCT
AAGGATCAATCCTCTCCATTTTCACTCAAATGCCTGGGGCCCAGCTCTGC
AATGACTGACTCCAGGGCCTCTTTCCTCACTGCCAGCATAGAAGTCAGGG
GAGCCAGCTGGGCCCTGCGGTCAGGAAGGTTCTCATTTTTGGAGCATTCC
CTGAGCCCAGATCATAGGAGCAGCTGTCCCTGGTGGGACACAGGAGTCAT
GACTCCTACCCTCCACCCTCCACACCCACCAGGCATTTAGCAGTCTGTCC
TATGCAAGACAGATGAATTCTCAGCCAGGATACCTCAAGGCAGGCAAAGG
TGAGTGGAGGGAAAATTCACAAACATTCAGGGTGTGTGGTGCTGGCATCA
CCATGGCCAAATCCAAGAGGTCTTCCTGGAAGAGGGCCCAAACTGGAACC
AAAAGAATGCTGTCAGCAGTTGGAATAGAGCTGTGAATT

Sequence ID 643
CTTTCCAAGAGGAATCCTCGGCAGATAAACTGGACTGTCCTCTACAGAAG
GAAGCACAAAAAGGGACAGTCGGAAGAAATTCAAAAGAAAAGAACCCGCC
GAGCAGTCAAATTCCAGAGGGCCATTACTGGTGCATCTCTTGCTGATATA
ATGGCCAAGAGGAATCAGAAACCTGAAGTTAGAAAGGCTCAACGAGAACA
AGCTATCAGGGCTGCTAAGGAAGCAAAAAAGGCTAAGCAAGCATCTAAAA
AGACTGCAATGGCTGCTGCTAAGGCACCTACAAAGGCAGCACCTAAGCAA
AAGATTGTGAAGCCTGTGAAAGTTTCAGCTCCCCGAGTTGGTGGAAAACG
CTAAACTGGCAGATTAGATTTTTAAATAAAGATTGGATTATAACTCT

Sequence ID 644
CTTTGATAGAGAAGAAAATTCTCCTAGGATACAAGAGCCTCAACATTTTA
AAGATTTTCTGCATCTCAAAAGCGTAGGCTCCTTGCTGGGCAAGGTGAGC
CTCTGTGAGTCCTCATAGGACCGAGCAAATCTGATTCACCCCAGAAAATC
CAATATCGAAGCTGAGCTTTGGCCTGAGCGGGTTCCATTTCCTCCCCAGA
TCCTATTTAGGAAGTGTCTCCTGACAACCTCCAAAAGGTGCTAACATGCA
ACGTTCTGAAGGGTTATTGCTCAAAAACAAGATTTTCCTTGTGGTCAAGA
CTCTGCGAGCCTCGAACACGATGAATCCGCTCGAATGGGCTTGGGCTTTG
CCCGGGTGGCGCACGCTCACACGCTGGAAGCACAGCTTTGACGATCTCCA
CACACGCACAGGCACACACGCCACAGATGATGCCGGCTCATTCTCAGGGG
GTGTCTAAGTTCTGCTTTAAATATTTACCCCCTAATTGTACAAACAATAG
GGGCATGAGCCTGGTACTCGATAAATGGGGACTTNCTTAAAA

Sequence ID - 645 nt: 649
CTACAGCCTGGGCAGCGCGCTGCGCCCCAGCACCAGCCGCAGCCTCTACG
CCTCGTCCCCGGGCGGCGTGTATGCCACGCGCTCCTCTGCCGTGCGCCTG
CGGAGCAGCGTGCCCGGGGTGCGGCTCCTGCAGGACTCGGTGGACTTCTC
GCTGGCCGACGCCATCAACACCGAGTTCAAGAACACCCGCACCAACGAGA
AGGTGGAGCTGCAGGAGCTGAATGACCGCTTCGCCAACTACATCGACAAG
GTGCGCTTCCTGGAGCAGCAGAATAAGATCCTGCTGGCCGAGCTCGAGCA
GCTCAAGGGCCAAGGCAAGTCGCGCCTGGGGGACCTCTACGAGGAGGAGA
TGCGGGAGCTGCGCCGGCAGGTGGACCAGCTAACCAACGACAAAGCCCGC
GTCGAGGTGGAGCGCGACAACCTGGCCGAGGACATCATGCGCCTCCGGGA
GAAATTGCAGGAGGAGATGCTTCAGAGAGAGGAAGCCGAAAACACCCTGC
AATCTTTCAGACAGGAAATCCAGGAGCTGCAGGCTCAGATTCAGGAACAG
CATGTCCAAATCGATGTGGATGTTTCCAAGCCTGACCTCACGGCTGCCTT
GCGTGACGTACGTANCAATATGAAAGTGTGGCTGCCAAAAACCTTGCAG

Sequence ID - 646 nt: 600
GAGATGTCTCGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTCTTTC
TGGCCTGGAGGCTATCCAGCGTACTCCAAAGATTCAGGTTTACTCACGTC
ATCCAGCAGAGAATGGAAAGTCAAATTTCCTGAATTGCTATGTGTCTGGG
TTTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGGAGAGAGAAT
TGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTTTCT
ATCTCTTGTACTACACTGAATTCACCCCCACTGAAAAAGATGAGTATGCC
TGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATAGTTAAGTGGGA
TCGAGACATGTAAGCAGCATCATGGAGGTTTGAAGATGCCGCATTTGGAT
TGGATGAATTCCAAATTCTGCTTGCTTGCTTTTTAATATTGATATGCTTA
TACACTTACACTTTATGCACAAAATGTAGGGTTATAATAATGTTAACATG
GACATGATCTTCTTTATAATTCTACTTTGAGTGCTGTCTCCATGTTTGAT
GTATCTGAGCAGGGTGCTCCACAGGTAGCTCTAGGAGGGCTGGCAACTTA

Sequence ID 647
CGAATGTGCAGGTTTGTTACATAGGTATATATATGCCATGATGGAAATAT
TTATTTTTTTAAGCGTAATTTTGCCAAATAATAAAAACAGAAGGAAATTG
AGATTAGAGGGAGGTGTTTAAAGAGAGGTTATAGAGTAGAAGATTTGATG
CTGGAGAGGTTAAGGTGCAATAAGAATTTAGGGAGAAATGTTGTTCATTA
TTGGAGGGTAAATGATGTGGTGCCTGAGGTCTGTACGTTACCTCTTAACA
ATTTCTGTCCTTCAGATGGAAACTCTTTAACTTCTCGTAAAAGTCATATA
CCTATATAATAAAGCTACTGATTTCCAAAAA

Sequence ID 648
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID - 649 nt: 425
CAAAAAAACGAAGAAAAGTGACGACAGTCTGAGGGACTTATGGGAGATCA
TCAAGTGAACCACTATATGTGTAATGTAAGTCTTGGAATGAGAAGAGAGA
AGGAGAAGGAGGAGAGAGCTTATTTGTAGAAATAATGGCTGAAAACATCC
CAAACTTTCCTTTTTTTGAGGAAAGAAATAGGCATACAAGTTCAAGAAAC
TCAAGGAACTCCAGAGAGGACAATTCTAAAGACACCCCCTCTAACATACA
TTATAATCAAATTGTCAAAAGTAAAATACAAAGAGAATCTTTTAAATTGA
CAAGAGAAAAGCAGCTGGTCACGTTCAAGGGAGTTCTATAAGAATTTCAG
CAGATTTCTCAGCAGAAACCTTGCAGGCCAACAGGCAGTGGGATGATACA
TTCAAAGTGCAAAAAAAAAAAAAAA

Sequence ID 650
CGAGAGTTTACCAGTNGCCTAATAATGCAATAAAAAATGCTTTGAGATAG
CTAACNGCCCATAAAACAAACTCAAATTGCTTATAAAGTTTCTTCCCATG
TTCCCATTTGATGAAAAGTCTTACATCACATATAACTGGGAAGCAGGGGT
CCCTCCTCAATTTTCAGACATTTTGAAAGGATGACAGTTCTGTTTGTTAG
ATGAGTAAACCTCTATATTCATAAGTTCTAAAATCCTTCATTATGAGGGA
TTCAAAGTATTTATAAAAACACTGCCCTCTAAAAATTTCCTCAGATCTGA
AGTATGGNCTTGGNCCTGAATATACAGTGTTATCCTATGTTTAAAAGGGT
GATCCAGACATGAGACGCAACTAGTTGGTGCATAAGAAGGCCCCACTTGG
CTATTTCATATCTACCTACAATTGACCAAAAAAAATTTTTTAGGCCAGCA
ATTATTATTTAGCTTCGCTCTTTCTAGTGCAAGAAACTGCAGGCTGGATC
AGTAGTTCAACAGCTAAACAGTCATAAAATAGTCATTGGCATGTTAAATT
TCTTTCAATGCTTCAAAGATAAATTCCAATTCTATTTACTTATTCATTGN
GACNGNATTACTAAACAGGTAAGGATGGGAATA

Sequence ID - 651 nt: 251
CTTTGGGAGGCCGAGGCGGGCGGATCACTTGAGGTCAGGGGTTCGAGACC
AGTCTGGCCAACATGGTGAAACCCCAACTCTACTAAAAATACAAAAGTTA
GCCAAGTGTGGTGGCAAGTGCCTGTAATCCCAGCTACTCGGGAGGCTGAG
ACAGGAGAATCACTTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCCAAGA
TCGTGCCACTGCACTTCAGCCTGGGCAACAGAGCAAGATTCCGTCCATCT
C

Sequence ID 652
CTTTCTTCAGCCTTGCAGACACCTAAACATCATGTAATTACCTAAGGAAT
TCCCAAGTGCCTCTTCCAGGTTATACGTGTAAATAGCTGTTTTTATGCAA
GATTAGTTAGATACTGCTCTTTACAGGATGAGTGGTGTTGTCTTTGGCTG
GGGGGGNCTTAAATGTGTTTCTAATGTGTGTGTCAAATAATTACCTGTTA
AACAGACTGCCAATCTGGCTGAAGCCAATGCTTCTGAAGAAGATAAAATT
AAAGCAATGATGTCGCAATCTGGCCATGAATACGACCCAATCAATTACAT
GAAGAAACCTCTAGGTCCACCACCTCCATCTTACACGTGTTTCCGTTGTG
GTAAACCTGGACATTATATTAAGAATTGCCCAACAAATGGGGATAAAAAC
TTTGAATCTGGTCCTAGGATTAAAAAGAGCACTGGAATTCCCAGAAGTTT
CATGATGGAAGTGAAAGATCCTAATATGAAAGGTGCAATGCTTACCAACA
CTGGAAAATATGCAATCCAACTATAGATGCAGAAGCATATGCAATTGGGA
AGAAAGAGAAACCTCCTTNTTACCAGAGAGCCATCTTNTTTCT

Sequence ID 653
GTTGTGACTCGTTGGCATGTGATCTGAAGTTCCTGCCCTGCAGCTGACGA
GCCAGTGTTTCAATAATTAAAAACAACTCAACTCACTGTCCTCCTGCCTT
GAATTTGATCATTGCGCTTTGCATGTATGTATCACAATACCACATGTACC
CCATAAATATGTACAAAGATTATGTGTCAATAAAAAACAAAAATTAAAAT
CCCAATTTTTA

Sequence ID 654
GTTGCTAGTAGCGGCAGGAAGATGTCAGGCTCACTTTCCTCTGATTCCCG
AAATGGGGGGAACCTCTAACCATAAAGGAATGGTAGAACAGTCCATTCCT
CGGATCAGAGAAAAATGCAGACATGGTGTCACCTGGATTTTTTTCTGCCC
ATGAATGTTGCCAGTCAGTACCTGTCCTCCTTGTTTCTCTATTTTTGGTT
ATGAATGTTGGGGTTACCACCTGCATTTAGGGGAAAATTGTGTTCTG

Sequence ID 655
GTCCCCGGGAATCGCGGCCGCGTCGACGGTTTATTTTCAGTGCTTGAAGA
TACATTCACAAATACTTGGTTTGGGAAGACACCGTTTAATTTTAAGTTAA
CTTGCATGTTGTAAATGCGTTTTATGTTTAAATAAAGAGGAAAATTTTTT
GAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTTTT

Sequence ID 656
TAGAGGCCTGAATAGGTAGACAATGGCAGCAGCGTTTTTAATCACAGTCC
TATTCATGCCCTAATTCGGGAGTGATGATTAAAGGACATTAGAGGGAGCA
CTTTGACATCTGATCCTTTGAACTGACGTCTGTGCAGGCTGCACTCCATA
GAGCTCACTTGGCCAAACTGATTTCCTTAAATAAAGTGCTGTGATTTCCA
ATGTAGGAAATATTACATTAGAGCCTATTGAAATGATTAGGAATTGAGGA
GCTTTTCTTTAGGTGGGAATGTGGTGTATGCTGTATACTCACAAAAGTGA
GATCATTAATATTGCATGTACTACTTTGAATATCAGGGACCACAGAGAAA
TAGCATGAGAAACGCCTTCCTGCAGTCATGCACTTAAAATGAATATGAAC
AAAAATGTGGAACTCTGCTGTCATAGCTCTCCG

Sequence ID 657
GGGGCTTCTGCTGAGGGGGCAGGCGGAGCTTGAGGAAACCGCAGATAAGT
TTTTTTCTCTTTGAAAGATAGAGATTAATACAACTCTTAAAAAATATAGT
CAATAGGTTACTAAGATATTGCTTAGCGTTAAGTTTTTAACGTAATTTTA
ATAGCTTAAGATTTTAAGAGAAAATATGAAGACTTAGAAGAGTAGCATGA
GGAAGGAAAAGATAAAAGGTTTCTAAAACATGACGGAGGTTGAGATGAAG
CTTCTTCATGGAGTAAAAAATGTATTTAAAAGAAAATTGAGAGAAAGGAC
TACAGAGCCCCGAATTAATACCAATAGAAGGGCAATGCTTTTAGATTAAA
ATGAAGGTGACTTAAACAGCTTAAAGTTTA

Sequence ID 658
GACCTTTGAGAAAATTAATTTAAATCCTAGAACTTTGGGTGAACCGAAGA
AATTTATAATATTTGTTTAGTTAATAACAGATAAAAAGGAAAGATTCAAG
CCTATTGGATGAGAATTTGTACATTATTTTAGAGCTAATAATAATGGTTT
TCAGTTTAGTGAGGATTTAAAAAATGTTTTTGAATCAAACTTTTTTTCTT
TATAATCCTTTTTAACTAACTCAGGAAATAAGGTATTATGAAATCCACAC
ACTGTTACCTCCTTAAAGTATGAGGATACTTCCCACTGTTTGGTCCACTA
GTGGCTGATTATTTTGTTTGTGGATTATTTGTAATTTTCTTTTTAATTCT
TCCTTAAAGAGCATGGCATTTGGAGTCACAGACCTATATTTGAATCCTGT
CATTTACTAGCGTTTTGACCTTGAACAATTATGCTCAGAGTCTCAGTTTT
TTCTTGTAAAGTGATGATGATACTACTTAACTCACAGGGTTGTAGTGAAG
ATCAAATGAGATCATGTCTGTANAACACCCTGCCCGGCACTCAATAAGTA
TTAATAGGAACCCATATACCTC

Sequence ID 660
TGTTTTTATTTTTTAAAAGGTATAAACACCAAAAAAAAAATTAACATTGT
ATGAAGATGGAAAATAAGAAGATGCACTTTCTGTAACTTTGTCTAAGGAT
TTAAATTACTAACTTATGAACTCCAATTTGAATTGAACTTAACTATCGGC
TTTCTTACTGGTAAAATTATATGGTTTATTTTAAATGCGTACATATTGAC
CAATGGCCTCTGAAAAAGCACATTTTAGATACTGAAATTGAAGGAAAGAA
AATGCATCTTCAAACATTTTTTGGAATCTCACCACATATACTTTGTTANA
TTTGTGTATTGTAGGGTGTTTGTTTTGTATTTTTGTATTGTATATGAACT
TTTTTTAAATGTGACAGTTAAACACATCTTTAAAAGCATAGTCACAGACA
AAAGCATACAGTATAAAAATTTCCTTGAAAACTCCTACAATATTATATTT
GGAGGCAGCTTCAGACTGTTTTATTGG

Seqeunce ID 661
CTCTGGCACACATTAGTTCCTCTTATATTACATTGATATAAGCAAGTCAT
ATGGATTTATCTGAGTGTAAGGAGAGCTGGAAAAAATAGTTTCTAGCAGG
TCAGCCACCTCCCAGTGAGGGCTGCATACCATAGAAGGGGAGAATGAATT
TTGGGAAAACAGGTAATTATCTCTGTCACAGAAGGGGATGAAAAGTATGG
TAGTTACNCAAGTTANACATCTGTATGGAAAATACCACTTGGTTCTACAA
ATGNGG

Sequence ID - 663 nt: 627
GCCTCCCGGGTTCAGGGATTTCTCCTGCCTCAGCCTCCTGAGTGGCTGCA
TTGCAGGCACCTGCCACCACGCCTTGCAAATTTTTGTGTTTTTAGTGGAG
ATGGGGTTTTGCCATGTTGGCCAGGCTGGTCTCGGACTCCTGACCTCAGG
TGATCCGCCCGCCTCAGCCTCCCAGAGGGCTGGGATTACAGGCGTGAGCC
ACTGTGCCTGGCCCCAAGTTTTGCATCTTTTAATGCCCTCTGAACAAATA
CATAGAGAAAACTCTCAGAACAATTAAAACCTGCAGAGCAACAGTGTCCT
CCATGTCTTAGGTTTCAAGTTTGCCTCTAAAATTCTAATCCATATTTTTC
TACTTCTCAGATAATTTATGTGTGTGTACTCTTCCTAGACGTACAAGAGA
CTTTTTAATGCTAAATATTTGTCAGTGCTTAACAAAAACTCAATTTCACA
TTACTCATATTGTTTTTGTTTTAATTGAATGTGAATTAAATTTTTATTAG
TTATTTGATTTGGAATGTTATGTATGCCATTAACACTATTAGGGGAATCT
CTAGCATTTCTGTATTTTTAAAGAATTTGATTCTTTTGTANATTCTGCCT
GTGTGGCATTTTAAACATGTGTGACAT

Sequence ID - 665 nt: 345
ACCGGCGACATGGCCAAACGTACCAAGAAAGTCGGGATCGTCGGTAAATA
CGGGACCCGCTATGGGGCCTCCCTCCGGAAAATGGTGAAGAAAATTGAAA
TCAGCCAGCACGCCAAGTACACTTGCTCTTTCTGTGGCAAAACCAAGATG
AAGAGACGAGCTGTGGGGATCTGGCACTGTGGTTCCTGCATGAAGACAGT
GGCTGGCGGTGCCTGGACGTACAATACCACTTCCGCTGTCACGGTAAAGT
CCGCCATCAGAAGACTGAAGGAGTTGAAAGACCAGTAGACGCTCCTCTAC
TCTTTGAGACATCACTGGCCTATAATAAATGGGTTAATTTATGTA

Sequence ID - 666 nt: 252
ATAATTCAGAACTTCTTCATATGCTCGAGTCTCCAGAGTCACTCCGTTCT
AAGGTTGATGAAGCTGTAGCTGTACTACAAGCCCACCAAGCTAAAGAGGC
TGCCCAGAAAGCAGTTAACAGTGCCACCGGTGTTCCAACTGTTTAAAATT
GATCAGGGACCATGAAAAGAAACTTGTGCTTCACCGAAGAAAAATATCTA
AACATCGAAAAACTTAAATATTATGGAAAAAAAACATTGCAAAATATAAA
AT

Sequence ID 669
TTACTTTTAACCAGNGAAATTGACCTGCCCGTGAANAGGCGGGCNTGACA
CAGCAAGACGAGAAGACCCTATGGAGCTTTAATTTATTAATGCAAACGGT
ACCTAACAAACCCACAGGTCCTAAACTACCAAACCTGCATTAAAAATTTC
GGTTGGGGCGACCTCGGAGCAGAACCCAACCTCCGAGCAGTACATGCTAA
GACTTCACCAGTCAAAGCGAACTACTATACTCAATTGATCCAATAACTTG
ACCAACGGAACAAGTTACCCTAGGGATAACAGCGCAATCCTATT

Sequence ID 670
GGCTGATTCCTGAGCTATAAAAGCATAATTGCTTTATATTTTGGATCATT
TTTTACTGGGGGCGGACTTGGGGGGGGTTGCATACAAAGATAACATATAT
ATCCAACTTTCTGAAATGAAATGTTTTTAGATTACTTTTTCAACTGTAAA
TAATGTACATTTAATGTCACAAGAAAAAAATGTCTTCTGCAAATTTTCTA
GTATAACAGAAATTTTTGTAGATGAAAAAAATCATTATGTTTAGAGGTCT
AATGCTATGTTTTCATATTACAGAGTGAATTTGTATTTAAACAAAAATTT
AAATTTTGGAATCCTCTAAACATTTTTGTATCTTTAATTGGTTTATTATT
AAATAAATCATATAAAAATT

Sequence ID 671
CAGGAAGTCACCTGGGATTGGCTGCCTCACCCACTCACAGTGCCATCCCT
GCCCCAGGCCTCCCAGTGGCAATTCCAAACCTGGGTCCCTCCCTGAGCTC
TCTGCCTTCTGCTCTGTCTTTAATGCTACCAATGGGTATTGGGGATCGAG
GGGTGATGTGTGGGTTACCTGAAAGAAACTACACCCTACCTCCACCACCT
TACCCTCACCTGGAGAGCAGTTATTTCAGAACCATTCTACCTGGCATTTT
ATCTTATTTAGCTGACAGACCACCTCCACAGTACATCCACCCTAACTCTA
TAAATGTTGATGGTAATACAGCATTATCTATCACCAATAACCCTTCAGCA
CTA

Sequence ID 672
CAGGAAGTCACCTGGGATTGGCTGCCTCACCCACTCACAGTGCCATCCCT
GCCCCAGGCCTCCCAGTGGCAATTCCAAACCTGGGTCCCTCCCTGAGCTC
TCTGCCTTCTGCTCTGTCTTTAATGCTACCAATGGGTATTGGGGATCGAG
GGGTGATGTGTGGGTTACCTGAAAGAAACTACACCCTACCTCCACCACCT
TACCCTCACCTGGAGAGCAGTTATTTCANAACCATTCTACCTGGCATTTT
ATCTTATTTAGCTGACAGACCACCTCCACAGTACATCCACCCTAACTCTA
TAAATGTTGATGGTAATACAGCATTATCTATCACCAATAACCCTTCAGCA
CTAGATCCCTATCAGTCCAATGGAAATGTTGGATTANAACCAGGCATTGT
TTCAATANACTCTCGCTCTGTGAACACACATGG

Sequence ID 673
GGGTTTTCTTTCGGAAGCGCGCCTTGTGTTGGTACCCGGGAATTCGCGGC
CGCGTCGACTGCTAAACAGAATACTGCTATTTTGAGAGAGTCAAGACTCT
TTCTTAAGGGCCAAGAAAGCCACNTGNNCCCTNGGNCTAATCTGGCTGAG
TAGTCAGTTATAAAAGCCNTAATNGCTTNNTNTTTGGNNTCNTTTTTNNC
NGGGGNCGGNCTTGGGGGGGGTTGCNTCCAAAGATANCATNTNTTTCCAA
CTTTNTNAANNNAANNGTTTTAAAATCCCTTTTCCNCCNGAAAANANNGC
CCTTTAAGNGCCNCAAAAAAAAANNGTNTTCTGCANNTTTTCTANTATNA
CAAANNTTTTNGTAGAANAAAAATTTTTTTTTAGNGGCTACCCTTTNTTT
NTTANNCANNGGAGTTTNTTTTTACAAAAAAAAAANATTGGGNCCCCTCC
ACAACCTTGGGTCTNTAATNGGGGGGTTTTTAAATAAANCNTNTNTAAAT
CCCCCNNNNNNNNNCNNNNNNNNNCCNNNNNNNNNNNNNNNCCCNNNAAA
AAATTTTTNCTCCCCCNCCCTTTTTCTTCCTGCCGGCCCCAATTTAAGCC
CNGGCGCTTGGGGCAAATCCCCCTTTAGNGGGGGGGTTTANAAAAACCNG
GGGCGGGGNTTTAAAACCNCGGGGNNNGGGGAA

Sequence ID 674
ACCTCTAGCATCACCAGTATTAGAGGCACCGCCTGCCCAGTGACACATG-
TTTAACGGCCGCGGTACCCTAACCGTGCAAAGGTAGCATAATCACTTGTT
CCTTAATTAGGGACCTGTNTGAATGGCTCCACNAGGGTTCACTTGTCTCT
TACTTTTAACCAGTGAAATTGACCTGCC

Sequence ID - 675 nt: 591
GTATAGAAAATAATGTCCCCAGNGCATAGAAAAAATGAGTCTCTGGGCCA
GTGAATACAAAACATCATGTCGAGAATCATTGGAAGATATACAGAGTTCG
TATTTCAGCTTTGTTTATCCTTCCTGTTAAGAGCCTCTGAGTTTTTAGTT
TTAAAAGGATGAAAAGCTTATGCAACATGCTCAGCAGGAGCTTCATCAAC
GATATATGTCAGATCTAAAGGTATATTTTCATTCTGTAATTATGTTACAT
AAAAGCAATGTAAATCAGAATAAATATGTTAGACCAGAATAAAATTAATT
ATATTCTGGTCTTCAAAGGACACACAGAACAGATATCAGCAGAATCACTT
AATACTTCATAGAACAAAAATCACTCAAAACCTGTTTATAACCAAAGAAT
TCATGAAAAAGAAAGCCTTTGCCATTTGTCTTAGAAAGTTATTTTTTAAA
AAAAAATCATACTTACTATTAGTATCTATGGAAGTATATGTAACAATTTT
TATGTAAAGGTCATCTTTCTGTGATAGTGAAAAAATATGTCTTTACTAAG
TTGAAATGAATACTTTCTGNCTTTGCTAATGGATAGTTATT

Sequence ID 676
CTCAATTCTACTAAAAAGCCCCCCAAGAAAAGCGAATGAGAAAACAGAGT
CATCCTCTGCACAGCAAGTAGCAGTGTCACGCCTTAGCGCTTCCAGCTCC
AGCTCAGATTCCAGCTCCTCCTCTTCCTCGTCGTCGTCTTCAGACACCAG
TGATTCAGACTCAGGCTAAGGGGTCAGGCCAGATGGGGCAGGAAGGCTNC
GCAGGACCGGACCCCTAGACCACCCTGCCCCACCTGCCCCTTCCCCCTTT
GCTGTGACACTTCTTCATCTCACCCCCCCCTGCCCCCCTCTAGGAGAGCT
GGCTCTGCAGTGGGGGAGGGATGCAGGGA

Sequence ID 679
GNANCNTTTCCTNTCGNAAANCGCGCCTTGTGTTGGTACCCGGGAATTCG
CGGCCGCGTCGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAANTNTAGAC
TCGANCAAGCTTATGCANGCNTGCGGCCGCAATTCGAGCTCGGCCGACTT
GGCCAATTCGCCCTATAGNGAGTCGTATTACAATTCACTGGCCGTCGTTT
TACAACGTCGNGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTT
GCAGCACATCCCCCTTTCGCCAGCTGGCGTAATANCGAANAGGCCCGCAC
CGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAANGGAAATTGT
AAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCT
CATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAA
GAATAGACGGAGATAGGGTTGAGNGTTGTTCCAGTTTGGAACAANAGTCC
ACTNTTAAAGAACGNGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATC
AGGGCGATGGCCCACTACGTGAACCATCNCCCTAATCAAGTTTTTTGGGG
TCGAGGNGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATT
TAAAGCTTGACGGGGAAAGCCCGGCGAACGTGGCGAAA

Sequence ID 682
CACCTGCAGTCCAAGTACATCGGCACGGGCCACGCCGACACCACCAAGTG
GGAGTGGCTGGTGAACCAACACCGCGACTCGTACTGCTCCTACATGGGCC
ACTTCGACCTTCTCAACTACTTCGCCATTGCGGAGAATGAGAGCAAAGCG
CGAGTCCGCTTCAACTTGATGGAAAAGATGCTTCAGCCTTGTGGACCGCC
AGCCGACAAGCCCGAGGAAAACTGAAACTTTGCTTAACNACCGAATGGNG
GGGANCTTTTCCAACGNTTTT

Sequence ID 683
TTGGTTTCATACTGNTGGGGNTTGAATGNTCCCTNCAACACTNATGTTGA
NACTTAATCCCTAATGNGGCAATACTGAAAGGTGGGGCCTTTGAGATGTG
ATTGGATCGTAAGGCTGTGCCTTCATTCATGGGTTAATGGATTAATGGGT
TATCACAGGAATGGGACTGGTGGCTTTATAAGAAGAGGAAAAGAGAACTG
AGCTTGCATGCCC

Sequence ID - 684 nt: 545
GTGGAAGNGACATCGTCTTTAAACCCTGCGTGGCAATCCCTGACGCACCG
CCGTGATGCCCANGGAAGACAGGGCGACCTGGAAGTCCAACTACTTCCTT
AAGATCATCCAACTATTGGATGATTATCCGAAATGTTTCATTGTGGGAGC
AGACAATGTGGGCTCCAAGCAGATGCAGCAGATCCGCATGTCCCTTCNCG
GGAAGGCTGTGGTGCTGATGGGCAAGAACACCATGATGCGCAAGGCCATC
CGAGGGCACCTGGAAAACAACCCAGCTCTGGAGAAACTGCTGCCTCATAT
CCGGGGGAATGTGGGCTTTGTGTTCACCAAGGAGGACCTCACTGANATCA
GGGACATGTTGCTGGCCAATAAGGTGCCAGCTGCTGCCCGTGCTGGTGCC
ATTGCCCCATGTGAAGTCACTGTGCCAGCCCAGAACACTGGTCTCGGGCC
CGATAAGACCTCCTTTTTCCAGGCTTTAGGTATCACCACTAAAATCTCCA
GGGGCACCATTGAAATCCTGAGTGATGTGCACTGATCAAGACTGG

Sequence ID 685
GGAAAGGGCCATTTTATTGCCTAAAACCACCTGGNTTTTNAGGTAACAGT
TCCAACATGTCCTTTTTTGAATAGCTGTTCTAATTATTATATATTCAGCT
GATTAATAGGAGTACTTGATAGGTGGACTGTGTCAGGTAGCCTCAGGCAA
TCCTACTTCAACAAGCTGTCAGGGAGCCATGCCATGCTTCTTTATGACAT
AGGTGAATTTGATAGGCTCACTAGCAGAACATGGGATCACAAGGTGGAAC
CNTTCCNTTT

Sequence ID 686
GACCCCTTCCTTACACCTTATACAAAAAAACTGAAACTGGACCCCTTCCT
TACACCTTATACAAAAATTAACTCAATTTTATTATGTTGTATTAAATTAA
GTTGGGTTTAATTAAGATGGATTAAAGACTTAATTATAAGACCTAAAACC
ATAAAAACCCTAGAAGAAAACCTAGGCCATACCATTCAGGACACGGGTAT
GGGCAAAGACTTCATAACTAAAACACCAAAAGCAATGGCAACGAAGTCCA
AATAGACAAATTGGACCTGATTAAACTAAAGAGCTTCAGCACAGCAGAAG
AGACTATCGTCAGAGTGAACAGGCAACCCACAGAATGGAAGAAAATTCTT
GCAATCTATCCATCTGACAAGGGGCTAATATCCAAAATCTACAAAGAACT
TAAACAAATTTACAAGGAAAAACACAAACAACCCCATCAAAAAGTGGGCT
AAGGATGTGAACAGACACTTCTCAAAAGAAAACATTTATGCAGCCAACAA
ACATGAAAAAAAGTTCATCATCACTGCTCATTAGAGACATGCAAATCAAA
ACCACAATGAGATCCCATCCCACACCAGTTAGAATGGCAATCATTAAAAA
TGT

Sequence ID - 687 nt: 268
TTTATGTGTTTTTGCTTGGGGGGCGCTGGGCCTAGCCCAGAGTAGTGCTT
GCTCCCCCTGCCTTGTCCCACCAGCGAGGCAGCAGACTCAGGCCCTCCAT
GGTCCTCTTTGTCATTTTGTTGACATGCATTCCTCCTTTTGTCATCTTGT
TGGGGGGAGGGGATTAACCAAAGGCCACCCTGACTTTGTTTTTGTGGACA
CACAATAAAAGCCCCGTTTATTTGTAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAA

Sequence ID - 688 nt: 569
CTTTAGCCAGCCTGATCAGAAAAAAACAAAAGAAGAGGAAAGACGTAGAT
TACCAACATCAAGAATGTGAGTTATGATATCACTACAGACTCTCCAGGTA
TTAAAAGCATAATTAGAGAATGATATGAGCAGCTATATGCAAATAAGTTC
AACATTGGACAAATGGACAAATTTCTTGAAAGATAAATTATGAAATTTCA
TTCTGAAAGAACTACATGACCTTAATTGTCTTACATCTATTAAATAAGTG
GAAATTGTAGTTTAGAAACTTTCCCACAAAGAAAACTCTAGGCCCAGATG
GCATCAAAATAATATTCAGATGAATGAAATGGAGAAAGGATAGCCTTTTC
AACAAATGGTGGTGGAACAATTGGATTTCCATATGCAAAAAAATAGAGAT
GGACGCAGAGGTGTGTGCTTAGGAGGCTGAGGTGAGAGGATTGTTTGAGG
CCAGCCTGGGCAACATAGCAAGACCCCATTTCAAAAACAAAAATAAAGAA
CTTGTAGCCTTACCTTGTGCCATATTATGAAAATGTATCATAGGCTTAAA
TGTGAAACGTAAAACAAAA

Sequence ID 689
CGCAGGGGCTTCTGCTGAGGGGGCAGGCGGAGCTTGAGGAAACCGCAGAT
AAGTTTTTTTCTCTTTGAAAGATAGAGATTAATACAACTACTTAAAAAAT
ATAGTCAATAGGTTACTAAGATATTGCTTAGCGTTAAGTTTTTAACGTAA
TTTTAATAGCTTAAGATTTTAAGAGAAAATATGAAGACTTAGAAGAGTAG
CATGAGGAAGGAAAAGATAAAAGGTTTCTAAAACATGACGGAGGTTGAGA
TGAAGCTTCTTCATGGAGTAAAAAATGTATTTAAAAGAAAATTGAGAGAA
AGGACTACAGAGCCCCGAATTAATACTAATAGAAGGGCAATGCTTTTAGA
TTAAAATGAAGGTGACTTAAACAGCTTAAAGTTTAGTTTAAAAGTTGTAG
GTGATTAAAATAATTTGAAGGCGATCTTTTAAAAAGAGATTAAACCGAAG
GTGATTAAAAGACCTTGAAATCCATGACGCAGGGAGAATTGC

Sequence ID 690
CGAAAAGCAAATATAACTTGCCACTAACCAAGATCACCTCTGCAAAAAGA
AATGAAAACAACTTTTGGCAGGATTCTGTTTCATCTGACAGAATTCAGAA
GCAGGAAAAAAAGCCTTTTAAAAATACCGAGAACATTAAAAATTCGCATT
TGAAGAAATCAGCATTTCTAACTGAAGTGAGCCAAAAGGAAAATTATGCT
GGGGCAAAGTTTAGTGATCCACCTTCTCCTAGTGTTCTTCCAAAGCCTCC
TAGTCACTGGATGGGAAGCACTGTTGAAAATTCGAACCAAAACAGGGAGC
TGATGGCAGTACACTTAAAAACGCTCCTCAAAGTTCAAACTTAGATTTCA
GATTT

Sequence ID 691
CCGGTCTCTACACAATATATAGAAATCTGGGCATGGTGGTGCCTGGCTGT
AGTCTCAGCTACCTAGTTGGGTGAGGTGGGAGAGTCGCTTGAGTCCTGGA
GGTTGAGGCTGTAGTGAGCCAGGGCTGCACCACTGCATTCCAGCCTGGGT
AACAGAGTGAGACCCTGTCTCAAAAAGAAAAAAAAAAATTGCTAATTTTA
ACAAATCACAAAACTGACTCAGGCAAGTTGTCTGACTCAAAAGCCCTTGA
AAAACCATCAAAGACAGTAGAATGTTAACTGGTCATTTACGTAAAATAGT
GTTCATTAAATTTTTGGTTCATTTAGGATAATCATTTTAAATGAGACTGT
ATTTGAGACTGTATACACATACATATACATGTTTACACACATATACGTAC
AATATATGTACATTCTATCTAAAAGATCATACATGTGTGTACATATATGT
TTTTAAAAGTCAAACTGACATATTAATGGAAACAGTGCTTACATCTCTGG
TAGTGATTTTCTATTAGCAGCAGCCCTACATATGCTGCGTCTCTGAACAG
CATGTCAGTGCCATGACTGTCTAAACATGCAAATATGACTGACAGACTCT
TGAGACAGCTTTCACCTTG

Sequence ID 692
AATTCGNGGCCGCGTCNNCCTANGAGGCACCAGGAAATCCCGCGGGGTGG
CCCATGCAGACCAGGCGCACGTGGCTCATGGGGCANAATTGCCAAGGACA
GCTCACGACAGTGCCACCTTCTCACCATTCCAGCCAAGGAGAGATGTGAC
GTTGGAACTGCTCTGGCACTTCTGTCAAGCCTCCCCCGCCCCAATTGCCT
TGAGATCTCTGCTCTTTGTCAGAGATTTGCAAAGACTCACGTTTTTGTTG
TTTTCTCATCATTCCATTGTGATACTAAGAAACTAAGAAGCTTAATGAAA
AGAAATAAAATGCCTATGTTGTTGTTCT

Sequence ID 693
CTAGAACCCATGACTCCTAGGTCTTATACTGCAACCACAGTATCAGCAAA
TAATCTTTCATAAGGGGATTATTCTCTGATTAACAGGAAATACAGGAATT
TAATTTGTGAACACGCTAGGTAGAAGCAGAAACCCAAATCCAAATCCAAA
TTTAAACATTTAAAATTCATTCTATAACTAAGATCTAACAGTCATTTTCT
TCCCAGTAAGAAATAACCAAAGCATGCTAAAAATCACTGGACTAAATTGG
TGTCAAAACTGCCACATTGCCAGGCATGGGGGGGTCATACTTGTAATCCC
AGCACTTTGGGAGGCCGAGGTGGGAAAATTGCTTGAGGCCAGGAGTTCGA
AACCAGCCTGGGCAACACAGTGAGACCCCATCTCCACAAAAAAAAAAAAT
TAAAAAACAAAACAAAACATTAGCTGGGCATGGTGGTACACGCCTGTAGT
CCCAGCTACTCAGGAGCCTGAAGTGAGAGGATCACTGAAGCCCAGGAGGT
AGAGCTATGACTGTAGTGAGCTATGACTGTGCCACTACACTCCACCTGGG
TGACAGGGGACTC

Sequence ID 694
CGACTTCCATTTGTATTAATGGAATACTAAGTCCCTCTGTGATTTCTGAA
CCAAGCTATTCCTAGGCCTGAGTTTTATTTTGTTGACACAGAAATAAATT
ANAAGGCCAAGCGTGGTGGCATGTGCCTGTAGTCCTAGTTGCTGAGGTAA
GAGGATTGCTTGAGCCCAGGAGTTCAAGGCTGCAGCAAGCTTTGATTGCG
CCACTGCACTCCAGCCTTGGCGACAGACTAAGACGCTGTCTCAAAAAAAA
ACAAAAA

Sequence ID 696
GGTTATCAATGAGATTAAGAGACAACTAGAGTAAAAACAAAAGAAAAGAA
AAGAAANGAAAACAACAGAAGCTCTATTAACTGACCTCTAACCAATACAA
CAGGTTAACTGATGTTCTCCATTCTGTATATAAAAATCCCAGTGGACACC
CACAACACAGGCTTCAGGCTTGTAGGACACTTTCTAGTTCATCTGAGCAC
TTTTGTTCTCAGCAGTTGAGCTGTATACTTAGCAACATTTGGTGCTTCCA
AACCCATTTGTGCCTGTAGCACTTACTATTGAAATACATAATTTAATTAA
ATATTATATAAAGGAATGGAATACGAGTTGGACAAGAAAAAGAGTTAAAT
CTGAAGGTTAGGTAAAAAGAGCAACTTCTTTTCTCTGTTTTGCAGGTTGG
CAAAATCATTTAAAAACAATTGGAAGTATTATATGTTCTGCATTAAGTTG
TCATTTTACTTAAAAACTAGGCATCAAAGATGATGCATAATAAATTTAGT
GTATGCAAGAATGACTGCTTGGGACCTCAATATATGAATTCTTAATCCAA
GGAAAGTCCTTGGCCTTACATTTAAAAGTCGGCAAATAAGTGTACGTTCA
TT

Sequence ID 697
GAACATTTAAAAATAATGCAAATAAGGCTGGGCGTGGGGGCTCACACCTG
TAATCCCAGCACTTTGGGAGGCCGAGGCAGGCAGATCACGAGGTCAGGAG
ATTGAGACCATCCTGGCTAACACAGTGAAACCCTGTCTCTACTTAAAAAA
TAAAAAAATTAGCCAGGCGTGGTGGTGGGCGCCTGTAGTCCCAGCTACTC
AGGAGGCTGAGGCAGGAGAATGGTGTGAACCCGGGAGGCGGAGCTTGCAN
TGAGCTGAGATCGTGCCACTGCACTCCAGCCTGAGCGACAGAGCGAGACT
CTGTCT

Sequence ID 698
TCATTAGAATCCAAGCTTTGAAAATTTCTGATTAATGCTCATGTATTTCT
TTATCTTTGTTTTTCCTTGTGAAGAAAGACTTTCACCACTGTCTGAGTGA
TGATGCTGTTGATAAGGATGATGTCGATGACTACTATATTGCATCTCTCA
GGAACAGCTGATGGGAAGGGAGGGGCTGCTGAGTTCCCTTGTTCTAGCTA
GCAGGACGCTCCTCANAGAGGGGGCCGAGTTACAGACAGCAGCCGCATTC
TCATGCAAAATTAGTTTTAAACTGCTAGTGTGGGCATCGGTACCTTTTGC
CTGGGTGATACCGAAGAATTGTTGAGGATTTAGTATGCTCCGTAGAGACA
GTTCAGCCAGTCATTTCTGCATTGGAGAGACTTCTCATACTTTCTTTGAA
GACTCATAGAAAGCTGGAT

Sequence ID 699
ATTAAGGTTTGTNCCCAACAAGAATAGATGTAATTAGAAAAAANTGNCTT
CCTTACCTATTGCCTCTGATNTTTACTTGCTTAAATTTTTTTTATTGNAA
ATCCAGAAAAAGNGGATTTAGAGAACAACACTAACTCCCACCTAATCTAT
GACAGANATGTACAANANAGTACCTGTGAAAAATGTGAAAGNATNTGAAA
AATGTAACCTTTGGCAGCCTGAGCATAGTCAACCAGAAAAACTATCTGAA
TTAAAATAATTGGTCCATAGGTACTATTTTATTTGGTCCATAAGGATTAT
TTTTTCAACTTTTTTTTCAAGTGTATTATTATGTCATTTCCCACGTAGGT
TACTGATACCTGAAGACTTTTTNCACCTTTAACCTTNCTCGTTGAGGAGC
TTTGTANTCTAATAAAAGAGAAATATAAGTAAATGTTAGATATATGGGNG
GATAATGGTAACTATGTGCTTAAAGAGGTATAAAAGAAGGGTAGGGAGCA
GATAAGACAAAGGAAGGGCTATATTATAANGAAGAATATTCCAAGTAGGG
AAGAGAAAAAGATATGTTATCCATATAATATTTTATGTGCAGTAGAGAAC
ATGTTCTATAGAANAGACAGAAGATG

Sequence ID 700
CTTGAGCCCAGGAATTCCAGCCTGGGCAATATAGTAAGACTCCGTCTCTA
CAAAAGATACAAAAATTAGCCAGATGTGGTGGTGCGTGCCTGTAGTTCCA
GATACTGGAAAGACTGAGGCAGGAGGATTGCTTGAGCATGGGAAGTTGAG
GCTGCAATGAGCTGTGATTACGCCACTACACTCCAGCCTGGGCAACAGAG
TAAGATCTTGTCTCAAAAAAAAAATTGAATTCAGCTAAAAATAATAAAAT
TTTAAAATAATTTTAAAAAGCCCTCAACAGCTTTGTTTTTCTCTCCTTGC
CAGCTTCTCTGCAGCCTATAGCCTGGAGGCTGGCTGCTGCGAGCCAGGAC
AAGCGGTGGGAAATGCAATCACAGCGTGAAATCTCTGTGTTCAGAGACAC
GCAGGAAGCAGGTGAACCATGAASGGCCAACACATGCCCCCAGTTAGCAG
GGTGTAGAGACCGGGGCAGGGCTTTCTTCTTCCTTCTGGGTTATAAATAT
CCATGTCCTGCCATTTGAAGCTGCAAGTGGCACACATGGATGCTGGACAG
GCGCTCGCACTTTCTGGGCAGGGCANGGGGCTCAAAGGCAGGACAGCTGG
GCAAAAGCACCTTGCGTGGGCCC

Sequence ID - 701 nt: 579
CTTTGGAGCTTCTGTCTGTGCTGTGGACCTCAATGCAGATGGCTTCTCAG
ATCTCGTCGTGGGAGCACCCATGCAGAGCACCATCAGAGAGGAAGGAAGA
GTGTTTGTGTACATCAACTCTGGCTCGGGAGCAGTAATGAATGCAATGGA
AACAAACCTCGTTGGAAGTGACAAATATGCTGCAAGATTTGGGGAATCTA
TAGTTAATCTTGGCGACATTGACAATGATGGCTTTGAAGGTAATTAAAAT
TATCAAATTGGTGCTTGATTTCTGCTTTTAAAATGGTTTATGGAAGAAAA
TATGATTAAAGTTTTGTATTGTTTTCCTTCCTATAGAAGATGGAGCCAGA
ATGGCATGCTAAGTTTTTTCTTTTCTTTAGTGTTATATATGACTTCTCCT
CAATTGTCACCCATTGATCTTTACCACTGTTAATAATGGATGATATTCAA
AATACCTTATTTCAGTGATTCTAAGGCACCATTGATTAGAAACTGCATTA
TTATTTATGTGTCCCTAAAAGCTACCTATTAAGCTGTTACACCCACCATT
TTTCTGTTAAGAAAATCCTGATTTCAGAA

Sequence ID 702
GTNNTCCTCTCGGAACGCGCCTTNTGTAGCCAGGTGCTACCAGACCNAAT
ACACGGTTGTTCCAGCTTGCGCATTCACCGATGGCGTAGATATCCGGATC
GGAAGTCTGGCAGGAATCATTAATGACAATACCCCCACGCGGAGCAACGT
CCAGACCACACTGGGTTGCCAGCTTATCGCGCGGACGGATACCGGTAGAG
AAGACGATAAAGTCGACTTCCAGTTCGCTGCCGTCGGCAAAACGCATGGT
TTTACGCGCTTCAACACCTTCCTGCACAATCTCAAGGGTGTTTTTGCTGG
TGTGAACGCGCACGCCCATACTTTCGATTTTGCGACGCAGCTGCTCGCCG
CCCATCTGATCAAGCTGTTCTGCCATCAGCATAGGGGCAAATTCGATAAC
GTGGGTTTCAATACCTAAGTTTTTCAGCGCGCCTGCGGCTTCCAGACCTA
ACAGGCCGCAATTCGAGCTCGGCCGACTTGGCCAATTCGCCCTATAGTGA
GTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAA
ACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCC
AGCTGGCGTAATAGCGAAAGAGGCCCGCACCCGATCGCCCTTTCCAACAG
TTGCGCACCTGAATGGCGAATGGAAATTGTAAGCGTTAATATTTTGTTAA
AATTCGCGT

Sequence ID 703
CTGCGCAGACCAGACTTCGCTCGTACTCGTGCGCCTCGCTTCGCTTTTCC
TCCGCAACCATGTCTGACAAACCCGATATGGCTGAGATCGAGAAATTCGA
TAAGTCGAAACTGAAGAAGACAGAGACGCAAGAGAAAAATCCACTGCCTT
CCAAAGAAACGATTGAACAGGAGAAGCAAGCAGGCGAATCGTAATGAGGC
GTGCGCCGCCAATATGCACTGTACATTCCACAAGCATTGCCTTCTTATTT
TACTTCTTTTAGCTGTTTAACTTTGTAAGATGCAAAGAGGTTGGATCAAG
TTTAAATGACTGTGCTGCCCCTTTCACATCAAAGAACTACTGACAACGAA
GGCCGCGCCTGCCTTTCCCATCTGTCTATCTATCTGGCTGGCAGGGAAGG
AAAGAACTTGCATGTTGGTGAAGGAAGAAGTGGGGTGGAAGAAGTGGGGG
TGGGACGACAGTGAAATCTAA

Sequence ID 704
CTTGTATTCAAGAACTACTGTAATGCATTAGTGGTCTGGCTTCATTTTGT
ATGATGCCAGATCCTTAATTTACCCAGCACAATCATTTCAGTAGTTTCCT
ATGGCTCCTGCAAAAATGCAAACAGAAACCACCACAGGAACAGCCCCTTG
CTGCCTCCTGTTGCTGAGGTAGTAGTCGCTAAAGAAAATTGAAGGCTCCT
TACAATCTATATTTGAAAACTAGAACTTCTGTAGAAACACACAGATCCCG
ATCTTAGAAGTTGTACAGGACAATCTGGTAAAACTGACATAATTGTGATT
TATTAACATGAATTAAAATGCCCAACCAGTGCTTCAGTGTGACAGTATAT
TTAAAATAAAAAAGAAATTAAAGGTCATATACTGTACTACTTTCACAAAG
ATCCACAGTTTTGCAAAAGACTTGTCATATGTACAATGCTATATATCAAA
TGAGAAAAGCTGTAAGCAATTATATACGCAAAAGAAATGGCAGTA

Sequence ID 705
TTCCAGTCCTTTCATTTAGTATAAAAGAAATACTGAACAAGCCAGTGGGA
TGGAATTGAAAGAACTAATCATGAGGACTCTGTCCTGACACAGGTCCTCA
AAGCTAGCAGAGATACGCAGACATTGTGGCATCTGGGTAGAAGAATACTG
TATTGTGTGTGCAGTGCACAGTGTGTGGTGTGTGCACACTCATTCCTTCT
GCTCTTGGGCACAGGCAGTGGGTGTAGAGGTAACCAGTAGCTTTGAGAAG
CTACATGTAGCTCACCAGTGGTTTTCTCTAAGGAATCACAAAGGTAAACT
ACCCAACCACATGCCACGTAATATTTCAGCCATTCAGAGGAAACTGTTTT
CTCTTTATTTGCTTATATGTTAATATGGTTTTTAAATTGGTAACTTTTAT
ATAGTATGGTAACAGTATGTTAATACACACATACATATGCACACATGCTT
TGGGTCCTTCCATAATACTTTTATATTTGTAAATCAATGTTTTTGGAGCA
ATCCCAAGTTTAAGGGAAATATTTTTGTAAA

Sequence ID - 706 nt: 496
CAACCCTCTCTCCTCAGCGCTTCTTCTTTCTTGGTTTGATCCTGACTGCT
GTCATGGCGTGCCCTCTGGAGAAGGCCCTGGATGTGATGGTGTCCACCTT
CCACAAGTACTCGGGCAAAGAGGGTGACAAGTTCAAGCTCAACAAGTCAG
AACTAAAGGAGCTGCTGACCCGGGAGCTGCCCAGCTTCTTGGGGAAAAGG
ACAGATGAAGCTGCTTTCCAGAAGCTGATGAGCAACTTGGACAGCAACAG
GGACAACGAGGTGGACTTCCAAGAGTACTGTGTCTTCCTGTCCTGCATCG
CCATGATGTGTAACGAATTCTTTGAAGGCTTCCCAGATAAGCAGCCCAGG
AAGAAATGAAAACTCCTCTGATGTGGTTGGGGGGTCTGCCAGCTGGGGCC
CTCCCTGTCGCCAGTGGGCACTTTTTTTTTTCCACCCTGGCTCCTTCAAC
ACGTGCTTGATGCTGAGCAAAGTTCAATAAAGATTTTGGGAAGTTT

Sequence ID - 707 nt: 397
CGGATGTGGTGGCAGGCGCCTCTAGTCCCAGCTACTCGGCAGGCTGAGGT
AGGAGAATGGCTTGAACCCAGGAGGTGGAGCTGACAGTGAGCCGAGATCG
CGCCACTGCACTCCAGCCTGGGCGGCAGAGCGAGACTCCATCTCAAAAAA
AAAAAAAAAAAAAATAGACTTTGAGACCAGCCTGACCAACATAGTGAAAC
CCGTCACTACTAAAAATACAAAAATTACCCGGGCGTGGTGACGGGCGCCT
GTAATCCCAGCTACTTGGGAGGCTGAGACAGGAGAATCACTTGAACCAGG
GAGGCGGAGGTTGTAGTGAACTGAAATCGTGCCCCTGCACTCCAGCCTGG
GTAACAAGAGCGAAACTCCGTCTCAAAAATAAATAAATAAATAAAAT

Sequence ID - 708 nt: 293
CCAGCTTTTTATGGTGTTTAATCTAATACACTTAAGCTGCAGTCCCAAAA
TTAGGGGTCCTTCAGTCTTGGAGACTATAAGGGAGCCTCTGCACCCAGGG
AAAATGTTACCCTTTACAGGGGGGAAGGGTAAACCAGTAGGGAATACAGT
ACAATCCCAACCCTACTGGGAGGGGCGGGAGGGAGGTGTTGCCGTCACTG
TATTAAGTCGATGTTGGGAAACGTTTTAACATCTGGAGCCTTTGTGGGTG
GAAATATGTCTCCAGTTACAACTCCGCAGTGGATGTGAAGAAG

Sequence ID 709
GGAAGCTACAATGATTTTGGGAATTACAACAATCAGTCTTCAAATTTTGG
ACCCATGAAGGGAGGAAATTTTGGAGGCAGAAGCTCTGGCCCCTATGGCG
GTGGAGGCCAATACTTTGCAAAACCACGAAACCAAGGTGGCTATGGCGGT
TCCAGCAGCAGCAGTAGCTATGGCAGTGGCAGAAGATTTTAATTAGGAAA
CAAAGCTTANCAGGAGAGGAGAGCCAGAGAAGTGACAGGGAAGCTACAGG
TTACAACAGATTTGTGAACTCAGCCAAGCACAGTGGTGGCAGGGCCTAGC
TGCTACAAAGAAGACATGTTTTAGACAAATACTCATGTGTATGGGCAAAA
AACTCGAGGACTGTATTTGTGACTAATTGTATAACAGGTTATTTTAGTTT
CTGTTCTGTGGAAAGTGTAAAGCATTCCAACAAAGGGGTTTTAATGTANA
TT

Sequence ID 710
TGGATTCCCGTCGTAACTTAAAGGGAAACTTTCACAATGTCCGGAGCCCT
TGATGTCCTGCAAATGAAGGAGGAGGATGTCCTTAAGTTCCTTGCAGCAG
GAACCCACTTAGGTGGCACCAATCTTGACTTCCAGATGGAACAGTACATC
TATAAAAGGAAAAGTGATGGCATCTATATCATAAATCTCAAGAGGACCTG
GGAGAAGCTTCTGCTGGCAGCTCGTGCAATTGTTGCCATTGAAAACCCTG
CTGATGTCAGTGTTATATCCTCCAGGAATACTGGCCAGAGGGCTGTGCTG
AAGTTTGCTGCTGCCACTGGAGCCACTCCAATTGCTGGCCGCTTCACTCC
TGGAACCTTCACTAACCAGATCCAGGCAGCCTTCCGGGAGCCACGGCTTC
TTGTGGTTACTGACCCCAGGGCTGACCACCAGCCTCTCACGGAGGCATCT
TATGTTAACCTACCTACCATTGCCCTGTGT

Sequence ID - 711 nt: 498
GTGGTACATATACACAAAGGAAAACTATGTAGCCATTAAAAGAAAAGGAA
CTCCTATCATTTGTAACAACATAAATAAATCTGGAGGAGATTAGGCTAAG
GTGAAATAAGCCAGGCACAAAAAGACAACTACCATATGATCTTACTTATA
CGTGTGTGGAATCTAAAAAGGTGGAATTTACAGAAGCAGAGAGTAGAATG
GTGATTACCAGAGGCTGGGGAGTGAGGGCAGGAGGTTGGAGAAATGTTGG
TCAAAGGATACAAAGTTTCAGTTATACAGGATGAATAAGTTCAAGAGATC
TATTGTACAACGTGGTGGCTATAGTTGATAACAATGTATTGTGTTCTTGA
AAAATGCTGAGAGAGTAGATTTTAAGTGTTCTCACCACAAAACATAAGTA
TGTGAGGTAATGCATGTGTTAATTANCTTAATTTAGACATTTCATAATGT
ATTATACATATTTCAAAACCACGTTGTACATGAGAAAGATACACAATT

Sequence ID 713
GCCCAGTCGACCCATGTTCTCCTTTCTACACCAGCATTAGACGCTGTCTT
CACAGATTTGGAAATCCTGGCTGCCATTTTTGCAGCTGCCATCCATGACG
TTGATCATCCTGGAGTCTCCAATCAGTTTCTCATCAACACAAATTCAGAA
CTTGCTTTGATGTATAATGATGAATCTGTGTTGGAAAATCATCACCTTGC
TGTGGGTTTCAAACTGCTGCAAGAAGAACACTGTGACATCTTCATGAATC
TCACCAAGAAGCAGCGTCAGACACTCAGGAAGATGGTTATTGACATGGTG
TTAGCAACTGATATGTCTAAACATATGAGCCTGCTGGCAGACCTGAAGAC
AATGGTAGAAACGAAGAAAGTTACAAGTTCAGGCGTTCTTCTCCTAGACA
ACTATACCCGATCGCATTCAGGTCCTTCGCAACATGGTCACTGTGCAGAC
CTGAGCAACCCCACCAAGTCCTTG

Sequence ID 714
CTGTAACAGAGATTCCTTTTTTCAATAATCTTAATTCAAAAGCATTATTA
GACTTGAAAGGGTTTGATAATCTCCCAGTCCTTAGTAAAGATTGAGAGAG
GCTGGAGCAGTTTTCAGTTTTAAATGAGTCTGCAGTTAATATCAAATGTG
AGTTTGGGACTGCCTGGCAACATTTATATTTCTTATTCAGAACCCTTGAT
GAGACTATTTTTAAACATACTAGTCTGCTGATAGAAAGCACTATACATCC
TATTGTTTCTTTCTTTCCAAAATCAGCCTTCTGTCTGTAACAAAAATGTA
CTTTATAGAGATGGAGGAAAAGGTCTAATACTACATAGCCTTAAGTGTTT
CTGTCATTGTTCAAGTGTATTTTCTGTAACAGAAACATATTTGGAATGTT
TTTCTTTTCCCCTTATAAATTGTAATTCCTGAAATACTGCTGCTTTAAAA
AGTCCCACTGTCAGATTATATTATCTAACAATTGAATATTGNAAATATAC
TTGGCTTACCTCTCAATAAAAGGGTCTTTTCTATT

Sequence ID 717
TCCACCCACCTTGACCTCCCAAAGTGCTGGGATTATAGGCGTGAGCCACC
TCGCCCAGCCCGATACTAGGACTTATGCAGAAAAAACCTTGACATGGAGG
AAAGTAAGATCTAAATAAATACTGTATTCATAGATTAAAAGACTCAGCAT
AATAAATATACCATTTCTCCCCAGATTGATGTACAGATTTAACACAATTC
CTATCAAGATCCCAGCAAGATTTTTGTAGATATGTAAAAGATTATTCAAA
AATGTAAAAGGAAGGACAAAGGACTAGAATAGATAAAACAAAATGGAGAA
AGATTTAATAGGAATCACTGTAACTGATTTTAAGACATACAGAACAATAA
TAGAAACTGCTTGTATTAGTCCATTTTCACGCTGCTGATAAAGACATACC
TGAGATTGGCAATTACAAAGGAAAGANGTTTATTGGCTTACAGTTCCCAT
GGCTGGGGAGGCCT

Sequence ID 718
CTCCTCTGGGTTGAAACCCGGGCGCCGCCAAGATGCCGGCTTACCACTCT
TCTCTCATGGATCCTGATACCAAACTCATCGGAAACATGGCACTGTTGCC
TATCAGAAGTCAATTCAAAGGACCTGCCCCCAGAGAGACAAAAGATACAG
ATATTGTGGATGAAGCCATCTATTACTTCAAGGCCAATGTCTTCTTCAAA
AACTATGAAATTAAGAATGAAGCTGATAGGACCTTGATATATATAACTCT
CTACATTTCTGAATGTCTGAAGAAACTGCAAAAGTGCAATTCCAAAAGCC
AAGGTGAGAAAGAAATGTATACGCTGGGAATCACTAATTTTCCCATTCCT
GGAGAGCCTGGTTTTCCACTTAACGCAATTTATGCCAAACCTGCAAACAA
ACAGGAAGATGAAGTGATGAGAGCCTATTTACAACAGCTAAGGCAAGAGA
CTGGACTGAGACTTTGTGAGAAAAGTTTTCGACCCTCAGAATGATAAACC
CAGCAAGTGGNGGGCTTGCTTTGTGAAGAGACAGTTCATGAACAANAGTC
TTTCAGGACCTGGACAGTGAAGGGAGCCCGGGCAGCCA

Sequence ID 719
CGNGGCCGCGTNAACTTTTGATCGTCAGCTGGGGCTGGCAGGCACCTAAA
TGGGAAGGGTGATAGCAGTGTGTTGGGGGGAGTTTAGGGAACGGTCCTCT
ACCGATAGAGGCAGCANCTCATTGGAATTTCCTCCTGAAGTTGTCTTGCC
CCTTGAATCCTGCAGGAAGGCTGGCAAATGGCCATTTCCCTTCCACTTGA
ATAGAGACCCATAACTCAAGTATCTGCCCTTAAGACACCACAGGACTGTT
CTTCGCGGGCCCTGCCCCTGGATTTGGGAGAGGCAGTCCANCTCACCCAA
CTAGGCTCTGCANGGGGACCANGAGGGATGGGTTGTGTCCACAGGACCAG
CCAGACTGATGAGGGATGCGGCAAGCATATTCTCACCACCTTCTTTCACG
TTTACAACANACCAGCNTTCCCTGTGTGGCAGGGGTTACATTGGTCACCG
AGGACCTANAATCATGGAGTGCTCTGGGGATCCGGGCTTGGA

Sequence ID 720
TCAGTGTTGAATTTTGTCAGACACTTTCTCTGCATCAATTGGTATGACCA
TGTGATTTTTTTTCTGTAGCCTGTTAATATGGTTAATTTTCAAATATTGA
GCTGATTAATTTTCAAATATTGAGCTCTCCTTGCATCTCTGGAATAAGTA
CCACTTGGTCGTGGTATATATTTCTTTTAATATATTGCTGAATTCTGTTT
GATCATGTTTTCTTAAAGACTTTCGTGTCTGTTTTCATGATAGATACTGG
TCTATAGTTTTGTTGTAATATCTTGGTTTGATTTTGATATCAGGATAATG
CTACCTTAATAGAATGAATTGGAGCCAAGTATGGTGGCAAATGCCTATAG
TCCTAGCTACTCAGGAGGCTGAGGTGGTGGGGACTGCTTGACCCANGAGT
TCAAATCTAGCTTGGGCAATGTAGCAAGAC

Sequence ID 721
TAGAAGGAATGACTATTCATGTCCAAAGTGAATGGTTTTGTGCAGTGAAC
AACACATGGCGAGGTACTAACTGAGAAACTTTTTCATGCTTTATGCCTAC
CTCTTGTAGTTGTTGCAGAGCAAATATAAATTGTAATAAGATAGCTAGGC
CTTGCAGAAACAAACAGAAAAACTTAAAAAAAAATGATATAAGAGCTGGA
GTCTAGTATTTATATGAATCTGTGAGAGATAATTTTTTTGGTCTCACTGC
AATGAACCAAAAGCGGCTGAGTTTGGTTTTTAATTGTAGCCATGTATTGA
AGGCATCTTTTTGACCAACTCTTGTTGGTTCTGTCTTGAACCATTGTTAA
TCACTGTGCTGTAATTAGTATAGCTAAATCTTTTCCTTCCTTGCTCCTCC
CCCAGCCCACCCCGTCTTCCCTTAACATTTTTTCAGGGGGGGTTGGGAGT
GGTTTCATTTTAATGTGAGTGGATGTTTTGATAGTTGTAAGGAAAAAATG
CATTTCAGACACATTTCACACATGAGCTATTTTCTTACACAGTATGTCTT
ATTGGTAATAAGAATGTAATTCAT

Sequence ID 722
CNTTCCNTAAGAATACAAAAAATTAGCTGGGCGTGGTGGCAGGCGCCTGT
AATCCCATCTACTCAGGAAGCTGAGGCTGGAGAATCGCTTGAACCCGGGA
GGCGGAGGTTGCAGTGAGCAGAGATCACGCCACTGCAGTCCAGCCTGGGC
AACAGTGCGAGACTCTGTCTCAAAAAAAAAATAAATAAATTACCTGGGTG
TGGCAGCGCGTGCCTGTAATCCCAGCTACCCAGGAGGCTGAGGCAAGAGA
ACTGCTTGAACCCAGGAGGCAGAGGTTGCATGGAGCTGAGATGGCGCCAC
TGCACTCCAGTCTGGTGACAGAGTGAG

Sequence ID 724
CTCTCTACTAAAAATACAAAAATTAGCTGGGCACGGNGGTGCATGCCTGT
AAACCCAGCTACCAGGTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAA
CCAGGGAGTCGGAGGTTGCGGCGAGCTGAGATCATGCCACTGCACTGCGG
CCTGGAGACAAGAGCAAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAA
AAAAAAGACNTCACCTAATTGCAGNGNGNGGACCTTATTTGGCTNTTAAT
TCAAACTATTAAAAATGTGAACN

Sequence ID - 726 nt: 260
CGGGGTCTGTACCGGGCTGGCCTGTGCCTATCACCTCTTATGCACACCTC
CCACCCCCTGTATTCCCACCCCTGGACTGGTGGCCCCTGCCTTGGGGAAG
GTCTCCCCATGTGCCTGCACCAGGAGACAGACAGAGAAGGCAGCAGGCGG
CCTTTGTTGCTCAGCAAGGGGCTCTGCCCTCCCTCCTTCCTTCTTGCTTC
TCATAGCCCCGGTGTGCGGTGCATACACCCCCACCTCCTGCAATAAAATA
GTAGCATCGG

Sequence ID 727
CTGAGTNTAGAAATGATGCCATTAATACTGATTGCAAAAACATTACAACT
CAGTACTGCAGCTTTCATTCAAATAGGTTATATGTATAAACTGAGTTCAA
CAATATTGTATTTGAGATGGTAAAGTTAAAGAAATGCAATAATGTAAATA
ATACTTAAGAAAATAAGATCTCAGGAAACTGTATATACTCTGTACTTTTA
TGCAACTTTATCAGATCATTTCAGTATATGCATCAAGGATATAGTGTATA
TGACATGAACTTTGAGTGCAAAAACTGTACTATGTACCTTTTGTTTATTT
TGCTGTCAACATCTAAATAAAGGTTTTTTTGTTTGTTTTTTGTTTTTTTA
ATTGTTTTGTTTTAAAGATTGTTTTAATTAATTAAAAAATTAATTGTTTT
AATTAAACAATTGTTTAATTGTTTTAAAGTCGCCAGGCTGAGGCAGGTGA
ATCACAAGCTTAGGAGTTGGAGGCTAGCCTGCCAACATGGTGAAACCCCG
TCTCTACTAAAAATACAAAAAAATTAACTGGGTGTGGG

Sequence ID 728
CCCATCTGCACCAGTACACAGGCAGGCATTATCATTCTTCACCTACTTTT
TAAATAGTGGCAACTTGGGATTCATTCTGGTGATTCTGAACCTTGCCTCA
TAGCTTAAAGTATAAAAAAGATTCAAGAGCAGTGAGGTTTGTTCTTTCCA
GTGAATGGTGGACTGAGTGGTGCGAGGTGGAGGGCTAACAAGAGGAAAGA
ACTACATTCTTCAGAATACAGTGATGAAAATTCATTTTGAAACTCAAATA
TTTTCATTTTGGATATTCTCCTGTTTTTATTAAACCAGTGATTACACCTG
GCCATCCCTCTAAATGTTCTAGGAAGGCATGTCTATTGTGATTTTGATGA
AGACAGAATTATTTTTCTCTGTAGAAACACAGATACCACTTTATCAGGGG
AAGTTAGTCAAATGAAATGGAAATTGGTAAATGGACAAAAGCTAGCTAGT
AAAAAGGACGACCCAGCAACATGCTTTAACCCCATTGTATGTTTGTGGAA
AGAGCATAGTTTAACATCTTGAGAAATTTGGGACATAAAAGTTTTCATNG
GTAGACAGTTCATGGCAGTATATGAATTGACATAATGGAAATAATCTGAT
TTTATTTTTACAACTAACATCCTTTCCCC

Sequence ID - 736 nt: 641
GGAATTCCAAGTGCTTGGGGATAATGATACCTCTGACCTTTCTTCCTTTT
GGGAAGTACTTGAGTGTGCAGCTGCATGAGGCCTCAGCAGGAGAGAGATT
TTAGGTCCAAGAAGCTATACCAGTAGGACAAGGCAGGAAAATACTACACT
TTCAGGATCAAGCCCCTCTGACTCTCATTTGGAAACTGGATGTTTGCTAA
GCACCTGCTTCTTAAGGATGCCGAGGGATTTAATGATACTCCCAGAAACC
TGGAGAGATTAATGGGGCCTATGGAGAAGTGCTCTGAACTCAGTGTTGGG
ACTTGAATAAAATTAACCATTGTCATGTTTTCAGAACAACTAAGCTGTTT
TATATTTCATGTGCATGAAAGCCCTAGAACTAAGTTGTGTTATTTCCAGA
AATGAAATAGATCCCACAGTTAGATGATGTGGCCATTAGGAAGTACCAAA
TTTATAAAAATCACTGGAGGTCTGTCTGAGCAGTACCTAATAAAATATAG
TATACTGAAAGTGAACAGATACTTTGTCTCTTTCTTTGGCTGCTTGATCT
TTATCTGTGTCTGCCGTACAGTGCACCCTTAAAGTATTCTACACCAGTGC
TTCTCAAACTGGAAATGTGCATGTAAGTCACCCANGGGTCT

Sequence ID 739
TGCATGCCCATAGTCCCAGCTATTTGGGAGGCTGAGGCAGGAAAATCGCT
TGAACCCGGGAGCCAGAGGTTGCAGTGAGCCGAGATCGCACTCCAGCTTG
GCGACAGAACAAGACTCTGTCTCAAAAAAAAAAAAAAAAGAAATCTTGGG
ATCCTGAACCCCTTACTCGAAGGGCTAAGGTAGCATCTCAGCATGTCTTA
TTCGAGACTTCGTANAACCAGACCTGCTGTTTGTAGATGTTAATTAATCA
AACCTTTCTCTACTCATTCTGGACCAGTTAAGGTTTTCTCCTTCTCCGTA
TGAGTTTTGATTTTCGTCCTCCTTGGTTGGAGATCACACTTTGGTCTGCT
GCTAAGTTGGATGCCTCCCACTGTCTTTCCCTAAGTCTAGGGCTTCANAC
CCCAGTGTGGGGAGAGGGACTTTCGTTTCCTGCCCCTCACCACATCAGAC
ACAGGCAGGCAAGAATAAGATGGCCAAAAGGCCGATGAACTTCTTGACCT
AGCCTGGGACATTACCTGTTACTAGGTGGACTTCACTGCCTGTGAATGGA
AGCTGAAGGGCTGTTTTTTTGGTTTGTATTTGGAGAGGCCAGGCTTANAG
AGGGAGAGAACTGGGCTACTCTTCAGCAGTGATCTTTAAAATGCC

Sequence ID 747
CAGAGTGCAAGACGATGACTTGCAAAATGTCGCAGCTGGAACGCAACATA
GAGACCATCATCAACACCTTCCACCAATACTCTGTGAAGCTGGGGCACCC
AGACACCCTGAACCAGGGGGAATTCAAAGAGCTGGTGCGAAAAGATCTGC
AAAATTTTCTCAAGAAGGAGAATAAGAATGAAAAGGTCATAGAACACATC
ATGGAGGACCTGGACACAAATGCAGACAAGCAGCTGAGCTTCGAGGAGTT
CATCATGCTGATGGCGAGGCTAACCTGGGCCTCCCACGAGAAGATGCACG
AGGGTGACGAGGGCCCTGGCCACCACCATAAGCCAGGCCTCGGGGAGGGC
ACCCCCTAAGACCACAGTGGCCAAGATCACAGTGGCCACGGCCACGGCCA
CAGTCATGGTGGCCACGGCCACAGCCACTAATCAGGAGGCCAGGCCACCC
TGCCTCTACCCAACCAGGGCCCCGGGGCCTGTTATGTCAAACTGTCTTGG
CTGTGGGGCTAGGGGCTGGGGCCAAATAAAGTCTCTTTCCTC

Sequence ID - 757 nt: 583
GAACCCTGCGGAGGGACTTCAATCACATCAATGTAGAACTCAGCCTTCTT
GGAAAGAAAAAAAAGAGGCTCCGGGTTGACAAATGGTGGGGTAACAGAAA
GGAACTGGCTACCGTTCGGACTATTTGTAGTCATGTACAGAACATGATCA
AGGGTGTTACACTGGGCTTCCGTTACAAGATGAGGTCTGTGTATGCTCAC
TTCCCCATCAACGTTGTTATCCAGGAGAATGGGTCTCTTGTTGAAATCCG
AAATTTCTTGGGTGAAAAATACATCCGCAGGGTTCGGATGAGACCAGGTG
TTGCTTGTTCAGTATCTCAAGCCCAGAAAGATGAATTAATCCTTGAAGGA
AATGACATTGAGCTTGTTTCAAATTCAGCGGCTTTGATTCAGCAAGCGAC
AACAGTTAAAAACAAGGATATCAGGAAATTTTTGGATGGTATCTATGTCT
CTGAAAAAGGAACTGTTCAGCAGGCTGATGAATAAGATCTAAGAGTTACC
TGGCTACAGAAAGAAGATGCCAGATGACACTTAAGACCTACTTGTGATAT
TTAAATGATGCAATAAAAGACCTATTGATTTGG

Sequence ID - 758 nt: 424
CTTGGCTCCTGTGGAGGCCTGCTGGGAACGGGACTTCTAAAAGGAACTAT
GTCTGGAAGGCTGTGGTCCAAGGCCATTTTTGCTGGCTATAAGCGGGGTC
TCCGGAACCAAAGGGAGCACACAGCTCTTCTTAAAATTGAAGGTGTTTAC
GCCCGAGATGAAACAGAATTCTATTTGGGCAAGAGATGCGCTTATGTATA
TAAAGCAAAGAACAACACAGTCACTCCTGGCGGCAAACCAAACAAAACCA
GAGTCATCTGGGGAAAAGTAACTCGGGCCCATGGAAACAGTGGCATGGTT
CGTGCCAAATTCCGAAGCAATCTTCCTGCTAAGGCCATTGGACACAGAAT
CCGAGTGATGCTGTACCCCTCAAGGATTTAAACTAACGAAAAATCAATAA
ATAAATGTGGATTTGTGCTCTTGT

Sequence ID - 764 nt: 626
GATTTTTTTTTTTTTTTTGAGATGGAGTCTTTCTCTGTCGCCCAGGCTGG
AGTGCAGTGGTGAAATCTCGACTCACTGCAACCTCCGTCTCCTGGGTTCA
AGCAATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCACCAG
CCACCACGCCCGGCTAATTTTTGTATTTTTAGTAGAGACAGGTTTTCACC
ATGTTGGCTAGGCTGATTTTGAACTCATGACCCCAAGTGATCTGCCCGCC
TCGGCCTCCCAAAGTGCTGGAATTACAGGTGTGAGCTACCACTCCCAGCC
AATGATTACATTTATAAGGTAAAATAACTTGTGCCAATCTGTACAAGTGA
ATTCAGATTTAAAATTTTAATTGTAAAAAGATATCCAGGTGATATTTCTC
CCTGAATAATTTAGTTTCCTTTTCTATTTCTTGATATAAAAGTACTCAGC
ATTGAAGTAATTGCTATCTTCACATTTCTTCCTATTTGAGCTGTCTAAAT
AAGTAGTCCTACATATTTTCCCCCCAACACAAAAAACCCAGAAAAGAATT
ATTTTATACTGGATTTTTTTGGTTGTAGCAGGAACCTAAAGGNGCCAATT
GTAACATGCATGTTCTTTTTGGCAAA

Sequence ID 766
GTCCATCCTGCAGGCCACAAGCTCTGGATGAGGAACTTGAGGCAAGTCAC
CAGCCCCTGATCATTTCGCCTAAAAGAGCAAGGACTAGAGTTCCTGACCT
CCAGGCCAGTCCCTGATCCCTGACCTAATGTTATCGCGGAATGATGATAT
ATGTATCTACGGGGGCCTGGGGCTGGGCGGGCTCCTGCTTCTGGCAGTGG
TCCTTCTGTCCGCCTGCCTGTGTTGGCTGCATCGAAGAGTAAAGAGGCTG
GAGAGGAGCTGGGCCCAGGGCTCCTCAGAGCAGGAACTCCACTATGCATC
TCTGCAGAGGCTGCCAGTGCCCAGCAGTGAGGGACCTGACCTCAGGGGCA
GAGACAAGAGAGGCACCAAGGAGGATCCAAGAGCTGACTATGCCTGCATT
GCTGAGAACAAACCCACCTGAGCACCCCAGACACCTTCCTCAACCCAGGC
GGGTGGACAGGGTCCCCCTGTGGTCCAbCCAGTAAAAACCATGGTCCCCC
CACTTCTGTGTCTCAGTCCTCTCAGTCATCTCGAGCCTCCGTTCAAAATG
ATCATCATCAAAACTTATGTGGCTTTTTGACCTTTGAATAGGGAATTTTT
TAAAATTTTTTAAAAATT

Sequence ID 768
CCAGCGCAGGGGCTTCTGCTGAGGGGGCAGGCGGAGCTTGAGGAAACCGC
AGATAAGTTTTTTTCTCTTTGAAAGATAGAGATTAATACAACTACTTAAA
AAATATAGTCAATAGGTTACTAAGATATTGCTTAGCGTTAAGTTTTTAAC
GTAATTTTAATAGCTTAAGATTTTAAGAGAAAATATGAAGACTTAGAAGA
GTAGCATGAGGAAGGAAAAGATAAAAGGTTTCTAAAACATGACGGAGGTT
GAGATGAAGCTTCTTCATGGAGTAAAAAATGTATTTAAAAGAAAATTGAG
AGAAAGGACTACAGAGCCCCGAATTAATACCAATAGAAGGGCAATGCTTT
TAGATTAAAATGAAGGTGACTTAAACAGCTTAAAGTTTAGTTTAAAAGTT
GTAGGTGATTAAAATAATTTGAAGGCGATCTTTTAAAAAGAGATTAAACC
GAAGGTGATTAAAAGACCTTGAAATCCATGACGCAGGGAGAATTGCGTCA
TTTAAAGCCTAGTTAACGCATTTACTAAACGCAGACGAAAATGGAAAGAT
TAATTGGGAGTGGTAGGATGAAACAATTTGGAGAAGATAGAAGTTT

Sequence ID 773
GAGGAAAGGGGAGTTAATATTTAGTGGACAGAATTTCAGTTTTACAGATG
AAAAGAGTTCTGGAGATAGACGGTGTTGATAGTTGCACAGCAGTGTGAAT
GTGCTCATTGTTACCGAACTTAAAAATGTTTAACATAGTATTATGTGATT
TTTATTTTGCCACTTAAAAAAAAAGAATGAAGTACTGATACATGCTACAA
CATGGGTGAGCTTTAAATACATTCTGCTCAGTGAAATAAGCCAGATGCAA
AAGATCACATATTATATAATCCACTTATACGAGATACCTAGAATAGGCAA
ATTCATAGAGACAGAAAGTAGAATAGTGGTTCCCAGGGGCTGGGGACAAG
GGGGCAGTGAGAGATTGAGAGTTATTATTAATGCGTACAGAGTTTCAGTT
TGGGCTGATAAAAAAGTTCTGAAGATGGATGGTGATGATGGTTGTACATC
AATGTGAGTGTAATTACCGCCACTGAACTGCCCTTAAAAACGTTTAAAAG
AGTAAATTTTATGTTGNGTATATTTTACCATAAT

Sequence ID 776
TTTTTTTTTCATAAGAGGCAAGTACAAGAAAAAGCTTAATTACTTTAACT
TCTAAGTAGTTTGGAATCTAAATAAATAGGAGTTACCAAATATATGCGCT
TCTGTGAATAGTTTTCCCCCACATGTTTATTTATATTTTTGCATCTCATC
AAACCTAACAGATTCTAAAGTCTCTGGTGATAATGACAATATCTGCTACG
GAGAGACTAGCCTGGGGGAAGAGGATCTCCCTGAACAAGGATAGCGGAGT
TGCTGCAGCTTTCAAATGAAGCTGGACATTTAGCTGCGGGGGTAGCACCC
TTTGATCAAGGCAGCCCAAAGATGAGTTTCAGGGATGGGACTGACAGAAG
AGAAAAGTTCTTCCCAGCCCTTTCTACTTTTTCTCTTTGTTTCTCAGGCT
TCTGGCCGTCTTCAGTTTTCACAAGTTTCACTCTCAACCCTAAACAGTAC
TTCTGTGAAGTACCCTTTGGCCCCTCGTTTTCAGCTCCTAAACTCACCTG
GAAATAGATGTCAATCTAATTTTGGGTCTGACTAGTGCAGTAGGCATTTT
TGGTGA

Sequence ID 782
CTCACACAGAACAAAAATGAATGAGTGTGGCTGTGTGCCACTATCACTGT
GTCTACAAAAACAGCCAGTGGGCCTGATTTGGCCCTTGGCTGCAGTGCGC
CCGTCTCTGTTTTTGAGGAATAAAATCGCATCATTTCATATGGCTAATGC
AATTTTTTTCCCATCTGGAAGCAACATCTGATTGGACTCATCTTGTATGG
TGCTTGTTACAGTCTCTGTAAATGGGAGAGGGTCCGAGAATAGCTCTTCC
TGTTTTCATCAGGACTGTTTTTAGGGATGGCAAAGAAGTCAGTGTGTCCA
GCCTGTGTCCTCCTCACCACGTGGCTGATTCCTGAATCTGCATGTGCANC
ACNTGCCGTTGTCTGGGGCATGATCTGTGTGA

Sequence ID - 785 nt: 556
CTTTTCTCTGGGTATAGATTTACCCTAGCACCTATCTCATTATATTGAAT
TTTCCAGCATATTTAAATAAACTATTAATTAGTCACACTATTTCTTAAAA
GTCACACTATCAACTAATCGTGACCGCAATTATCTAGGGGTGATAATCTG
CTGAGTCTACTCTTTAAATACACTGGGACCCAGCATATTGAGTTATATTG
GCACAGAAACTTCACTCTGGGTATAGATTTACCCTAGTACCTTGCCGGCA
GGATCCTATTATTCATGGTTGTACAAGCAAGGTTCAGGGAAGAGGCTGGC
ACAGAGAAGGTACCTGGTAACTGTTGTTTGAGGCTGAATTCAGCTCAACT
CAGCTCCAGTAGAGATGGTGTCCCCTTCTCTACCGTGTTGAGATAGTGTG
CAGTCCCTTCCTAAGGGCTGTTACCCACCGCAATAGGACTTGTCAGCTTC
AACTTTTAAATTTCTCTGCTCCCGCTGGGACCCACCCGCTTCAAAAATCA
TCATGGNGGNTTTAGCACCAATTTAGTAAACACAAACTGTCTGAAATATT
TTGGAT

Sequence ID 796
GAACATTCAAGATAGTGAGAGGAAGAAAAAGATATGGCTGTACGGGACCG
AGGTCTCTTCTATTATCGCCTCCTCTTAGTTGGCATTGATGAAGTTAAGC
GGATTCTGTGTAGCCCTAAATCTGACCCTACTCTTGGACTTTTGGAGGAT
CCGGCAGAAAGACCTGTGAATAGCTGGGCCTCAGACTTCAACACACTGGT
GCCAGTGTATGGCAAAGCCCACTGGGCAACTATCTCTAAATGCCAGGGGG
CAGAGCGTTGTGACCCAGAGCTTCCTAAAACTTCATCCTTTGCCGCATCA
GGACCCTTGATTCCTGAAGAGAACAAGGAGAGGGTACAAGAACTCCCTGA
TTCTGGAGCCCTCATGCTAGTCCCCAATCGCCAGCTTACTGCTGATTATT
TTGAGAAAACTTGGCTTAGCCTTAAAGTTGCTCATCAGCAAGTGTTGCCT
TGGCGGGGAGAATTCCATCCTGACACCCTCCAGATGGCTCTTCAAGTAGT
GAACATCCAGACCATCGCAATGAGTAGGGCTGGGTCTCGGCCATGGAAAG
CATACCTCAGTGCTCANGATGATACTGGCTGTCTGTTCTTAACAGAACTG
CTATTGGAGCCTGGAAACTCAGAATGCAGATCTTTTGTGAACAAAATGAA
GCAAGAACCGGAGACNCTGAATAGTTTTATTTCTGTATTAAAAACTGNGA
TTGGAACAATTGAAGA

Sequence ID 801
CCACTCCACCTTACTACCAGACAACCTTAGCCAAACCATTTACCCAAATA
AAGTATAGGCGATAGAAATTGAAACCTGGCGCAATAGATATAGTACCGCA
AGGGAAAGATGAAAAATTATAACCAAGCATAATATAGCAAGGACTAACCC
CTATACCTTCTGCATAATGAATTAACTAGAAATGAGGATTCTGACCTTGA
CTTTGATATCAGCAAATTGGAACAGCAGAGCAAGGTGCAAAACACAGGAC
ATGGAAAACCAAGAGAAAAGTCCATAATAGACGAGAAATTCTTCCAACTC
TCTGAAATGGAGGCTTATTTAGAAAACAGAGAAAAAGAAGAGGAACGAAA
AGATGATAATGATGATGAGTCAGGTAAAAGTTCCAGAAATGTGAACAACA
AAGATTTTTTTGATCCAGTTGAAAGTGATGAAGACATAGCAAGTGATCAT
GATGATGAGCTGGGTTCAAACAAGATGATGAAATTGCTGAAGAAGAAGCA
GAAGAAGGAAGCATTTCTGAAATATGAATGAAAAAAATTACATCTTTAGA
AAAAGAGTTATTAGAAAAAAGCCTTGGCAGCCGTCNGGGGGAAGTGACGC
ACAGAAGAGACCAGAGAATAGCTTCCTGGANGAGACCCTGCACTTTACCC
ATGCTGCTGGATGG

Sequence ID - 808 nt: 641
CCGGGTTTTAGTATTTAACCAAGAGCCTTTTAAATATTGAAAACCCATAG
TTCAGAAAATGTTAGTATTGCTGCCCTTCTTCACATAAATTTTTTTTTAA
ATTATACTATTATTTTGCTTAATTTTATATTGGGTTAAAACAACCTTCAA
GAAGGTTAACTAGGAAAGAAGACCTTTTTGTTTTATTTTTACTATTTATA
TATAGAAGACAAATCAGCATTTGGTGATAGTTTTACATGACCAGTTATCA
AACGGTCATAGTATGAAGTGTGCAGTTGTTCATTATTAGTAAATTATGTT
TGATTTTTAAACTATTTAGTACTAATAGTTGAGATGAAAACTGAAGAAAA
ATGCCAATGTGACGTTTGTGTATAGCTAGCCTTAAAAAACTTCCCATGTT
TTTAGGTGACTTTTTTCCCCCTCTTAGTACTCTGGAGAAACAATGAAGAT
GGGCCATCTCAATTCCAGATGTAAACAAAAAGTAATTTTTATTTCAACAT
TTAATGTAACTGCTATTATTGNGGATTCTTGNCTTGNGTATTTTCTTTCC
CTTATTCAAGTAATATAGAATAACTTTCCTTAAAATGATTTGATCCAAGA
TACGTCATTTCTGTATTGGCAAAATGCCNCTATTAAAGTGT

Sequence ID - 814 nt: 132
GTTAAAGTGATACATTTTTATACCAAATGTGTTTATTTTTTTGTGCAAGT
AATCCTTAAAATTGCAATTGTATTAGGTGTTAAAATAAAGTTTTTAAAAA
ATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID 817
GACAACCTTAGCCAAACCATTTACCCAAATAAAGTATAGGCGATAGAAAT
TGAAACCTGGCGCAATAGATATAGTACCGTAAGGGAAAGATGAAAAATTA
TAACCAAGCATAATATAGCAAGGACTAACCCCTATACCTTCTGCATAATG
AATTAACTAGAAATAACTTTGCAAGGAGAGCCAAAGCTAAGACCCCCGAA
ACCAGACGAGCTACCTAAGAACAGCTAAAAGAGCACACCCGTCTATGTAG
CAAAATAGTGGGAAGATTTATAGGTAGAGGCGACAAACCTACCGAGCCTG
GTGATAGCTGGTTGTCCAAGATAGAATCTTAGTTCAACTTTAAATTTGCC
CACAGAACCCTCTAAATCCCCTTGTAAATTTAACTGTTAGTCCAAAGAGG
AACAGCTCTTTGGACACTAGGAAAAAACCTTGTAGAGAGAGTAAAAAATT
TAACACCCATAGTAGGCCTAAAAGCAGCCACCAATTAAGAAAGCGTTCAA
GCTCAACACCCACTACCTAAAAAAATCCCAAACATATAACTGAACTCCTC
ACACCCAATTGGACCAATCTATCACCCTATAGAAGACTAATGTTAGTATA
AGTAACATGAAAACATTCTTCTNCGCATAAGCCTGCGTCAGATTAAAACA
CTGAACTGACAATTAA

Sequence ID - 821 nt: 370
AAAGAGCTCCCAAATGCTATATCTATTCAGGGGCTCTCAAGAACAATGGA
ATATCATCCTGATTTANAAAATTTGGATGAAGATGGATATACTCAATTAC
ACTTCGACTCTCAAAGCAATACCAGGATAGCTGTTGTTTCANAGAAAGGA
TCGTGTGCTGCATCTCCTCCTTGGCGCCTCATTGCTGTAATTTTGGGAAT
CCTATGCTTGGTAATACTGGTGATAGCTGTGGTCCTGGGTACCATGGCTG
GTTTCAAAGCTGTGGAATTCAAAGGATAAATTAATGAAGAAAACAAGCGG
AGCTGAAGAAGAAAGTACAATATGGTGCTGTCTTCCTAATGAAATAAATT
CACTAAATGGACATTAAAAA

Sequence ID 825
AGACTCGAGCAAGCTTATGCATGCATGCGGCCGCAATTCGAGCTCGGCCA
CTTGGCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCG
TTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGC
CTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCG
CACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGAAAT
TGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCA
GCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCA
AAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAG
TCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCT
ATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTG
GGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCG
ATTTAAAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AAAAAGCCAAANGGAGCCGGCGCTAGGGCCTGGCAAGTGTACGGGCACGC
TGCGCGTAACCACCCACACCCCGCCGNGCTTAATGCCCCNTTCAGGGCGC
GTNCTGATGCCGNATTTTNTCTTACNCATNTGTGCNGGNTT

Sequence ID 833
TAAAATAATGGCAAAAAACAAACAAAAAACAAGTTCTCTAAACAGAAAGG
AAATTACTAAAGAAGGAATCTTGAAATAACAGGAAAGAGGAAATACCACA
GTAGGCAACATTATGGGTAAATAAAACAGACTTTCCTTCTTTAGTTTCCT
AAAATATGTTTGATGATTAATGCAAAAATTACAATATTTTCTTATGTAGC
ACTAAAGGTATGTAGAGAAAATATTTAAGATAATTGTACTGTAAGCGGGA
GATGACAGTGACATAAAGGCAACGTTTTTATACTTCACTCAAACTTTATG
TATTAATGTAATCCATAAAGCAACCAAAAAAGCTATACTAAGTACATTCA
AAAACACAATAGATAAACCAAACAAAATTCTAAAGGATGTACAAGTAACC
CACTGGAAGCTGCAAAAAATGTAAACAGAAACTAAAAACAGAGAATAAAT
GAAAAATTAAAAACGAAATGGCAGACTTAGGCCCTAATATACAAATTATC
ACATTAAATATAAATGGTCTAAATACACCAACTGTAAGACAGAGATTAGC
AAAGTCGATTTAAAAACATGACTCAACTACGTGCTGTCTACAAGAAACTC
ACTTCAAATATACCAAGATAGGAAGGTTGAAAGTAAAACGATGGAAAAAG
ATGTATCATGTGAACATTAATCAAAGGAAAGCAGGGGTGGCTATATTAAC
ATCAGGTAAAATAAACTTT

Sequence ID - 837 nt: 603
TGAGGNTGGTCATGATGCANAAGCTACTCAAATGCAGTCGGCTTGTCCTG
GCTCTTGCCCTCATCCTGGTTCTGGAATCCTCAGTTCAAGGTTATCCTAC
GCGGAGAGCCAGGTACCAATGGGTGCGCTGCAATCCAGACAGTAATTCTG
CAAACTGCCTTGAAGAAAAAGGACCAATGTTCGAACTACTTCCAGGTGAA
TCCAACAAGATCCCCCGTCTGAGGAGTGACCTTTTTCCAAAGACGAGAAT
CCAGGACTTGAATCGTATCTTCCCACTTTCTGAGGACTACTCTGGATCAG
GCTTCGGCTCCGGCTCCGGCTCTGGATCAGGATCTGGGAGTGGCTTCCTA
ACGGAAATGGAACAGGATTACCAACTAGTAGACGAAAGTGATGCTTTCCA
TGACAACCTTAGGTCTCTTGACAGGAATCTGCCCTCAGACAGCCAGGACT
TGGGTCAACATGGATTAGAAGAGGATTTTATGTTATAAAAGAGGATTTTC
CCACCTTGACACCAGGCAATGTAGTTAGCATATTTTATGTACCATGGNTA
TATGATTAATCTTGGGACAAAGAATTTTATAGAAATTTTTAAACATCTGA
AAA

Sequence ID - 839 nt: 71
ATTTATCTAATATTTGGTTTAATAAAATGTGAATAATGAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAA

Sequence 849 nt: 622
TTTTTTTTTATTTTTTGAGAATGGAGTCTTGCTCTGCCGTCCAGGCTAGA
GTTCAGTGGTGCGATCTCAGCTCACTGCCACCTCACCTCCTAGGTTCCAG
AGATTCTTGTGCTTCAGCCTCCTCAGTAGTTGAGAATACAGGAACACGCC
ACCACGCCTAGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCAT
GTTGGCCAGGCTGGTCTCAAACTCCTGGCCTAAGTGACCCACCTGCCTCA
GCCTCCCAAAGTGCTGGGATTATAGGCGTGAGTCATTGTCCCCAGCCGGA
TGTTTTCATCTTGATTTGCCTTAGTTTCTAAATCTCATCCTCTCCATTTT
CTCCTGTTAGTAGTCACAGAGAACCAAATTCTGTCAAGTTATGAAACTAA
AGTCTCTCTTCCACAAGTCTTCCTGTGTTCTGCCTCAAGTGAACTTGAAA
GAACATCAGTTTGTGGGAAGGTTGAAGACCGAATGATCTGCTGGGAAATC
ACTGAGGCATTGCCATTCTCTTGAGGAATTTCATTTTCATCGAAGTTTCG
GTTTATATCCCTTTCTTGGTGAGTACTATTGCTGTTATGTAAATTAAATG
AGTCGTCATCCTTCTTNTGAGC

Sequence ID - 860 nt: 501
GTGAAATCACTTTCATGGATTATTAATGGATTTAAGAGGGCATCAATCAG
CTCAACTCAAGATTTCATAATCATTTTTAGTATTTAGATTGTGCCTCAAA
GTTGTAGTACCTCACAATACCTCCACTGGTTTCCTGTTGTAAAAACCTTC
AGTGAGTTTGACCATTGTGCTCTTGGCTCTTGGGCTGGAGTACCGTGGTG
AGGGAGTAAACACTAGAAGTCTTTAGTACAAAACTGCTCTAGGGACACCT
GGTGATTCCTACACAAGTGATGTTTATATTTCTCATAAAGAGTCTTCCCT
ATCCCAAGGTCTTCATGATGCCAGTAGCCATATATGATAAATTATGTTCA
GTGATAACTTAGTTATCAGAAATCAGCTCAGTGGTCTTCCCCGCCATGAT
TCACATTTGATGAGTTTTTAAAAATCAAAGTGATTTTGAAAATCTCTAAT
GGCTCAGAAAATAAAAACATCCAGTTTGTGGATGACTATATTTAGATTTC
T

Sequence ID 864
TTGTGTTTTTAGGACTCCTTATCTAAATTAAGGCAGAGAAGTTACAGTAT
TTATATCTGCATTAAATCTCAATTCCAGAAAAACCTTTTGAAAAATTATT
TAATCCTCTGGAAACTATTGATATGATACAGGAGAAATTTTCAGAAGTTT
ATTGAATAATTTAATATCATTTAATAGGACACTCTGGCTTGTATATAAGC
AGATACGTTACTCAGACTTCTTGGCTGTACTCTAAAATAATATATGTACT
AGTCTCCTAAATATTACTAGCTCACCTTTCAAAATGCATACTAATATTTC
AATGTCTTTCTTCAATTTGAAAAGCTCTTGAATATCTACTTGTGATAGCC
CTAAGAGCTGAGATAATTATTTCCAGGAGGTTGAATCCCTGATTCTTAAC
TGTTCAGCAATGCATAAGCAAGAGAGAATATGACATAAGAGGACCATTTC
TACATTAGCCATTTTTTTTCACAAGATACCTATGTGAATACAGGGCACCT
GGGAGGGTAAGTGGAGGACTATTTCTAACTATATTTATAAGCACATACTG
ATATTGGTGAATCAAAACCTACAGCAGTGCTTCTCAGATGGGAAGGGAGA
CAATGTGTAAGGAGATCAGGAATTCATTAG

Sequence ID - 865 nt: 122
CCANAATCCACTCTCCAGTCTCCCTCCCCTGACTCCCTCTGCTGTCCTCC
CCTCTCACGAGAATAAAGTGTCAAGCAAGAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID 867
TTTTTTTTTTTTTTTTTTTCAGAGTCACAGATATTGTATAGCTGAGGTAA
GCATTTTACAACTTTTCAGACACAAGTAAGTACATAAATATTATTTTACA
ACCAACAATNTTTAATATTTCCACATTGAANAATAGATGTGATAATTAAA
TCTTTTATAAGGTTTTAAAAAGACATGAAACATAAACCTAATTATACATA
AAAGAAAAGAATTTTAAACAAGAGCTTATTGNGATGACATTACTCATAAC
TTTTACCTTTAAAACCTTTTCTTGGGTAGCTATTCAAAAGTAAAGACCAC
AAGTTTTGTTGCCCANATTTCTTATGTTTNGTATATTTAAGCTCTTTATT
TATTGAACAGATGNGTCATTAATTCATTNGGAGCATTACTATTATCAGTA
AAATTTGATTTTTTTTTCCCCTCAGTCATAGGTAAATCAGCTCCACCTGG
AATTTCTAAGGACCCAGTTTTAGTCAATATTTTCAAGTAATCATGACCTC
AGAAATAGTCTTAATTAAGATAACAAATATTAGCCATCAAAATGGAACCA
AGACAAGATTCTAATGTTTGTAAACAGTCAATCCATATTTATGAATATTA
GCATATATTGGNGAATAGTTAAGGCAAAAGGGTCTAGCAG

Sequence ID - 869 nt: 667
TTGTGTTTTTAGGACTCCTTATCTAAATTAAGGCAGAGAAGTTACAGTAT
TTATATCTGCATTAAATCTCAATTCCAGAAAAACCTTTTGAAAAATTATT
TAATCCTCTGGAAACTATTGATATGATACAGGAGAAATTTTCAGAAGTTT
ATTGAATAATTTAATATCATTTAATAGGACACTCTGGCTTGTATATAAGC
AGATACGTTACTCAGACTTCTTGGCTGTACTCTAAAATAATATATGTACT
AGTCTCCTAAATATTACTAGCTCACCTTTCAAAATGCATACTAATATTTC
AATGTCTTTCTTCAATTTGAAAAGCTCTTGAATATCTACTTGTGATAGCC
CTAAGAGCTGAGATAATTATTTCCAGGAGGTTGAATCCCTGATTCTTAAC
TGTTCAGCAATGCATAAGCAAGAGAGAATATGACATAAGAGGACCATTTC
TACATTAGCCATTTTTTTTCACAAGATACCTATGTGAATACAGGGCACCT
GGGANGGTAAGTGGAGGACTATTTCTAACTATATTTATAAGCACATACTG
ATATTGNTGAATCAAAACCTACAGCAGTGCTTCTCAGATGGGAAGGGAGA
CAATGTGTAAGGAGATCAGGAATTCATTAGTCACCTTTCAGATGGTTTAA
TGCATACAGCTGTACCG

Sequence ID 870
GGAGTTTGAGCAGATCCTTCAGGAGCGGAATGAACTCAAAGCCAAAGTGT
TCCTGCTCAAGGAGGAACTGGCCTACTTCCAGCGGGAGCTGCTCACAGAC
CACCGGGTCCCCGGCCTTCTGCTCGAGGCCATGAAGGTGGCTGTCCGGAA
GCAGCGGAAGAAGATCAAGGCCAAGATGTTAGGGACACCAGAGGAAGCAG
AGAGCAGTGAGGATGAGGCTGGCCCATGGATCCTGCTCTCCGATGACAAG
GGAGACCATCCCCCACCCCCGGAGTCCAAAATACAGAGTTTCTTTGGCCT
ATGGTATCGGGGTAAAGCTGAATCCTCTGAGGATGAGACCAGCAGCCCTG
CACCCAGCAAGCTAGGGGGAGAAGAGGAGGCCCAACCACAGTCTCCAGCT
CCTGATCCGCCCTGTTCTGCCCTCCACGAACACCTTTGTCTGGGGGCCTC
AGCCGCCCCAGAGGCCTGACTTAGGGGTCTGGCTGTGGAAGGATGTGTGG
CCTCAAATGAGGACAGGGCTCCCGCCTTCACAGCCCTCGCCAGGGGTCTG
CCCCAATCCTGGCCTGCATCAGGCAAGGACGGGGTCTCAGC

Sequence ID - 871 nt: 642
GCAAGTCTTCAGTATGTACATTTATCCCCTAGAAGAAGAAAAATTAGTTG
TGCATGAAAAAGAAACATTAACTGCAAAGCTAAATGCTCACACTCTAAAT
CAGTGCTCTCCAAAGTACAGCAGGCGGGAAAAGAAAATGGTAGATTTTTT
TCTTCCAATTACTTTAACTTATTCTTTTTAATGGACACTTCATACATAAA
TATATTCACAATATATTAATATATACATAATGTATAAGCATACATATTGA
ATGTGCAGTCAAAAAATGTACTAATGGAATGCTCTACCAAAACAAGTTCA
CGTTCATCTGTAAAATGGGAATAATATTTTTAAAAGGCATACAGTCTGAA
CATTTTTAGATTATTCATAAAATCTATTCAGAAAGTTAAACTAAAAAATT
TAACGTATGCCTATAACAAATTTTGTACTTAATGTAATTGNTTTTCATCC
TGAGATCTAATATCCTCGTTTTTAAGTAGAGCCACTTGTTTGCTACAGTT
TAGTCAAAACGTTAACATTAGATGGGTAAAGTAATATGAAATCTTTCTAC
TACTCCAAAATAGAAAACAGAACATTAAAAAGATAAAAATTCAAACATAC
TTACCAGTAGATTTTCAACTGNGCAAAAGCTCATTGCATGGG

Sequence ID 873
GTTTTCCACCGTGAAGAGAACATTTCCTCTGGGAATGACAAAGCCCTCAG
GAACNGCTTTTATTTCTATTGGAAGATGCCCATCATACTTCTGGCAGGAT
AAAATGATAAATTTATTTATTCAACAGATGATACTCAATTCCCTGCTGTT
TTACTAAAGGTTCTTTACGTTTTATAGAAGCTAAATTTACTGTCATAGAA
ATTGCAATTGTAGATGTTACTGTAATCTAGTCAGAATATCCTTATCCTTC
TAAAATAAAACTAGTTAAAATTATTAACATACGTACTGATATTAATTTTT
AAGTTTAATGCTGCCACGTGCTTCTGCTAAGAACATTTATCACTACAAGT
GGCAGAAAATTCCAAACTCATCAAAACCAAACTGTTGCTTCTTCCCTGCT
TTTTCAGAAAATGAGAAAGGATGACTTTATTCCAACATATTCTAAAAGTA
TTCCAAGAACACTACCTTTATTCTAAATTCGTTATTTTCACAAAATAAAG
GCTGCAGATTGAAAGATAAAGGATTGCTATTAAAGAACAAAAGAAAACAA
AACCGAGAGAGAAGGAGAGCTAGGGAAATCCCTGCANAANAACCGAATAN
GGTCCCTCTATTCTGGGCCGGGGCCTGAAACTATGAAACAGGCCAACACA
GAATCTTGGCA

Sequence ID 875
CCTCTGACTCGCTCAGCTCACCCACGCTGCTGGCCCTGTGAGGGGGCAGG
GAAGGGGAGGCAGCCGGCACCCACAAGTGCCACTGCCCGAGCTGGTGCAT
TACAGAGAGGAGAAACACATCTTCCCTAGAGGGTTCCTGTANACCTAGGG
AGGACCTTATCTGTGCGTGAAACACACCAGGCTGTGGGCCTCAAGGACTT
GAAAGCATCCATGTGTGGACTCAAGTCCTTACCTCTTCCGGAGATGTAGC
AAAACGCATGGAGTGTGTATTGTTCCCAGTGACACTTCANAGAGCTGGTA
GTTAGTAGCATGTTGAGCCAGGCCTGGGTCTGTGTCTCTTTTCTCTTTCT
CCTTAGTCTTCTCATAGCATTAACTAATCTATTGGGTTCATTATTGGAAT
TAACCTGGTGCTGGATATTTTCAAATTGTATCTAGTGCAGCTGATTTTAA
CAATAACTACTGTGTTCCTGGCAATAGTGTGTTCTGATTAGAAATGACCA
ATATTATACTAAGAAAAGATACGACTTTATTTTCTGGTAGATAGAAATAA
ATAGCTATATCCATGTACTGNAGTTTTTCTTCAACATCAATGGTCATTGN
AATGTTACTGATCATGCATTGGTGAGGNGGTCTGAATGTTCTGACATTAA
CAATTTTCCAT

Sequence ID - 876 nt: 115
AAACTTTTGTGGCAACAGTGCACTAATTTGGATAATGTTTGTTCCCAATA
AATTAAGAGCCAAATTGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAA

Sequence ID - 878 nt: 634
GCCAGGCTTTGTGAATTACAGGACATTTGAGACAATCGTGAAACAGCAAA
TCAAGGCACTGGAAGAGCCGGCTGTGGATATGCTACACACCGTGACGGAT
ATGGTCCGGCTTGCTTTCACAGATGTTTCGATAAAAAATTTTGAAGAGTT
TTTTAACCTCCACAGAACCGCCAAGTCCAAAATTGAAGACATTAGAGCAG
AACAAGAGAGAGAAGGTGAGAAGCTGATCCGCCTCCACTTCCAGATGGAA
CAGATTGTCTACTGCCAGGACCAGGTATACAGGGGTGCATTGCAGAAGGT
CAGAGAGAAGGAGCTGGAAGAAGAAAAGAAGAAGAAATCCTGGGATTTTG
GGGCTTTCCAATCCAGCTCGGCAACAGACTCTTCCATGGAGGAGATCTTT
CAGCACCTGATGGCCTATCACCAGGAGGCCAGCAAGCGCATCTCCAGCCA
CATCCCTTTGATCATCCAGTTCTTCATGCTCCAGACGTACGGCCAGCAGC
TTCAAAAGGCCATGCTGCAGCTCCTGCAGGGACAAGGACACCTACAGCTG
GCTCCTGAAGGAGCGGAGCGACACCAGCGACAAGCGGAAGTTNCTGAAGG
AGCGGCTTGCACGGCTGACGCAGGCTCGGCGCCG

Sequence ID 879
GTTGCCGGGTCCTGTGATAACTCTGTTTAACATTTTGAGGAACTGTTGAA
TGGTTTTTCACAGCAGCTGCCTCATTTTTTATTCCCATCAGCAGTACTTC
TTGGTTCTAATACCTCCACGTTCTCGCCAACACTTGTTGTTGTCTGTAAT
TTCGTTGTTAGCCATCCCAGTGGGGATGAAGTAGTATCTTACTGTGGTTT
TCAGTTGCGTTTCCCTGATAATTAATGATGGTGAACATCTTTTCATGTTC
TTGTTGGCCATTTGTATGTCTTCTTGGGAAAAAAAAAATGTCTGTTCAAA
TCCTTTACAAAGTATTTATTTTTTATGTCAACAATATAACCACTCAGTAC
ACTGCTTTTTANACAATGATCTTTTAAAGGTTTGTTTACAACATTTAGCA
CTTGAAATTTTAAGGTTATGCCCTCAAAAAAATTGCTGAGGGAGCTAAGC
TATGAAGATGCAAAGGCATAANAATTATACAATGGACTTTGGGGGAATCC
AGGGAAAGGGTGGGAGGGGGGTGANGGA

Sequence ID 881
TCGACTCTGATTTTTTTTTCTCCTTCCTCGCAGCCGCGCCAGGGAGCTCG
CGGNGCGCGGCCCCTGTCCTCCGGCCCGAGATGAATCCTGCGGCAGAAGC
CGAGTTCAACATCCTCCTGGCCACCGACTCCTACAAGGTTACTCACTATA
AACAATATCCACCCAACACAAGCAAAGTTTATTCCTACTTTGAATGCCGT
GAAAAGAAGACAGAAAACTCCAAATTAAGGAAGGTGAAATATGAGGAAAC
AGTATTTTATGGGTTGCAGTACATTCTTAATAAGTACTTAAAAGGTAAAG
TAGTAACCAAAGAGAAAATCCAGGAAGCCAAAGATGTCTACAAAGAACAT
TTCCAAGATGATGTCTTTAATGAAAAGGGATGGAACTACATTCTTGAGAA
GTATGATGGGCATCTTCCAATANAAATAAAAGCTGTTCCTGAGGGCTTTG
TCATTCCCAGAGGAAATGTTCTCTTCACGGTGGAAAACACAGATCCAGAG
TGTTACTGGCTTACAAATTGGATTGAGACTATTCTTGTTCAGTCCTGGTA
TCCAATCACAGTGGCCACAAATT

Sequence ID 883
TCATTTACATTAATACTCAAAACTGCTCGATTAAGCAGGTGCTGTTCTTA
TCGCCATTTTGCATATGATGAGAAAGGGTAAGGTCACCCAGCTAGTATTT
GGCTCACAGCAGGCCTTAAGACTTGGTTTGTGTGACTCATCAGTCCACGC
TCCTAAAACCACTAAGTTGTTCTACCCTTTAATGTTGAATTAACATTGGA
TAGTGTTCAAGTTTANATGGGTGGGTGAGGGCCCAAGGACCTTTCAAACT
CAGATCTCTTATTTAATAACCTGGTCCCAGATCCATTCCTCTGTCGAAGA
GGAAGTCATCCTTCAGTGGCTATTCATTGTGGGGTTAAGAGCGCAGACTA
TGAATTCAGTCTTTTTGGGTCCCAGTTTGCCAGACCTTGAGTGAGTGCCC
CGAGTTTACTTACTTGTAAAGGTAGGTGGAGGTAATATAATTAAATAAAC
TTAAAAAACTAATTAAAAACAAAACAAATGAACTAAGGTCTTAGGATATC
TGGCGTCTATTTTGCGCCAAATCACATAATGTCTATTGTTGTGTGTTGGA
CTATAGGATTGTCCTTTAACAGGGAAGGGTTTATTTCTGTAATCAAGTCT
GTCAATATTATGACCATGTTGATAATAGCTACCTTTAATTGAGGGCTTCC
ATGTGCCAA

Sequence ID 885
TCAGTGGAAAAGGGCAGGTTGAATCAAGGTGAATCAATCTGAAATTGAGC
ACACCTGCCTGCCATCGCTGTTCCTTCAACTGAGTGCTGCACATCATGGG
CTCTGTCTGTGAGAGAAAAATCCCGGTGCTTGGTGTCCTTGCATGACATG
GAGTTTTGCATGTAGATCAATTTAAAATGTACCTCTTGTTTACATAATTT
GCATAATTTTAAAAGATAATGTTGCCAAACTTTGGAAATGTTAATGTTCA
NACTGAAAATCTCCACTACATGTAACTTTCTTCCTCTGGATCAGTGGCAT
GGCTTATAATCCCAGCCAGTGGTTTGAACTGTTCCAGTGTCAACTGCCAT
GTGCTCTGCTTCAAGGGGGAACTAGCCTTTTGTGAATTTTTTGTACATAA
GTATTTGTTACAAATATTTTAGCAAATGCTTTCTATTTCTCTTGCTTGTG
CATATCTTGGCTGGCGTTACAGAAAAATAGTGTAAACATTATTTCCTTAC
CGGGGAATGAGGGTTTT

Sequence ID 887
AGCACCTGGCACAGAGTAGTAGCTAACACAGATGTTAATTTTGCTGCGTC
AAATGTTTTCACTTTGAATCTCTCTTGAGTATTGTTCTCCTTATTGATTA
CATGATGACATCCTGTTTTCTCTCCCTGACCTTTACTGTTTGTTTAGAAA
AAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID 889
CAGAGAGCTTGTTCCCTCCCTCCCTGTGCATGCAAACAAGAGGGCATGGG
AGCACACAGAGAGATGGCAGCCACCTACAAGCCAAGAGGAGAAGCCTCAC
AATCAAACTCTCGCTGCTGGCGAGAGTCTTGGACTCTGTCTTGGACTTCC
AGCCTCCAGACTGTGAGAAACAAATTTCTGTTGTTTCAGCTTCTCAGTCT
CTGGTGTTTTGTTATTGCAGCCTGAGAACACAGCTGTACNATTATNAGGG
AAACAGAAAACACTGATACTTAACAATGCTAATGCAATTATTTATTTGCT
TTTCAGTCTCTACAAAACGTTCTAAAACACTAATCTAAATATTAACAGTA
AAATATTTGCATAACTAATGGAAACTAAGAAATCATATGACCAATATTTC
ACTTATTGGTAATCTTACTCTACTGATTTCCCCCCAGACTGTGATTTTTG
AACTTCCTTGCCTTTCTCCTGTCTTTCTGNGTTTATTCATGGAATTCCAG
TTATCTGGGCTTGAAATTGCAGGCTCTCCTAACTTAAGCAAAATCTGACA
GATCAGCAAAATGAGATAAATGTTTCTTTTTTCTTTCTGACTGCATTAAA
TCAGATACAACTCAGCATTAAAAAGCTATCTTTGNAAAATGNTGGTACTA
ATAAATTAGTCTTA

Sequence ID 890
CCAGTTCCACATTCAGTGAAGTCATGAACTTGAAATTGGCCATGATCAAA
AAGTATTTAAATCACAGAAGTTGCAAATGCCACAAATCAAGGTCTTTTTC
TCTTGGAGAACCTGTTAAACATTTACCAACTCACGACCGCCATGCACCCA
ATACTGCAATAGGTCTATAGATGCAGATACTGTCTCCATGAATCTTATAG
GCTAGAAAGGAAATAGATAAGTAGTCCTACCAGAAGAACATGATGAAGGC
ATTTGTGGTAAACAGAATGATGGCCCCCCAAAGATGTCCACATCCTAATC
CCTGAAGCCTATGAATATACTACTTTACTTGGCAAAAGGGACTTTGCCAC
AGGTTTTTAATTAAGGACCTTGAAATAGAGAGATTATCCTGGATAATCCA
AGCCAGAGTCAGAGAAGGAGACGTAGCAATGGAGGCAGAGGTCANAGAGA
GATCTGCAGATGCTGCTGTGTTGGCTTTGAAAATGAGGAATGGAGGTGAC
CTCAANGNGCTAGATGATGCAAGGAAACAAATAATCTCCTATGAACCCTA
GGATGGGCATTATTATGAGTCCTATTTTATAAACAAGGAACTGACNTCCA
GAAAGATAAATGC

Sequence ID - 891 nt: 626
GGCAGAGGTTGCAGTGAACTGAGATCATGCCATTGCAATCCAGCCTGGGC
AACANGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAGACAAGAGTNT
CCACTCTAAACACTTNTATTCAACATAGTCCTGAAAGTCGTAGCCACAGC
AATTTAACAAGATAAAGCAATAAAATGTATTCAAATAGAAAAAGAGGAAG
TCAAATTATCTTCACTGGNGATATAATTCTCTACCTGGGAAACTTCACCG
AAAAAGATTTCACCAAAAGATTTCTAAGCCTAAATAATGACTTCAGCAAA
GTCTCACCATACAAAATCAACATACACAAATGAGTAGCATTTCTGTGCAC
CAATAATATTCAAGCTGAGAAAAAAAGAACATGGTTCTATTTACAATAGC
TACAAACAAAAAAATATGTACCTAGTAATACATTAAATCAAGGNGGTAAA
ATATCTNTACAACAAGAACTACAAAACTGCTGAAAAAAAATAGAGACACG
CAAATAAGTAAAAAGGCACTCCATGCTCATGAATTTAAAGAATCAATATA
ATTAAAATGTCCGNGCTGCCTAAAGCAACTTACAGATTAAAGGCTATTTC
TCTCAAACTATAAATGCACCTTTTTA

Sequence ID - 893 nt: 585
GTCATTGCTGGGTGGCGCCAGCCCTCAGACTTGCCTCTTTGCAGTAGGAA
GAAGGCCTCCCCACATACCTTCCCACACTCATCACCTTAAGCCAGACTCG
GTGTCCAGTGAATATGACCATCTCTTGCCCATTTTCTAATGAGTGTTTTC
ATTAATGAGTTATAAGAATGTGGTGGGTAAATCTATGGGCTTTGAACTAG
TGAATCAACTTGGTTTCAGAATCTGGCACTGCTACTTACTAGTGAATTTA
AGCAAGTTATTTCACCTTTCAGAGTGTCAGTTCCCTCATGCATACAAGGA
AGATAAAAAATAATGTNTACNAAAGTATTGGAGTAATTAATACATGGAGA
ACTACATGTAAAGCGTTTAGCATGATGTCTGACATATTAAGCATCCAATA
TTAGTNGCTTGCAGAATTATTAGTAAAAGAGATTGCTTCTGAAAGCCATT
CCAATTCTTAAATTTTATAATGCCACATTTGAGGTCACCTGAAGTCGTGT
ATAACATGTGTACATTTTTGCGATTTATTTTTTCAATTCCCANATTAAAG
GCATAGAGATATCCTAGCNANGGACTCCAAGTGTG

Sequence ID - 895 nt: 560
GTAATTGCAGCCTGGGCAACGGAGTGAGAGACTGTCTCAGGAAAAAAAAA
AGAAAAAAAACTACTGAGGTAGTTGAATATATCCTCCATTCCCCATTTGT
GGATTAGTTAGTAAATGGGGCATCTTAGGGTTTAAATATGTCCAGGGTCA
CTGAGGATCAGATCCTAGGGTTCCTTTGACTCAAGGCTTTTGTCTCAGCA
AAACGTCACCTTCCAGCAGGAAGGCTTTCTCAGGCAAGTAGCAGGGTGGC
TACTATGTATCGCTTCTTTATTTTTTCTTTTTTAAAATAATGCAGGCACC
GTGCGCATAATTTAAAAAATCAGTGCTAAAACCCTTAAAAAAAAAAAGCT
GTTCTCATCTCCTGTCTTTCTTTTTTTTTTCTTTTTATTTTTTTCTTTTA
TTATTATTATACTTTAAGTTTTAGGGTACATGTGCACAACGTGCAGGTTT
GTTACATATGTATACATGTGCCATGTNGGTGAGCTGCACCCATTAACTCG
TCATTTAGCATTAGGTATATCTCCTAATGCTATCCCTCCCCCCTCCCCCC
TTTTTTTTTT

Sequence ID 896
GGGAATGTCTTAGGCACTGGGACTGTAAGTGCAAAGACCCTGTGGCACAA
GGGAATGTTAATTATCTACCTTTCANAAACTGGAANAAGGCCTAGCCTAG
AGCATTGAAAACAATAAGGGAAAGGAGGAGTAAGGCTGGANAGATAGGAA
TGGTTTAAAGTCTTTGTTAAAAATTTTTTTAAAAAAATCTTTATCACAAG
AAGAGGATTGGCNTGATCAAATTTGACTTTTAAAAANATTACTTGGGTTG
GGCATGATCAAATACTACTTAGGGAGATTAGTTTANATGATAATGGCATT
CTGGACCANAGTGGAGTCAGAGGTGAAAAGAGGTAGATATTCCANAATTG
AGGGATTTGTGAGGTGAAATCATTTGTTACAGATATTAAAGGATAAGGAG
CTTTGTCAAAGGGGATCTTAAGTTTCTGGTATGGTAACTGGGTTAGAGAG
CCCTGGAACATGACCAGCTTTAAGGGAAGAGAGCTTGAGCTCTGTTCTTG
TTAAGCTCAGTTTGAGATCTTTGTGGAATCAAGTGGAGAGGTCTAAGCAG
GGAACTGGCTTGGCTAGGCTGTAAAGATGAATCTGAGAGTCCCAAGAATA
TGGTAATTATTAATAAAAGCCTTAGGTANATGAAATTGTTTTGGG

Sequence ID - 897 nt: 509
GCAAATCTACACATTTGATTAAATGATAGGGAACTATGCACACACATAAT
ACATATAATGCTAGTTTCTTGGTTTTGATATTGTACCATAGTTATGTAAG
ATGTAACCATTGGGGGAAACTGGGTGAAGGCTACATGAGACCTCTCTGTA
CTTAATCTTTGCAACTTATGTGAATCTATAATTATTCCAAAATAAAAAGT
TTTAAAGAACCTAAGTATCCTTATTACTGAGGGTCATCGTGCTAGACAGC
AAGGTTGGGCCAGAGCTTCTAGTTATTTAAAATACTAAATACCAGCCTGG
GCAACATAGCAAGACCCTGCCTCTACAAAAAGCAAAAAAATTAGCTGGGC
ATGGTGGTACATGCCTGTGGTCCTAGTTACTCTTGGAGGAGTCTGAGGTG
GGGAGCTTGAGCCTAGGAGTTTGAGGCCGCAGTGAGCCTTGATTGTGTCT
CTGTACTCCAGTCTGGGCCACAGAGCAAGACCCGGTCTCTAAAAATAAAT
AAATAAATA

Sequence ID 898
ANTGCACTCCAGCTTGGTGACAGAGGGAGACTCCATNTTAAAAAAAAAAA
AAAAAAAAAAAAAGGGAGTAGCTTGAAGCCACATAGTAGTTAGTGGTAAA
GGCCACCCCTTTTCCCACAACTCACACCAGCACCACAAGCTAGCCTTTNT
AATTTCCAAGCCAGTGCCCTTTCAACGCACACACCCCTGTGTCAGTTCCC
TTTCTGCTGCAAGCTCTCTGGAGGCAGATACTGTTGAGTCCCTGGCCTGC
CTATGAGAACGGCTCATGATCTCTATTTCTTCTGCTTAATGACCATCTCG
AAGTAACAAGTTTAGCCTAAAATAAACTTGCTAAGTTAGCAAAGGAAGTC
CTTAGCAGCCACCATTTCTCGATTCCTCCATCACCTCCCCTGCCCCTCAA
CTCCCTCATTTCTCCCAAGATATGGGCTCCAGGCTGGGCGCGGTGGCTCA
CGCCTATAATCCTAGCACTTTGGGAGGCTGAGGTGAGCAGATCACTGAGG
TCAGGAGTTCG

Sequence ID 899
TCNTTCGGAACGCGCC

Sequence ID 900
CTGGAGGGATGGGTAGGATTTTGACAAGAGTGGTTGAAGGTATTCTAATT
CACTTAGTACCTACATGTGCGAGGCAGCATGAAGGCAAAAAAGCCTGGGG
CATGTTCAGAGAATAGCAAGTATTCTAGTTTGAGTGGCACCTGGTACGTA
TATAAGGGAATAGTAAAAGATCTGGCTGGAAAGGAAAAGTAGGGGCAGGT
TACGAAGGACCTCTGAAAGTCAGACTGTGGAACTGGAACTTTTATCAGGA
AGCAGTAGTTAGTTTTTTCAAGCAAAAGCTAATTAGAGTTGATATTTAGG
AGGATGAATCTAACAGTTGTGTGCAAGGATGCCTTCAAACTGAGTGAGAC
TAGTACTGGAGACTGGTTAAGAGACTACAACAATAACCTGAGTAAGAATT
AATACAGGCCTGACCTAGTTTTGAGTGAGTAGGATTGGAAACAAGAGTTT
TAGGTATTATAGGATTTATGCATATAAAATGGACTTGACAGAACTTGAAG
AAAGAGAAAGTGTCAAAAGGACACAGAAAGTGAGGCAGGATATCTTACAA
TGTTAAAGGAAAGGAATAATAGAAGTTAC

Sequence ID 903
GGAAACATAAGCTTGTTTCAGTACACTCACGCTGTAGATTAATTCTGATA
TTACATATCTCCATCAGACTTTGTACCCTCTCTCTTCCATCCCTTACCCT
TACCGATTAGGTTGGTATTACCTAAAAATCCATAGAAAATGTCCAGGTGA
ATTGCCTTATGCTTTCTACCCCATAAGGTATAATT

Sequence ID 904
CTCTGTGGTGTGAGAACACAGTGGGTGACCAAGGCTTTCCAGATGAACCC
AAGGAAAGTGAAAAAGCTGATGCTAATAACCAGACAACAGAACCTCAGCT
TAAGAAAGGCAGCCAAGTGGAGGCACTCTTCAGTTATGAGGCTACCCAAC
CAGAGGACCTGGAGTTTCAGGAAGGGGATATAATCCTGGTGTTATCAAAG
GTGAATGAAGAATGGCTGGAAGGGGAGTGCAAAGGGAAGGTGGGCATTTT
CCCCAAAGTTTTTGTTGAAGACTGCGCAACTACAGATTTGGAAAGCACTC
GGAGAGAAGTCTAGGATGTTTCACAAACTACAAAGCTGAAGAAAATGAAG
CCCTATTACTTGTTTGTAAGATTTAGCACCCTTCTGCTGTATACTGTACT
GAGACATTACAGTTTGGAAGTGTTAACTATTTATTCCCTGTTAAAATTTA
ACCTACTAGACAATGATGTGAGTACCCAGGATGATTTCCTGGGGCACAGT
GGGTGAGGAGATGGGGACAGGTGAATGGAGGAGTTAGGGGAGAGGAAAAG
TGGATGGAAGTGTCTGGAAAGGGCACCAAAAAAGTCTTCCAGGTCTGATC
CTGTTTCTTGCTCTGAGTGCTAGCTACCACTGTGTCACACTGTAACATN

Sequence ID - 905 nt: 655
CTCAGCTCTTGCCTGGTCACCTTGTGGCTTTTACCATCCTCATCCCCTGT
GCCACCCACATCCTGCCACTTCTGCATGGAGTTGGGGTGGGGCCATTGGA
GAAAAGAGGTTAAACAAGCAGTAATTTACTTGAGTACAGTCTTTGAGCCA
ATGAAATGCCAGTCATCATTTCCCAGGGGTACTTGTCATCTTGTCAACAA
CCCGCTGATAATGCTCCTTCAATGTGAATAGCAAAAGTAGGGAGAGACGC
TGAATGAAGAAGATGCCTACCCCTCAGGAAGACTGCTGTCCGCCTCCAGG
CCTGCATGCACACACCCATGCCCACCTGCACCCCCAGCACCACGCCCACA
CTCACTCGCACACACCCACATGCCAGTGTTTTGGGGTTGGCAGCCTGGAC
ACTGCTGAGGCAAACACAAGTCATCAAGGATAATTCTCATTCTCTCCTTC
TGTCTCTGTTTTAGTTACAGGAATTTGGTCAGTTTAGAGGATTTAATAAG
TCCGTGGAAAATTTGTTTCTGTCTCTTGCTACCCACGTGAAAAGTAAGTG
CATGCTTCATGATGTGTTTTCCCACTACCTTCCAGGCCAGCCGAGCCCAC
TGGCCANGGCCTGGCCCGGTGACCTCGGTTGACACTGTCCTCANGCCACT
CACTT

Sequence ID 906
CAGAATTTCATGTTTATGCTGCACAAGGCCTGTATTTTATAATGGTGGCT
CTTTTGGACGATGACTTCCTCGATGGTGAAACTTCCAGTAATCTCCCTCA
TCATACTGAAATGATATCAGTATATCATCAGAACACCATGGAGCTTGTCA
TTTGAGGGACACAGCTTGCTTGTGTGCTTGGGAAAGAAGAGGTTTAGCAT
GGTTTCAGGTCAGTGATGAGTCCAATGATCTCTGCAAGTTCCCTTAGCTC
TGANAATTCTGATGTCATATGCACTTCTGCCGCCAGAGTTGCTGCTTACT
GGATGCGTAAGAAGAAAAGAAAAAAAAAAAAAAA

Sequence ID - 907 nt: 582
CTTCCATTGGGGGTAAAGATCAAACTTTAGGCGAGCCAGGTCTGTATCTC
CATTCCTGTCTCTGACTGCTTCCCTGTAGGGATTGTCTGCAAGCGCACAC
CTGCATTTTCTTGTCCACAAGTCTATGCTCTAACTCTGTCACCTGCATGG
CTGCAAATTAGCTTCCTTCTTCCTGCCCTCTTCTCTCTAGCTTGGATTTT
GAATTTGAATGGCAGGCATGGGATGTCCGTGTGTGTGTACTGCTGATGTG
TACAGCCGCTTGTTAGCGCTCTCATTGTCTTCAAATGTAAGTCATTTTGG
CTGGGTGCGGTGGCTCATGCGTATAATCCCACGCTTTGGGAGGCTGAGGT
GAGCTGATCATTTGAGGTTAGGAGTTCGAGACCAGCCTGGCCAACATGGC
AAAACTCCATCTCTACCAAAAATACAAAAATTAGCTGGGTATGGTAGTGC
ACGCCTGTAATCCCAGCTACTTGGAATGCTGAAGCAGGAGAATTGCCTGA
ACCCANGAGGCGGAGGTTGCGGTGAGCCAAGATCACGCCACTGCACTCCA
ACCTGGGTGACAGAGCAAGGCTGTGTCTCAAA

Sequence ID 908
ACCTGACTTCAAACTATACTACGAGGCTACAGTAATCAAAACAGCATGGT
ACTAGTACAAAAACAGACCAATGGAACAGAATAGAGATCTCAGAAATAAA
ACTGCACATCTACAACCATCTGATCTTCAACAAACCTGACAAAACGAGCA
ATGGGGAAAGGATTCCCTATTTAATAAATGGTGCTGGGAGAACTGGCT-A
GCCATGTGCAGAAAATTGAAACTGGACCCCTTCCTTACACCTTATACAAA
AATTAACTCAAGATGGATTAAAGACTTAAATGTAGAACCCAAAACGATAA
AAACCCTAGAAGAAAATCTAGGCAATATCATTAAGGACATAGACATGGGC
AAAAATTTCATGATGAAAACATCAAAAGCAATGGCAACAAAAGCAGAAAC
TGACAAATGGGCTTCTGCACAGCAAAAGAAACTATCGTCAGAGTGAACAG
ACAACCTACAGAATGGGAGACAGTTTTTGCAATCTATCCATCTGACAAAA
GTCTAATATCCAGAATCTACAAGGAATTTAA

Sequence ID 910
CAAAAAACAAGAATTACCCGGGCTTGGTGGTGCATGTCTGTAGTCCTATC
TACTCAGGAGGCTGAGGCTGAAGGATCACTTGAGCCCAGGAGTTTGAGGC
TGCAGTGAGTGAGCCATGATCATGCCAGTGTACTCCAGCCTTGGCAGACT
GAGCAAAACTTGGTCCCTCGCAAAATGTTGAAGCCCAGTTTTCACTATTA
ACCTGTATTTCAGTTTCCCCATGCTAACTTTGAAACACTGGGGCTGGCCT
GAGGGTATAAAGGCTTATTCAAACTCAGTAATTTAAACTTAAAATCCTAA
GGAACTTCAAAAAGTGTAATCTAGTCCAAATGGGGCATCAATTCTAAAGC
ATTTGCTTGTTTGAGCAGATTTTCTGTGTCTGAGGTATATAGATAACTTA
TCTTTTTATGACTAAATCCAAGTCCTTAGTTCCTGTTGGAATTCAAAATC
ATATTTAAAAATTGATGCTTTGTTCTATAATTAATGCTTTGATTGTATAA
ATAATAAGTATTCTTCCAAATCCCTTTTTACAGATGATGATTCTGATACC
GAGACGTCAAATGACTTGCCAAAATTTGCAGATGGAATCAAGGCCNGAAA
CAGAAATCAGAACTACCTGGNTCCCAGTCCTGTNCTTAAAATTCTAACTC
GAC

Sequence ID - 911 nt: 595
GAGGGTGTAGAAGAGAAGAAGAAGGAGGTTCCTGCTGTGCCANAAACCCT
TAAGAAAAAGCGAAGGAATTTCGCAGAGCTGAAGATCAAGCGCCTGAGAA
AGAAGTTTGCCCAAAAGATGCTTCGAAAGGCAAGGAGGAAGCTTATCTAT
GAAAAANCAAAGCACTATCACAAGGAATATAGGCAGATGTACAAANCTGA
AATTCGAATGGCGAGGATGGCAAGAAAAGCTGGCAACTTCTATGTACCTG
CAGAACCCAAATTGGCGTTTGTCATCAGAATCAGAGGTATCAATGGAGTG
AGCCCAAAGGTTCGAAAGGTGTTGCAGCTTCTTCGCCTTCGTCAAATCTT
CAATGGAACCTTTGTGAAGCTCAACAAGGCTTCGATTAACATGCTGAGGA
TTGTAGAGCCATATATTGCATGGGGGTACCCCAATCTGAAGTCAGTAAAT
GAACTAATCTACAAGCGTGGTTATGGCAAAATCAATAAGAAGCGAATTGC
TTTGACAGATAACGCTTTGATTGCTCGATCTCTTGGTAAATACNGCATCA
TCTGCATGGAGGATTTGATTCATGAGATCTATACTGTTGGAAAAC

Sequence ID - 912 nt: 651
CATTTCCAGAGTTTATGTGAATTGAATTGAACTATGGTTTTATGTTACTG
TCAGTAGAATGAAGTACGAATATTTGAAAAATACACCTTCAACTTCAAAG
TGATTCTTGACAAAAATTATAAGGAATCATTTTGGACACATTTTCTGGTA
GAGCCTTGTAAAAATTAAAACCAAGTGTTGTTTTCAAGAAGAACTGTAAT
ACATAATCAGGAATTTGAGTAGGGAGATTATTTTGTTATTTAAAATTAAA
GTGGCTGTGTAGTTTTAACTTTAGTATTGCAGGTAGAGTAAGCTTACATG
ATAACAAAAATCTTGGTCTTAGTGACTTAATGATTCTGATATTTATTGAT
TGATTGGTTATCATTCCAAATATTTTAAAAGATAATAGCTGGCTGGGTGC
GGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCCAGGACGGGCGGA
TCACGAGGTCAGGAGATCAAGACCATCCTGGCTAACACGGTGAAACCCCG
TCTCTACTAAAAATCAAAAAATTAGCCGGGTGTAGTGGCGGGCACCTGTA
GTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATGGCATGAACCTGGGAG
GCGGAGCTTGCAGTGAGCTGAAATCGTGCCACTGCCTCCACCTGGCGACA
A

Sequence ID 913
GTGAGGTGGGGACTTCATTCATTGTCCTATTTCTATCTCCACTTTGTGCC
TGGAGAGCTTTCAGGGGAGGTGGAGGAGGAGGGTCTGCCAAGCTACTGCA
ACATCTGTCACCCACTATACCCAGTTACTTGGGGGAGGACAGACACTGTG
GTGTCATTAAAGTTGTTTGAACCAAAGTGGCGGCTGCATCTTTGTCCCGA
TGCTAGCCGTGCCGGTCTCCCATCATCCGCTCGCCCTCCTTTNCCCTGGG
CTGCGCCCACTTGTCTTCCTGGATATTTGGGGGTGACTCGCCATGCTTGG
CACCCTCTGCTTCCTGGTGCTGCTCTGACTCGAAGACGGGACAGTCCCTG
GTGCACATCCAGGGAAGAGGAGTGTCGGTAGTTCTTGCAGTAGGCACTTT
ATCAGGACCTGACCTGTTGCTGGGTGATTTTAGTCTCTACAAACAGAAAG
CGTTTCAAAGCGTCAGCTGTGGGAGCAGAGTGACCCTTTGCTGATGCTGG
GGGGAGGGGATCTAAATCCTCATTTATCTCT

Sequence ID 914
GGCGCCTGCTGGAGGAGGAGAGAGCTCTGCTGGCATGAGCCACAGTTTCT
TGACTGGAGGCCATCAACCCTCTTGGTTGAGGCCTTGTTCTGAGCCCTGA
CATGTGCTTGGGCACTGGTGGGCCTGGGCTTCTGAGGTGGCCTCCTGCCC
TGATCAGGGACCCTCCCCGCTTTCCTGGGCCTCTCAGTTGAACAAAGCAG
CAAAACAAAGGCAGTTTTATATGAAAGATTANAAGCCTGGAATAATCAGG
CTTTTTAAATGATGTAATTCCCACTGTAATAGCATAGGGATTTTGGAAGC
AGCTGCTGGTGGCTTGGGACATCAGTGGGGCCAAGGGTTCTCTGTCCCTG
GTTCAACTGTGATTTGGCTTTCCCGTGTCTTTCCTGGTGATGCCTTGTTT
GGGGTTCTGTGGGTTTGGGTGGGAAGAGGGCCATCTGCCTGAATGTAACC
TGCTAGCTCTCCGAAGCCCTGCGGGCCTGCTTGTGTGAACCGTGTGGACA
GTGGTGGCCGCGCTGTGCCTGCTCGTGTTGCCTACATGTCCCTGGCTGTT
GAGGCGCTGCTTTAACCTGCACCCCTNCCTTG-CTCATANATGCTCCTTT
TGA

Sequence ID - 915 nt: 230
TTTGAGACCAGCCTAGCCAACATGGTGAAACCCCATCTCTACTAAAAATA
CAAAAATTAGCCGGGCGTGGCGGCACATGCCTATAATCCCACTTACTTGG
GAGGCTGANGTAGGAGAATCGCTTGAACCCANANAGGCAGAGTTTGCAGT
GAGCCGAGATTGTGCCATTGCACTCCAGCCTGGGCGACAGAGCGAGACTC
CATCTAAAANAAAATAAATGAATAAAATAA

Sequence ID 917
NNCAGATTTTTTTTTTTTTTTCAGNGTTAGACCATCTTTCAATTCCTGGA
ACAAACTTAACTTTCCATGATATGTATTTTTTATACATTGCTGGATTTTA
TTTGCTAATATTTTACTTAGGATTTAATTTTCTAAGTNGACCTATAATTN
TCCTGTATAAAATTGCATTTGTCACATTTTAGTATCAAGGTTGTCCTANC
NCCATGAAATGGATTTANAATGGTTTATGTAANATAAAGTACATTTCTTC
TAAAGGTTTGNGTGGATTAACTTTCAAATCTGCCANAGNGNGTTTTTTTC
CTTTTTTTTTTTTTTTCATTTNAAGGGAGNGCAAGTANCTTTTCAAATNC
TGATTTAATTTTTAAAATATTTNCAAGTNTNTTTANAGTTTTTATTTNTT
NTNGAANGTTAACATTTTTATANAAAANGGTNTTATCTTTTTAAATTCTT
TGACATCAGTTTCTTCANAATTCCTTCTTTTAA

Sequence ID 926
GTCATATCTCTTCCCAGGGAAAGCAGGAGCCCTTCTGGAGCCCTTCAGCA
GGGTCAGGGCCCCTCGTCTTCCCCTCCTTTCCCAGAGCCATCTTCCCAGT
CCACCATCCCCATCGTGGGCATTGTTGCTGGCCTGGCTGTCCTAGCAGTT
GTGGTCATCGGAGCTGTGGTCGCTACTGTGATGTGTAGGAGGAAGAGCTC
AGGTAGGGAAGGGGTGAGGGGTGGGGTCTGGGTTTTCTTGTCCCACTGGG
GGTTTCAAGCCCCAGGTAGAAGTGTTCCCTGCCTCATTACTGGGAAGCAG
CATCCACACAGGGGCTAACGCAGCCTGGGACCCTGTGTGCCAGCACTTAC
TCTTTTGTGCAGCACATGTGACAATGAAGGACGGATGTATCACCTTGATG
GTTGTGGTGTTGGGGTCCTGATTTCAGCATTCATGAGTCAGGGGAAGGTC
CCTGCTAAGGACAGACCTTAGGAGGGCAGTTGGTCCAGGACCCACACTTG
CTTTCCTCGTGTTTCCTGATCCTGCCTTGGGTCTGTAG

Sequence ID 938
TGGCCATCCTTTTCCCCCCAAACACACCCCCTTAACCTATCTCTTGGGAC
TTAGCCCGACCCTCCCTCTCATTTCCCATTAAGTCTGAGAGGCAAGAGCT
AGGTTAGGCAAGGAGGTGGTTGGCCAGAGATGGGGAACAGCCAGGTGCCC
CAGTCCTCTGATTTTTCCTCCATCCTGCTTACCACCTCCCTGGGTACTTA
CAGCCTTCTCTTGGGAACAGCCGGGGCCAGGACTGGGTCACCTATGAGCT
GAATCAGCATCTCCTCCTGAGTCCCAGGGCCCCTGCAGTTCCCAGTCTCT
TCTGTCCTGCAGCCCTTGCCTCTTTCCCACAGGTTCCACTTTATATCCAC
CTTTTCCTTTTGTTCAATTTTTATTTTTATTTTTTTTATTATTAAATGAT
GTGGTCTATGGAAAAAAAAATAAAAATCTGACTTAGTTTT

Sequence ID - 939 nt: 513
GGAACCCAGTGTATTACCTGCTGGAACCAAGGAAACTAACAATGTAGGTT
ACTAGTGAATACCCCAATGGTTTCTCCAATTATGCCCATGCCACCAAAAC
AATAAAACAAAATTCTCTAACACTGCAAAGAGTGAGCCATGCCTGTTAAC
ACTGTAAAGAATGTAACATGTGGGGGACACACAGGGGCAGATGGGATGGT
TTAGTTTAGGATTTTATTAGTGCATGCCCTACCCTCTGGGGGAACGTCCC
ATCTGAGGTTTTCTTCTCGGTGGGGGGATTTAACTTCTGTCCTAGGGAAA
ACAGTGTCTGATGAGGAGTGTTTCCAACACAGGCTACATGAATTCCCCTA
TACCAGTGCGAAAGCAGCCAGGAGTCCCCGTTGGAAAAGAACAATGCCAC
TCTCTTTTATGTATCTTGGTTCTGCAACTCATTTGTTGTAAGTAGGGTTA
ATCGAGTATCAGGTTCACAGTATCCTGCCCTTATTATTTTATGATTCACT
GACTCAAGTTCCA

Sequence ID 947
GAGAGTGAAAAAATTCTGGTACAAATTGGGAAATTAGTATATAACAACAT
AGTGTTAAATTCAATGGGAAAAGTTTAATAAGAGGATTTGGTATCAACTG
GCTGTCCAAAGATAAAAATGGACCGTCCTATCACATACAAAATTGTTTTT
TAGATAAAGATTTAAATACAGGCACTCCTTCATTTGCGTGGTGCACCTTG
AGGTGTTGCAGAAATGATGAGAGCTGAAACTGCAAAGCAATTTTAATACT
TTATCTGTTGGAAATCTTATAGTTTTCCTGTGACCGTTAAAATTTTCATT
AAACTATTAAAAACACCCATGACTGGTCACAAATGTATTGGGAAATGGAA
AAGAATTAATACACTAAAAATACAAAAAATAGAAAATATTTAAAATTATC
TAAAAATTTGAAACATTAGAAAAATTGAGAACTAGGCAGGGCGTGGTGGC
TCACATCTGTAATTTTAGCCCTTTGGGAGGCTGANGCAGGTGGATCACCT
GANGTCAGGAGTTCGAGACCAGCCTGCCAACGTGGGGAAACCCCGTCTCT
ACTGAAAATACAAAAATTANCCGGGCATGGTGGCACAAGCCTGTAATNCT
TGCTNACCAGGANGCTGAGGCAGGAGAATCACTTGAACCCANGANG

Sequence ID 949
GTTTCACATGAGAAGGTAGTATTATGTACAGTGACCTTGTTTAAAGTGTC
NGTTTAATGTTACCACTAAGGCCCTGCCCCAGCTTTATCACCTGAGCACT
AACAAGTGCTGTGTGGAGTTCAGTCCATGCTGGTAACTNTTGAGTATTCA
GTGGGTCTTTTAACAATTACCACCGTGGAGGANANAGCAAGGAAGAGAAA
TGCTGTGATCTTTTNCTGTTTTTAATTAGNGAAAGAGGGATTANATTAAA
CAAATGTTACAGAGNTGTGACTNTGATCCCCCAGNGGTAAGCAATAATTG
TANAGACTGGATTTNANAAGCCCTGAGAGTTTATTTTCAACCTATNTATT
ATAGNNCAATCC

Sequence ID 1028
ACAAGGCTTGGGGGCTGGACTCCCTCTACTGCCTCTGGCCATACCCCCTC
CTGGAGATGGGGTCAAGGCACCAGGACTGA

Sequence ID - 1056 nt: 435
TCGCTTGTAAAGCCTGAGACAGCTGCCTGTGTGGGACTGAGATGCAGGAT
TTCTTCACACCTCTCCTTTGTGACTTCAAGAGCCTCTGGCATCTCTTTCT
GCAAAGGCATCTGAATGTGTCTGCGTTCCTGTTAGCATAATGTGAGGAGG
TGGAGAGACAGCCCACCCCCGTGTCCACCGTGACCCCTGTCCCCACACTG
ACCTGTGTTCCCTCCCCGATCATCTTTCCTGTTCCAGAGAAGTGGGCTGG
ATGTCTCCATCTCTGTCTCAACTTCATGGTGCGCTGAGCTGCAACTTCTT
ACTTCCCTAATGAAGTTAAGAACCTGAATATAAATTTGTTTTCTCAAATA
TTTGCTATGAAGGGTTGATGGATTAATTAAATAAGTCAATTCCTGGAAGT
TGAGAGAGCAAATAAAGACCTGAGAACCTTCCAGA

Sequence ID 1071
NGATATAGTNCCGCATGGGAAAGATGANCAGGTATAACCNAGCNTNATAT
AGCAAGGACTAACCCCCCTGCCTTCTGCATAATGAATTAACTAGAAATAA
CTTNGCAAGGAGAGCCAAAGCTAAGACCCCNGAAACCAGACGAGCTACCT
AAGAACAGNTAAAAGAGCACACCCGTCTATGTAGCAAAATAGTGGGAAGA
TTTATAGGTAGAGGCGACAAACCTACCGAGCCTGGTGATAGCTGGTTGTC
CAAGATAGAATCTTAGTTCAACTTTAAATTNGCCCACAGAACCCTCTAAA
TCCCCTTGTAAATTTAACTGTTAGTCCAAAGAGGAACAGCTCTTTGGACA
CTAGGAAAAAACCTTGTAGAGAGAGTAAAAAATTTAACACCCATAGTAGG
CCTAAAAGCAGCCACCAATTAAGAAAGCGTTCAAGCTCAACACCCACTAC
CTAAAAAATCCCAAACATATAACTGAACTCCTNACACCCAATTGGACCAA
TCTATCACCCTATAGAAGAACTAATGTTAGTATAAGTAACATGAAAACAT
TCTCCTCCGCATAAGCCTGCN

Sequence ID - 1074 nt: 689
GGGAGGCGGAGGCTGCAGTGAGCTGAGATCGTGCCACTTCATTCCAGCCT
GGGCAACAAAGCGAAACTCTGTCTCAAAAAAAAAAAAAAAAAAAATTTGT
TGACTGTTGTAATTTAAAGCTTGTCATTTTTTATTTAGTAATAACACTCA
TTAGTGTAGTATCTATGATGAACCAGGTTCTGCACAAAGTACCTTATGTT
CATGGCCTCATATCGTCTTCTCCAAAACTCTGCAAGATAGGATTCATCAC
CACTTATAGGGAGAGATCTGAAAGTTTAAAATTGTACCCAAGGTCACACA
GCTGGTAAGTGCCAGAGCTGGGATTCCGTAGGGTGTTCANAGTGCCTCTC
CTGCCGTAGGCTTATCACAAAAAGTCAAAGTTTGGTCATAATAAAGCCTG
AAGTTTGGCAGGATTTAAAAATAGTCACCANACTTTTGAGTTGGAGCATC
CCACCTCACTGCTGTTCACCTTCTGTGGCAGGGAGAGTCATCATTTCCAT
TTCAGCTTGTGGAATATCTTGTCATTAACATTCTCATGCAAAAGCCATTT
TATGGTGCCCAATGAANATGGTTAAGCTACTGCCCCAAGCCTNTGGAAGC
CTTCCTAATTTTGGACTTGCACTATGCAAATTGNATAATATTTTCTCTAC
CCTAAGCCAAATATTTTCTTCACTTTTCATTCATTCTAC

Sequence ID 1081
CGCCGCCGCGCCGCCGTCGCTCTCCAACGCCAGCGCCGCCTCTCGCTCGC
CGAGCTCCAGCCGAAGGAGAAGGGGGGTAAGTAAGGAGGTCTCTGTACCA
TGGCTCGTACAAAGCAGACTGCCCGCAAATCGACCGGTGGTAAAGCACCC
AGGAAGCAACTGGCTACAAAAGCCGCTCGCAAGAGTGCGCCCTCTACTGG
AGGGGTGAAGAAACCTCATCGTTACAGGCCTGGTACTGTGGCGCTCCGTG
AAATTAGACGTTATCAGAAGTCCACTGAACTTCTGATTCGCAAACTTCCC
TTCCAGCGTCTGGTGCGAGAAATTGCTCAGGACTTTAAAACAGATCTGCG
CTTCCAGAGCGCANCTATCGGTGCTTTGCAGGAGGCAAGTGAGGCCTATC
TGGTTGGCCTTTTTGAAGACACCAACCTGTGTGCTATCCATGCCAAACGT
GTAACAATTATGCCAAAAGACATCCAGCTAGCACGCCGCATACGTGGAGA
ACGTGCTTAAGAATCCACTATGATGGGAAACATTTCATTCTC

Sequence ID - 1083 nt: 198
GCGCGTCGACTTTGTTTAGACATTGAATGACTTTGTTAAAGGCACAATTA
ATCACATTGGTTGTACTCTGNNGACAGCCTTCTTTAAAAAAAAAATAAAC
AATTTAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAANTTTTAACC

Sequence ID - 1084 nt: 198
GCGCGTCGACTTTGTTTAGACATTGAATGACTTTGTTAAAGGCACAATTA
ATCACATTGGTTGTACTCTGNNGACAGCCTTCTTTAAAAAAAAAATAAAC
AATTTAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAANTTTTAACC

Sequence ID - 1099 nt: 561
TGCATGCTTGTGGATTGGAAAAACTTTGGAGACTGATTACTTTTCATTAT
ATATGTGTCACAGTGAAACAGCTTTTATGTGTCATGTAAGATTACTGCTT
GCCTCTCTAAGGAAGGTCGTGACTGTTTAAATAGACGGGCAAGGTGGAAC
CTTTTGAAAGATGAGCTTTTGAATATAAGTTGTCTGCTAGATCATGGTTT
GTATTGAACTAACAAGGTTTGCAGATCTGCTGACTTATATAAAGCTTTTT
GATTCCTACTAAGCTTTAAGATTTAAAAAATGTTCAATGTTGAAATTTCT
GTGGGGCTCTATTTTTGCTTTGGCTTTCTGGTGAGAGAGTGAGGAAGCAT
TCTTTCCTTCACTAAGTTTGTCTTTCTTGTCTTCTGGATAGATTGATTTT
AAGAGACTAAGGGAATTTACAAACTAAAGATTTTAGTCATCTGGTGGAAA
AGGAGACTTTAAGATTGTTTAGGGCTGGGCGGGGTGACTCACATCTGTAA
TCCCAGCACTTTGGGAGGCCAAGGCAGGCAGAACACTTGAAGGAGTTCAA
GACCAGCGTGG

Sequence ID 1109
TTTGNCGGTNTTGGANNNNNANAANTTTCTTCCANNCNTNACNTNTTGGT
GGNCTAAATTAANATGGNTTTNGNGGGTTCNTTNCTNNNTNNNNCATGGG
ANANAATTNATTNTCNTNCNNNTTCCTTNNCCCTNAANCTACCTTCCCCC
NATTTTCTCCCCTNTTCNTNAATTANCATCCTCTCCNCNTANNTCNANAC
NTTAATGGCAANACTATCTAATANCNANNATAANANCTCCTGTNNNCCAC
ATNTCTTATTNNNCGCNNCANGTTNCANNCCCNCAGAGTNAACTCATCCT
CNNCNNAANTTCATATCGTGNNCTNTNNNCNNTNGCGCGANATATTAANN
ANACCNGTANNTNNNANACANNANNTNNGNAANAANCCTTCTNANNTTTT
AGCNTCNNGCNNTAACNNNNNTCTTNGTGNNNNCNCAGCTTTCNCNNCAT
NATNCTNCNNCGAANTNTCANNCNTCTCCNCTTNAATGNNTTCCCATGNA
TTAANTNCCTCGNNNANAGCACTATCGTNNNNGAGNNNATTATNGNCNNT
TTACNTCATGTGGTCCANTNNCGTTNGNCGCNNNNAATNTTCGTNNNNCN
N

Sequence ID 1118
GGATTTTAGAGGAAGGCGCTNGGTTACATTGGAGAACTGGAGTGGTCTGG
AGTTCCACGGTGTAGTGGACCAGAGGCCACCTCTCCTGGGCTTCTCAGTG
TCTCGCCGGCGGGGTTCGGCCTGAGCTGGATTGACATAGCCCTTGGCGGA
TTTAAACAACCTAAACATTAAGCAGTACAGCTGCCTCAAACCTTTGGGAT
TTTCAGAATGACTGACACTGCCGAAGCTGTTCCAAAGTTTGAAGAGATGT
TTGCTAGTAGATTCACAGAAAATGACAAGGAGTATCAGGAATACCTGAAA
CGCCCTCCTGAGTCTCCTCCAATTGTTGAGGAATGGAATAGCANAGCTGG
TGGGAACCAAAGAAACAGAGGCAATCGGTTGCAAGACAACAGACAGTTCA
GAGGCAGGGACAACAGATGGGGGTGGCCAAGTGACAATCGATCCAATCAG
TGGCATGGACGATCCTGGGGTAACAACTACCCGCAACACAGACAAGAACC
TTACTATCCCCAGCAATATGGACATTATGGTTACAACCAGCGGCCTCCTT
ACGGTTACTACTGATAGAAATGTTGGCAGCTTTTAGTAAAAGCATTTACT
CTGTTACCATGAGAAA

Sequence ID 1125
NGACTGGCTCCCGAAAAGAAGGGTGGCGAGAANAAAAAGGGCCGTTCTGC
CATGGACGAAGTGGTAACCCGCGAATACACCATCAACATTNACAAGCGCA
TCCATGGAGTGGGCTTCAAGAANCGTGCACCTCGGGCACTCAAAGAGATT
CGGAAATTTGCCATGAAGGAGATGGGAACTCCATATGTGCGCATTGACAC
CAGGCTCAACAAANCTGTCTGGGCCAAAGGAATAAGGAATGTGCCATACC
GAATCCGTGTGCGGCTGTCCANAAAACGTAATGAGGATGAAGATTCACCA
AATAAGCTNTATACTTTGGTTACCTATGTACCTGTTACCACTTTCAAAAA
TCTACAGACAGTCAATGTGGATGANAACNAATCGCTGATCGTCAGATCAA
ANAAANT

Sequence ID - 1139 nt: 503
CAGCACTGCCAGTGGAGATGGGCGTCACTACTGCTACCCTCATTTCACCT
GCGCTGTGGACACTGAGAACATCCGCCGTGTGTTCAACGACTGCCGTGAC
ATCATTCAGCGCATGCACCTTCGTCAGTACGAGCTGCTCTAAGAAGGGAA
CCCCCAAATTTAATTAAAGCCTTAAGCACAATTAATTAAAAGTGAAACGT
AATTGTACAAGCAGTTAATCACCCACCATAGGGCATGATTAACAAAGCAA
CCTTTCCCTTCCCCCGAGTGATTTTGCGAAACCCCCTTTTCCCTTCAGCT
TGCTTAGATGTTCCAAATTTAGAAAGCTTAAGGCGGCCTACAGAAAAAGG
AAAAAAGGCCACAAAAGTTCCCTCTCACTTTCAGTAAAAATAAATAAAAC
AGCAGCAGCAAACAAATAAAATGAAATAAAAGAAACAAATGAAATAAATA
TTGTGTTGTGCAGCATTAAAAAAAATCAAAATAAAAATTAAATGTGAGCA
AAG

Sequence ID - 1148 nt: 587
TGAAAAATAAAGTTTTTATGTATATTCTACATATGTATATGTTGGTAGAA
AGCAAAAACGCTAGGTAAAAATAAATGTAATACAATTTTAGCTATGAACC
AAAAAACCATTTGTGGTGTGGATGCAAGAAAGTCTGGATGGGTGCAGAGT
TCTCCATGTTTCACTTCTGACATTTGAAAATACGCAGTTTGCATTTGATA
CGTCAAATGTTATTTTTAAGAAAACCAATAAAATCATTAAAACCGAAAAG
GCAGTTTTGCTTGTTTTTACCTTAGTTGGAGTTATCTGCAATTGCCGTAT
TAGTGTTTTAAGGAACTTGTAAGTAAGCTCCTTAGTCCCCTTTAGAGCTA
CGAAACATGTCAATTTTACTTTTCTCCAGCTTTTTGGAATCTTATCTAAA
TTACCATGTAGAGTTCTGCATAGCTTCAAATTCTCTTAGCCAATGTGGTC
TGTAAGTGTCTATCGATGAATTTCACCGTTAATTGCCGTAGTATACTGTC
CTGTACCGGATGTGAAGAGGAGCAACTCTGCACAGTGCACTGGTTGCTCC
CATGGTAGGAANGAATGGCTTATCAATGGTCGGATTT

Sequence ID - 1160 nt: 650
GGAGGATGGAGCAGTGAGCGGGTCTGGGCGGCTGCTGGCAGCGCCATGGA
GACGGTACAGCTGAGGAACCCGCCGCGCCGGCAGCTGAAAAAGTTGGATG
AAGATAGTTTAACCAAACAACCAGAAGAAGTATTTGATGTCTTAGAGAAA
CTTGGAGAAGGGTGAGTGTAAAGAAACTATAGGTAGGTCATTGGGTCCCA
GTCTTTTTCCTGCCCCAGAAGAAGCAGAAGGATATGAACCTTTCAGCATT
GTTCTAGGTGGGGTGGAAGGTAAATTTACAGCTTGTGATGTCCTTCTTCG
CTTTACTCCAATCCCTATTATAGACAGATTTAGTGATTCCTGGTCTTTTT
AACACGAAGAATATCTATTGTTTTCTCTTTTGTAGGATCTGTATGATTTT
ATCTACTTAACAGATAGCACTAATTAGATTAAAATTCTATAAGAAACTTT
TTAATTTGCTGTTCATAATTTCTGATTGGTATGCAATAACTGTTTCAATG
AAAATCAATGTAATTTAGTATTTTAATATTTGCACCTTTGTGAAATATAG
TAAATAAATTAAGCACTATCACCACCTTCACAGCTACTTAGGAGATCCAC
AATCCTGGGTTGGGAGCCAGTGGATTTCCTGAAACACAGATTTGTTAATG

Sequence ID - 1165 nt: 502
CTCAAGTGAATCCTGGCTTCTTGGAAGCGCTTGCCTAGACGAGACACAGT
GCATAAAAACAACTTTTGGGGGACAGGTATGTTTTCTTGCAGCTGCGGTT
GTAAGGTCTTGGCAAGACAAGCAGTGTGGCCAGAATTTTGAACTTCTGAT
GAATGTGTAATGCAAAGGACCTTGTACATTTTTTTGTTTCAAGGTCCTCA
AAATGAGCACATGAAGAGGTTGCTGTGAAACTTTAAGTGGCCCTACTGCG
CAGAAGCATTCAGATGTCACTTGATGATCTGTAAGGGAACTTGCTGATTT
GGGAATGTGCTTAGGGAACACACATTCCTTTTGACAGGGTCTGTCACTGG
GTGGGTGATGAATTATACAGATGACATGTGCTTTTTTTTCTTTTTTCAAC
CTCAATGGTATTCCTACAGGAAATGGATAACCATTTTAACTGTATTTTTT
GCAGCCCGTACCTTCTTGGGAATACAATTGTCTAACTTTTTATTTTTGGT
CT

Sequence ID - 1172 nt: 648
CCACAATAATAAGAGAAAAACAGGAGCAAAAGGATATACAAAACCACCAG
AAAACAAATAACAAAGTGACAGGAGTAAGTCCTTAACTGGCAATAATAAC
CATGAATCTAAATGGATTCCATTTCCCACTTAAAAGATAAAGACATGCTG
AATGGATAAAAAGCTGTCACCCAGTTATATGCTGCCTACAACAAACTCAC
TTCACCTGTAAACATACATATGGATGGAAAGAGAAGGCATGGGAAAAGAT
ACTCTACTCAAATGAAAACAAAAACCAAACAAAGGTGGCTATTCTTATAT
GAGATAATACAGACATTAAATCAAAAACTGGAAACAAACACAAAGTCATT
GTATAATGATGAATTCAATTATATCATGATGAATTCAATTATATCCTCCT
TCCTGATCAATTCAGAAAGGAGGATATAATCTTTTTAAATATATATACAC
CCAACACCAGAGCATATAAATATGTAAAGGAAGATAAAGGGAGTCCTGTG
ATCAAGAATAAATATAACAATTATAAATATTTTATCTAAAGTGATAGATA
GACTGTAATACAATAATAGGGTGGTGACATTAACACCCCCTCTCACATTG
GACTGATCATCTAGAAGGGAGAAAAAGCTTTATGATTGGAAAAGCCAT

Sequence ID 1178
ATTGTGTTGGCCACCCGGGAATTCGCGGCCGCGTCGACCTACGCACACGA
GAACATGCCTCTCGCAAAGGATCTCCTTCATCCCTCTCCAGAAGAGGAGA
AGAGGAAACACAAGAAGAAACGCCTGGTGCAGAGCCCCAATTCCTACTTC
ATGGATGTGAAATGCCCAGGTGAGGAGACGGCTTGCTGTAGTGGGGAAAG
CACTGGACCTCAACAGTTGGAAAATGTTGTAGTGTTAGCTGTCTCGTATC
CTTGAAGCTGTGCAGCAGCTTCAGTTTCTTCGCCTGTGGAAAATATTTTC
CCTGATACTCTTAAAATTTGAATGTATGAGACTGGCAAAGTTTTGCATCT
TAGGAGGAGTGATTCATTTCACCGTGATCTCTCATCACATTTCACATACA
ACCCCTACGTTTTTTTGTGTTGGGAAACAATGTAATGGATGATGAGTTGG
GCATAAGTGCAGGAAAGACGGGTGTAATAGAGGAAAAAAATGTTATCTGC
TTTTCTTTCAGGATGCTATAAAATCACCACGGTCTTTAGCCATGCACAAA
CGGTAGTTTTGTGTGTTGGCTGCTCCACTGTCCTCTGCCAGCCTACAGGA
GGAAAAGCAAGGCTTACAGAAGGATGTTCCTTCAGGAGGAAGCAGCACTA
AAAGCACTCTGAGTCAANATGAGTGGGAAACCATCTCAATAAACACATTT
TGGAT

Sequence ID - 1180 nt: 622
CTTTTCCTCCCGCTGTCCCCCACGGGAGGGGACTGCTCTCCCCCGCTGCA
TCCTTTCTGTGAGGTACCTTACCCACCTCAGCACCTGAGAGGGTGAAATA
GAATTCTAACCTCGACATTCGGGAAGTGTTTTTGAGAAGTCTCGGTCGGT
AAGGGAAGTCTTCCAAGTCCGTGCAGCACTAACGTATTGGCACCTGCCTC
CTCTTCGGCCACCCCCCAGATGAGGCAGCTGTGACTGTGTCAAGGGAAGC
CACGACTCTGACCATAGTCTTCTCTCAGCTTCCACTGCCGTCTCCACAGG
AAACCCAGAAGTTCTGTGAACAAGTCCATGCTGCCATCAAGGCATTTAAT
GCAGTGTACTATTTGCTTCCAAAGGATCAGGCCCTGAGAACAATGACCTT
ATTTCCTACAACAGTGTCTGGGTTGCGTGCCAGCAGATGCCTCAGATACC
AAGAGATAACAAAGCTGCAGCTCTTTTGATGCTGACCAAGAATGTGGATT
TTGTGAAGGATGCACATGAAGAAATGGAGCAGGCTGTGGAAGAATGTGAC
CCTTACTCTGGCCTCTTGAATGATACTGAGGAGAACAACTCTGACANCCA
CAATCATGAGGATGATGTGTTG

Sequence ID - 1181 nt: 155
CGCCACTTATCCAGTGAACCACTATCACGAAAAAAACTCTACCTCTCTAT
ACTAATCTCCCTACAAATCTCCTTAATTATAACATTCACAGCCACAGAAC
TAATCATATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAA

Sequence ID 1182
CATTGTGTTGGCNCCCGGGAATTCGCGGCCGCGTCGACTTTTTGTGTTGT
TTGGAGCAGAAATACTAAAGAAGATTCCGGGCCGAGTATCCACAGAAGTG
GACGCAAGGCTCTCCTTTGATAAAGATGCGATGGTGGCCAGAGCCAGGCG
GCTCATCGAGCTCTACAAGGAAGCTGGGATCAGCAAGGACCGAATTCTTA
TAAAGCTGTCATCAACCTGGGAAGGAATTCAGGCTGGAAAGGAGCTCGAG
GAGCAGCACGGCATCCACTGCAACATGACGTTACTCTTCTCCTTCGCCCA
GGCTGTGGCCTGTGCCGAGGCGGGTGTGACCCTCATCTCCCCATTTGTTG
GGCGCATCCTTGATTGGCATGTGGCAAACACCGACAAGAAATCCTATGAG
CCCCTGGAAGACCCTGGGGTAAAGAGTGTCACTAAAATCTACAACTACTA
CAAGAAGTTTAGCTACAAAACCATTGTCATGGGCGCCTCCTTCCGCAACA
CGGGCGAGATCAAAGCACTGGCCGGCTGTGACTTCCTCACCATCTCACCC
AAGCTCCTGGGAGAGCTGCTGCAGGACAACGCCAAGCTGGTGCCTGTGCT
CTCAGCCAAGGCGGCCCAAGCCAGTGACCTGGAAAAAATCCACCTGGATG
AGAAGTCTTTCCGTTGGTTGCACAACGAGGACCAGATGGCTGTGGAGAAG

Sequence ID - 1183 nt: 479
CGTGGCAGCCATCTCCTTCTCGGCATCATGGCCGCCCTCAGACCCCTTGT
GAAGCCCAAGATCGTCAAAAAGAGAACCAAGAAGTTCATCCGGCACCAGT
CAGACCGATATGTCAAAATTAAGCGTAACTGGCGGAAACCCAGAGGCATT
GACAACAGGGTTCGTAGAAGATTCAAGGGCCAGATCTTGATGCCCAACAT
TGGTTATGGAAGCAACAAAAAAACAAAGCACATGCTGCCCAGTGGCTTCC
GGAAGTTCCTGGTCCACAACGTCAAGGAGCTGGAAGTGCTGCTGATGTGC
AACAAATCTTACTGTGCCGAGATCGCTCACAATGTTTCCTCCAAGAACCG
CAAAGCCATCGTGGAAAGAGCTGCCCAACTGGCCATCAGAGTCACCAACC
CCAATGCCAGGCTGCGCAGTGAAGAAAATGAGTAGGCAGCTCATGTGCAC
GTTTTCTGTTTAAATAAATGTAAAAACTG

Sequence ID - 1185 nt: 628
CTTTGATTACCTTTGAGTATTAGGTTGAAAGCTTCTCTGTGCTTGATTGA
ACATTGTGATGATGTTGATTGGGTCATGTCAGATTTAGACAGTGTTGTGT
TTAAGATAAATGTTTAATGGCTCTTAGCAGTGTTCATGCCTCCCCTTTTC
CCCTGATACTTTAAAAACAGAATATACAGAAAAGGGGAGTTGGGTGAAGA
ATCACCATATTCTCATTACCAGAGTAGTGTCTACCAGCTGTTTTCACATT
TTTCTGTTTCCTTCTGTCCTTGGAATCCTTTTTTTAGATCCTTGTAATAC
TAGTAAAGATATTCCACTCTGTGTTGTAAGCATTTTTCCATTTTGCTCCA
TGGTCTTCATAATGCCCTGTGGTCCTTTATTAAGGGGATGCACCATGTAG
AGGTGAAAGGCTTTCCTTGACTTGGCCACCATTTCTGTATTTTCCTTAGA
GGAGGAGGTTTCCAACATTTCTTTTTTAGAGACAGAGTCTCGTTCTGACA
CGCAGGCAGGAGTGCAGTGGCATGATAACAGCTCACTGCAGCCTCGAACT
CCTGGGCTCAAGTTATCCTCCCACCTCAGCTTCCTGAGTAGCTAGGACTG
CAGGTGCCTGCCACCACACCCAGCTAAT

Sequence ID - 1186 nt: 494
CAGCCCTCCGTCACCTCTTCACCGCACCCTCGGACTGCCCCAAGGCCCCC
GCCGCCGCCTCCAGCGCCGCGCAGCCACCGCCGCCGCCGCCGCCTCTCCT
TAGTCGCCGCCATGACGACCGCGTCCACCTCGCAGGTGCGCCAGAACTAC
CACCAGGACTCAGAGGCCGCCATCAACCGCCAGATCAACCTGGAGCTCTA
CGCCTCCTACGTTTACCTGTCCATGTCTTACTACTTTGACCGCGATGATG
TGGCTTTGAAGAACTTTGCCAAATACTTTCTTCACCAATCTCATGAGGAG
AGGGGAACATGCTGAGAAACTGATGAAGCTGCAGAACCAACGAGGGTGGC
CGAATCTTCCTTCAGGATATCAAGAAACCAGACTGTGATGACTGGGAGAG
CGGGCTGAATGCAATGGAGTGTGCATTACATTTGGAAAAAAATGTGAATC
AGTCACTACTGGAACTGCACAAACTGGCCACTGACAAAAATGAC

Sequence ID - 1188 nt: 599
GGGAGACAAGCCCAGCCTTTCGGCGAGNATACGTCTAACCCTGTGCAACA
GCCACTACATTACTTCAAACTGAGATCCTTCCTTTTGAGGGAGCAAGTCC
TTCCCTTTCATTTTTTCCAGTCTTCCTCCCTGTGTATTCATTCTCATGAT
TATTATTTTAGTGGGGGCGGGGTGGGAAAGATTACTTTTTCTTTATGTGT
TTGACGGGAAACAAAACTAGGTAAAATCTACAGTACACCACAAGGGTCAC
AATACTGTTGTGCGCACATCGCGGTAGGGCGTGGAAAGGGGCAGGCCANA
GCTACCCGCAGAGTTCTCAGAATCATGCTGAGAGAGCTGGAGGCACCCAT
GCCATCTCAACCTCTTCCCCGCCCGTTTTACAAAGGGGGAGGCTAAAGCC
CAGAGACAGCTTGATCAAAGGCACACAGCAAGTCAGGGTTGGAGCAGTAG
CTGGAGGGACCTTGTCTCCCAGCTCAGGGCTCTTTCCTCCACACCATTCA
GGTCTTTCTTTCCGAGGCCCCTGTCTCAGGGTGAGGTGCTTGAGTCTCCA
ACGGCAAGGGAACAAGTACTTCTTGATACCTGGGATACTGTGCCCAGAG

Sequence ID 1189
GGGAGACAAGCCCAGCCTTTCGGCGAGATACGTCTAACCCTGTGCAACAG
CCACTACATTACTTCAAACTGAGATCCTTCCTTTTGAGGGAGCAAGTCCT
TCCCTTTCATTTTTTCCAGTCTTCCTCCCTGTGTATTCATTCTCATGATT
ATTATTTTAGTGGGGGCGGGGTGGGAAAGATTACTTTTTCTTTATGTGTT
TGACGGGAAACAAAACTAGGTAAAATCTACAGTACACCACAAGGGTCACA
ATACTGTTGTGCGCACATCGCGGTAGGGCGTGGAAAGGGGCAGGCCAGAG
CTACCCGCAGAGTTCTCAGAATCATGCTGAGAGAGCTGGAGGCACCCATG
CCATCTCAACCTCTTCCCCGCCCGTTTTACAAAGGGGGAGGCTAAAGCCC
AGAGACAGCTTGATCAAAGGCACACAGCAAGTCAGGGTTGGAGCAGTAGC
TGGAGGGACCTTGTCTCCCAGCTCAGGGCTCTTTCCTCCACACCATTCAG
GTCTTTCTTTCCGAGGCCCCTGTCTCAGGGTGAGGTGCTTGAGTCTCCAA
CGGCAAGGGAACAAGTACTTCTTGATACCTGGGATACTGTGCCCAGAGCC
TCGAGGAGGT

Sequence ID 1190
GTTTAAATTTGACAAACTAAAGCTNAThACTGCTATAAGAGTAATAACTG
CTCATTTTCCATAACTCATTCTTAAAGTTTTAGTAATGTAAAAGTTATTT
TTTTGCAGTAAGTTATAATGATAGAAGCTTACATGTTTTTTCATGCCTCA
TCTGTTTCCCCTTAAAACTATAATTATCAGTAAAAGTCCTGTGGTATTTT
TCAATTTGTAAGAACTAGGCTATATATACATTGGGAAAAACAGCCTTCAT
TTGTCAATGCACTAGTGTTCCAAAGGTTTCTGGTAATTGTGTGCTATTGC
TTTTTGTTGACTTGCAAAAAAAAAAAAAAAAAAATTACTATGACTTGNGG
TAGCCCTGCAACCTTCGGAAGTGCTTAGCCCAGTCTGACCATACATTTAT
ATTTANAATGCTTAGGTAAATAAATAATATGCCTAAACCCAATGCTATAA
GATACTATATAATATCTCATAATTTTAAAAATCACTGTTTTGTATAATAA
TAAAACAAGGCAGGCAAGCTGTTCTACAATGACTGTTGGTAAGGGTGCTG
AGGAAGAAAAACAAACAATCTTGATTCAGGGATAGTGAATAGACAAAAAA
TGTCCTAATCAATGAAGCTGTGTGATGATTCTGATTGACAGAGA

Sequence ID 1191
GTGCAAAGTGTTATATCCACTTTCAACAAAGAGAGAAGCTGAAAAGCTAA
CCCAATGTTAATTTTGGATCACACACATTCAGTGTAGACTTTAAGATTTT
ACTTCTGTTGGAGTAGCTATATTATTTCTAGTTAAAAAACTCTCTATATA
CATATTTATTTGTTTTTCTACTTGTTTAATATTTTTCTCTTCCAATTAGG
AACTCAATATGGAATAAAAAATATTTAAATGTATTTTACTCAAACGTGTG
TGTATATATGTTTGTGTGCATGATAAGGAGAGTGAGAGCAAGAGTAAGAG
AGAGAGAGCACGCATAGATGGAAGCACACATTTAATGTCTATGAAATGAG
AAAACATTAAGGCTAAGATATTTTTCCTTCTGAACTAGCAGATTGTATCA
ATGGCTGGTCACTTAAATTAATCAGTTTGTAAAGATATTTAAAAGGTATG
TCTACCTTCTTGCAATTAATTTGATTATGTTCTAATGGCATGGCAAGAGA
AATGAAAGAAGATAACTAAAAGTTAAAAGTCGTTGCATGTTTTTGTTGCA
GCATACCCTTCTTTCAGGCTACCGAATAACCTTGATTGACATTGGATTAG
TAGTAGAATACCTCATTGGTAGAGCATATCGCAGCANCTACACTAGAAAA
CAT

Sequence ID 1192
GTCTGGAACTCCAGACCTCAGGTGATACCCCTGCCTCAGCCTCCCAATGT
GCTGGGATTACAGCTGTGAAGCCACCGCGCCCGGCTGCTGTGATAGTTGA
GATGTAAACCAAAAATAAAATTCTAAGCCACCCAATCCGACTGAATGGAC
CCTTCCTGTTGAGCAAGGACATTCCAAAGTAAACTGAAAAGACCAGCTTA
GGCCATGATGGGAAGGGGAGGTGTCAACATGCCTCATTCTACCTTCCTCC
CTCTGGAATCCAGACACAACTGACCAGCATTAACATTAAAACAGAGATCT
TAAGCTGGGCACGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCC
AAGGTGGGATCACCTGAGGTCGGAAGTTCAAGACCAGCCTGGCCGGTATG
GTGAAGCCATGTCTCTACTGAAAATGCAAAATTGGCCGGACATTGTGGTG
CA

Sequence ID 1193
TNCNTTTTTTTTCCCNCGGGAAAGCGCGCCATTGTGTTGGTCCCCGGGAA
TTCGCGGCCGCGTCGACGAGAAATGGCTTGAACCCAGTAGGCAGAGGTTG
TAGTGAGCCCAGAATNGGNCACCTGCACNTTTANCCNTGGGTGACAAAAN
TGAAAACTTTGTCTNAAAAAAAAAAAAAAAAAATTTTAANTNAAATNAAA
AANCCTTTNCNTTNTTTTTNAAANNGGGGGGGGNNTTTTTNGGGNTTNGN
NNTGGTAAAAANTNNNTTTTTTTTTTTTTAGGGGCCNANNCCCCNTTTTA
NAAAANCCNGNTTTTNAAAAAANTTTTTTNCCCNCNNTTNGGGGGGGGGG
NTTTTNANCNNTNTTNGGGGGGGNNCCCCTNTTANNACCNNCAAANTTTT
TANTTTTTTGNNNAANNNCCCCCTTTTTTNNTTTTTTTTGNGGGGGGGGG
GNNGCCCCCNNCCTTTNGGGGGGGGGGNTTNNGNAAAANNACTTTTNAAA
ANNAAGGGNNGGGGGNANATNNCCCCCCCNGGNTTTTTTTTTTAAAAANT
NAANNGGGGGGGGNNNCTNANTNGGGGCNCCCANNGGGGGNTTANAANNA
TTTTCTNCCCAAACCCCCNGNTTTTATNNCCCCCCCCCCCCNCNNNNGAA
NGGGNGGNCCNTTTTTTTTATTTTTNNGGNGGGNAAAAAANTTTNAAAAA
NNANNATNTTTTTTCCCCCCCCCCCCNCTTTTNGGNAAANCCNNGGGGGG
NTCCTTTTTNAAANNNNCCCCCAAAAAAAANTTTTTTTNTTNTNTTTTTC
TCTNGGGGNCCNNANTTNTANANTTTTNCNCCNAAAAAAAANGGGNCCCC
TTTTTTTNGNGGNNGGNNCCCAAAANNTTTTTTTTNAAAAAAAAAAAAAA

Sequence ID 1195
GTTCGTGACNTTCGGAGCTACCTGACAGAGCAGAGTCAACCAGGNTCTGC
CCAAAGAGAGTGTTAGGCCTGAGCTTGAGAGCCCTGGAGAGACGTGTGCA
CAAAATGTGACCTGAGGCCCTAGTCTAGCAAGAGGACATAGCACCCTCAT
CTGGGAATAGGGAAGGCACCTTGCAGAAAATATGAGCAATTTGATATTAA
CTAACATCTTCAATGTGCCATAGACCTTCCCACAAAGACTGTCCAATAAT
AAGAGATGCTTATCTATTTTA

Sequence ID - 1196 nt: 412
GTCGACGCGGCCGCGGTCGCTGGAGNCGATCAACTCTAGGCTCCAACTCG
TTATGAAAAGTGGGAAGTACGTCCTGGGGTACAAGCAGACTCTGAAGATG
ATCAGACAAGGCAAAGCGAAATTGGTCATTCTCGCTAACAACTGCCCAGC
TTTGAGGAAATCTGAAATAGAGTACTATGCTATGTTGGCTAAAACTGGTG
TCCATCACTACAGTGGCAATAATATTGAACTGGGCACAGCATGCGGAAAA
TACTACAGAGTGTGCACACTGGCTATCATTGATCCAGGTGACTCTGACAT
CATTAGAAGCATGCCAGAACAGACTGGTGAAAAGTAAACCTTTTCACCTA
CAAAATTTCACCTGCAAACCTTAAACCTGCAAAATTTTCCTTTAATAAAA
TTTGCTTGTTTT

Sequence ID 1197
CCGCCAACATGGGCCGCGTTCGCACCAAAACCGTGAAGAAGGCGGCCCGG
GTCATCATAGAAAAGTACTACACGCGCCTGGGCAACGACTTCCACACGAA
CAAGCGCGTGTGCGAGGAGATCGCCATTATCCCCAGCAAAAAGCTCCGCA
ACAAGATAGCAGGTTATGTCACGCATCTGATGAAGCGAATTCAGAGAGGC
CCAGTAAGAGGTATCTCCATCAAGCTGCAGGAGGAGGAGAGAGAAAGGAG
AGACAATTATGTTCCTGAGGTCTCAGCCTTGGATCAGGAGATTATTGAAG
TAGATCCTGACACTAAGGAAATGCTGAAGCTTTTGGACTTCGGCAGTCTG
TCCAACCTTCAGGTCACTCAGCCTACAGTTGGGATGAATTTCAAAACGCC
TCGGGGACCTGTTTGAATTTTTTCTGTAGTGCTGTATTATTTTCAATAAA
TCTGGGACAA

Sequence ID 1198
CAGAGGTGGGAGGATTGCTTCAGTTCAAGAGTTTGAGACCAGCCTGGGTA
ACATGGCGAAACCCTGTCTTTACAAAAAATGCAAACCTTTGCCGCATGTG
TTGGGGTGCGCCTGTAGTCCCAGCTTCTCGGGAGGCTGAGGTGGGGGGAC
CACCTGAGCCATGGAGGTTGAGGCTGCAGTGAGCCGTGATACCACCACTG
TACTCTAGCCTGGGCCATAGAGTGAGACACCCTGCCTCAGAAATA

Sequence ID - 1199 nt: 439
CCCATCCCCTCGACCGCTCGCGTCGCATTTGGCCGCCTCCCTACCGCTCC
AAGCCCAGCCCTCAGCCATGGCATGCCCCCTGGATCAGGCCATTGGCCTC
CTCGTGGCCATCTTCCACAAGTACTCCGGCAGGGAGGGTGACAAGCACAC
CCTGAGCAAGAAGGAGCTGAAGGAGCTGATCCAGAAGGAGCTCACCATTG
GCTCGAAGCTGCAGGATGCTGAAATTGCAAGGCTGATGGAAGACTTGGAC
CGGAACAAGGACCAGGAGGTGAACTTCCAGGAGTATGTCACCTTCCTGGG
GGCCTTGGCTTTGATCTACAATGAAGCCCTCAAGGGCTGAAAATAAATAG
GGAAGATGGAGACACCCTCTGGGGGTCCTCTCTGAGTCAAATCCAGTGGT
GGGTAATTGTACAATAAATTTTTTTTTGGTCAAATTTAA

Sequence ID - 1200 nt: 526
CTGGAGACGACGTGCAGAAATGGCACCTCGAAAGGGGAAGGAAAAGAAGG
AAGAACAGGTCATCAGCCTCGGACCTCAGGTGGCTGAAGGAGAGAATGTA
TTTGGTGTCTGCCATATCTTTGCATCCTTCAATGACACTTTTGTCCATGT
CACTGATCTTTCTGGCAAGGAAACCATCTGCCGTGTGACTGGTGGGATGA
AGGTAAAGGCAGACCGAGATGAATCCTCACCATATGCTGCTATGTTGGCT
GCCCAGGATGTGGCCCAGAGGTGCAAGGAGCTGGGTATCACCGCCCTACA
CATCAAACTCCGGGCCACAGGAGGAAATAGGACCAAGACCCCTGGACCTG
GGGCCCAGTCGGCCCTCANAGCCCTTGCCCGCTCGGGTATGAAGATCGGG
CGGATTGAGGATGTCACCCCCATCCCCTCTGACAGCACTCGCAGGAAGGG
GGGTCGCCGTGGTCGCCGTCTGTGAACAAGATTCCTCAAAATATTTTCTG
TTAATAAATTGCCTTCATGTAAACTG

Sequence ID - 1201 nt: 613
CTTAAGTATGCCCTGACAGGAGNATGAAGTAAAGAAGATTTGCATGCAGC
GGTTCATTAAAATCGATGGCAAGGTCCGAACTGATATAACCTACCCTGCT
GGATTCATGGATGTCATCAGCATTGACAAGACGGGAGAGAATTTCCGTCT
GATCTATGACACCAAGGGTCGCTTTGCTGTACATCGTATTACACCTGAGG
AGGCCAAGTACAAGTTGTGCAAAGTGAGAAAGATCTTTGTGGGCACAAAA
GGAATCCCTCATCTGGTGACTCATGATGCCCGCACCATCCGCTACCCCGA
TCCCCTCATCAAGGTGAATGATACCATTCAGATTGATTTAGAGACTGGCA
AGATTACTGATTTCATCAAGTTCGACACTGGTAACCTGTGTATGGTGACT
GGAGGTGCTAACCTAGGAAGAATTGGTGTGATCACCAACAGAGAGAGGCA
CCCTGGATCTTTTGACGTGGTTCACGTGAAAGATGCCAATGGCAACAGCT
TTGCCACTCGACTTTCCAACATTTTTGTTATTGGCAAGGGCAACAAACCA
TGGATTTCTCTTCCCCGAGGAAAGGGTATCCGCCTCACCATTGCTGAAGA
GAGAGACAAAAGA

Sequence ID 1202
GGAATTCGCGGCCGCGTCGACCTCTGCTCGAATTGACAGAAAAGGATTCT
GTGAAGAGTGATGAGATTTCCATCCATGCTGACTTTGAGAATACATGTTC
CCGAATTGTGGTCCCCAAAGCTGCCATTGTGGCCCGCCACACTTACCTTG
CCAATGGCCAGACCAAGGTGCTGACTCAGAAGTTGTCATCAGTCAGAGGC
AATCATATTATCTCAGGGACATGCGCATCATGGCGTGGCAAGAGCCTTCG
GGTTCAGAAGATCAGGCCTTCTATCCTGGGCTGCAACATCCTTCGAGTTG
AATATTCCTTACTGATCTATGTTAGCGTTCCTGGATCCAAGAAGGTCATC
CTTGACCTGCCCCTGGTAATTGGCAGCAGATCAGGTCTAAGCAGCAGAAC
ATCCAGCATGGCCAGCCGAACCAGCTCTGAGATGAGTTGGGTAGATCTGA
ACATCCCTGATACCCCAGAAGCTCCTCCCTGCTATATGGATGTCATTCCT
GAAGATCACCGATTGGAGAGCCCAACCACTCCTCTGCTAGATGACATGGA
TGGCTCTCAAGACAGCCCTATCTTTATGTATGCCCCTGAGTTCAAGTTCA
TGCCACCACCGACTTATACTGAGGTGGATCCCTGCATCCTCAACAACAAT
GTGCAGTGAGCAT

Sequence ID - 1203 nt: 692
TGCAGAGGGGTCCATACGGCGTTGTTCTGGATTCCCGTCGTAACTTAAAG
GGAAACTTTCACAATGTCCGGAGCCCTTGATGTCCTGCAAATGAAGGAGG
AGGATGTCCTTAAGTTCCTTGCAGCAGGAACCCACTTAGGTGGCACCAAT
CTTGACTTCCAGATGGAACAGTACATCTATAAAAGGAAAAGTGATGGCAT
CTATATCATAAATCTCAAGAGGACCTGGGAGAAGCTTCTGCTGGCAGCTC
GTGCAATTGTTGCCATTGAAAACCCTGCTGATGTCAGTGTTATATCCTCC
AGGAATACTGGCCAGAGGGCTGTGCTGAAGTTTGCTGCTGCCACTGGAGC
CACTCCAATTGCTGGCCGCTTCACTCCTGGAACCTTCACTAACCAGATCC
AGGCAGCCTTCCGGGAGCCACGGCTTCTTGTGGTTACTGACCCCAGGGCT
GACCACCAGCCTCTCACGGAGGCATCTTATGTTAACCTACCTACCATTGC
GCTGTGTAACACAGATTCTCCTCTGCGCTATGTGGACATTGCCATCCCAT
GCAACAACAAGGGAGCTCACTCAGTGGGTTTAATGTGGTGGATGCTGGCT
CGGGAAGTTCTGCGCATGCGTGGCACCATTTCCCGTGAACACCCATGGGA
GGTCATGCCTGATCTGTACTTCTACAGAGATCCTGAAGAGAT

Sequence ID 1204
TTTTTTTTTTTTTCCTGCGGGAAAGCGCGCCATTGTGTTGGTACCCGGGA
AATTCGCGGCCGCGTCGACACAGGCCCCAGCATCAAGATCTGGGATTTAG
AGAGGAAAGATCATTGTAGATGAACTGAAGCAAGAAGTTATCAGTACCAG
CAGCAAGGCAGAACCACCCCAGTGCACCTCCCTGGCCTGGTCTGCTGATG
ACACAGGTTGGGCNGGNNCNCNGGGGNGGNNNNGNNNNGCNGNNGGNNCN
GNNNNCNNNNNGCNNNNGNNNNTNNNCNNNGNNCNNNNNNNNNNNNNNNN
NGNTCNNGNNGCNGGGGCCNGGNCGNCGCGGNCGCGNNTNNNNGGGTNCN
NNCNCNNNGGCGCGC

Sequence ID 1205
CAGACTCTGACCCAGCCTCAGTCCTAACTCCTGGGGCTGGGCTGAGGGGA
ACAAGCATTTGCTGAAACTTGAAAAAACAAAGCAAATCAAAAACAGGAAA
AAATTGTACCTGGTACTTTTTTTTAGAAAAAAAGATTAAAAAAGAAAGAA
TAAATTCTTGTTTGGAAACTTGAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTTTAAACTCTNNNNNTNNC
NNCNANTAANNCANNTCNANNNNANNNAATTACTTNNANGTNNNTCACN

Sequence ID - 1207 nt: 642
ACGAGAAGCCAGATACTAAAGAGAAGAANCCCGAAGCCAAGAAGGTTGAT
GCTGGTGGCAAGGTGAAAAAGGGTAACCTCAAAGCTAAAAAGCCCAAGAA
GGGGAAGCCCCATTGCAGCCGCAACCCTGTCCTTGTCAGAGGAATTGGCA
GGTATTCCCGATCTGCCATGTATTCCANAAAGGCCATGTACAAGAGGAAG
TACTCAGCCGCTAAATCCAAGGTTGAAAAGAAAAAGAAGGAGAAGGTTCT
CGCAACTGTTACAAAACCAGTTGGTGGTGACAAGAACGGCGGTACCCGGG
TGGTTAAACTTCGCAAAATGCCTAGATATTATCCTACTGAAGATGTGCCT
CGAAAGCTGTTGAGCCACGGCAAAAAACCCTTCAGTCAGCACGTGAGAAA
ACTGCGAGCCAGCATTACCCCCGGGACCATTCTGATCATCCTCACTGGAC
GCCACAGGGGCAAGAGGGTGGTTTTCCTGAAGCAGCTGGCTAGTGGCTTA
TTACTTGTGACTGGACCTCTGGTCCTCAATCGAGTTCCTCTACGAAGAAC
ACACCAGAAATTTGTCATTGCCACTTCAACCAAAATCGATATCAGCAATG
TAAAAATCCCAAAACATCTTACTGATGCTTACTTCAAAAAGA

Sequence ID 1208
CCCTATACCTTCTGCATAATGAATTANCTAGAAATAACTTTGCAAGGGAG
AGCCAAAGCTAAGACCCCCGAAACCAGACGAGCTACCTAAGAACAGCTAA
AAGAGCACACCCGTCTATGTAGCAAAATAGTGGGAAGATTTATAGGTAGA
GGCGACAAACCTACCGAGCCTGGTGATAGCTGGTTGTCCAAGATAGAATC
TTAGTTCAACTTTAAATTTGCCCACAGAACCCTCTAAATCCCCTTGTAAA
TTTAACTGTTAGTCCAAAGAGGAACAGCTCTTTGGACACTAGGAAAAAAC
CTTGTAGAGAGAGTAAAAAATTTAACACCCATAGTAGGCCTAAAAGCAGC
CACCAATTAAGAAAGCGTTCAAGCTCAACACCCACTACCTAAAAAATCCC
AAACATATAACTGAACTCCTCACACCCAATTGGACCAATCTATCACCCTA
TAGAAGAACTAATGTTAGTATAAGTAACATGAAAACATTCTCCTCCGCAT
AAG

Sequence ID - 1209 nt: 620
CTCTCCTGTCAACAGCGGCCAGCCTCCCAACTACGAGAATGCTCAAGGAG
GAGCAGGAAGTGGCTATGCTGGGGGCGCCCCACAACCCTGCTCCCCCGAC
GTCCACCGTGATCCACATCCGCAGCGAGACCTCCGTGCCCGACCATGTCG
TCTGGTCCCTGTTCAACACCCTCTTCATGAACACCTGCTGCCTGGGCTTC
ATAGCATTCGCCTACTCCGTGAAGTCTAGGGACAGGAAGATGGTTGGCGA
CGTGACCGGGGCCCAGGCCTATGCCTCCACCGCCAAGTGCCTGAACATCT
GGGCCCTGATTTTGGGCATCTTCATGACCATTCTGCTCGTCATCATCCCA
GTGTTGGTCGTCCAGGCCCAGCGATAGATCAGGAGGCATCATTGAGGCCA
GGAGCTCTGCCCGTGACCTGTATCCCACGTACTCTATCTTCCATTCCTCG
CCCTGCCCCCAGAGGCCAGGAGCTCTGCCCTTGACCTGTATTCCACTTAC
TCCACCTTCCATTCCTCGCCCTGTCCCCACAGCCGAGTCCTGCATCAGCC
CTTTATCCTCACACGCTTTTCTACAATGGCATTCAATAAAGTGTATATGT
TTCTGGTGCTGCTGTGACTT

Sequence ID 1210
TTCGTAATTAGAATACTGTTTGGACTTGCTCAACAAGCACCTTATCTTAA
CAAAAAGTAACTTATAGAAAAGGGAGACATTCATTTAACTTCAAGCCCAT
ATTATTCTTAAAAGCTGACTCTTGAAATAGTATTTATTGAGTCATAGTGG
AGTCATGGGACTTTTTAAGGGCCGGAAGGGACTATTTAGATCATCCAGTC
CCACCCTGTCATTTTATGGAGGAGGAAACTGAGGCCTAGATAAGATAACC
AGTTAGTGGGTCCACTGACCTTTAGGACAGTAGTCTATCCGTAAGAGACA
ACATGGAGAAAGAAATACAACGTTTTTATAGTGAATTATCATCTTACAAA
GAATATTCTTCCCATATCGCACTTTTAAAAAGTGGGTACCTTAGTCAAAT
AGGAGAAAAAACCACTTGAGTAGTTTCATCCTCAGGTTTTAGGTGAGGAA
ACTGATACTCAGATTAAATAACTTTAAGCACACAGAGCCTGAATGATAGT
CTTATTTGAGCTCATCTGTGCTTTTAATGTGTACTACGTTAGGTGTTTTC
ACTTGCATTTCCTTTAGTCTTATTTGAGCTCATCTGTGCTTTTAATGTGT
ACTACGTTAGGTGTTTTCACTTGCATTTCCTTGTTTGACGTTGACAATAA
ATCGTGAAGCTGCCTTATCTAAGGAAGTCCTAAAGTAAATCATTGGAACA
CA

Sequence ID 1211
CCATTGTGTTGGNACCCGGGAATTCGCGGCCGCGTCGACGGAGTTTTACC
TTATTACACTTTAATCTCTGGATTTACCCCATCTCATTTCTCTTTTAGGA
AAACTGTTTGTATGTGGTGGCTTTGATGGTTCTCATGCCATCAGTTGTGT
GGAAATGTATGATCCAACTAGAAATGAATGGAAGATGATGGGAAATATGA
CTTCACCAAGGAGCAATGCTGGGATTGCAACTGTAGGGAACACCATTTAT
GCAGTGGGAGGATTCGATGGCAATGAATTTCTGAATACGGTGGAAGTCTA
TAACCTTGAGTCAAATGAATGGAGCCCCTATACAAAGATTTTCCAGTTTT
AACAAATTTAAGACCCTCTCAAACTAACAGGCTTAGTGATGTAATTATGG
TTAGCAGAGGTACACTTGTGAATAAAGAGGGTGGGTGGGTATAGATGTTG
CTAACAGCAACACAAAGCTTTTGCATATTGCATACTATTAAACATGCTGT
ACATACTTTTTGGGTTTATTTGGAAAGGAATGCAAAGATGAAGGTCTGTT
TTGTGTACTTTTAAGACTTTGGTTATTTTACTTTTTGGAAAAGAATAAAC
CAAGAATTGATTGGGCACATCATTTCAAGAAG

Sequence ID - 1212 nt: 374
AGAGCAGCAGCCATGGCCCTACGCTACCCTATGGCCGTGGGCCTCAACAA
GGGCCACAAAGTGACCAAGAACGTGAGCAAGCCCAGGCACAGCCGACGCC
GCGGGCGTCTGACCAAACACACCAAGTTCGTGCGGGACATGATTCGGGAG
GTGTGTGGCTTTGCCCCGTACGAGCGGCGCGCCATGGAGTTACTGAAGGT
CTCCAAGGACAAACGGGCCCTCAAATTTATCAAGAAAAGGGTGGGGACGC
ACATCCGCGCCAAGAGGAAGCGGGAGGAGCTGAGCAACGTACTGGCCGCC
ATGAGGAAAGCTGCTGCCAAGAAAGACTGAGCCCCTCCCCTGCCCTCTCC
CTGAAATAAAGAACAGCTTGACAG

Sequence ID - 1213 nt: 567
GAATTATTGACTTTGAATTGCATTTCAGTACCATGAAGTCAAAGTCAGTG
GTGTATTTGCTCATTTGTTCATTCTTTCTTTTCCACCAACATTACTGCCT
GCAGAGCCAGAGGTGAGTGCAGAAATCCTGTCAATTCGTCACTTGTGGAC
AACCTGCAGCTTGCCACAGCCTACAGTTCCACCACTGTGACCTCTGAAAA
CCTCCTGAACAAAAGGAAGGAGACTTGGAAATCCTGAATGGGCTTGGAGA
CATTAAGGGAGAACTGCCTCCCTGGACCAAGGCAGAATTCAATAGAACCA
GCAAGAAATTTTCCTATGAATGGGAAAGCAGGTGGCAGGGGGCAGGGGTG
GAAAAGCTTTGTACAGGAATTGTGGAAAAGCTTTTGCATTATCTCTAGTC
TGAAAGTCACATTTCTCAGTTCCTTTCCACTCTCTTCTGTCAACTTGCTG
TGAGTAAATGACATCTGTCACCTGTGACACGGGCCAGGGACTATCACCAT
ATGGCCCCCACACATTATCTAGTACCAGCCTGCCTGGGCCATGCCTTTTC
CAGTCACTGTACCAGCC

Sequence ID - 1214 nt: 620
CTCTCCTGTCAACAGCGGCCAGCCTCCCAACTACGAGAATGCTCAAGGAG
GAGCAGGAAGTGGCTATGCTGGGGGCGCCCCACAACCCTGCTCCCCCGAC
GTCCACCGTGATCCACATCCGCAGCGAGACCTCCGTGCCCGACCATGTCG
TCTGGTCCCTGTTCAACACCCTCTTCATGAACACCTGCTGCCTGGGCTTC
ATAGCATTCGCCTACTCCGTGAAGTCTAGGGACAGGAAGATGGTTGGCGA
CGTGACCGGGGCCCAGGCCTATGCCTCCACCGCCAAGTGCCTGAACATCT
GGGCCCTGATTTTGGGCATCTTCATGACCATTCTGCTCGTCATCATCCCA
GTGTTGGTCGTCCAGGCCCAGCGATAGATCAGGAGGCATCATTGAGGCCA
GGAGCTCTGCCCGTGACCTGTATCCCACGTACTCTATCTTCCATTCCTCG
CCCTGCCCCCAGAGGCCAGGAGCTCTGCCCTTGACCTGTATTCCACTTAC
TCCACCTTCCATTCCTCGCCCTGTCCCCACAGCCGAGTCCTGCATCAGCC
CTTTATCCTCACACGCTTTTCTACAATGGCATTCAATAAAGTGTATATGT
TTCTGGTGCTGCTGTGACTT

Sequence ID 1215
CACAAGATAGAATGGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
TTTTAAGTGACAGTGCCATAGTTTGGACAGTACCTTTCAATGATTAATTT
TAATAGCCTGTGAGTCCAAGTAAATGATCACTTTATTTGCTAGGGAGGGA
AGTCCTAGGGTGGTTTCAGTTTCTCCCAGACATACCTAAATTTTTACATC
AATCCTTTTAAAGAAAATCTGTATTTCAAAGAATCTTTCTCTGCAGTAAA
TCTCGCAGGGGAATTTGCACTATTACACTTGAAAGTTGTTATTGTTAACC
TTTTCGGCAGCTTTTAATAGGAAAGTTAAACGTTTTAAACATGGTAGTAC
TGGAATTTTACAAGACTTTTACCTAGCACTTAAAATATGTATAAATGTAC
ATAAAGACAAACTAGTAAGCATGACCTGGGGAAATGGTCAGACCTTGTAT
TGTGTTTTTGGCCTTGAAAGTAGCAAGTGACCAGAATCTGCCATGGCAAC
AGGCTTTAAAAAAGACCCTTAAAAAGACACTGTCTCAACTGTGGTGTTAG
CACCAGCCAGCTCTCTGTACATTTGCTAGCTTGTAGTTTTCTAAGACTGA
GTAAACTTCTTATTTTTAGAAAGTGGAGGTCTGGTTTGTAACTTTCCTTG
TACTTAATTGGGTAAAAGT

Sequence ID - 1216 nt: 484
CAACCTTAGCCAAACCATTTACCCAAATAAAGTATAGGCGATAGAAATTG
AAACCTGGCGCAATAGATATAGTACCGCAAGGGAAAGATGAAAAATTATA
ACCAAGCATAATATAGCAAGGACTAACCCCTATACCTTCTGCATAATGAA
TTAACTAGAAATAACTTTGCAAGGAGAGCCAAAGCTAAGACCCCCGAAAC
CAGACGAGCTACCTAAGAACAGCTAAAAGAGCACACCCGTCTATGTAGCA
AAATAGTGGGAAGATTTATAGGTAGAGGCGACAAACCTACCGAGCCTGGT
GATAGCTGGTTGTCCAAGATAGAATCTTAGTTCAACTTTAAATTTGCCCA
CAGAACCCTCTAAATCCCCTTGTAAATTTAACTGTTAGTCCAAAGAGGAA
CAGCTCTTTGGACACTAGGAAAAAACCTTGTAGAGAGAGTAAAAAATTTA
ACACCCATAGTAGGCCTAAAAGCAGCCACCAATT

Sequence ID 1217
GACAGGCGGGGGCCCAGCGGCCGGGTGAAGGCCGGGTGGCTCTGTGAATC
AAAGGAGAGTCCCAGAAAACCTGTGACTGTTGAAGAAAATTCATCTGTGA
ATTTTTATATTCAAGGAGTCAGTATTTATATTCATCTTTTAAACTGGGAA
GATTTATATTTTACTTTAAAACTTCTTGATAATAATTTACAATGAATGGA
CACAGTGATGAAGAAAGTGTTAGAAACAGTAGTGGAGAATCAAGGTAAGT
AAGCACTTTGTTATCAATTGTTTACTATGAAGAGAGTTGAAAACTTGACT
TTTTTCTTTATTGTTATTGTTGTTATTTAGTTTTCCTCATAGGTAGCAGA
GTTTTCAGGTTTTCCTCTTAGCTATCCAAATACTAAAAAAATTCTGATAT
ACGAACCTTTTTTCATAATACAGGTTTTAATTATATTTTTCATTCAGATA
CACAGTAGATCTTAAATATAGAAAGTTTTTGTTTACTTAAATCTATTTGG
AAGTTTATATTTGAGCTAATAATTAAGCTGGAGCATGTATAATAGATTTA
AATTGTTTTGACTGTTAGTGAAATTT

Sequence ID 1218
CTCACTTGGTGGGTGAGCCTCCAATGACTACACCCAAGGAGGATTTAACA
CAGGGATTTTATGACTTGCAACAAGTCAGGAGGACATGGGGTTGGGGTAG
TTCAGCAGTGCCTGTCTGAACAAAGGTGAAAATTGGGCTTTTATTGGGCT
GATCAAGGGGGAGTAAAGGCAGCCAGGAGCAGTCGCCTGTCATGCTTCTA
CCTATATTGCATGTATAGAAAAGGGAAAATAAACTCCTTCCTGGGCAGGG
TTTTAGTATGCTAAGGAGGGGAGTTATTCAACTTCAATCCAACTCAAGCA
TCAGCATTGCTGCGTCCATCCCAGTTTTGTTTTGCTGGGGCTGAACTTCT
TCCTATAACTTTTTGAAACAACAAGAACTCAAGGTGTGACAGTTACAAGT
GGGCCCTTTTTCACAGTGTGTACCTAAACACGTGAGGACCCTGGATTACA
GAATGACAGACTCGAAGTGACTCAAGTTCCGGTTGTTCATCTTTAGATGG
TAAAGATGGCTGTACGTACTATCCTTGCTTATTTCCAATCTATTGTTTAA
ACTCTTGTATATGTAATACCGCAGAGGCTAGAGATACAACCTTTGACCAA
ATGAGTGAATTCAAGTAATCCATTACTAATGTGATCTGGAAACAAACATG
GTGTTGAATGTGCATATGT

Sequence ID - 1219 nt: 559
CTTGGCAGCTCCGTTATGTGCCCAGCTCTTTGCAAGGGCATACTGGGAAA
TGAGTGGAGATAAAGGACCCAATCATAAGCATTTTACAGTATGGATACCC
CATTTTAAAAAGGTAAACTGAGGCACAATGCAATTTTTTTTTTTTTTTAA
GGAGTTTATTTGAGCAAACAGTGATTCATGAATCAGGCAGCACCAAACCA
GAAGGAGGCTTTGCTGAANAAGGATGAGGGACAAGCATTTATAAAGTGAA
TGTAGATGTAATACAAAGAAAATATTTGAACCGGGTGCGGTGGCTTACAC
TTGTAATCCCAACACTTTGGGAGGCCAAGGCGGGCAGATCACAAGATCAA
GAGATCGAGACCATCCTGGTCAACATGGTGAAACCCCATCTNTACTAAAA
AATACAAAAATTANCTGGGCGTGGTGGTGCGTGCCTGTAGTCCCAGCTAC
TTGGGCGGCTGAGGCAGGANAATTGCTTGAACCCGGGAGGTGGAGGTTGC
AGTAAGCCGAGATTGCACCATTGCACTACTCCAGCCTGGTGACAGAGAGA
GACTCCATC

Sequence ID 1220
GANNNGTGCGATANNATGNNTGTCTTTTTTTTAAAGTNTTTCNNATNGNA
GNGAANCCCCCNNANNTNNCATAANGAGAGATNACTACNGTACANATAGN
GNCANACNGATAGTAGTANCAANATTGTNTTAGCTANATNANTCAATAGA
TATCNAGATANAANAANANCNNGGATATACAGCGATGTNTNANNGGNNNN
NNNANGGAACGAACATCNACNTTAANNATAAGCTNGNGGAGAGAGACANG
TANGTTATANANNAGAATNGNAGTAGGNGTGATCATAATAGNNNNNANNT
ANTATATANGATNTTANTGNNCTNTNNTNNGTTTATCNNNAATNTCTATN
CTNGAGAGNAGCNNNATNNNNAGGCGANGANATTGGGNNNTNCTCNTNAT
AGANANCTGGTGTCNNANAANTACNTCATCTATTNANCTCTCACNANATG
GNANNATANAGNAGNGNNNTNNANAGGANTANGCATAGNGNNTNNCTNAA
ACAAAANNNATAAGANNTCTCGNNAANANGGGCCTNTNNTNTAGCGAGGN
NTTANTTTNTATANTTNTTCNCTCTTNNAATANNTANGATANATGANCTN
GNNGTGATANATANNNNNTACNGTNAANNTNTANTCNTATAATAGATANA
AATATAGGATNTTNCTCTGGCNGGTNGAANANTTNNTNCNNTTTNAATAA
TGNTGTTAGNGACNGNGNTNTNANANNNNNTTAGAAAGGTACTCTATATA
CTNNTATGNTNCGGCNNATAATANAACAGATGTTTGTATNAATATNAAAN
AAGGTCNNTTTCGNCAAGAGAANNNTGNCTGGTNATAGAATTAGCATAAN
TTANNTANTATGATNNANTNNTNCTACNANTNTTAGCNNTTNGCAGNAGT
CATTNNGNATNTATNNNGNNTANTAGTNANTTGGGNCTNNTNCAGANTAT
ATTNTGNGAANATGAANNTACGNANTCCTNNGNANTATNATNNTGANTAN
GANAANCNANANNTNTTNTANNANTGNCTATANATTGCCNNGATANATTN
TNNNAATGAANCGATAGCCCGCNCTAAGGANNTNNGTNANNTAAANNTCT
CAGATAANNTACNTNTTNNTTATTAANCNANNATCACANTATANCNGNGA
CANNNGCGANANTATATGTATGNNANTATNACNGNTCCNNNCCGNGAANN
TANTCNTANNAGGCATTCNGNNGAGCTNTTCTNCTAGACNATTTNNANTG
AAANNATGCNGNNAAAAACGACNNNCTTNAANTTNTGTCTACANTCCGCN
NTNTTTNTACAGATNGCAGNTAAGNNNANTNANNGCTCTCANCTNGCTNN
NACT

Sequence ID - 1221 nt: 741
AAGCAGAANTNTCTCTAAAAACATTATCTCCTTAAAATCTTGAGGTGCAT
ATNAGAGCCACAGGCAATCTCTGACATATAAAATTGCAGTACAGGCCTTT
CAAATTTGGCATTTCACTGGTACAATACAACAACCAAGATATATAATAAC
TGTACAGTGCCTAGACATTCCAGTAAGAACCATTATTTTCTTTAATGTAG
AATGATTAATACATATTCTACAAGGGGCAGTAAGGTTAGTAATTCTATAG
GGTATGTCCCGACATAATTTTCAAATTGTACAATAACACAAACAACTTTG
TTAAGGCCATGTTTTATTTGCTGATTAATGGACAAAAGGCAATGTAATTT
ATTTTCAAGTATTTTCTTGAAAGTCTGTGCTCATAAAAATCATGAAAAGT
TGGAAAGACTGTTAAATCACTGAAACTTCAAATATATCTTACACAATCTT
GTTTGTACAAAAATACAAGTTAAATATAAACATAAAGCAATCATGGTAAT
TTTATGCAAATCTGTTTTATGTGATCATCAGTTATATATAAAAGTTTCTC
AGTTCTGTTATTTGTGAAAAGATCAATACCAGATTGAATGACTACCTATT
GGCAAAGGGCCCTAAAAAGCTTACTTTAGCACTCATCTTTTACATGGTTA
AATGCATTTCCTAATTTGAGATCACCTAAACACTGGAAAAGAAAAAAAAT
GAAAGGGCAGTATGTCCATAAACCAACAAATAATTTGGCTG

Sequence ID - 1224 nt: 485
CGAAATTTCCTTGTGACACAGAGGAAGGGCAAAGGTCTGAGCCCAGAGTT
GACGGAGGGAGTATTTCAGGGTTCACTTCAGGGGCTCCCAAAGCGACAAG
ATCGTTAGGGAGAGAGGCCCAGGGTGGGGACTGGGAATTTAAGGAGAGCT
GGGAACGGATCCCTTAGGTTCAGGAAGCTTCTGTGCAAGCTGCGAGGATG
GCTTGGGCCGAAGGGTTGCTCTGCCCGCCGCGCTAGCTGTGAGCTGAGCA
AAGCCCTGGGCTCACAGCACCCCAAAAGCCTGTGGCTTCAGTCCTGCGTC
TGCACCACACAATCAAAAGGATCGTTTTGTTTTGTTTTTAAAGAAAGGTG
AGATTGGCTTGGTTCTTCATGAGCACATTTGATATAGCTCTTTTTCTGTT
TTTCCTTGCTCATTTCGTTTTGGGGAAGAAATCTGTACTGTATTGGGATT
GTAAAGAACATCTCTGCACTCAGACAGTTTACAGA

Sequence ID 1226
GGTTTTTATACTTGCCATGAAACTGTTCTTTGGGATATTATTTTGTTCAG
GTTCCCCACTTGGACAGCAGAGGGGGTGACTCTGCCCATCCCTGCCACTG
GTAGCCAGGCGGGCAATGTCTGCTAGCAGTCTGCTTCTGTCTGAACTCAG
CCAGCAGAGGCAAACTCCCGGTTCCCCGAGAAACACTCTGAAGGCAGGGT
GGGTGACTCCACCCACCACCGCCTCTCCTAGCCATGCAGGCCATGTCTGC
TAGAGCTTCCAGCGCAGTGGTCCTAATTCTGTCTGAATCCGGCTGAGGGG
TGCAGCCTCCTGTTACTGCCCAGGGAAACACCCAGATGGCAGGGTGGGTG
ACTCCAACCACCTCTGCCTGTGGTAGCCAGATGGGCCACACCTGCTAGAG
CTTCCAGCCCAGCAGTCCCGCTACTCTGTGGGTGGGTGCCATCCCCTGTT
CCTCTGGGAAGCACCCAGACAGCTGATTACGTGACCCCACCCACTTCTGC
AGATCCTAGCTGAGCAGGACTTGCTGGTTTGGACAATGCCCAAGCAGGGA
AGAGCCCTCATTCTCTTATCACTGACAGAGGTGAGATGTCCGANTTTGTA
NGCTGGTGGAGGAGTGAGGTGGAGGAGGTATGCCTCT

Sequence ID 1228
GTTATTCAGGTATCCATCAAAATTTTATAAGAGGGCCGGAAACATCGGCT
CACACCTGTAATCCCAGCACTTTGGGAGGCTGAGGCAGGTGGTTCACTTG
AGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGCAAAACCCCGTCACT
ATTAAAAATACAAAACATTAGCTGGGTGTAGTGGCAGGTGCCTGTAATCC
CAGCTATTCGGGAGGCCTAGGAAGGAAAATGGCTTGAACCTGGGGGTGGA
GGTTGGAGTGAGGCAAGATCACACCACTGCACTCCAGCCTGGGCGACAGA
GCGAGACTCCATCTCAAAAGAAGAAAAAAAAAACAACAAAAAAACCTTTA
TCAGATTATCAGAGGTTATCACTACAGAGGGAGGTAAAATTGGAGGGAAA
AGGGTACAAATTTATTTCAC

Sequence ID - 1230 nt: 741
AAGCAGAANTNTCTCTAAAAACATTATCTCCTTAAAATCTTGAGGTGCAT
ATNAGAGCCACAGGCAATCTCTGACATATAAAATTGCAGTACAGGCCTTT
CAAATTTGGCATTTCACTGGTACAATACAACAACCAAGATATATAATAAC
TGTACAGTGCCTAGACATTCCAGTAAGAACCATTATTTTCTTTAATGTAG
AATGATTAATACATATTCTACAAGGGGCAGTAAGGTTAGTAATTCTATAG
GGTATGTCCCGACATAATTTTCAAATTGTACAATAACACAAACAACTTTG
TTAAGGCCATGTTTTATTTGCTGATTAATGGACAAAAGGCAATGTAATTT
ATTTTCAAGTATTTTCTTGAAAGTCTGTGCTCATAAAAATCATGAAAAGT
TGGAAAGACTGTTAAATCACTGAAACTTCAAATATATCTTACACAATCTT
GTTTGTACAAAAATACAAGTTAAATATAAACATAAAGCAATCATGGTAAT
TTTATGCAAATCTGTTTTATGTGATCATCAGTTATATATAAAAGTTTCTC
AGTTCTGTTATTTGTGAAAAGATCAATACCAGATTGAATGACTACCTATT
GGCAAAGGGCCCTAAAAAGCTTACTTTAGCACTCATCTTTTACATGGTTA
AATGCATTTCCTAATTTGAGATCACCTAAACACTGGAAAAGAAAAAAAAT
GAAAGGGCAGTATGTCCATAAACCAACAAATAATTTGGCTG

Sequence ID - 1231 nt: 203
TTGAGGAAGGGTCTACTGTCTTTTTAAATGGCACAATTTTAAGAGGTTTG
AGAGGTACAGTCCCTTAACCTGCCACGGGAGAGGGGCCCCCAAACTTTCT
TCCCCCCACACTTCTGGTTTTCTGTGTGGAGGGGGAGCAGGGATATCTAA
GCTGTGGTGTGAAAGGGTAGGAGAGATGCTGGAGGTGGGGGTGCTGTGTT
CTA

Sequence ID 1239
TTTCCTCGGGAAGCGCGCCATTGTGTTGGTACCCGGGAATTCGCGGCCGC
GTCGACATTTTTTTTTTTTTTTTTTTTTAGAATGATTAACAATTTATTGA
GTTTTATTTATCTACAAAAATATAGCAATACAGNGAACTTCACCAAATCC
TAAATATTCAGTACCTGAACTGGCTACAACACCGNGTGCACACCCAGTTC
CTGCAGAATCTCTTGCAGATATGGGAGAGTCAGCCAGTGAAAAGATCCAT
TTCTTGGGAATCCTTGTCAACAAGACCAGTTCAGAAATCCAGGATATATA
GAAGCCTACTGTAATTTAAAAACAGTAACAAAAACCCCAACAAAACCCAA
ATCAACAAAGACCAAGATAAAGGNGTGATAAACATTAATTGTAATGGTTT
TCCTTTACATGCAATACATGCATTTTAAAATCACTAAGAAACACGAAATT
TTGTAGAGCAAAGTTTGNGTTTCACGTAAGTGCAAATGAATATATATTTT
ATTTTTTATACTATTAAATTATATATATTTTTTCCATACAAAAGCACACA
GTGTTAATCTATAAAATGACATCCAAGTGGATGATGATTGTTTTTGCATG
TCCCCCTGCTTAGATTTTTTTAAAATATATAGTCAAAAATTAACATCCTT
CTTTAAAAATACAGAAGGGAAAAANGGGCAAAAAAAAAAATCTAGACTCG
AGCAAGCTTATGCATGCATGCGGCCGCAATTCGANCTCGGNCGACTTGGC
CAATTCGCCCTATAGNGAGTCGNATTACAATTCACTGGGCCGNCGNTTTA
CAACGTCGNGACTGGGAAAACCCTGGCGTTACCCNNCTNATCGNCTTGNA
ACAATNCCCNTTTNGCCAGNGGGG

Sequence ID 1255
TCACTTCGTATNGAANCTGTTTGGACTTGCTCAACAAGACCTTATCTTAA
CAAAAAGTAACTTATAGAAAAGGGAGACATTCATTTAACTTCAAGCCCAT
ATTATTCTTAAAAGCTGACTCTTGAAATAGTATTTATTGAGTCATAGTGG
AGTCATGGGACTTTTTAAGGGCCGGAAGGGACTATTTAGATCATCCAGTC
CCACCCTGTCATTTTATGGAGGAGGAAACTGAGGCCTAGATAAGATAACC
AGTTAGTGGGTCCACTGACCTTTAGGACAGTAGTCTATCCGTAAGAGACA
ACATGGAGAAAGAAATACAACGTTTTTATAGTGAATTATCATCTTACAAA
GAATATTCTTCCCATATCGCACTTTTAAAAAGTGGGTACCTTAGTCAAAT
AGGAGAAAAAACCACTTGAGTAGTTTCATCCTCAGGTTTTAGGTGAGGAA
ACTGATACTCAGATTAAATAACTTTAAGCACACAGAGCCTGAATGATAGT
CTTATTTGAGCTCATCTGTGCTTTTAATGTGTACTACGTTAGGTGTTTTC
ACTTGCATTTCCTTTAGTCTTATTTGAGCTCATCTGTGCTTTTAATGTGT
ACTACGTTAGGTGTTTTCACTTGCATTTCCTTGTTTGACGTTGACAATAA
ATCGTGAAGCTGCCTTATCTAAGNAGTCCTAAAGTAAATCATTGGAACAC
ATGTANCCAGTTTGTTGTTTTTATTTGCCAGGTNTCAAATATAACTGAAA
ACCCATGCTAACTGACTNATTTTAAAAGNTGTNTGGGGCATGAAANGATT
GCTCTGCCTGGGCGGGNGGTTNANCCTGNGTCCCCCNTTTNGGAGNCCAC
CCANGANGCGATATTTNAGGGNNGATTCNAAACCCCTGGCACGNGNNAAC
CCCNTTTTTAAANANAAAANANCGGNNG

Sequence 1256
TTGTGTTGGTACCCGGGAATTCGCGGCCGCGTCGACGGAGTTTTACCTTA
TTACACTTTAATCTCTGGATTTACCCCATCTCATTTCTCTTTTAGGAAAA
CTGTTTGTATGTGGTGGCTTTGATGGTTCTCATGCCATCAGTTGTGTGGA
AATGTATGATCCAACTAGAAATGAATGGAAGATGATGGGAAATATGACTT
CACCAAGGAGCAATGCTGGGATTGCAACTGTAGGGAACACCATTTATGCA
GTGGGAGGATTCGATGGCAATGAATTTCTGAATACGGTGGAAGTCTATAA
CCTTGAGTCAAATGAATGGAGCCCCTATACAAAGATTTTCCAGTTTTAAC
AAATTTAAGACCCTCTCAAACTAACAGGCTTAGTGATGTAATTATGGTTA
GCAGAGGTACACTTGTGAATAAAGAGGGTGGGTGGGTATAGATGTTGCTA
ACAGCAACACAAAGCTTTTGCATATTGCATACTATTAAACATGCTGTACA
TACTTTTTGGGTTTATTTGGAAAGGAATGCAAAGATGAAGGTCTGTTTTG
TGTACTTTTAAGACTTTGGTTATTTTACTTTTTGGAAAAGAATAAACCAA
GAATTGATTGGGCACATCATTTCAAGAAGTCCCCTCTCCTCCACATTTGT
TTTGCCAATTTGCACATTAAATGACTCTTCCCTCAAATGTGTACTATGGG
GTAAAAGGGGTAGGGNTTAAANATGTAAACAGTTGGGTTTTTTAAGGGNC
CTTTTTCATAACTGGAACACTCTNTACAAGGNTNCTTNTTAAATAAATAA
CTTGACTTTTTTGTTTTNTAAANGNANCTTCNTGCTTCCATAAAAAAAAA
AATTTAANTNGNCANCTNTGCTGCTGCGNCCANTTNGCTNGNCCNTGGCA
TTCCCTAGGGANGNTNAATANTGGCNNNTTAACNNGGCNGNAACNNNNNC
CANT

Sequence ID 1331
GGGCGATGCATGCTTTATTAAGGCTCTTGTTTCACCTGGCAGTGTACTGT
ATCAACGTATAATACAGAAAAAAAATCTCTTTAAGGTCCTCCTTCACAAA
GACATAGAGTGAAACTCCCTTTACATGTCAGTATTTGTTCAACACTTTAG
GCAACTTGACTGTCAGTGTTAAAATGGAAAACAGGAAAATGGAAAAATCT
GACCAATTCTGCCACCTTGAGACTTTCATATAGACCTTGCACAACAATTG
TATAGATCACACACCGGCTGTATTTAATATGTAACATTTTCACACATATT
AAAGATACAGAAGTATTAAAAAACCCCCAATGTTAATGTATTTGCTTAAA
AGGCACAAGTTTCACATATCTGTCTAGCTATCTGTTGGTAATACAGAAAG
TATACTACTTTTTTAAAAAAGTGGGCAGAATTCTTGTGTATGTATATTTG
TGTGTACAGTATGTGTATGTGTGTATATATATATATTATATATATAGATA
ATATATAAATATTTTTTTTAAGGAGAAACTAGAATGTTTAGCTAGAAAAT
TCCACAGCCTGTGAAGAAATATTTCAAAATGGCCATAAAGGAGGTAAAAA
TGAAAACCATAACCTAACTTTTATAGAGGCTTTATCTTTAATTTAACGAT
GTGCGGAGGACTTTCTTGCTTGAATCTGTTCCGGGCTGTCTGCTCTGTCC
ATCAAATGGGCAGGTCTGGGAATGAGGCACCTTCGGCCGTTCAGAAGTGG
CCTGAACAGAATGCTGGAACCCAGGCTGGACTCGGAC

Sequence ID 1332
CAAACCTGCATGTTCTGCACATGTATCCAGGAACTTAAAAAAAAAAAAAG
ATAGTTTGTGTGTCTTAATTGAATAATAGTAGATTTATAGATTAAAGATC
TATGGGTTTTTAATATGGATTAGAAATCTGTGGGTTTTTGATATGGATTA
GAAATCTGTGGGTTTTTAATATGGATTGGAAATCTGTGGGTTTTTAATAT
GGATTAAAAAACATCTGTGGGTTTTTAATATGGATTAAACATCTGTGGGT
TTTTAATATGGATTAAACATCTGGGTTTTTAATATGGATTAAACATCTGT
GGGTTTTTAATATGGGTTAAAAATCAAAAGAAAATGAACTATTTGCTCCA
GTGCAGGAAAATACAGGCAATACTGGATACAATTAGATGGTCAGGAGCGA
TAACCCGGTTGCCATTGTTTGAAGAAGAGAATAAGGTGCTAGCATTCCTA
TCCGTAGATAATTTGACAGCTAGGAAATAGGGGGAGTCTTCTATGTAGTT
AGTGAAGGCTAAATGAACTATTATATGCAGTTATCGTAGAAGAGTACTCA
AAAAAATCTGTAAAAAATAAAGAAAGGCCGGGCGCGGTGGCTCACGCCTG
TAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCATGAGGTCAGGAG
ATCGAGACCATCCTGGCTACCANGGTGAAACCCCCGTCT

Sequence ID 1335
CAAGACTCCATCTCAAAAAAAAAAAAAAATCTACAGTGCTGAGTATATAA
AATTATTAACACATTTCACAACAATATGTGTTTGTGGAGTTAAATATTTT
TTGTCTTTAAAACAGGTAATTTTAGTGCATACTTAATTTGATGATTAAAT
ATGGTAGAATTAAGCATTTTAAATGTTAATGTTTGTTACATTGTTCAAGA
AATAAGTAGAAATATATTCCTTTGTTTTTTATTTAAATTTTTGTTCCTCT
GTAAACTAAAAGAACACGAAGTAATTGGTCACAATTACTGGTGTTTAACT
GCCAAATATGGGTAAATAAGGGAAAATTTTGTTTAATATTTAGTCCTTCT
GAGATGGCTTGAATATTTGAATTTTGTTGTACGTCTATACTGGGTAGTCA
CAAGTCTTATAAACACTTTAGAGGAAAGATGGATTTCAGTCTGTATTTTT
AAACATCATTTATTTTAAATCTGGTGCTGAAAAATAAGAAAAAAATTAAA
CTGCATTCTGCTGTTCTTCTTTAGAAGCATTCCTGCGTAAATACTGCTGT
AATACTGTCATGCAAAGTGTATCCTTTCTTGTCGTATCCTTTTTGGGGCA
GTGTTTTTTTGTTTTTTTCCTAGAAATGTTTGTCCTTCCCCCACCTGTTG
ATCCAGGTTAAGGAATACTTTTTTACACTTTATTCAAA

Sequence ID 1336
CTTTTCCTCCCGCTGTCCCCCACGGAGGGGACTGCTCTCCCCCGCTGCAT
CCTTTCTGTGAGGTACCTTACCCACCTCAGCACCTGAGAGGGTGAAATAG
AATTCTAACCTCGACATTCGGGAAGTGTTTTTGAGAAGTCTCGGTCGGTA
AGGGAAGTCTTCCAAGTCCGTGCAGCACTAACGTATTGGCACCTGCCTCC
TCTTCGGCCACCCCCCAGATGAGGCAGCTGTGACTGTGTCAAGGGAAGCC
ACGACTCTGACCATAGTCTTCTCTCAGCTTCCACTGCCGTCTCCACAGGA
AACCCAGAAGTTCTGTGAACAAGTCCATGCTGCCATCAAGGCATTTATTG
CAGTGTACTATTTGCTTCCAAAGGATCAGGCCCTGAGAACAATGACCTTA
TTTCCTACAACAGTGTCTGGGTTGCGTGCCAGCAGATGCCTCAGATACCA
AGAGATAACAAAGCTGCAGCTCTTTTGATGCTGACCAAGAATGTGGATTT
TGTGAAGGATGCACATGAAGAAATGGAGCAGGCTGTGGAAGAATGTGACC
CTTACTCTGGCCTCTTGAATGATACTGAGGAGAACAACTCTGACAACCAC
AATCATGAGGATGATGTGTTGGGGTTTCCCAGCAATCAGGACTTGTATTG
GTCAGAGGACGATCAAGAGCTCATAATCCCATGCCTTGCGCTGGTGAGAG
CATCCAAAGCCTGCCTGAAGAAAA

Sequence ID 1337
CAAGAACTCTGGGACATTTGCAAAGGGTATGGCATATGTGTAATGGGAAT
ACCAGAGGAGAGGAAAGACAGGAAGTCAAAAAAAGAATTTTTCCAAATTA
ATGATAGGTTCCAAACCACAGATGCAGGAAGCTTAAACACCAACAGGATA
AATAAAACAAAATCTACGCTTAAGCATATCATACTTAACCTGCAGAAAAT
TACAGACAAAGAAAAAACACCAGAGGGGAAGCTGGCAGAAACATACCACC
TATAGCGGAAGAAGAATAAGAATTACATCAGACTTCCCTTCAGAAATCTT
GCAAACAAAAAGATGTAGCACAATATTTAAAGTATTAAAGGAGGCCGGGC
CCGGTGGCTCGGGCCTGTAATCCTAACACTTTGGGAGGCTGAGGCAGGAG
GACCATGAGGTCAGGAGATCGAGACCATCCTGGTGATGGTGATACCCCAT
CTCTACTAAAAATACAAAAAATTAACCGGGCATGGTGACACGCACCTGTA
ATCCCAGCTACTTGGGAGGCTGAAGCAGGAGAATCGTTTGAGCCCAGGAG
GTGGAGGTTGCAGTGAGCCGAGATCACATCACTGCACGCCTGGGCAACAG
AGCGAGACTCCATCTCAAAAAA

Sequence ID 1338
CGACCCGTTTTAGTCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCC
TGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCC
GGCGTAAATCAGGTTTTTTAAATGTTTGCCAAACCTTATCACTGACTTTT
ATAACAAAATTATTTACTATAATCATTAGGGAATATTTAAGTTCTGCTAA
TACTTAAAATTGCAGAGTGCTAAAACCAGCAGTGAGTTTAGAATCAAGCT
AAGCTTTATTGTTGCTACTATTTGAGGCATATTAGTTGACTGGTGTTCAT
ATGCAAGGCAGTCTACTGGGTGCAACAAGGGTTAGAAGGATATTTTTAAA
AAACTGACCCTATTCTCAGGATGAAAATAATACACTAGTAATAGTCTGCT
CTGTTGGTTAACTCCTCGTAAGGAGGTACAATTAAAATGCTGTAGTGTTG
CAAGGGAAGGAGAGGAAGAATCATATTCCTTCACTAGCAGGATCAAGAAA
GCTTTTATAGAAATATACAAAATCTTCACTTCTTGAAGGATTGGTAAAAT
TTAATAGCCAACATTGGGCACTTATTCATTCTCTGAGTAAATATTTATTG
CATGCTTATCTTGTATCAAGCATTGTGATGAAAGCACAAGAATGAAAGAG
GAGGGAGAATGTTTAGAGAATAAGGGCTGAAACACAGATTTTGTAGGGAG
CGTAGGGGAGACTGANAAGACAGGTTCAGGTTAGTAAGGGCGCTCATATT
TTGACCCTGAATGTTAACTATGTGCACATCATGCTAGCTATTCTAAATCA
GGCATTTTCAAATGGAAGCAGGCACTGACATTTT

Sequence ID 1344
CGTGAAGGGTCTTTATGTATTAGTATTAGAGTGATCTTTTGATTATTTTC
CTCACTATAAGGAAATTATTTCCTCAGGATGAGCTGCCATAACATTCCAC
TGTCTGATGGCAATTTTAAAGCCTGAAATTGAAGCCCATGGCTAGGCTAT
GAGAACCCTAGTTCGTATAGTAAAGTTGATATCTTCTGGATGTATACTAA
TTTTAGGCTTTATTTTAAAACTGCTGGAAACTGAAACTTAGACAAAAGTA
TTTTCAGGACATCATTTACAATGTTTAGCCCTAAAGAGTCAAGCTGTGGG
ATTCTGAGTCTTTCATATGTTACAGCAGAAACTTAAAAGCAAGAGGAAAT
TGGCTGGGCACAGTGGCTCTGTAATCCCAGCACTTTGGGAGGCTGAGGTG
GGTGGATCATGAGGTCAAGAGATTGAGACCATCCTAGCCAACATGGTGAA
ACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGCACACG
CCTGTAATCCCAGCTAGTCAGGAGGCTGAGGCAGGAGAATATCTTGAACT
TGGGAGGCAGAGGTTGCAGTGAGCCAAGATTACATCACTGCACTCCAGCC
TGGTGACAGAGCGAGACTCCGACT

Sequence ID 1348
CTGAAACTGCACTGAACCCACAGGTAGGTTACATCACAGGACAGAAATCT
GAGGAGCTGGAGAAAGCAAAAGAATAAAGGATGGGCTGACACCAGAAGGA
ATTAAAGGAATTTTTATACTGAACTTCAATTACTTGTTCATTTGAAGTTT
GTTTTTTTAATGAACGTTTTTGCTGTTACTTAAATATAGTGTTTTGAAAG
TGTTTCAAATGTATTCAAGTTGGGATTTTCCATATTTTACTACAGTTCTG
TCTTAGTATGTTCACCATAAAACACTTATCATTAAAGCTCACAAAGTGCT
TTTTTGTAATATGAGGATAAAATGAAGCCATATAAGAATTTTTTTATATC
TGTACATTTAACCCACATTTGAGCTTTAGCCAAAATATATAGCTTTTTTT
TTTCTGACCTGGCCAACGTATTATCCAGCAAACATCAACTGAAGCAATAT
GGAAACACTTCCAAATGTTTGCCAATAATGCTATTAAGTGACTGATGTCA
ACATTAGTTACATGGCAAACTAAAGAGGCATTATACATTTTTAAAACACA
CTAACATATAACTGTAGATAATGTAAGGTTTATTTATATGCATATTTCAT
AGTATATTTAAATGTTTAAATATAAAAAAGGGTTTTTAAACACTTTTAAT
TTTTATCTTTGATTTTTTTTATTGATATCTCTTTCCAGGCTACTAATAAA
ATTGCCAGAACTAAACTATCAGGTAAAGGTTAAGGCATCAATTGACAAGT
AAGTTTTCTAATTTCGTTTTGAATTACAATTCCAAATGTAAGACTTTTAA
AAATGAATGGCCTTTATTTTATAGAATAATTTTGACCTTTTAAATTTACT
TATCTAACATTATATAATGAATGTACTTCAAATATTTGACTTTGAAGTCA
ACATTAACAAATTCATGGATCCTAATTAAAATTTACTATAAAACTGGAAT
CATTTATTACTTCCTT

Sequence ID 1351
TTTTTTTTTTTTTAAAAGAGATGGGTTCTCACTATGTTGCCCATAATGTT
TATGAGATTAAGTTCATCTTTTTTATCTGAGTAGTATTTTATTGTATGAA
TATACCACCATTTATTTATCTGTTGGTTATTTCCAGTTTTGGGCTATAAT
CCAAAATGCTTTTTTCAAACAATAGGCTATATATCATTAATGTCCGTTTA
TCAGCAGTATAAAATATCTTACCATAAATATTAATAAAAGAAGCATTCAT
ATATAAAATATAGATATTTCAAACCCTACAGAGGGCCTTTTAATGATTAA
ATATTTTGTCCTTACAAAAAGGTCCAGGTAATTACACCCATGAGGTTAAC
CTGCCTTAGTGCAGGACTTAAAATAAGGCTTCTCCTGCCATCTCTCTCCA
TTTGTAGAATGTGAAATTCTTTAAAATGCATCCTATATTAGGAATACTAT
AGCTGTGCACTGGTGTTTGTTCTCTTCTTTAAACTCGGGACCGTATATAT
CTGCTCAAATTGCCCAAGTATACATATGCTGCACTCCATCAAGTGTCAGG
CCACATTCTATCAGCACAGCGTGACTGCCTATCAGTGACAATATAAGTGA
GCTCTATTTGGATCCCTCTTACCCTACCTTTTATATTTATGACAGCATTA
TCATAAAACTCCAATATTCTTCAATAACTTACATGTTTGTTGTAGGATAA
AATTATTACCCTCAATGAACTACAT

Sequence ID 1352
ACCAGCTTCTTCACAGGTTCCACGAGTCATGTCAACACAGCGTGTTGCTA
ACACATCAACACAGACAATGGGTCCACGTCCTGCAGCTGCAGCCGCTGCA
GCTACTCCTGCTGTCCGCACCGTTCCACAGTATAAATATGCTGCAGGAGT
TCGCAATCCTCAGCAACATCTTAATGCACAGCCACAAGTTACAATGCAAC
AGCCTGCTGTTCATGTACAAGGTCAGGAACCTTTGACTGCTTCCATGTTG
GCATCTGCCCCTCCTCAAGAGCAAAAGCAAATGTTGGGTGAACGGCTGTT
TCCTCTTATTCAAGCCATGCACCCTACTCTTGCTGGTAAAATCACTGGCA
TGTTGTTGGAGATTGATAATTCAGAACTTCTTCATATGCTCGAGTCTCCA
GAGTCACTCCGTTCTAAGGTTGATGAAGCTGTAGCTGTACTACAAGCCCA
CCAAGCTAAAGAGGCTGCCCAGAAAGCAGTTAACAGTGCCACCGGTGTTC
CAACTGTTTAAAATTGATCAGGGACCATGAAAAGAAACTTGTGCTTCACC
GAAGAAAAATATCTAAACATCGAAAAACTTAAATATTATGGAAAAAAAAC
ATTGCAAAATATAAAATAAATAAAAAAAGGAAAGGAAACTTTGAACCTTA
TGTACCGAGCAAATGCCAGGTCTAGCAAACATAATGCTAGTCCTAGATTA
CTTATTGATTTAAAA

Sequence ID 1353
ACATTCTGGAAAAGGCAAAAGGGAGGAAGAACTGATTAGTGGTTAGCCCA
GGGTTAGAGTTGGGGAGAGGATATAATGAGGGAACTTTTGTGGATTCTGT
ACCATGATTATGATTACACAAACCTATGCATACATTGAAACACATAGAAC
TATACGTTGAAAAAAGTGAATCTGCCTGTATGTAAATTTAAAAGAAAAAT
ATTTTTTTAAAAAAACAGATGCTTCTTAACACATTATCATCTATGTCAGT
TTAACAGTTAGTAGACTTAGGCCAGGTGTCATGGCTCACTCCTGTAATCC
CAGTGCTTTGGGAGTCTGAGGTGGGACGATCTCTTGAGACTAGGAGGGAG
TTTGAGACAAACCTAGGCAATGTAATGAGACTCTTTCTCTACAAAAAATT
TTAAAGTTATCTGGACATGGTGGTGCCTGCCTGTAGTCCCAGCTACTTGG
GAGGCTGAGGTGGGAGGATTCCTTGAGCCCAGAAGTTCAAGGCTACAGTG
TGCTATGATAGAGCCACTGCACTCCAGCCTGGGCAACCAGGTGAGACCTT
GTCTCTAAAATGAATAAATAAAT

Sequence ID 1355
TGGTCTTTCACCCAGCCAGGGAGAAGGTTCTTCGCTCAGTATGAAGAAAA
GCAACCCAAAACTCTCAATCTGATTTGTTTTTGTTTATGTCGATGCCCTG
TAGTTTGAAAGTGAAGTAAAGATTTAGAATTCACCTAAGTCCAAAGGAAA
ACACGTGGTTTTTAAAGCCATTAGGTAAAAAAAGTTCTCAATAAAGGCAT
TACAATTTTTTAGGTTTAGAAAGATGGACTTTTCTGATAAATCTTGGCAG
ACATCTAAAAAAAAAACCATATTTTTCACAAGAAAATGCAAGTTACTTTT
TTTGGAAATAATACTCACTGATTATGGATAAAATGGAATATTTTCAGATA
CTATATTGGCTGTTTCAAAATAGTACTATTCTTTAAACTTGTAATTTTTG
CTAAGTTATTTGTCTTTGTTGTATCTATAAATATGTAAAAAATATTTAAA
TAGATGTACCTGTTTTGCTTTCACACTTAATAAAAAATTTTTTTTTGT

Sequence ID 1359
CGGGATCCCTAGTATAACACATTCAGTGTTCCCCTTTCAGTCTTACTACT
TTGACCGCGATGATGTGGCTTTGAAGAACTTTGCCAAATACTTTCTTCAC
CAATCTCATGAGGAGAGGGAACATGCTGAGAAACTGATGAAGCTGCAGAA
CCAACGAGGTGGCCGAATCTTCCTTCAGGATATCAAGAAACCAGACTGTG
ATGACTGGGAGAGCGGGCTGAATGCAATGGAGTGTGCATTACATTTGGAA
AAAATGTGAATCAGTCACTACTGGAACTGCACAAACTGGCCACTGACAAA
AATGACCCCCATGTGAGTATTGGAACCCCAGGAAATAAATGGAGGAAATC
ATTTGCCTTAGGGATTGGGAAAGCTGCCCACTAACTGTCTTCCCCATTGT
TTTGCAGTTGTGTGACTTCATTGAGACACATTACCTGAATGAGCAGGTGA
AAGCCATCAAAGAATTGGGTGACCACGTGACCAACTTGCGCAAGATGGGA
GCGCCCGAATCTGGCTTGGCGGAATATCTCTTTGACAAGCACACCCTGGG
AGACAGTGATAATGAAAGCTAAGCCTCGGGCTAATTTCCCCATAGCCGTG
GGGTGACTTCCCTGGTCACCAAGGCAGTGCATGCATGTTGGGGTTTCCTT
TACCTTTTCTATAAGTTGTACCAAAACATCCACTTAAGTTCTTTGATTTG
TACCATTCCTTCAAATAAAGAAATTTGGTACC

Sequence ID 1360
TGCGCAGACCAGACTTCGCTCGTACTCGTGCGCCTCGCTTCGCTTTTCCT
CCGCAACCATGTCTGACAAACCCGATATGGCTGAGATCGAGAAATTCGAT
AAGTCGAAACTGAAGAAGACAGAGACGCAAGAGAAAAATCCACTGCCTTC
CAAAGAAACGATTGAACAGGAGAAGCAAGCAGGCGAATCGTAATGAGGCG
TGCGCCGCCAATATGCACTGTACATTCCACAAGCATTGCCTTCTTATTTT
ACTTCTTTTAGCTGTTTAACTTTGTAAGATGCAAAGAGGTTGGATCAAGT
TTAAATGACTGTGCTGCCCCTTTCACATCAAAGAACTACTGACAACGAAG
GCCGCGCCTGCCTTTCCCATCTGTCTATCTATCTGGCTGGCAGGGAAGGA
AAGAACTTGCATGTTGGTGAAGGAAGAAGTGGGGTGGAAGAAGTGGGGTG
GGACGACAGTGAAAT

Sequence ID 1361
TATAAATACACTCCGGGATGATTTACCCCCGGAGGTCAGCTAGTAAAATA
CATGAGTAGAATTCCTTAAAGTATGTGATAATTGCTCATCACTATCCAAG
TGTGACATAAATCATAAAAAGAATTGACAAAATCAGGGTCGCAAAGAGAA
TTGAAAAAAATCTGTCACAACCAAAATTTAAATTGACCTCTGTCCTAGAG
TATGAGAGCCACACTGAACAGAAAAACCAGATAAATCTTTTATAAAATAT
TCATTTGCAGCCCCATTAACGTTGCTTGTCACCCCACCTCCCCATGTCCT
TGGACAAACTGAATGTATAGTAACATCATCCCAGGCCAGGCGCGGTGGCT
CATGCCTGTAATCCCAGCACTTTGTGAGGCTAAGGCAGGCAGATCAGGAG
GTCAGGAGTTCAGGACCAGCCTGGCCAAAAAGGTGAAACTCCGTCTCTAC
TAACAATACAAAAATTAGCTGGGTGCGGTAGTAGGCGCCTGTAATCCCAG
CTACTCGGGAGGCTGAGGCAGGAGAATTGCTCAAACCCGGAAGGTGGAGG
TTGCAGTGAGCTGAGATCGTGCCACTGCACTCCAGCCTGGGTGACAGAGC
AAGACTCTGTCTCGGGGAGGGGGGTGGCGGAGATAAAGAAATAACATCAT
CTTATACTGTCAAGCTCAAGGTGTCTGCAGCCTTATCTTCAGGGGAAGTT
GTGTCTTTCTCAGGGAAGATACAGATTTCAATTTAGAGCAAGACAGAGAG
AAGTTACATTCAGAGAGGAAAATGCAGTAGTCTAACTG

Sequence ID 1364
GCGGCCGCGCTCTTTTCAATTTTTAAAAAGAAGTTTGTTTTCCATTTCAG
TAATTTCTGCTTTGATCTTCCTTATGTCCTCCTATTGAGTTGATCAGCTT
TCTTTATTCTTGCCTTTTCTCCTCTGTGTGCCCTTTCTATTAACGTATTT
ACCCTTAGGCTGGGCACAATGGCTGATGCCTGTAATCCCTGCACTTTGGG
AGGCCGAGGCAGGTGGATCACCTAAGGTCAGGAGTTCAAGACCAGCCTGG
CCAACATGGTGAAACCTGGTCTCTACTAAAAACACAAAAATTAGCCAGGC
ATGGTGGTGTGCACCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAG
AATTGCTTGAACCTGGGAGGCGGAGATTGTGCCAAAGCACTCCAGCCTGG
GCAACAAAATGAGACTTTGTGTC

Sequence ID 1365
CACCAGGCTGTCTTCAGATACTTCATACAGAAATGAGCCTCCCTGTGGGG
TCCTCTTCCCTCCTTCAGCCTGTCCATCAACACAGCATTGCGGGATCCTT
ACCATGGCATCCAGCCCTGGAGATGCTTCAGGAAAGTTGCAGGTCCATGC
TGCAGGACAGGCTCAGATCAGCAGAGACGCATCTCACATCGGGCTGTGAA
ATTCAAGTTGAGCTGCAATTGGCAATGAGAA

Sequence ID 1366
GTTATTCACTGAGACCGTGCCCCGGTTATGAGGTTGTACCAGAAAGCAAG
TATTCACTATGCACACTATTCACCGCTCACCCTAGCATTGAAGCCAGCCT
GTAGCCTGAAAGCCTTTGCTTTGAGGGCAGGTCTTTCCCCAAAATGCAGA
CACGAAGGTGCAAAGTGAAGCTGCCAGTCTTGCAAAAGATGTAACTTGTC
ACGAAGGCCACGAGTGGCAGGGAGAGCTGTCCCACATTTGCGGAAGTGGC
TATGTGAGGACGGGGGAGGCGGGTCCCTTAGAGATGAGACAATCATAAGG
GGAGATATCAGAGAAAATCGTAAGGGGAGCAGATGGTTGTCAAGAGAATA
GGCTGACCATCGAAGGACTGGCAGAAGCTTTCAGAAAACCACTGGACGGC
TGGGCACAGTGGCTTAGGCCTGTAATCCCAGCACTTTGGGAGGCTGACGC
AGGTGAATCACTTGAGGTCAGGAGTTCCAGACCAGCCTGGCCAACATGGT
GAAACCCCATCTCTACAGAAAATATAAAAATTAGCCAGGCGTGGTGGCAC
AAGCCTAGAATCCCAGCTACTTGGGAGGCTGAGGCAGGCGAATGGCTTGA
ACCCAGGAGTCAGAGGCTGCAGTGAGTCGAGATTGTTCCACTGCACTCCA
GCCTGGGTGACAGTGCAAGACTCCTTCCAAAAAAAAA

Sequence ID 1367
TTCGTGAGTGATGGCGTCCCGGGTTGCTTGCCGGTGCTGGCCGCCGCCGG
GAGAGCCCGGGGCAGAGCAGAGGTGCTCATCAGCACTGTAGGCCCGGAAG
ATTGTGTGGTCCCGTTCCTGACCCGGCCTAAGGTCCCTGTCTTGCAGCTG
GATAGCGGCAACTACCTCTTCTCCACTAGTGCAATCTGCCGATATTTTTT
TTTGTTATCTGGCTGGGAGCAAGATGACCTCACTAACCAGTGGCTGGAAT
GGGAAGCGACAGAGCTGCAGCCAGCTTTGTCTGCTGCCCTGTACTATTTA
GTGGTCCAAGGCAAGAAGGGGGAAGATGTTCTTGGTTCAGTGCGGAGAGC
CCTGACTCACATTGACCACAGCTTGAGTCGTCAGAACTGTCCTTTCCTGG
CTGGGGAGACAGAATCTCTAGCCGACATTGTTTTGTGGGGAGCCCTATAC
CCATTACTGCAAGATCCCGCCTACCTCCCTGAGGAGCTGAGTGCCCTGCA
CAGCTGGTTCCAGACACTGAGTACCCAGGAACCATGTCAGCGAGCTGCAG
AGACTGTACTGAAACAGCAAGGTGTCCTGGCTCTCCGGCCTTACCTCCAA
AAGCAGCCCCAGCCCAGCCCCGCTGAGGGAAGGGCTGTCACCAATGAGCC
TGAGGAGGAGGAGCTGGCTACCCTATCTGAGGAGGAGATTGCTATGGCTG
TTACTGCTTGGGAGAANGGCCTAGAAAGTTTTGCCCCCGCTGCGGCCCCA
GCANAATCCAGTGTTGCCTGTGGCTGGAGAAAGGAATGTGCTCATCACCA
GTGCCCTCCNTTACGTCAACAATGTCCCCCACCTTGGGAACATCATTGGT
TGTGTGCTCAGTGCCCGATGTCTT

Sequence ID 1368
CAGTGAGCCAAGATCACACCACTGCACTCCAGCCTGGACAACAGAACGAG
ACTCCATATCAAAAAAATTAAATTAAAATATAATAAATTTCTTGCCGGGC
GCAGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCG
GATCACGAAGTCAGGAGATTGAGACCATCCTGGCTAATACAGTGAAACCC
CGTCTCTACTATAAATACAAAAAATTAGCTGGGCATGGTGGCGGGCGTCT
GTAGTCCCAGCTACTCAGGAGTCTGAGGCAGGAGAATGGTGTGAACCCGG
GAGGCGGAGCTTGCAGTGAGCCGAGATCGTGCCACTGCAATCCAGCCTGG
GCAGCAGAACGAGACTCCATCTCAAATAAATAAATAAATAAAATGAATTT
CAGCTAGAAGAGCCTTATTCCATTTTCCTTTTTATTAAACATCTGGCATA
AGTTGGTAAGTATGTGAAGTTTATCATATATTCTTATGCGAATTATTATT
TTCGCCTTTTTTTTTATAATTCTGTCTGGGATTTGAATAGTAGAGTTTGA
ATTCAGGAAGGACACCTGTGATAGGACAATAAAAT

Sequence ID 1369
CTGATTGCAAAAACATTACAACTCAGTACTGCGGCTTTCATTCAAATAGG
TTATATGTATAAACTGAGGTTCAACAATATTGTATTTGAGATGGGAAAGT
TAAAGAAATGCAATAATGTAAATAATACTTAAGAAAATAAGATCTCAGGA
AACTGTGTATACTCTGTACTTTTATGCAACTTTATCAGATCATTTCAGTA
TATGCATCAAGGATATAGTGTATATGACATGAACTTTGAGTGCAAAAACT
GTACTATGTACCTTTTGTTTATTTTGCTGTCAACATCTAAATAAAGGTTT
TTTTG

Sequence ID 1370
CGAAAGGACTACAGAGCCCCGAATTAATACCAATAGAAGGGCAATGCTTT
TAGATTAAAATGAAGGTGACTTAAACAGCTTAAAGTTTAGTTTAAAAGTT
GTAGGTGATTAAAATAATTTGAAGGCGATCTTTTAAAAAGAGATTAAACC
GAAGGTGATTAAAAGACCTTGAAATCCATGACGCAGGGAGAATTGCGTCA
TTTAAAGCCTAGTTAACGCATTTACTAAACGCAGACGAAAATGGAAAGAT
TAATTGGGAGTGGTAGGATGAAACAATTTGGAGAAGATAGAAGTTTGAAG
TGGAAAACTGGAAGACAGAAGTACGGGAAGGCGAAGAAAAGAATAGATAA
GATAGGGAAATTAGAAGATAAAAACATACTTTTAGAAGAAAAAAGATAAA
TTTAAACCTGAAAAGTAGGAAG

Sequence ID 1371
GTCCAGNAGAAAGTTCAGTGACTTGTCCAGAGCTGCAGGTCTTAAGAGGC
TGAAATCTCGCCTCTGCCTCGAGGCTGCGGTTCCACTGACCCATACTACT
TGCCTTCAGGAAAGAGAAATGGTGTAGGAAGGCTGTGGATGAAGACGCTT
ACATTCATGAAGGATTTGGATAGGCGAACATGAGCTTTTCCACCAAATTT
CAGAATTTTAAGAAATGCCTTAAATTATTTCTTAAAAATCAATTTGGGGC
AGACGAGAAGTTCTGATAATAGTTTTTAGGGAACATGATAAAATTCTGAC
CTTAGAAGTGGTATACCAGTTTGAGAAGAAGAACAAGCTATAAACGGTGT
AGATAACATTCACGGCTATTTAAGAAAGAGTTACTAAGGGAAACCAGAAT
GACTTAAGAGTGTTACTCTTCTTTTTCTGAGAGAACAATAGCATCATCTC
AGAAAGCCTTTCATGCCATTAATAGGTAAGAATCTGGGCTTCTTGGACCA
TGGGTTAGACTTTCTTACAAAACCATAATATGCATTTCCTAGCAAAATTT
ATGCTATTACATTTCCTTATCTCAACAAAGACTGGTAAATTCAGTACTTA
TTCCTCAATTTTCCTACCCTTAAAATGGGGATATTCTGCCTCTCCAAGGA
ATGCTGGGAACAAGCAAGTCCTCATGTTAGGGGTCTTTGAGTTTTCATGG
AAGTTTAGGTTATTTATATGATGACATAGTTGTCAACTTACTTTCAGGAT
GGACTTTTCTTTTGTGAGTTTGTGACCTAAATACAATAGTTGTTATGCAT
GTCCAGTTTATGGAAGTACCACTGCAATANCAG

Sequence ID 1372
CAGTGCAGCCAAGTATCACACCACTGCACTCCAGTCCTGGACAACAGAAA
CGANTACTCCATATCAAAAAAATTAAATTAAANGATAATAAATTTCTTGC
CGGGCGCAGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGT
GGGCGGATCACGAAGTCAGGAGATTGAGACCATCCTGGCTAATACAGTGA
AATCCCCGTCTCTACTATAAATACAAAAAATTAGCTGGGCATGGTGGCGG
GCGTCTGTAGTCCCAGCTACTCAGGAGTCTGAGGCAGGAGAATGGTGTGA
ACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGTGCCACTGCAATCCA
GCCTGGGCAGCAGAACGAGACTCCATCTCAAATAAATAAATAAATAAAAT
GAATTTCAGCTAGAAGAGCCTTATTCCATTTTCCTTTTTATTAAACATCT
GGCATAAGTTGGTAAGTATGTGAAGTTTATCATATATTCTTATGCGAATT
ATTATTTTCGCCTTTTTTTTTATAATTCTGTCTGGGATTTGAATAGTAGA
GTTTGAATTCAGGAAGGACACCTGTGATAGGACAATAAAATCTA

Sequence ID 1374
GAAAGCACATATGATATACATGTGTGTCATATGTATTATTTTGTTTGCCA
TCTGAGTCTTCAAAATTTGTTACAGAATACCTGCATATTAATATTTCAAG
GTATGGATTAAT

Sequence ID 1378
CTGAGTATTAACTAAAAAAAAAAAAAAAAAAAAAAAAAAA

Sequence ID 1380
CCAAACCCAACTGGTCCAGTAGGATACTCACCTTACAGGGGGCGTCTCAA
GAGTCTCACAGTTCCCTTGGGTCTTAAGAGACTCACTGTTGGACCAGGCG
TGGTGACTCACGCCTGTAAAACCAGCACTTTGGGAGGCCGAGGCGGGCGG
ATCAGTTGAGGTCAAGAGTTCAAGACCAGCCTGACCAAGGTGCTGAAACC
CCGTCTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGTGTGCGCCT
GTAATCCCAGCTACTCCAGAGGCTGAGGCAGGAGAATCTCTTGAACCCAG
GAGGTGGAGGTTGCAGTGAGTCGAGATCATGCCACTGCACTCCAGCCTGG
GTGACAGAGCGAGACTCCGTCTTAGAAAAAAAAAAAAAAAAAAAAAGAAC
CTCACAGTTCAGCAGGGTTCTAGCATGAGACAATGAGGACAAGGGTAGGT
GAGCAGGTGGAAAGAGTGAGAACAGGTCAATTGTGATGGAGAAAATAATA
AAGACAGAAAAGGCAGAAGACTGCCTGGCAGAAGACCTGTCCCAGCAGAT
ACAAAAATACAGACAACAGGAGCCAGCATAGACCCTTGACCTGTGTAAGT
CTTTCTCAGGCCTTCTTTTAAGTAGAAACATGCCTTTGAAAAAAAGTTTT
AATAAACAGGAAAATCATAAATCCCTATTTACATAAATAATATATCCTGG
TCTTATTCTTAAAACCATTGATTTTTCACGGCTCATTAANAAAGCTGGGC
GAGGTGGCTCACGCCCGTCATCCTAGCACTTTGGGAGGCCGAGGCGGGCA
NATCACAAGGTGAGGAGTTGGGAGACCAGCCTGACCAACACGGTGAAACC
CAGTCTCTACTAAAAATACAAAAATTANCTGGGGGTGGTGGTGTGTGCCT
GTAATCCAAGCTACTCGGGAGGCTGAGGCAGGA

Sequence ID 1382
CTTACTACCTCCAACATGAAACAAGCAGCCCCGCACTTCTCGAAGGTCTG
AGTTACTTGGAATCGTTTTACCACATGATGGACAGAAGGAATATTTCAGA
TATCTCTGAAAACCTCAAGCGTTACCTTCTTCAGTATTTTAAGCCAGTGA
TTGACAGGCAAAGCTGGAGTGACAAGGGCTCAGTCTGGGACAGGATGCTC
CGCTCGGCTCTCTTGAAGCTGGCCTGTGACCTGAACCATGCTCCTTGCAT
CCAGAAAGCTGCTGAACTCTTCTCCCAGTGGATGGAATCCAGTGGAAAAT
TAAATATACCAACAGATGTTTTAAAGATTGTGTATTCTGTGGGTGCTCAG
ACAACAGCAGGATGGAATTACCTTTTAGAGCAATATGAACTGTCAATGTC
AAGTGCTGAACAAAACAAAATTCTGTATGCTTTGTCAACGAGCAAGCATC
AGGAAAAGTTACTGAAGTTAATTGAACTAGGAATGGAAGGAAAGGTTATC
AAGACACAGAACTTGGCAGCTCTCCTTCATGCGATTGCCAGACGTCCAAA
GGGGCAGCAACTAGCATGGGATTTTGTAAGAGAAAATTGGACCCATCTTC
TGAAAAAATTTGACTTGGGCTCATATGACATAAGGATGATCATCTCTGGC
ACAACAGCTCACTTTTCTTCCAAGGATAAGTTGCAAGAGGTGAAACTATT
TTTTGAATCTCTTGAGGCTCAAGGATCACATCTGGATATTTTTCAAACTG
TTCTGGAAACGATAACCAAAAATATAAAATGGCTGGAGAAGAATCTTCCG
ACTCTGAGGACTTGGCTAATGGTTAATACTTAAATGGTCAATAGAAAAAG
TAGGCTGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGA

Sequence ID 1387
AAAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTCAGTGTTAAAGTAGGTTTGTCGACGCGGCCACGAATTTCCCG
GGGACCAA

Sequence ID 1389
TTTTTTTTTTTTTTTGGGAGTCAGTTTTCTTTTCTTTTCTTTCTTTTTTT
TTTTTTGNTTTTCGGAAACGGAGTCTCGCTTTCTCGCCCACTCTGGAGTG
GNGCAGTGGGGNGGTCTCAGCTCACCACAGCCTCCACCTCCTGGGCCCAA
GCGATCCTNTCACCTCAGCCTCCTGCGTAGCTGGGACTACAGGCGTGCAC
CACCATTCCCAGGTAATTTTTGTATTTTTTTGTANANACAGGTTTCACTG
TTGTTGCCCAGGCTGGTCTCGAACTCCTGCTTCAGTCTGCCANAATGCTG
GATTCTAGGCGTGAGCCACCGNGCCTGGCCCAAAAGTTACTTTTCTTACA
GAAGCAAAGCTTTAATGCATTTTACTGAATGCTTATAGCTTTGTAGATAC
TGAAAAGAGTATGAGCGTCACATACAGACACATNTAACAGCACTGCCTCC
AACCAGCCCCTACCCACTGGTCAGGNGAGTAANAATCAAAATTCTTTTCT
GNGAGTGGAACGGAAATTTCATCTCTCCTCCTCAGGCAAGTAGTTAANAG
GCTGGNGGGAGTCATGGCCCCATTTTGTTCAAAATACAAGCTCCACAGGA
ACAAAAGGCTGAACTGCTCACCTCCCAACTGATGAACCTCGTCTTTGTTC
CATGTCAAAGGGGCCTTTGTGTTACTGCAGCAGAAACTCCAGCTATCAAA
CCATCAGGCACCAAAAGTAAAACTCCTTTCTCTAAAAAGACCTCTCTTTA
CCTGAGCCTTTCAATGCATCTTTGCCCCCANATAATCCTGGATGAGATAA
TCCCCAGAGGAANACCAGCGCTTGCCTAGTGAAATTATACTATGAGACAA
GGGTAAAAGACCTCAAANACCGGGTTGGCAGGTAAGGGAGTAGGGN

Sequence ID 1390
TCNGTGGCACCCGTTTCCGGCACCTTCAGACTCTGAAGAGCCACCTGCGA
ATCCACACAGGAGAGAAACCTTACCATGTACGTAAGCCTCTTGAGGCCGC
TCTCTGACCTGCGGGGATGTGGAGGGCAGGGAAGGAGGTGGAGCGCAGGG
AAGGAGGTGGAGCAGGGAGGCAGTGGAACTGTTTGCTCCCATCTCAAGCA
CACAGTGGGGCAACCACTACGCTAATGGTTGGAAGACCTAGATCTGGGCC
CAATGGCCAGACACCCTGCTTGACCTTGGCCCAAGCATTAGGGGACTCAT
CTTTAAAATGAGGGTATGGGACTAGATGATCTGGGCCTTAGGAGAGGAGT

Sequence ID 1391
CGGCTNCTACCCTGCGGAGATCACACTGACCTGGCAGTGGGATGGGGAGG
ACCAAACTCAGGACACCGAGCTTGTGGAGACCAGGCCAGCAGGAGATGGA
ACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAG
ATACACGTGCCATGTTCAGCACGAGGGGCTGCCGGAGCCCCTCACCCTGA
GATGGAAGCCGTCTTCCCAGCCCACCATCCCCATCGTGGGCATCGTTGCT
GGCCTGGCTGTCCTGGCTGTCCTAGCTGTCCTAGGAGCTATGGTGGCTGT
TGTGATGTGTAGGAGGAAGAGCTCAGGTGGAAAAGGAGGGAGCTGCTCTC
AGGCTGCGTCCAGCAACAGTGCCCAGGGCTCTGATGAGTCTCTCATCGCT
TGTAAAGCCTGAGACAGCTGCCTGTGTGGGACTGAGATGCAGGATTTCTT
CACACCTCTCCTTTGTGACTTCAAGAGCCTCTGGCATCTCTTTCTGCAAA
GGCATCTGAATGTGTCTGCGTTCCTGTTAGCATAATGTGAGGAGGTGGAG
AGACAGCCCACCCCCGTGTCCACCGTGACCCCTGTCCCCACACTGACCTG
TGTTCCCTCCCCGATCATCTTTCCTGTTCCAGAGAAGTGGGCTGGATGTC
TCCATCTCTGTCTCAACTTCATGGTGCGCTGAGCTGCAACTTCTTACTTC
CCTAATGAAGTTAAGAACCTGAATATAAATTTGTTTTCTCAAATATTTGC
TATGAAGGGTTGATGGATTAATTAAATAAGTCAATTCCTGGAAGTTGAGA
GAGCAAATAAAGACCTGAGAACCTTCCANAATCCG

Sequence ID 1392
TGAAACAAAATGAATTTNTATGGGTAAGAGAGGGTAATATTTTAGAGTTG
TGTTACAAAACTACAAATTTTTATTAAATTAATAAATCAGAATACTAAAT
CCATGTGTTTTTTTCTTTCTTAAAAAATATCTTTTGGCTGGGCACGGTAG
CTCATGGCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGTGGATCGCC
TGATGTCAGGAGTTCAAGACCAGCCTGGTCAACATGTTGAAACCCCATCT
CTACTAAAAATATAAAAATTAGCCGGTGTGGTGGTGGGCGCCTGTAATCC
CAGCTACTCAGGAGGCTAAGGCAGGAGAATTGCGTGAACCCAGGAGTTCA
GTGATGTAGCGGGGAGCTGAGATTGTGCCACTACACTCCAGCCTGGATGA
CAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAA

Sequence ID 1394
GCATAATGTGAGGAGGTGGAGAGACAGCCCACCCCCGTGTCCACCGTGAC
CCCTGTTCCCATGCTGACTTGTGTTTCCTCCCCAGTCATCTTTCCTGTTC
CAGAGAGGTGGGGCTGGATGTCTCCATCTCTGTCTCAACTTTATGTGCAC
TGAGCTGCAACTTCTTACTTCCCTACTGAAAATAAGAATCTGAATATAAA
TTTGTTTTCTCAAATATTTGCTATGAGAGGTTGATGGATTAATTAAATAA
GTCAATTCCTGGAATTTGAGAGAGCAAATAAAGACCTGAGAACCTTCCAG
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAA

Sequence ID 1395
CTTACCATGTCAGTGCACAGAAATGCTGTCTTGGGATGTAGGAAAAATAA
ATCCACAAAAGCTACCAAGTTTGAAGGGGACCATGAGTCTTCAGGCTGGA
GCTTCCAAACCAGATGAAAACCCCACAATTAACCTGCAGTTTAAGATCCA
GCAGCTGGCCATTTCTGGACTCAAGGTGAATCGTCTGGATATGTATGGAG
AAAAGTACAAACCCTTTAAGGGCATAAAATACATGACCAAAGCTGGGAAG
TTCCAAGTTCGAACCTGAAGGGAGCATTTGCTGAGGGAATAGTCTTGCAC
ATTTTTTCATTTCTTACTTGTCTAAAAGTAAAAAAAAATATCAGCCTGTC
TCCTAGGTCAGTCCCCTCCTGGACCCACCCGCTCCCTTTTTTCCTTAGCC
TTCAGTGCCATGGAACTAATCAAGGGAGGAAAAGGTCACCAGGGAGAACT
GGACAGAACTGAAACACAGCAACACCAGTTCTCAAGGACAAGGTGTGTGA
TGGGGGTAGGAAGCTTGGTGCTTATGTAACCATTTTAAACGTGGTTTCTA
TAGGAAAGACCAACATTTGTTTAGCTTGCTTGGCTTTAATTATCTAAAGC
CAATGAAAGACTTCTTTGTTGATTTTTTAAGATAGAAAGATT

Sequence ID 1396
CAAACACTATGTTATTTTATGAANAAGACTTGAACATCTATGGATTTTGG
TATTTGCAAGGGGTGAATGGGGTATTTGCAAGCAGTGAATGAGGAGGCCT
GGAACCAATCTTCTGCTGATATTGAGGCACAACTGAAAAAGGTATATTAC
TTAAATCTCTTATTGTATTGTAAACTGTATAAGTAATGAAATTAAAAGGC
AGAAATTGTCAGACTGAATAAAATGAAAAGACCAAACAATATGCTGCTTA
CAAGAAACACAATTCAAATATAAGGACACAATTAGTTTAAAGGAAAAGAA
CTGGAAAAGATATACCATGATAACACAAGTCAGAAGAAAGCTGCTGTGGA
TATATTAATATGAGATGTAGATTTCAGAGCAGTGAATATTGCCAGGCATA
AAGAAAGTTATTACATAATAATTAAGGTATCAGTTCATCAAGAAGATGTA
ATAACCCTAAGTATTTATACAACTAATATCAGAGCTTCAAAATACATGAA
GCAAAAACCAGTGGAATTGATAGGAGAAACACACAATTACACAATTATAG
TCAGAATTTTCAACATATCTTTCTCAATGGAGAAAACAACTAGACAGGAA
ATCATTAAGGATATAGATGATTTAAATTATATGATCAACTACCTGGACGT
AATTGGCATTTATGGAACACTGCACCACCAACAGCAGAGTACATATTATT
TTCAAGTACACAGAAAACAGTTACCAATATAGACCATTTTCTGGGTCATA
AAACACATCTCAATAAATGTAAAACAATTAATGTTATATAAAGTATGTGC
TCTGACCNCAAAGGAATTAGAGATCAATAAAAGAACATCTTTGAAAAATC
TCACNTATTTAAAAACTAATAACTCACTTCTAAATAACTCCTGTNTCAAG
AGAATNAAANGG

Sequence ID 1397
CCCAGCCTCACTGCGCCCCGTCAGGCCAGGCAGCTGCCCTCAGGGTCTGC
CAAGGTGGGGGTCAAGGGCCATGGGGGCAGGTAGCTCTGCCTGCAAAGCC
CACAAGCATGTCAGATCACCTGGGCTGCAGACAGACAAACACCTGAGCTG
TTCTGAATACCTTCAGGTTCCTGGCCTCGCTGAGCAAGTGCAGAAATTTT
TACCTTCAAGGATCAGGGTTTTTCTGTTTGTTTGTTTTTTAACACACACA
TATGTGAACAAAGAGTATGCGTTTGTACTGGCAGAAGAAGCGTCTGGTAA
GACAACCAGCAAGTTAACAATGGTCACCTCCAGAAATGGGCTGGGTAAAC
CAAAGAATTTTTTTGTTTTTGTTTTTTTTGAGTCAGGGTCTAGCTCTGTC
ACCCAGGCTGGAACGCACTGGTGTGATCACGGCTCACTGCAGCCTTGACC
TCCCTGGCTCAAGCAATCCTCCCAGCTCAGCCTCCTGAGTCGTTGGGACT
ACAGGCACGTGCCACCACGCCTGACACATTTTTTAAATTTTTGTAGAGAC
AGTGTTTCACCATGTTGCCCAGGCAGGTCTCAAACTCCTGGGCTCAAGTG
GTCCTCCAGCTTCAGCCTCCCAAAGTGCTAGGATTATAGGTGTGAGCCAC
AGTGCCCAGCCCCGTAGTGGAGAATTTCTGTTGAATGAACCAAAAGCAAC
TGCCAACCTCTCCATGCACCATGTGTTTCAGAGGAGAAAGCACAGTGAAG
AATGCAGTGTGTTCTGAGGTCCTGTCACCCCTGAGGCTGTGTGTGTCCTT
TGCCAAATTAAAGAGTCTTACTGAATGCGGTGCATCCAGGAGACAGGCCN
AGGTTTGGACTGGTAAAAAAAAA

Sequence ID 1399
CAGACACCTGGNAGAACGGGAAGGAGACGCTGCAGCGCGCGGACCCCCCA
AAGACACATGTGACCCACCACCCCATCTNTGACCATGAGGCCACCCTGAG
GTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACACTGACCTGGCAGC
GGGATGGCGAGGACCAAACTCAGGACACCGAGCTTGTGGAGACCAGACCA
GCAGGAGACAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGG
AGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGC
CCCTCACCCTGAGATGGGAGCCATCTTCCCAGTCCACCGTCCCCATCGTG
GGCATTGTTGCTGGCCTGGCTGTCCTAGCAGTTGTGGTCATCGGAGCTGT
GGTCGCTGCTGTGATGTGTAGGAGGAAGAGTTCAGGTGGAAAAGGAGGGA
GCTACTCTCAGGCTGCGTCCAGCGACAGTGCCCAGGGCTCTGATGTGTCT
CTCACAGCTTGAAAAGCCTGAGACAGCTGTNTTGTGAGGGACTGAGATGC
AGGATTTCTTCACGCCTCCCCTTTGTGACTTCAAGAGCCTCTGGCATCTC
TTTCTGCAAAGGCACCTGAATGTGTCTGCGTCCTTGTTAGCATAATGTGA
GGAGGTGGAGAGACAGCCCACCCTTGTGTCAACTGTGACCCCCTGTTCCC
ATGCTGACCTGTGTTTCCTCCCCAGTCATCTTTTTTGTTCNCAATAGGTG
GGGCCTGGATGTCTCCATCTCTGTNTCA

Sequence ID 1440
TTATAAGGTACTTTTAAGGTATTTTAGTTGTCTTAGTCTATATTTCTGTA
CTCACCTTTCTTTATCCACTCATCAGTTGATGGGCATGTAGGTTGGTTCC
ATATCTTTGCAATTCTGAATTGTGCTGTGATCAGGTGTCTTTTTAGTATA
ATGATTTACTCTCCTTTGGGTAGATACCCAGTAGTGGGATTGCTGGATCG
AATGGTTTTTATAATTTTCTATTTTACCACAGTTTCTCTCTGCATTTTTC
CTCTTTGACCACTAACCATGTGAAATTCTCATATTGACCTTTATAATGAT
CATGAACTCTTAGTATCATTGGGAAGGCCACATTTGCCACTTATGATTGT
AAACCTTATCCTCCATTTTTCCTGTTATTGTTGGTGCAAAAAGCACCTAT
TATACCAGGACTTTAAAAATCAGTCTGATAAGTCTTTGATAAGTCTAATA
ATAATAACTGATAAGTCCATTGAATTTGCTTCTGATTACTTTTTCTTTAG
TAGCTAAACATGTATGTACTCCTATGATTACAATGAACACTCCTCTCCAT
TTAAATTAATTATTTACATTGATGAAATAGCAAAATGTTAATGACTAAAT
ACTGTCTTGGTTTTTTCGTTCCAGGTCAGTCAATATTAACTTCTTATAAT
TTTCTTTTTTTTCTTT

Sequence ID 1447
GCAAGGACTAACCCCTATACCTTCTGCATAATGAATTAACTAGAAATAAC
TTTGCAAGGAGAGCCAAAGCTAAGACCCCCGAAACCAGACGAGCTACCTA
AGAACAGCTAAAAGAGCACACCCGTCTATGTAGCAAAATAGTGGGAAGAT
TTATAGGTAGAGGCGACAAACCTACCGAGCCTGGTGATAGCTGGTTGTCC
AAGATAGAATCTTAGTTCAACTTTAAATTTGCCCACAGAACCCTCTAAAT
CCCCTTGTAAATTTAACTGTTAGTCCAAAGAGGAACAGCTCTTTGGACAC
TAGGAAAAAACCTTGTAGAGAGAGTAAAAAATTTAACACCCATAGTAGGC
CTAAAAGCAGCCACCAATTAAGAAAGCGTTCAAGCTCAACACCCACTACC
TAAAAAATCCCAAACATATAACTGAACTCCTCACACCCAATTGGACCAAT
CTATCACCCTATAGAAGAACTAATGTTAGTATAAGTAACATGAAAACATT
CTCCTCCGCATAAGCCTGCGTCAGATTAAAACACTGAACTGACAATTAAC
AGCCCAATATCTACAATCAACCAACAAGTCATTATTACCCTCACTGTCAA
CCCAACACAGGCATGCTCATAAGGAAAGGT

Sequence ID 1448
GGCCACCGGGTGCAAGGTCAGGGCTGGGGTGGAGGCTGGGAAGCCCAGGG
CTTGGCCCACTGTGGCCGCCTTGTGTGGTCACTGCTTTCCTGGGCCTGCT
GTGAGCTCCCTCTAGGACCCCAGGCCTGTCTGGTGGGTCACTGTGACCAC
CACCTTGCACAGCACCTGGCGCGTGGCAGGTGCTCAAACATTACTTGTTT
CGGAATGAACTTCATCTTGCTCTTGGCTTTTTGACTAATGCTGTGGAACA
TCTGACTAATTAGTGACTCTTTGGGGCCCCCAGTTTCCCAGCTATAAAGT
GGTAATATTAAGATAATAATTCGGCCGGGCGCGGTGGCTCACGCCTGTAA
TCCCAGCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACGAGGTCAGAAG
ATCGAGACCATCCTGGCTAACACGGTGAAACCCCATCTCTACTAAAAATA
CAAAAAATTANCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCA
NGAGGCTGANGCAGGAGAATGGTGTGAACCCGGGAGGCAGAGGTTGCAGT
GAACCAAGATCGNNCCACTGCACTCCAGCCTGGGCAACAGAGCGAGACTC
CATCTTAAAAAA

Sequence ID 1449
AATCAGGGCCGCAGTGTGTTCTGCGCCTGCCCAGAGCTGACTCCTGATTT
AACCGCTGGCGTAACCGCGGGTTGCACGCATGCGTGCTGAAAAGCCTTTC
ACCCTCACGTGGTTTCTTTTTTAACCAGTCATCAAGCGAGGCTCGCGCGC
AGGCCCCGCGTTGGAAAATGGCGGGGAAGCTGAAACCTCTGAATGTGGAG
GCGCCAGAAGCTGCTGAGGAGGCTGAAGGTAGTGAGGGCAAGTGGGCTGC
ACTCCTTTCTCTCCAACCAGGGCAGAAAGGAGGGAGGATTCGTCCCATTA
CAATAATGAAATAATGATATTCTAATTTTTTTAAATAAAATGTTAAGCCT
TTTGTTATTGAA

Sequence ID 1450
GGAAANCATGAGGCTTCGGGAGCCGCTCCTGAGCGGCAGCGCCGCGATGC
CAGGCGCGTCCCTACAGCGGGCCTGCCGCCTGCTGGTGGCCGTCTGCGCT
CTGCACCTTGGCGTCACCCTCGTTTACTACCTGGCTGGCCGCGACCTGAG
CCGCCTGCCCCAACTGGTCGGAGTCTCCACACCGCTGCAGGGCGGCTCGA
ACAGTGCCGCCGCCATCGGGCAGTCCTCCGGGGAGCTCCGGACCGGAGGG
GCCCGGCCGCCGCCTCCTNTAGGCGCCTCCTCCCAGCCGCGCCCGGGTGG
CGACTCCAGCCCAGTCGTGGATTCTGGCCCTGGCCCCGCTAGCAACTTGA
CCTCGGTCCCAGTGCCCCACACCACCGCACTGTCGCTGCCCGCCTGCCCT
GAGGAGTCCCCGCTGCTTGGTAAGGACTCGGGTCGGCGCCAGTCGGAGGA
TTGGGACCCCCCCGGATTTCCCCGACAGGGTCCCCCANACATTCCCTCAG
GCTGGCTCTTCTACGACAGCCAGCCTCCCTCTTCTGGATCAGAGTTTTAA
ATCCCANACAGAGGCTTGGGACTGGATGGGAGAGAAGGTTTGCGAGGTGG
GTCCCTGGGGAGTCCTGTTGGAGGCGTGGGGCCGGGACCGCACAGGGAAG
TCCCGAGGCCCCTCTAGCCCCAAAACCANAGAAGGCCTTGGAGACTTCCC
TGCTGTGGCCCGAGGCTNAGGAAGTTTTGGAGTTTTGGGTCTGCTTANGG
CTTCNAGCAGCCTTGCACTGAGAACTTTGGTAGGGACCTCGAGTAATCCA
CTCCNTTTTNGGGACTGACGTGAGGCTCCCGGTGGGGAAAGANACTGACC
TNTC

Sequence ID 1453
CCGACCTGTCTCGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTCTT
TCTGGCCTGGAGGCTATCCAGCGTACTCCAAAGATTCAGGTTTACTCACG
TCATCCAGCAGAGAATGGAAAGTCAAATTTCCTGAATTGCTATGTGTCTG
GGTTTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGGAGAGAGA
ATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTTT
CTATCTCTTGTACTACACTGAATTCACCCCCACTGAAAAAGATGAGTATG
CCTGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATAGTTAAGTGG
GATCGAGACATGTAAGCAGCATCATGGAGGTTTGAAGATGCCGCATTTGG
ATTGGATGAATTCCAAATTCTGCTTGCTTGCTTTTTAATATTGATATGCT
TATACACTTACACTTTATGCACAAAATGTAGGGTTATAATAATGTTAACA
TGGACATGATCTTCTTTATAATTCTACTTTGAGTGCTGTCTCCATGTTTG
ATGTATCTGAGCAGGTTGCTCCACAGGTAGCTCTAGGAGGGCTGGCAACT
TAGAGGTGGGGAGCAGAGAATTCTCTTATCCAACATCAACATCTTGGTCA
GATTTGAACTCTTCAATCTCTTGCACTCAAAGCTTGTTAAGATAGTTAAG
CGTGCATAAGTTAACTTCCAATTTACATACTCTGCTTAGAATTTGGGGGA
AAATTTAGAAATATAATTGACAGGATTATTGGAAATTTGTTATAATGAAT
GAAACATTTTTGTCATATAAGATTCATATTTACTTCTTATACA

Sequence ID 1454
TAAATAGGGAATCCTTTCCCCATTGCTTGTTTTTCTCAGGTTTGTCAAAG
ATCAGATAGTTGTAGATATGCGACGTTATTTCTGAGGGCTCTGTTCTGTT
CCATTGATCTATATCTCTGTCACATGCACACGTATGTTTGTTGTGGCACT
ATTCACAGTGGCAAAGACTTGGAACCAACCCAAATGTCCAACAATGATAG
ACCGGGTTAAGAAAATGCGGCACATATACACCATGGAATACTATGTAGCC
ATAAAAAATGATGAGTTCGTGTCCTTTGTAGGGACATGGATGAAATTGGA
AATCATCATTCTCAGTAAACTATCGCAGGAACAAAAAACCAAACACTGCA
TATTCTCACTCATAGGTGGGAATTGAACAGTGGGAACACATGGACACAGG
AAGGGGAACATCACACTCTGAGGACTGTTGTGGGGTGGGGGGAGGGAGGA
GGGATAGCATTGGGAGATATACCTAGTGCTGGATGACGAGTTAGTGGGTG
CAGCGCACCAGCATGTCACATGTATACATATGTAACTAACCTGCACATTG
TGCACATGTACCCTAAAACTTAAGGTAT

Sequence ID 1456
CCGCAACAAACACGGGAGTGCAGATATCGCTGCGATGGGCTGATTTCCTT
TATTTGGGTATATACCCAGCAGTGGGATTGCTGGATTGTATGGTAGCTCT
ATTAGTTTTTTGAGGAACCTCCAAACTGTTCTNCATAGTGGTTGTACTCA
TTTACATTCCCACTGTGAACCCTGAAAATTTGAGGCAGGTCTCAGTTAAA
TTAGAAAGTTGATTTTGCCAAGTTGGGGACACGCACTCGTGACACAGCCT
CAGGAGGAACTGATGACATGTGCCCAGGTGGTCAGAGCACAGCTTGGTTT
TATACATTTTAGGGAAACCTGAGCCATCAATCAACATACGTAAAATGGGC
CGGGCACAGCAGCTCAAGCTGTAATCCCAGCACTCTGGGAGGCCGAGGCG
GGTGGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTG
AAACCCCGTCTCTATTAAAAATACAAAGCTTAGCTGGATGTGGTGGCGCA
TGCCTGTAGTCCCAGCTGCTCTAGGAGGCTGAGGCATGAGAATTGCTTGA
ACCTGGGAGGCAGAGGCTGCAGTGAGCCGAGATCGAGCCACTATACTCCA
GCCTGGTCAACAGAGTGAGACCCTGTCT

Sequence ID 1460
CCACAACTGTGTTCACTAGCAACCTCAAACAGACACCATGGTGCACCTGA
CTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTG
GATGAAGTTGGTGGTGAGGCCCTGGGCAGGCTGCTGGTGGTCTACCCTTG
GACCCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTG
TTATGGGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCC
TTTAGTGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTGCCAC
ACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCA
GGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAA
GAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTGGTGGCTGGTGT
GGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTCC
AATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGG
GGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACAT
TTATTTTCATTG

Sequence ID 1490
ATGGGCATCTCTCGGGACAACTGGCACAAGCGCCGCAAAACCGGGGGCAA
GAGAAAGCCCTACCACAAGAAGCGGAAGTATGAGTTGGGGCGCCCAGCTG
CCAACACCAAGATTGGCCCCCGCCGCATCCACACAGTCCGTGTGCGGGGA
GGTAACAAGAAATACCGTGCCCTGAGGTTGGACGTGGGGAATTTCTCCTG
GGGCTCANAGTGTTGTACTCGTAAAACAAGGATCATCGATGTTGTCTACA
ATGCATCTAATAACGAGCTGGTTCGTACCAAGACCCTGGTGAAGAATTGC
ATCGTGCTCATCGACAGCACACCGTACCGACAGTGGTACGAGTCCCACTA
TGCGCTGCCCCTGGGCCGCAAGAAGGGAGCCAAGCTGACTCCTGAGGAAG
AAGAGATTTTAAACAAAAAACGATCTAAAAAAATTCAGAAGAAATATGAT
GAAAGGAAAAAGAATGCCAAAATCAGCAGTCTCCTGGAGGAGCAGTTCCA
GCAGGGCAAGCTTCTTGCGTGCATCGCTTCAAGGCCGGGACAGTGTGGCC
GAGCAGATGGCTATGTGCTAGAGGGCAAAGAGTTGGAGTTCTATCTTAGG
AAAATCAAGGCCCGCAAAGGCAAATAAATCCTTGTTTTGTCTTCACCCAT
GTAATAAAGGTGTTTATTGTTTTTGTT

Sequence ID 1491
CTTNCACATACTGATTGATGTCTCATGTCTCTCTAAAATGTGTAAAACCA
AGCTGTGCCCCAACCACCTTGGGNACATGTGGNGAGGACCTCCTGAGGCT
GTGTCATGGGCACACCTTAACCCTGGGAAAATAAACTTTCTAAACTGACT
TGAGAGCTGTCTCAGATATTCTGAGCTTACAGTTATTGTGAAATCATTTT
AATTATAAATTAAGTGGAGATTTACTTAAAATCATGTGTAGAAGTAGCCT
GTGATATAGTCCTAGATACATACATTATCATCTTATGTATCTTCCCTCCC
TCTTCCAGGTTCTGATAAAAACAGATGAAATCTGAAAGACCATGACAGTA
GTATTTTGAAAATGACAGTATTTGAAATTAAAAAATTGTAAAAGTGTTCT
GTTCTATCACTGCCAAAGGATAAGTTACAAATTGGTTCTTGGAACGTAAT
ATGTACTATGTGCTTGCTATTTAATAATTTACCAGTCTTAGTCTTTTTTA
TTCAGACTAATTTTACCTTTTTTTAACCTATGACTCTTTAGTTATAGTAG
TACAAAAAAGTAGTTTTAGTTATAGTTTTAGTTGTAGTACAAAAAAGCAT
TTTCTGTAAGCTTAATTTCTTTCCCCTTCCCGCTTTCCCAGTCAGATGAC
TTTAGTGATTTGGAGTTGTGTGCTTTATAAGTGCATTCCTCAGAGGACTT
AATATTACTAAGATTTTAGCAACNCTGAAATATGTT

Sequence ID 1492
TGTNCCTGTAGTCCTGTGTGGGAGGATTGCCTGAGCCTAGGAGCTCAAAG
TTGCAGTGAGCCCAGATCGNGNCATTGCAGTCCAGCCTGGGTGACAGAGT
GAGACCCCATGTCAAAAAAAAAAAAACAAAAAACAGGGGCCTGCCTCANC
CAGCAGGTGAGGTCTGCCACTGAGAGCACTTCTAGCAGCAGGAACAGCCT
CCACCCCCACACTGCAATCAAGTTTTTTGGGTCAGCCTTAGGAGCTAANA
AAGGGCCTAGTTTGNCTAAATAGCAGGAGTTATATCCAGGGATCTTCAGG
CCCAGGAATGCTAATGAGTAGGCATTCCATGGGCCCTGGGAATGGCTTTG
TGTGCCANAAATGATGGCCACAAAGGCCTTGCTGCCTTTTTTCAAAATGG
CTGCATCCAGCTGAGTGCTCTCTGCCAAAGGGGANAANAAAATAAGTCTC
CAGTGCATTTAGATTGGTCTCTCATCATCTCTCTCCTTTTTGTTTTTATT
AGTCTCCTTAACCAAAACTGCCAAGAAAGGCTTGGAATTGAAACAAAACC
TGATANAANAGGTAAGAGGTTGTTCTTTT

Sequence ID 1493
TGTNTCAAAAAAAAAAAAAAGAACGGNAATGTACTGGAGATGTATTTGAT
AACCAAGGNTTTAGGTAAATTTTCACCAGTATTAGTTNTATTTGCAAACT
GAAAAATGTTGTAGGCTTAATATAAAATAACCACATTAGTGAACATTATA
TCTCTTAGAAGAAAGGCCATATTTTGCTCCTGCTTCTGTAAAAATATTAT
TTGTTTGAAGGGGAAATAATGGTAGTGTGACCTTTCACTTAATTCCTACT
CCCTTAATGTGAGAGAGACAAAATGAGCTGAAGAAGGAAAATTCTGGAGT
TACACTCCACAACCTTGAACATACTGACGGACATCTCTGTTTTGACAACG
ATTTCTCCATGCCACCCATGCTNTAATGCCTTGTGGATCACGGACAACCC
TCTTTGCACAAGCTACAGCATCAGCGATGTTATCTTGCAGCAAAGCACTG
CAGGATAAATGACAGGCATTAACTGCTCCTGGGGTTTTGCCATCATTACA
CCAGTAGCGGCTATTGATCTGAAATATCCCATAATCAGTGCTTCTGTCTC
CAGCATTGTAGTTTGTAGCTCGTGTGTTGTAACCACTCTCCCATTTGGCC
AAACACATCCAGTTTGCTAGGCTGATTCCCCTGTAGCCATCCATTCCCAA
TCTTTTCAGAGTTCTGGCCAACTCACACCTTTCAAAGACCTTGCCCTGGA
CCGTAACAGAAAGGAGGACAAGCCCCAGAACAATGAGAGCCTTCATGTTG
AC

Sequence ID 1494
TTGGTACCCGGGAAATTCTTTGCCGCGTCGACGGCCGGTGAGGCAGATCA
CCTGAGCCCAGGAGTTCAGGACCAGCCTGGGCAGCATACCGGGATTCCAT
CTNNACTAAAAACAGTAGGCTGGGTGTGGTGGCTCATGTCTGTAAGCTCA
GGACTTTGGAAGGCCAAGATGGGAGGATCACTTGAGCCTGGGAGTTTGAC
ACCAGCTTGAGCATCGTAGCCAGGCCCTGACTCTACAAAAAAGTGAAATA
ATTAGCCGAGTGTGGTGGTTCACACCTGTAATCCCAGCTGCTCAGGAGGC
TGAGGTAGGAGAATCATTTGAACCCGGGAGGTGGAGGTTGCAGTTAGCCG
AGATCACGCCATTGCACTCCGGCCTGGGCGATAAAGCGAGACTCTGTCTC
AAAAAAAAAAAAAA

Sequence ID 1495
ATTCGGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTGTGCTCGCGCTACT
CTCTCTTTCTGGCCTGGAGGCTATCCAGCGTACTCCAAAGATTCAGGTTT
ACTCACGTCATCCAGCAGAGAATGGAAAGTCAAATTTCCTGAATTGCTAT
GTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGG
AGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACT
GGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCCACTGAAAAAGAT
GAGTATGCCTGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATAGT
TAAGTGGGATCGAGACATGTAAGCAGCATCATGGAGGTTTGAAGATGCCG
CATTTGGATTGGATGAATTCCAAATTCTGCTTGCTTGCTTTTTAATATTG
ATATGCTTATACACTTACACTTTATGCACAAAATGTAGGGTTATAATAAT
GTTAACATGGACATGATCTTCTTTATAATTCTACTTTGAGTGCTGTCTCC
ATGTTTGATGTATCTGAGCAGGTTGCTCCACAGGTAGCTCTAGGAGGGCT
GGCACCTTAGAGGTGGGGAGCAGAGAATTCTCTTATCCAACATCAACATC
TTGGTCAGATTTGAACTCTT

Sequence ID G6
GGATTTTTGGTCCGCACGCTCCTGCTCCTGACTCACCGCTGTTCGCTCTC
GCCGAGGAACAAGTCGGTCAGGAAGCCCGCGCGCAACAGCCATGGCTTTT
AAGGATACCGGAAAAACACCCGTGGAGCCGGAGGTGGCAATTCACCGAAT
TCGAATCACCCTAACAAGCCGCAACGTAAAATCCTTGGAAAAGGTGTGTG
CTGACTTGATAAGAGGCGCAAAAGAAAAGAATCTCAAAGTGAAAGGACCA
GTTCGAATGCCTACCAAGACTTTGAGAATCACTACAAGAAAAACTCCTTG
TGGTGAAGGTTCTAAGACGTGGGATCGTTTCCAGATGAGAATTCACAAGC
GACTCATTGACTTGCACAGTCCTTCTGAGATTGTTAAGCAGATTACTTCC
ATCAGTATTGAGCCAGGAGTTGAGGTGGAAGTCACCATTGCAGATGCTTA
AGTCAACTATTTTAATAAATTGATGACCAGTTGTTAAAA

Sequence ID - 61 nt: 362
CTTATTGAAAATTTTACTAATTTCTTACTTTTTAGGTTTTAGGAGAATAC
TTTTGGATAATTGACTAGCCTCACATTATATTGATAGAGGTTCTTGAAAA
CTTTAATGCCAATTCATGTATCTTATGACTAAAATAGATAATCCATTTAG
AAATTTAAGTCATTCTTGCGTGCTTGATATGTGTCAGCACTATCCAAGTT
GCTAGGGGATACAATGGTGAAGTGAAAATATCAGCTAGGTGCCGGTGGCT
CACACCTGTTATCCCAACAGTTTGGGAGGCCAGGGTGGGAGGATCACTCA
AGCACANGCGTTTCACACCAGCCTGGACAACATACAAGACCCCATCTTTA
CCAAAAGTTAAG

Sequence ID - 490 nt: 382
TTTTCTTAGAACTTTATTTTTTCTGGCCAGGCGCAGTGGCTCACACCTGT
AATCCCAGCACTTTGGGAGGCCAAGGCAGGTCGATCACCTGAGGTCAGGA
GCTCAAGACCAGCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAAT
ACAAAAATTAGCTGGGCGTGGTGGCGCATGCCTGTAATCCCANCTACTCA
GGAGGCTGAGGCAGGAGAATTGTTTGAACCCGGGAGGCGGAGGTTGCANT
GAGCCGAGATTGCGCCACTGCACTCCAGCCTGGGCAACAGAGCGAAACTC
CATCTCAAAAAAAAAAAAAAAAAACAACCTTTATTTTTTCTGATTTTAAA
AGTAATAACTAGTTTGTAGAAACATTAAAAGT

Sequence ID - 892 nt: 559
TCTTTCGGAAGCGCGCCTTGTGTTGGTACCCGGGAATTCGCGGCCGCGTC
GACGCGGTCGTAAGGGCTGAGGATTTTTGGTCCGCACGCTCCTGCTCCTG
ACTCACCGCTGTTCGCTCTCGCCGAGGAACAAGTCGGTCAGGAAGCCCGC
GCGCAACAGCCATGGCTTTTAAGGATACCGGAAAAACACCCGTGGAGCCG
GAGGTGGCAATTCACCGAATTCGAATCACCCTAACAAGCCGCAACGTAAA
ATCCTTGGAAAAGGTGTGTGCTGACTTGATAAGAGGCGCAAAAGAAAAGA
ATCTCAAAGTGAAAGGACCAGTTCGAATGCCTACCAAGACTTTGAGAATC
ACTACAAGAAAAACTCCTTGTGGTGAAGGTTCTAAGACGTGGGATCGTTT
CCAGATGAGAATTCACAAGCGACTCATTGACTTGCACAGTCCTTCTGAGA
TTGTTAAGCAGATTACTTCCATCAGTATTGAGCCAGGAGTTGAGGTGGAA
GTCACCATTGCAGATGCTTAAGTCAACTATTTTAATAAATTGATGACCAG
TTGTTT

Sequence ID - 77 nt: 464
GCGGCTGCTGTTGGTTGGGGGCCGTCCCGCTCCTAAGGCAGGAAGATGGT
GGCCGCAAAGAAGACGAAAAAGTCGCTGGAGTCGATCAACTCTAGGCTCC
AACTCGTTATGAAAAGTGGGAAGTACGTCCTGGGGTACAAGCAGACTCTG
AAGATGATCAGACAAGGCAAAGCGAAATTGGTCATTCTCGCTAACAACTG
CCCAGCTTTGAGGAAATCTGAAATAGAGTACTATGCTATGTTGGCTAAAA
CTGGTGTCCATCACTACAGTGGCAATAATATTGAACTGGGCACAGCATGC
GGAAAATACTACAGAGTGTGCACACTGGCTATCATTGATCCAGGTGACTC
TGACATCATTAGAAGCATGCCAGAACAGACTGGTGAAAAGTAAACCTTTT
CACCTACAAAATTTCACCTGCAAACCTTAAACCTGCAAAATTTTCCTTTA
ATAAAATTGCTTG

Claims

1. A set of oligonucleotide probes, wherein said set comprises at least 10 different oligonucleotides, wherein each oligonucleotide is selected from:

an oligonucleotide having a sequence as set forth in SEQ ID No. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 1:49, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 339, 341, 342, 343, 344, 345, 346, 347, 348, 351, 352, 353, 355, 356, 357, 359, 361, 363, 364, 365, 366, 367, 368, 369, 370, 371, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 409, 411, 414, 415, 416, 418, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 444, 445, 447, 448, 451, 452, 454, 455, 458, 459, 460, 461, 463, 464, 465, 467, 468, 471, 472, 473, 474, 475, 476, 480, 481, 482, 484, 487, 489, 490, 496, 497, 498, 499, 500 or 501,

or an oligonucleotide fragment of said sequence, which fragment is at least 15 bases in length, or an oligonucleotide with a complementary sequence, or a functionally equivalent oligonucleotide which hybridizes under conditions of high stringency to any of said aforementioned oligonucleotides.

2. A set of oligonucleotide probes as claimed in claim 1, wherein said oligonucleotide probes are each selected from:

an oligonucleotide having a sequence as set forth in SEQ ID No. 1, 2, 3, 4, 5, 11, 12, 13, 19, 25, 31, 32, 33, 34, 36, 37, 39, 45, 46, 47, 48, 50, 55, 56, 60, 61, 64, 66, 68, 73, 74, 75, 76, 77, 78, 80, 83, 85, 86, 90, 96, 98, 99, 100, 101, 105, 106, 107, 109, 111, 114, 115, 116, 117, 119, 120, 121, 122, 123, 124, 125, 127, 128, 130, 131, 132, 133, 135, 136, 137, 138, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 161, 162, 163, 164, 165, 166, 168, 169, 171, 173, 174, 175, 176, 177, 178, 179, 180, 182, 183, 185, 186, 187, 190, 191, 195, 197, 198, 199, 200, 202, 204, 206, 207, 210, 212, 214, 216, 217, 218, 219, 220, 221, 222, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 243, 244, 245, 249, 251, 256, 258, 259, 260, 261, 262, 267, 268, 270, 272, 273, 274, 275, 276, 278, 279, 280, 282, 284, 286, 287, 289, 291, 292, 295, 296, 297, 298, 299, 301, 303, 305, 307, 308, 309, 310, 311, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 351, 352, 353, 355, 356, 357, 359, 361, 363, 364, 365, 366, 367, 368, 369, 370, 371, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 457, 458, 459, 460, 461, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 484, 487, 489, 490, 496, 497, 498, 499 or 501,

or an oligonuceotide fragment of said sequence, which fragment is at least 15 bases in length, or an oligonucleotide with a complementary sequence, or a functionally equivalent oligonucleotide which hybridizes under conditions of high stringency to any of said aforementioned oligonucleotides.

3. A set of oligonucleotide probes as claimed in claim 1, wherein said oligonucleotide probes are each selected from:

an oligonucleotide having a sequence as set forth in SEQ ID No. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 339, 341, 342, 343, 344, 345, 346, 347, 348, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 409, 415, 445, 447, 448, 451, 452, 454, 455, 456, 458, 459, 460, 461, 462, 463, 464, 465, 467, 468, 471, 472, 473, 474, 475, 480, 481, 482, 483, 484, 485, 486, 487, 488, 491, 492, 493, 494, 495, 496, 500 or 501,

4. A set of oligonucleotide probes as claimed in claim 1, wherein each probe in said set binds to a different transcript.

5. A set as claimed in claim 1, wherein said set consists of from 10 to 500 oligonucleotide probes.

6-8. (canceled)

9. A set of oligonucleotide probes as claimed in claim 1, wherein said probes are immobilized on one or more solid supports.

10-12. (canceled)

13. A kit comprising a set of oligonucleotide probes as claimed in claim 1 immobilized on one or more solid supports.

14-15. (canceled)

16. A method for determining the gene expression pattern of a cell, comprising at least the steps of:

a) isolating mRNA from said cell, which may optionally be reverse transcribed to cDNA;

b) hybridizing the mRNA or cDNA of step a) to a set of oligonucleotide probes as defined in claim 1; and

c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce said pattern.

17. A method of preparing a standard gene transcript pattern characteristic of a disease or condition or stage thereof in an organism comprising at least the steps of:

a) isolating mRNA from the cells of a sample of one or more organisms having the disease or condition or stage thereof, which may optionally be reverse transcribed to cDNA;

b) hybridizing the mRNA or cDNA of step a) to a set of oligonucleotide probes as defined in any claim 1 specific for said disease or condition or stage thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation; and

c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce a characteristic pattern reflecting the level of gene expression of genes to which said oligonucleotide probes bind, in the sample with the disease, condition or stage thereof.

18. A method of preparing a test gene transcript pattern comprising at least the steps of:

a) isolating mRNA from the cells of a sample of said test organism, which may optionally be reverse transcribed to cDNA;

b) hybridizing the mRNA or cDNA of step a) to a set of oligonucleotidee probes as defined in claim 1 specific for a disease or condition or stage thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation; and

c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce said pattern, which reflects the level of gene expression of genes to which said oligonucleotide probes bind, in said sample.

19. A method of diagnosing or identifying or monitoring a disease or condition or stage thereof in an organism, comprising the steps of:

a) isolating mRNA from the cells of a sample of said organism, which may optionally be reverse transcribed to cDNA;

b) hybridizing the mRNA or cDNA of step a) to a set of oligonucleotide probes as defined in claim 1 specific for said disease or condition thereof in an organism and sample thereof corresponding to the organism and sample thereof under investigation;

c) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce a characteristic pattern reflecting the level of gene expression of genes to which said oligonucleotide probes bind in said sample; and

d) comparing said pattern to a standard diagnostic pattern prepared by

i) isolating mRNA from the cells of a sample of one or more organisms having the disease or condition or stage thereof, which may optionally be reverse transcribed to cDNA;

ii) hybridizing the mRNA or cDNA of step i) to said set of oligonucleotides probes; and

iii) assessing the amount of mRNA or cDNA hybridizing to each of said probes to produce a characteristic pattern reflecting the level of gene expression of genes to which said oligonucleotides bind, in the sample with the disease, condition or stage thereof, wherein the sample is from an organism corresponding to the organism and sample under investigation,

to thereby determine the degree of correlation indicative of the presence of said disease or condition or a stage thereof in the organism under investigation.

20-21. (canceled)

22. A method as claimed in claim 17, wherein said probes are oligonucleotide probes selected from:

an oligonucleotide having a sequence as set forth in SEQ ID No. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 2701, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 339, 341, 342, 343, 344, 345, 346, 347, 348, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 409, 415, 445, 447, 448, 451, 452, 454, 455, 456, 458, 459, 460, 461, 462, 463, 464, 465, 467, 468, 471, 472, 473, 474, 475, 480, 481, 482, 483, 484, 485, 486, 487, 488, 491, 492, 493, 494, 495, 496, 500 or 501,

or an oligonucleotide fragment of said sequence, which fragment is at least 15 bases in length, or an oligonucleotide with a complementary sequence, or a functionally equivalent oligonucleotide which hybridizes under conditions of high stringency to any of said aforementioned oligonucleotides and said disease is Alzheimer's disease.

23. A method as claimed in claim 17, wherein said probes are oligonucleotide probes selected from:

an oligonucleotide having a sequence as set forth in SEQ ID No. 1, 2, 3, 4, 5, 11, 12, 13, 19, 25, 31, 32, 33, 34, 36, 37, 39, 45, 46, 47, 48, 50, 55, 56, 60, 61, 64, 66, 68, 73, 74, 75, 76, 77, 78, 80, 83, 85, 86, 90, 96, 98, 99, 100, 101, 105, 106, 107, 109, 111, 114, 115, 116, 117, 119, 120, 121, 122, 123, 124, 125, 127, 128, 130, 131, 132, 133, 135, 136, 137, 138, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 161, 162, 163, 164, 165, 166, 168, 169, 171, 173, 174, 175, 176, 177, 178, 179, 180, 182, 183, 185, 186, 187, 190, 191, 195, 197, 198, 199, 200, 202, 204, 206, 207, 210, 212, 214, 216, 217, 218, 219, 220, 221, 222, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 243, 244, 245, 249, 251, 256, 258, 259, 260, 261, 262, 267, 268, 270, 272, 273, 274, 275, 276, 278, 279, 280, 282, 284, 286, 287, 289, 291, 292, 295, 296, 297, 298, 299, 301, 303, 305, 307, 308, 309, 310, 311, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342; 343, 344, 345, 346, 347, 348, 349, 351, 352, 353, 355, 356, 357, 359, 361, 363, 364, 365, 366, 367, 368, 369, 370, 371, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 457, 458, 459, 460, 461, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 484, 487, 489, 490, 496, 497, 498, 499 or 501,

or an oligonuceotide fragment of said sequence, which fragment is at least 15 bases to length, or an oligonucleotide with a complementary sequence, or a functionally equivalent oligonucleotide which hybridizes under conditions of high stringency to any of said aforementioned oligonucleotides and said disease is breast cancer.

24-27. (canceled)

28. A method as claimed in claim 17, wherein said pattern is expressed as an array of numbers relating to the expression level associated with each probe.

29. A method as claimed in claim 17, wherein said organism is a eukaryotic organism, preferably a mammal.

30. A method as claimed in claim 29 wherein said organism is a human.

31. (canceled)

32. A method as claimed in claim 17, wherein said disease is cancer or a degenerative brain disorder.

33. A method as claimed in claim 17, wherein said sample is tissue, body fluid or body waste.

34. A method as claimed in claim 17, wherein said sample is peripheral blood.

35. A method as claimed in claim 17, wherein the cells in the sample are not disease cells, have not been in contact with such cells and do not originate from the site of the disease or condition.

36-37. (canceled)